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Background: The prevalence of type 2 diabetes mellitus (T2DM) and of cardiovascular disease (CVD) is
believed to be higher among people with intellectual disability (ID) than in the general population.
However, research on prevalence and prevention in this population is limited.
Objectives: The objectives of this programme of work were to establish a programme of research that
would significantly enhance the knowledge and understanding of impaired glucose regulation (IGR) and
T2DM in people with ID; to test strategies for the early identification of IGR and T2DM in people with ID;
and to develop a lifestyle education programme and educator training protocol to promote behaviour
change in a population with ID and IGR (or at a high risk of T2DM/CVD).
Setting: Leicestershire, UK.
Participants: Adults with ID were recruited from community settings, including residential homes and
family homes. Adults with mild to moderate ID who had an elevated body mass index (BMI) of ≥ 25 kg/m2
and/or IGR were invited to take part in the education programme.
Main outcome measures: The primary outcome of the screening programme was the prevalence of
screen-detected T2DM and IGR. The uptake, feasibility and acceptability of the intervention were assessed.
Data sources: Participants were recruited from general practices, specialist ID services and clinics, and
through direct contact.
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Results: A total of 930 people with ID were recruited to the screening programme: 58% were male, 80%
were white and 68% were overweight or obese. The mean age of participants was 43.3 years (standard
deviation 14.2 years). Bloods were obtained for 675 participants (73%). The prevalence of previously
undiagnosed T2DM was 1.3% [95% confidence interval (CI) 0.5% to 2%] and of IGR was 5% (95% CI
4% to 7%). Abnormal IGR was more common in those of non-white ethnicity; those with a first-degree
family history of diabetes; those with increasing weight, waist circumference, BMI, diastolic blood pressure
or triglycerides; and those with lower high-density lipoprotein cholesterol. We developed a lifestyle
educational programme for people with ID, informed by findings from qualitative stakeholder interviews
(health-care professionals, n = 14; people with ID, n = 7) and evidence reviews. Subsequently, 11 people
with ID (and carers) participated in pilot education sessions (two groups) and five people attended
education for the feasibility stage (one group). We found that it was feasible to collect primary outcome
measures on physical activity and sedentary behaviour using wrist-worn accelerometers. We found that
the programme was relatively costly, meaning that large changes in activity or diet (or a reduction in
programme costs) would be necessary for the programme to be cost-effective. We also developed a quality
development process for assessing intervention fidelity.
Limitations: We were able to screen only around 30% of the population and involved only a small
number in the piloting and feasibility work.
Conclusions: The results from this programme of work have significantly enhanced the existing
knowledge and understanding of T2DM and IGR in people with ID. We have developed a lifestyle
education programme and educator training protocol to promote behaviour change in this population.
Future work: Further work is needed to evaluate the STOP Diabetes intervention to identify cost-effective
strategies for its implementation.
Trial registration: ClinicalTrials.gov NCT02513277.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme
and will be published in full in Health Research Programme Grants for Applied Research; Vol. 5, No. 11.
See the NIHR Journals Library website for further project information.
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Plain English summary
Adults with intellectual disability (ID) have more health problems than the general population. They areless likely to access help, and are more likely to be overweight and not get enough exercise. This may
increase their chances of getting diabetes.
Type 2 diabetes (T2DM) is a long-term condition that can cause damage to blood vessels and nerves.
Impaired glucose regulation (IGR) happens when blood sugar levels are higher than normal but not high
enough to be T2DM. People with IGR are more likely to develop T2DM, heart disease and stroke, but they
can make changes to their lifestyle to prevent this.
Our research aimed to:
1. screen people with ID for T2DM and IGR
2. develop a lifestyle education programme to help people with ID stay healthy.
We recruited 930 people and collected blood samples from 675 of them to test for diabetes. We found
that about 1 in 100 people had undiagnosed T2DM and 5 in 100 had IGR. More than two-thirds (68%)
were overweight or obese.
We developed a lifestyle education programme. We asked a few small groups of people with ID
(and carers) to come to the 8-week programme. Attendance at the education sessions was good.
Overall, people felt positive about the education.
To conclude, fewer people had T2DM or IGR than we expected. However, we found that many people
with ID were overweight or obese. We succeeded in developing a lifestyle education programme to help
people do more physical activity, eat healthier and lose weight.
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Easy-read summary
   
   
   
 
 
We want to tell you about the STOP 
Diabetes Research Study. 
 
A research study is a way we try to find out 
about the answers to questions. 
 
         Our research study was about diabetes. 
 
We want to tell you what we found out. 
  
What is diabetes? 
 
        
 
Diabetes is an illness. 
         
 
 
           
 
People with diabetes have too much sugar 
(glucose) in their blood. 
 
 
Their body cannot use sugar properly. 
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People with diabetes may feel: 
 
      
 
• Tired and ill 
      
 
• Thirsty 
    
 
• And need to go to the toilet a lot. 
  
Why did we do this research study? 
     
 
We want people with learning disabilities to 
be healthy. 
    
        
 
We wanted to know if people with learning 
disabilities have diabetes. 
 
We wanted to know if people with learning 
disabilities could get diabetes in the future. 
 
 
 
We wanted to know the best way to stop 
(prevent) diabetes. 
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Who did the research study? 
      
 
Professor Khunti 
      
 
Professor Bhaumik 
     
 
And a research study team to help them. 
   
 
• Nurse 
    
 
• Secretary 
   
 
• Researcher 
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How did we do the research study? 
    
 
We asked people with learning disabilities 
and their carers about their health. 
 
 
      
 
       
    
 
We checked: 
 
• How tall they were. 
 
 
• How much they weighed. 
 
 
• What was their blood pressure. 
      
 
We tested their urine (wee). 
   
 
We tested their blood. 
 
    
 
 
We invited some people and their carers to 
be part of a small group. 
 
This group learned about staying healthy. 
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What did we find out? 
 
More than 900 people with learning 
disabilities took part in our research study. 
 
 
 
• Slightly more men than women 
took part. 
 
 
• 9 people had diabetes. 
 
 
• 35 people had too much sugar in their 
blood. 
 
The good news is that not many people 
had diabetes! 
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But 
 
We found a lot of people weighed too 
much. 
529 people weighed too much 
 
 
And others were not very active. 
 
 
 
Some of these people learned about 
staying healthy. 
 
We want to teach more people about 
staying healthy in the future. 
 
 
    
 
We want to thank everyone who has 
helped us! 
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The images and symbols used in the easy-read summary are reproduced with permission from the
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Change Picture Bank. © CHANGE www.changepeople.org
Somerset Total Communication. © STC 2016. All rights reserved. These symbols may not be reproduced as
a whole by any means.
Somerset Total Communication (STC), c/o Resources for Learning, Parkway, Bridgwater, Somerset, TA6 4RL.
Telephone: 01278 444949. E-mail: stc@somerset.gov.uk. www.somersettotalcommunication.org.uk;
www.SupportServicesforEducation.co.uk.
People First.
Widget. Widgit Symbols © Widgit Software 2002–2017. www.widgit.com
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Scientific summary
Background
Type 2 diabetes mellitus (T2DM) is a serious chronic condition that is associated with an increased risk of
cardiovascular disease (CVD) and affects approximately 6% of the UK adult population. Impaired glucose
regulation (IGR), whereby blood glucose level is elevated above the normal range, is a precursor to T2DM
and affects approximately 12% of the UK adult population. T2DM can be prevented through changes
to lifestyle, and lifestyle education interventions have been shown to be cost-effective in delaying or
preventing the transition to T2DM in people with IGR in the general population.
Intellectual disability (ID), also known as learning disability, is a lifelong condition with onset before
adulthood, characterised by a reduced ability to understand new or complex information and to learn
new skills, and a reduced ability to cope independently. The prevalence of T2DM is believed to be higher
among people with ID owing to the increased prevalence of a number of risk factors, including obesity
and lack of exercise. However, there has been very little research in this area, and the evidence base for
detection and prevention of T2DM has not yet been applied in a population with ID.
The focus of this research programme was to conduct a diabetes screening programme among people
with ID and to develop a lifestyle multicomponent education programme for the prevention of T2DM and
CVD, suitable for use in this population.
Objectives
The objectives of the programme were to:
l establish a programme of research that significantly enhances the knowledge and understanding of
IGR and T2DM in people with ID
l test strategies for the early identification of IGR and T2DM in people with ID
l develop a lifestyle education programme and educator training protocol to promote behaviour change
in a population with ID and IGR [or high risk of T2DM/CVD based on elevated body mass index
(BMI) score].
To achieve these objectives, three distinct work packages (WPs) were developed:
1. WP1 – development and assessment of the feasibility of a structured screening programme to
determine the prevalence and demographic risk factors for T2DM and IGR in people with ID. This WP
also included the validation of the Leicester Self-Assessment diabetes risk score in people with ID, a
cost-effectiveness analysis and the establishment of data linkage mechanisms.
2. WP2 – development of a lifestyle education programme for people with ID and IGR (or at high risk of
T2DM/CVD based on elevated BMI).
3. WP3 – development of an intervention fidelity process for the assessment of the educators delivering
the intervention.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxvii
Service user involvement
Service users were integral to the research programme. People with ID helped to promote the programme,
develop study documentation and research processes, recruit and train staff, test procedures and disseminate
the findings.
Methods
Work package 1: screening programme
We recruited adults with ID from community settings, including residential homes and family homes.
Potential participants were approached through general practices, specialist ID services (using the
Leicestershire Learning Disability Register) and specialist ID clinics, and through direct contact with the
research team. We collected information on demographics, medical and family history, depression,
behaviour problems, lifestyle factors and activity levels. We also collected biomedical measures (plasma
glucose, glycated haemoglobin, lipids, urea and electrolytes, liver function tests, thyroid function and
albumin), anthropometric measures (height, weight, BMI, and waist and hip circumference) and blood
pressure (BP).
Work package 1: physical activity substudy
Adults who consented to take part in the screening programme and who were able to walk unassisted
were asked if they would be willing to wear the ActiGraph (Pensacola, FL, USA) waist-worn accelerometer
or the GENEActiv (Activinsights Ltd, Cambridge, UK) wrist-worn accelerometer to assess physical activity
and sedentary behaviour.
Work package 1: validation of the Leicester Self-Assessment risk score
The Leicester Self-Assessment risk score for detecting those at risk of undiagnosed IGR/T2DM was
validated using the data from the screening programme. The sensitivity, specificity, positive predictive value
and negative predictive value were calculated with 95% confidence intervals (CIs) for a cut-off point of
≥ 16 points.
Work package 1: cost-effectiveness study
Economic work was undertaken to estimate the cost-effectiveness of the STOP Diabetes lifestyle education
programme (see Work package 2: lifestyle education programme), compared with current routine care,
in reducing cardiometabolic comorbidities among individuals with ID.
Work package 2: lifestyle education programme
Adults with mild to moderate ID with a BMI of ≥ 25 kg/m2 and/or IGR were invited to take part in the
STOP Diabetes lifestyle education programme. This involved initial intervention and curriculum development,
two cycles of testing and evaluation, and a final refinement of the programme, and included interviews
with adults with ID, carers and health professionals.
Feasibility was assessed by collecting primary outcomes (physical activity and sedentary behaviour) and
secondary outcomes (weight, height, BMI, waist circumference, BP and dietary intake) before delivering the
education programme and 3 months after delivering the programme.
Work package 3: intervention fidelity
We conducted preliminary work towards developing an intervention fidelity process and tool that was
specifically tailored to people with ID.
SCIENTIFIC SUMMARY
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Results
Work package 1: screening programme
In total, 930 (29% of those originally approached) took part in the screening programme. Their mean age
was 43.3 years. Fifty-eight per cent were men, 80% were white and most were overweight (31%) or
obese (37%). Anthropometric measures were available for at least 86% of participants. Bloods were
available for 675 participants (73%) to assess the prevalence of IGR/T2DM.
Among people with ID, the overall prevalence of screen-detected (undiagnosed) T2DM was 1.3% (95% CI
0.5% to 2%) and of IGR was 5% (95% CI 4% to 7%). Abnormal glucose regulation was almost four
times more common in those from non-white ethnic groups [odds ratio (OR) 3.93, 95% CI 2.10 to 7.33]
and over three times more common among those with first-degree history of diabetes (OR 3.35, 95% CI
1.64 to 6.86). Similarly, increasing weight, waist circumference, BMI, diastolic BP and triglycerides and
decreasing high-density lipoprotein cholesterol were all associated with an increased risk of abnormal
glucose regulation.
Work package 1: physical activity substudy
Of 203 people approached, 97 (48%) agreed to wear the waist-worn accelerometer. Valid data (≥ 8 hours
per day for 3 days) were obtained for 55 participants (57%). Similarly, of 76 people approached, 47 (62%)
agreed to wear the wrist-worn accelerometer. Valid data were obtained for 39 of these participants (83%).
Thus, compliance could be improved by wearing wrist-worn accelerometers.
Work package 1: validation of the Leicester Self-Assessment risk score
Of 88% of adults with data available, 82% of people with abnormal glucose regulation were correctly
identified as being at high or very high risk (sensitivity). Ninety-eight per cent of participants with
low/medium risk scores were correctly identified as being at low risk.
Work package 1: cost-effectiveness
The findings from the health economic component of the analysis showed that, in its current form, the STOP
Diabetes education programme that we developed in WP2 would not be cost-effective at a £20,000 cost per
quality-adjusted life-year (QALY) threshold. However, there were scenarios in which the intervention may
be effective if commissioners/payers were willing to fund the intervention up to a threshold of £30,000
per QALY.
Work package 2: lifestyle education programme
The interviews carried out at the initial curriculum development revealed that people with ID liked to use
visual aids to help them to learn. Health professionals also highlighted the importance of allowing for
the diverse ability levels of people with ID, such as different attention spans and ability levels. Important
considerations included the need to use recall and repetition to support learning, ensuring familiarity and
consistency, and allowing generalised behaviour change goals to allow for different levels of physical ability.
For the testing cycles, we found that learning was facilitated by the group dynamic, recapping main
messages, using concrete examples and walking exercises. However, conceptual exercises, abstract examples
and giving too many messages did not work so well.
The preliminary findings suggest that it was both acceptable and feasible to collect outcome measures,
including physical activity and sedentary behaviour, at baseline and 3 months post intervention delivery
for this study. In this small sample (n = 5), all of the anthropometric outcome measures, 80% of BP data
and 60% (three out of four individuals who agreed at baseline) of accelerometer data were available at
3 months’ follow-up.
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Work package 3: intervention fidelity
We completed the first step in developing a tool for assessing intervention fidelity of the education
programme. The preliminary findings suggest some variance among educators. The new tool involved
focusing on educators’ teaching at the group’s pace; avoiding abstract concepts, abbreviations and jargon;
and engaging the learners without asking them to summarise key messages.
Conclusions
This programme of work has significantly enhanced the existing knowledge and understanding of T2DM
and IGR in people with ID. It has also allowed us to test strategies for the early identification of IGR and
T2DM in this population. Further work is needed to evaluate the intervention that we have developed and
to identify cost-effective strategies for its implementation.
Trial registration
This trial is registered as NCT02513277.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Rationale
The focus of this research programme was to estimate the prevalence of type 2 diabetes mellitus (T2DM) and
impaired glucose regulation (IGR) among people with intellectual disability (ID) and to develop and test a
lifestyle education programme for the prevention of T2DM that would be suitable for use in this population.
This research programme was developed to address gaps in the evidence base with regard to determining
the prevalence of T2DM and IGR in adults with ID, and the lack of suitable prevention programmes that are
specially tailored for people with ID. Since this research began, priorities set out in the 2015–16 UK NHS
England Business Plan1 have highlighted the need to improve services for people with ID and to establish a
national ID mortality review, with both diabetes and obesity identified as health priorities.2 An additional
health priority that was identified for all patients is the prevention of obesity and T2DM via a national
‘evidence-based lifestyle management programme’ to support people to make healthy lifestyle changes.1
The current evidence base for screening and successfully managing those at risk of diabetes – through
diet, exercise and behaviour therapy – relates to the general population. It is not currently known whether
or not screening for T2DM and IGR or prevention strategies through lifestyle education can be successful
in people with ID.
Aims and objectives
The aims of the programme were to:
l establish a programme of research that significantly enhances the knowledge and understanding of
IGR and T2DM in people with ID
l test strategies for the early identification of IGR and T2DM in people with ID
l develop a lifestyle education programme and educator training protocol to promote behaviour change
in a population with ID and IGR [or high risk of T2DM/cardiovascular disease (CVD) based on elevated
body mass index (BMI) score].
Overview of the programme of research
To achieve these aims, three distinct work packages (WPs) were developed (Figure 1).
Work package 1
The aims of WP1 were to:
l develop and assess the feasibility of a diabetes screening programme in a community setting for adults
with ID (see Chapters 5 and 6)
l determine the prevalence and demographic risk factors for T2DM and IGR in people with mild to
profound ID (see Chapters 5 and 6)
l validate the Leicester Self-Assessment diabetes risk score in people with ID (see Chapters 5 and 6)
l determine the cost-effectiveness of lifestyle intervention (see Work package 2), compared with current
care (see Chapter 12)
l establish data linkage to Hospital Episode Statistics and the Office for National Statistics (ONS)
(see Chapters 5 and 6).
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Work package 2
The aims of WP2 were to:
l develop a lifestyle education programme for people with ID and IGR (or high risk of T2DM/CVD based
on elevated BMI) (see Chapters 8 and 9)
l assess the feasibility of collecting outcome measures before and 3 months after attendance at lifestyle
education (see Chapter 10).
Eligible people recruited from general
practices, Leicestershire ID case
register, clinics or direct contact
Participants attend screening
appointment(s)
Participants’ diabetes status identified
according to results
Participants (and carers) who expressed 
interest in development phase
Normal
BMI of 
> 25 kg/m2
Subgroup invited 
to attend education
programme and
give feedback
Subgroup invited 
to attend education
and have baseline and
3-month follow-up
data collected
Educator
training and
intervention
fidelity
process WP3
WP2
WP1
Subgroup invited 
to participate 
in qualitative 
interview
Relevant 
health-care 
professionals 
invited to 
participate in
qualitative 
interview
Education
programme
developed
BMI of 
< 25 kg/m2
T2DM
Not invited to
participate in
further stages
IGR (high risk)
FIGURE 1 Programme of work.
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Work package 3
The aim of WP3 was to:
l develop a quality assurance (‘intervention fidelity’) process for the assessment of educators who are
delivering the education (see Chapter 11).
Scope of the report
The remainder of this chapter provides a brief overview of the ethics and governance arrangements, and
provides the detailed background for this research programme.
Subsequent chapters contain individual summaries, but, briefly, comprise:
l a systematic review of the prevalence/incidence of T2DM in people with ID (see Chapter 2)
l a systematic review of multicomponent behaviour change interventions in people with ID
(see Chapter 3)
l details of the involvement of people with ID throughout the programme of research (see Chapter 4)
l methods for the screening programme (see Chapter 5)
l results from the screening programme (see Chapter 6)
l methods and results from a physical activity substudy (see Chapter 7)
l details of the development of the lifestyle education programme (see Chapters 8 and 9)
l methods and findings from a feasibility phase collecting pre- and post-intervention outcome measures
(see Chapter 10)
l details of the development of the intervention fidelity process (see Chapter 11)
l methods and results for the economic analysis undertaken (see Chapter 12)
l discussion of findings and conclusions (see Chapter 13).
Ethics and governance
Approvals
The University of Leicester acted as sponsor for the programme of research. NHS research ethics approval was
obtained from the East of England – Cambridge Central Research Ethics Committee (reference 12/EE/0340).
Research and development approval was obtained for the research sites from Leicestershire Partnership NHS
Trust (LPT); Leicester City Clinical Commissioning Group (CCG), East Leicestershire & Rutland CCG and West
Leicestershire CCG; and the University Hospitals of Leicester NHS Trust.
Adherence to mental capacity legislation
Obtaining consent was the largest ethics consideration for this programme. Strict standard operating
procedures needed to be established to ensure that valid consent was obtained in accordance with English
capacity legislation,3 while taking into account the heterogeneity in capacity of individuals. More details on
the assessment of capacity and taking consent are contained in the methodology section for the screening
programme (see Chapter 4). This included providing people with all of the information that was relevant to
making the decision on whether or not to participate in the research, and communicating this information
in a way that was appropriate to them (such as using simple language and visual aids).
The process for those who lacked capacity involved talking to a ‘consultee’, whose role was to consider
the study from the participant’s perspective (see Appendix 1, Figure 26). Regardless of whether or not the
person with ID had the capacity to decide on participation, the research was discussed with the individual
to help him or her to understand the project as far as he or she had the capacity to do so, and to ascertain
any opinion that he or she had on participation. For example, if a person without decision-making capacity
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appeared even slightly anxious or reluctant to take part, then this was respected, and he or she was not
recruited to the study.
Programme steering group
Strategic oversight and direction of the research programme was provided by the programme steering
group (Figure 2), which comprised the chief investigator (KK), the lead researcher/project manager (AD)
and co-applicants listed in the application, with ad hoc attendance from service users. The meetings were
held four times per year and were independently chaired by Dr Colin Greaves, University of Exeter
(see Figure 2). The meetings involved discussion of contractual issues, staffing, protocol and ethical
amendments, public involvement (a rolling agenda item), recruitment progress, economic analysis,
education development, anticipated timelines and progress against project aims.
Operational groups
The research team (researchers, ID research nurses and research administrator) met frequently throughout
the programme to plan the individual components of the programme and to discuss progress. The details
of these meetings were fed back to the steering group.
The education development team [a multidisciplinary team of health-care professionals (HCPs) and researchers
with expertise in the field of both ID and developing diabetes and CVD prevention programmes] met regularly
to oversee and facilitate the development of the lifestyle education programme (WP3). Progress and key
decisions were fed back at steering group meetings.
Service user groups
A number of service users were involved in the research programme, but two service user self-advocacy
groups were particularly influential. The groups met regularly, facilitated by an experienced supporter, and
their comments were fed back to the steering group. More information about these and other service
users’ involvement is detailed in Chapter 4.
Steering group 
Independent chairperson:
Colin Greaves
Co-applicants, research
assistant, programme
administrator
Ad hoc attendance from
service users/carers
Stakeholders 
NHS
Policy-makers
Academics
Voluntary
Service users
Family carers
Paid carers
Service user
group 1
Service user
group 2
Operational project
groups
NETSCC
University of Leicester
Leicester Diabetes
Centre
FIGURE 2 Governance structure of the STOP Diabetes programme. NETSCC, NIHR Evaluation, Trials and Studies
Coordinating Centre.
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Data protection
A six-digit study code was used to identify all of the study participants. This code was used for all hard and
electronic copies of data that were collected for this programme (including questionnaires, anthropometric
data and blood samples), which were retained in a secure setting.
The Leicester Clinical Trials Unit (UK Clinical Research Collaboration registration number 43) was
responsible for the development of a secure database for the data that were collected as part of this
research programme.
Background
Definition of intellectual disability and case identification
Intellectual disability, also known as learning disability, is a lifelong condition with onset before adulthood,
characterised by a reduced ability to understand new or complex information and learn new skills, and a
reduced ability to cope independently.4 Severity levels for ID are typically categorised by broad intelligence
quotient (IQ), alongside the required deficits in independent living skills, into mild (IQ 50–69), moderate
(IQ 35–49), severe (IQ 20–34) and profound (IQ < 20) ID.5 Acknowledging the wide variation that exists
between individuals with ID, typical abilities suggested for each category are outlined in Table 1 [based on
World Health Organization (WHO) International Classification of Diseases, Tenth Edition (ICD-10)].5 More
recently in the UK, the Learning Disabilities Public Health Observatory has offered a ‘working definition’,
which includes brief practical guidance to improve the recognition of ID and to assist agencies in targeting
services.6
The aetiology of ID can be broadly divided into problems that occur in the antenatal, perinatal or postnatal
periods, or as a result of multiple factors. Common causes of ID include genetic and chromosomal
disorders – both non-inherited (e.g. Down syndrome)7 and inherited (e.g. fragile X syndrome) – and
non-genetic factors, such as infection and environmental factors. However, in the majority of cases no
specific cause is found.8
A recent meta-analysis of population-based studies suggests that, overall, around 1% of people worldwide
have ID, with wide variation dependent on age group and the income of the country (lower, middle and
higher); for adults, the proportion is around 0.5%.9 The evidence from existing ID registers and general
practice lists in England suggests that the prevalence of ID is approximately 3–5 per 1000 individuals.10,11
TABLE 1 Intellectual disability categories and suggested abilities
Severity of ID Suggested abilities and skills IQ level
Mild l Good verbal communication, and basic reading and writing skills
l Usually independent in self-care and practical domestic tasks
l Often able to form/maintain good social relationships
l May have employment
▲jModerate l Limited languagel Able to achieve some independence with support, but requirementsfor support will varyl Usually fully mobileSevere l Uses some words and gesturesl Activities need to be supervised and ongoing support is necessary
l May have problems with movement
Profound l Communication is very limited
l Support is needed for all daily living activities
l Mobility is usually severely impaired
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However, it is thought that the true prevalence could be as high as 2% of the adult population, as people
with mild ID are generally under-represented.11
For the current research programme, cases were identified via (1) records held on adults with ID in general
practices and (2) a register of adults attending ID services owned by the local mental health trust (LPT),
the Leicestershire Learning Disability Register (LLDR; see below).
General practices in the UK are now incentivised to maintain a register of people with ID.12,13 Locally,
for practices within Leicester City, East Leicestershire and Rutland, and West Leicestershire CCGs, the total
number of adults (aged ≥ 18 years) on general practice registers with an identified ID is estimated to be
around 4300 (based on figures provided by LPT).
The LLDR comprises adults with ID (aged ≥ 19 years) who live in the unitary authorities of Leicester city,
Leicestershire and Rutland.14 The register was established in 1987 to help facilitate the provision and
monitoring of services, and to enable the collection of public health data. It is currently a joint venture
between LPT and Leicester City CCG. Enrolment is via a large network of service providers, including
specialist ID services, social services and primary care. Currently, there are ≈3900 people with mild to
profound ID on the register. However, as the learning disability register is based on service use, some
adults, particularly those with mild ID who have little or no support from services, may not currently be
identified. This potentially accounts for some of the differences between the number of people identified
on this register and the number on local general practice registers.
Type 2 diabetes and impaired glucose regulation
Type 2 diabetes is a serious chronic disease, characterised by prolonged hyperglycaemia.15 Its symptoms
can reduce quality of life and lead to serious health complications, including blindness, renal failure and
amputation; 50% of new cases have demonstrable atherosclerosis at diagnosis.15–17 The prevalence of
diabetes in England is estimated to be 6.2%,18 rising to 8.0% [95% confidence interval (CI) 5.7% to 11.7%]
when undiagnosed cases are included.19 T2DM accounts for around 85–90% of diabetes cases; it creates a
huge economic burden on NHS resources, at a cost of £8.8B annually (≈10% of total NHS expenditure).20
Impaired glucose regulation is a condition in which blood glucose concentrations are elevated above the
normal range but do not satisfy the criteria for T2DM.21,22 Approximately 12% of the UK adult population
have IGR, of which an estimated 5–12% go on to develop T2DM each year. Observational studies show a
consistent and continuous association between glycaemia and CVD risk, whereby people with IGR have
a significantly elevated risk of CVD.23–25 Given the economic burden associated with this condition and
its related comorbidities, this group represents an important target for preventative strategies.26 Other
commonly used terms to describe IGR include pre-diabetes, non-diabetic hyperglycaemia and high risk of
diabetes; throughout the report, this high-risk group will be referred to as having IGR.
Previously in clinical practice, T2DM and IGR were identified using the ‘gold standard’ oral glucose
tolerance test.22 However, since the publication of updated WHO guidance in 2011 and subsequent
National Institute for Health and Care Excellence (NICE) guidance in 2012, there has been a shift away
from the use of the oral glucose tolerance test to the glycated haemoglobin (HbA1c) test.27
,28 The potential
benefits of the HbA1c test include it being a non-fasting blood test, less inter-test variability and its ability to
provide an indication of longer-term hyperglycaemia (over 6–8 weeks).29 A HbA1c level of ≥ 48mmol/l (6.5%)
is suggestive of T2DM, whereas a level of 42–47mmol/l (6.0–6.4%) is suggestive of IGR or a high risk of
diabetes.27 Further details on the methods used to identify T2DM and IGR for this programme of research
are provided in Chapter 5 (see Outcomes) and Figure 15.
Risk factors for type 2 diabetes and cardiovascular disease in people with
intellectual disabilities
In the general population, increasing levels of obesity and sedentary lifestyles have been associated with a
rise in non-communicable diseases, including T2DM and CVD.30–33
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Chronic conditions are becoming increasingly important for people with ID as their life expectancy
increases.34 There are a number of risk factors for T2DM that are known to be highly prevalent in people
with ID, suggesting that T2DM and CVD may be more prevalent in this group. These risk factors include:
l sedentary behaviour35–38
l a high prevalence of obesity32–34,39
l increased antipsychotic drug use for the management of challenging behaviour40,41 and psychosis,42
which are associated with weight gain, hyperglycaemia and worsening of other metabolic CVD
risk factors43–45
l genetic conditions associated with obesity (e.g. Prader–Willi syndrome).46
Physical inactivity and sedentary behaviour are both common among people with ID, with only a minority
(18–33%) achieving the recommended 30 minutes of moderate to vigorous physical activity (MVPA)
daily,47,48 and < 15% of people with ID complete the recommended 10,000 steps per day.49 Furthermore,
< 10% of adults with ID who live in supported accommodation have an intake of fruit and vegetables that
is sufficient for a balanced diet.50 The evidence suggests that paid carers know little about public health
recommendations on dietary intake.50
However, little is known about T2DM, CVD and associated risk factors in the population with ID. UK-based
data on the prevalence of T2DM are currently unclear.32 Current estimates for diabetes prevalence in the UK
are based on routinely reported data rather than on population-based studies. The suggested prevalence of
diagnosed diabetes in people with ID in England is around 6–7%, but estimates are unable to distinguish
between T2DM and other forms of diabetes.13,51 Similarly, the prevalence of CVD among people with ID is
reported to be greater than that among the general population, but the overall prevalence is unclear.52
Further information on the current prevalence of T2DM, CVD and related risk factors in the ID population
is presented in the systematic review in Chapter 2.
Diabetes screening
Given the increasing prevalence of diabetes, and the conferred risk of developing CVD, early identification
and intervention through screening has been shown to be a useful approach in the general population.53,54
The value of screening for IGR has also been demonstrated.
It is currently unknown if screening for asymptomatic glucose disorders is viable within UK populations
with ID; there is a lack of evidence on feasibility, acceptability, outcomes and benefits. People with ID have
been recommended by NICE as being an important group to consider in terms of diabetes prevention
strategies, given their supposed high risk of developing diabetes.27
General practitioners (GPs) in England have been incentivised to provide annual health checks to adults
with ID since 2008–9 (for those aged ≥ 14 years since 2014). Recent data suggest that, nationally, the
uptake of checks is around 44%.55 However, the proportion who additionally have bloods taken as part of
the health check, including HbA1c (7%) and cholesterol (30%), is extremely low.13
Risk scores for the early identification of impaired glucose regulation and
type 2 diabetes
A staged approach to screening is recommended by NICE for those at risk of diabetes in the general
population.56 This involves using a risk score to pre-screen for individuals at the greatest risk of T2DM
followed by a blood test in those at the highest risk. However, this approach has not been tried with
populations with ID.
Risk scores are a non-invasive way of stratifying a population for targeted screening. They use information
data from non-invasive risk factors to calculate an individual’s score: a higher score reflects a higher risk.
Risk scores can be applied to (1) an individual as a questionnaire (these scores generally require data from
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only non-invasive risk factors, which would be known by members of the public) or (2) a population
(e.g. in primary care, for which software is used to calculate the score using routine data from electronic
medical records) and then screening invitations can be sent to those at highest risk. A number of diabetes
risk scores have been developed and validated for use in the UK general population.56–60 One such score is
the Leicester Self-Assessment risk score (see Appendix 2), which allows people to easily assess their own
risk of having undiagnosed IGR or T2DM and then self-refer for screening with a HCP.58 The score contains
seven questions that ask about age, sex, ethnicity, BMI, waist circumference, family history of diabetes and
high blood pressure (BP). The score has been validated for use in a multiethnic UK population58,61 and is
specifically recommended by NICE for identifying people who are at risk opportunistically.56
To date, we are not aware of any risk scores that have been specifically assessed for use in populations
with ID. However, it cannot be assumed that a risk score that is developed for a specific population will
work well in another;62 for people with ID, there may be different risk factors, or weightings for specific
risk factors may change, when compared with the general population. Therefore, this programme of work
will seek to validate the Leicester Self-Assessment risk score in a population with ID (this work is presented
as part of the screening study; see Chapters 5 and 6).
Diabetes prevention in adults with intellectual disabilities
People with ID experience a disproportionate burden of health inequalities compared with the general
population, including poorer mental and physical health and higher rates of mortality.63–66 Despite their
increased health needs, they often find it difficult to access primary care services and to participate in
health promotion activities.67–69
Given the health inequalities among people with ID, and the possible increased risk of developing
diabetes, people with ID have the potential to benefit from lifestyle changes (with appropriate support)
that are addressed in lifestyle education programmes. However, the evidence base for diabetes prevention
relates to the general adult population; literature focusing on ID is scarce. Details of the key literature on
lifestyle behaviour change interventions aimed at modifying risk factors for T2DM and CVD in people with
ID are presented in the systematic review in Chapter 3.
Current evidence from studies conducted in the general population suggest that intensive multicomponent
lifestyle interventions aimed at weight loss, a healthy diet and increased physical activity can successfully
reduce the risk of diabetes by 30–60% in those with IGR, and are likely to be cost-effective in the long
term.54,70
Increasing physical activity is fundamental to diabetes prevention initiatives, as research suggests that
inactivity may have more impact than increased body weight in the development of insulin resistance.71
For both obesity management72 and prevention of T2DM,27 NICE recommends that lifestyle interventions
should be multicomponent, involving both dietary and physical activity advice, and incorporating behaviour
change techniques. However, at present there are no national prevention programmes that suitable for
people with ID, despite ongoing recommendations to make ‘reasonable adjustments’ to health-care
services to address inequities in provision.73
Education, exercise and leisure pursuits are often determined or influenced by carers (paid or family carers),
who may have a range of competing time demands and a number of people for whom to provide support.
For people with limited carer support, difficulties in understanding health risks could also influence motivation
to change lifestyles. Therefore, there is the potential for this group to benefit from the development of a
lifestyle education programme that is targeted at both people with ID and their carers in order to encourage
changes in lifestyle behaviours that could reduce the long-term chances of this high-risk group developing
diabetes.
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Concluding remarks
This chapter has provided the rationale and aims for the research programme, and an overview of the
programme of work undertaken. The next chapter presents a systematic review conducted to consolidate
the evidence on rates of T2DM, CVD and associated risk factors in adults with ID.
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Chapter 2 Systematic review and meta-analysis:
rates of type 2 diabetes, cardiovascular disease
and associated risk factors in populations with
intellectual disability
Overview
In this chapter, we describe the first of two systematic reviews carried out for the research programme.
We present the existing evidence in relation to the prevalence of T2DM, CVD and associated risk factors
among people with ID. We have used the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) checklist74 as a guide to reporting the methods and findings from the review.
Rationale
It is recognised in the literature that ID populations may be at increased risk of developing T2DM and
subsequent CVD through increased risk factors, such as obesity. The global increase in the prevalence of
obesity, CVD and T2DM, and current discrepancies between studies focusing on prevalence of such
conditions in those with ID, suggested a need for a systematic review of literature in this area.
Two recent reviews75,76 have focused on diabetes prevalence among people with ID. The reviews were unable
to distinguish between T2DM and other types of diabetes. Similarly, the prevalence of CVD among people with
ID is reported to be greater than that among the general population, but the overall prevalence is unclear.52
The overall aim of this component of the research programme was to consolidate the evidence for current
rates of T2DM, CVD and associated risk factors, restricting to population-based studies of adults with ID.
If sufficient data were available, we also intended to conduct a meta-analysis. A secondary aim was to
compare these data with the general population, when possible.
Objectives
The objectives of this review were to establish the prevalence of:
l T2DM in a population with ID
l CVD in a population with ID
l risk factors for T2DM and/or CVD (obesity, adverse lipid profiles, IGR and hypertension) in a population
with ID.
Methods
Protocol and registration
This systematic review was registered with the International Prospective Register of Systematic Reviews
(PROSPERO CRD42015019048).77
Eligibility criteria
The review was guided by the population, intervention, comparison, outcomes, study design (PICOS)
model.78 We defined the population as adults (aged ≥ 18 years) with ID (whole study population or a
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defined subsample). The items of interest were defined as T2DM, CVD and their associated risk factors.
Context was defined as population-based studies. We defined the outcomes as prevalence and/or
incidence rates (or data to enable this calculation). Study designs included cross-sectional, retrospective and
prospective cohort studies (Table 2).
All studies published since 1 January 2000 (until 21 April 2015) and in the English language were eligible.
We contacted lead authors for further information when inclusion/exclusion could not be determined.
We chose to limit studies to those published in and after the year 2000 so that the current prevalence of
T2DM and CVD could be estimated accurately; it is known that the prevalence of both of these conditions
has increased substantially in recent decades.
Information sources
For this review, we searched the databases EMBASE, MEDLINE and PsycINFO. The last date of the search
was 21 April 2015. We also searched the reference lists of relevant articles for possible additional studies.
Search
We combined medical subject heading terms and key words for T2DM, CVD, overweight/obesity,
hypertension, hyperlipidaemia, elevated glucose level/impaired glucose tolerance, metabolic syndrome and
ID (MEDLINE search strategy; Box 1). The search was limited to English-language studies with cohorts of
adults aged ≥ 18 years, depending on the database.
Study selection
Full texts were identified after titles and abstracts were read separately by two investigators (TC and AD)
who discussed discrepancies in selection at a later meeting. Only full-length articles were included; review
TABLE 2 Inclusion and exclusion criteria for systematic review of prevalence and risk factors
PICOS elements Inclusion criteria Exclusion criteria
Population Whole study population or defined subsample
of adults (aged ≥ 18 years)a
Restrictively selected cohort, based on outcome
(e.g. all of the participants were obese at time
of data collection)
Items of interest T2DM/diabetes
CVD (atherosclerotic)
Overweight/obesity
Hypertension
Hyperlipidaemia
Elevated glucose level/IGR
Metabolic syndrome
Context Population-based studies
Outcomes Prevalence
Incidence
Study designs Cross-sectional
Retrospective cohort
Prospective cohort
a Because the focus of the review was to obtain prevalence rates that were generalisable to the adult population with ID
as a whole, studies with > 20% aged < 18 years, > 20% with a disability other than ID and > 25% with a specific ID
were excluded.
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BOX 1 Search strategy for MEDLINE electronic database
1. exp Diabetes Mellitus, Type 2/
2. (diabet* adj3 type adj ‘2’).ti,ab.
3. T2DM.ti,ab.
4. (diabet* adj3 type adj ii).ti,ab.
5. niddm.ti,ab.
6. (non-insulin-dependent adj2 diabet*).ti,ab.
7. (adult-onset adj2 diabet*).ti,ab.
8. Or/1–7
9. exp Hypertension/
10. hypertens*.ti,ab.
11. (blood adj pressure adj3 (high or elevated or increased or raised)).ti,ab.
12. or/9–11
13. exp Metabolic syndrome x/
14. (metabolic adj syndrome).ti,ab.
15. (cardiometabolic adj syndrome).ti,ab.
16. (Insulin adj resistance adj syndrome).ti,ab.
17. MetSyn.ti,ab.
18. MetS.ti,ab.
19. or/13-18
20. exp. Hyperlipidemias/
21. Hyperlipid*.ti,ab.
22. dyslipid*.ti,ab.
23. hypercholes*.ti,ab.
24. hypertriglycer*.ti,ab.
25. (cholesterol* adj2(high or elevated or raised or increased)).ti,ab.
26. (triglcerid* adj2(high or elevated or raised or increased)).ti,ab.
27. (lipid adj profile adj2(adverse or abnormal)).ti,ab.
28. or/20-27
29. exp. Glucose intolerance/
30. (impaired adj glucose adj(tolerance or regulation)).ti,ab.
31. (impaired adj fasting adj glucose).ti,ab.
32. IGT.ti,ab.
33. IFG.ti,ab.
34. IGR.ti,ab.
35. exp Prediabetic state/
36. prediabet*.ti,ab.
37. pre-diabet*.ti,ab.
38. or/29–37
39. (cardiovascular adj diseas*).ti,ab.
40. CVD.ti,ab.
41. CHD.ti,ab.
42. exp. MI/
43. (infarct* adj2 myocardial).ti,ab.
44. exp Coronary disease/
45. (coronary adj2 diseas*).ti,ab.
46. (acute adj coronary adj syndrom*).ti,ab.
47. exp angina pectoris/
48. angina.ti,ab.
49. exp myocardial ischemia/
50. (isch* adj2 heart adj2 diseas*).ti,ab.
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51. (Myocardial adj2 isch*).ti,ab.
52. exp. Stroke/
53. strok*.ti,ab.
54. (cerebrovascular adj2 diseas*).ti,ab.
55. (cerebrovascular adj2 accident*).ti,ab.
56. (cerebral adj2 diseas*).ti,ab.
57. (cerebral adj2 accident*).ti,ab.
58. CVA.ti,ab.
59. TIA.ti,ab.
60. (brain adj1 infarc*).ti,ab.
61. (brainstem adj1 infarc*).ti,ab.
62. exp ischemic attack, transient/
63. (isch* adj2 attac* adj2 transient).ti,ab.
64. exp Atherosclerosis/
65. atheroscle*.ti,ab.
66. (arteriosclerotic adj vascular adj diseas*).ti,ab.
67. exp Peripheral Arterial Disease/or exp Peripheral Vascular Diseases/
68. (peripheral adj2 arter* adj2 diseas*).ti,ab.
69. (peripheral adj2 vascular adj2 diseas*).ti,ab.
70. (peripheral adj1 angiopath*).ti,ab.
71. or/39-70
72. exp obesity/
73. obes*.ti,ab.
74. overweight.ti,ab.
75. (body adj weight adj2 (high or elevated or increase*)).ti,ab.
76. (bodyweight adj2 (high or elevated or increase*)).ti,ab.
77. (body adj mass adj3 (high or elevated or increase*)).ti,ab.
78. (waist adj2 (large or elevated or increas*)).ti,ab.
79. exp body mass index/
80. (BMI adj2 (high or elevated or increase*)).ti,ab.
81. or/72-80
82. exp Intellectual disability/
83. (learning adj1 disabilit*).ti,ab.
84. (developmental adj1 disabilit*).ti,ab.
85. (intellectual adj1 disabilit*).ti,ab.
86. (impair* adj2 intellectual adj2 function*).ti,ab.
87. (mental* adj1 impair*).ti,ab.
88. (mental* adj1 handicap*).ti,ab
89. exp mentally disabled persons/
90. (mental* adj1 disabl*).ti, ab
91. (mental* adj2 retard*).ti, ab
92. Or/82-91
93. 8 or 12 or 19 or 28 or 38 or 71 or 81
94. 92 and 93
95. limit 94 to yr=2000-current
96. limit 95 to English language
97. (animals not humans.mp) [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier]
98. 96 not 97
BOX 1 Search strategy for MEDLINE electronic database (continued)
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articles were removed after being examined for references. Once we had retrieved the full texts of the
articles, these were examined separately (by TC and AD) to check their suitability for inclusion.
Data collection process
We designed a data extraction form specifically for this review. Data were extracted by one investigator
(TC) and verified for accuracy by another investigator (AD).
Data items
For each study, the first author’s name, title of the paper, year of publication, country of the cohort, study
type, sampling method, dates of data collection and inclusion/exclusion criteria were extracted. We also
extracted total sample size or subpopulation size, mean ages, proportion of male/female, severity of ID and
ethnicity. For each of the outcomes, we also extracted how it was defined, how it was measured and the
total number, and proportion, of people for whom it was measured. We extracted data separately for males
and females, when reported. When framing the research question and designing the search strategy, we did
not consider physical activity/sedentary behaviour, dietary factors or smoking; however, we extracted this
information for studies that reported it. We also extracted information on general population data.
Risk of bias in individual studies
We used funnel plots79 and the Egger’s test80 to examine potential publication bias in the literature for the
outcomes T2DM, ischaemic heart disease, obesity, hypertension and undefined CVD.
Summary measures
The main outcome measure for the meta-analysis was the prevalence of T2DM and CVD. The secondary
outcome measures were the prevalence of:
l overweight/obesity
l hypertension
l hyperlipidaemia
l elevated glucose level/impaired glucose tolerance
l metabolic syndrome.
Synthesis of results
Owing to the variation in reporting of outcomes, we extracted descriptions and definitions of each outcome
for analytic purposes and subcategorised for meta-analyses. We subcategorised circulatory disease outcomes
as ischaemic heart disease, cerebrovascular disease and undefined CVD. We subcategorised diabetes
outcomes as T2DM and pooled diabetes. BMI outcomes were labelled as obese (BMI of > 30 kg/m2) and
overweight (BMI of 25–29.9 kg/m2). In some articles, overweight and above (BMI of > 25 kg/m2) was used as
an outcome. We combined papers reporting both obese and overweight data to create an overweight and
above outcome. The outcome definitions can be seen in Appendix 3 (see Table 60).
Owing to the large amount of variability between studies, we used a random-effects model to pool the point
prevalence for each outcome. We conducted a secondary meta-analysis including data from a subset of
10 papers,81–90 which additionally reported general population comparison data (from the same population
and time period). We assessed heterogeneity using the I2 test.80
Additional analysis
After the meta-analysis, metaregression was used to determine if study characteristics could explain
heterogeneity (as measured using the I2 test). These study characteristics were severity of ID, mean age
and method of data collection (self-/carer reported, researcher collected, retrospective records/database).
We conducted all of the analyses using Stata® statistical software, version 14 (StataCorp LP, College
Station, TX, USA). Significance was set at the 5% level (p < 0.05) and 95% CIs are presented throughout.
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Results
Study selection
In total, we identified 4513 articles via the literature searches. After duplicates were removed, 3645 articles
remained to be screened. We reviewed the full texts of 148 articles once seven articles from other sources
had been added (Figure 3). The authors of seven studies91–97 were contacted for information regarding
their studies; five authors replied and two studies94,95 were deemed suitable to be included in the systematic
review and meta-analysis. We also included a study93 by one of the authors who did not reply, after we
had reread and discussed the article collectively in more depth.
After review, 62 articles50,81–90,93–95,98–145 were included. Four of these articles90,102–104 reported findings from
the same study and a further two articles109,125 reported findings from the same study, leaving 58 studies
(see Table 3) remaining for the final systematic review and meta-analysis.
Study characteristics
The 58 studies included in the quantitative synthesis presented data on > 47,000 individuals. The characteristics
of each of the studies are presented in Table 3.
Records identified through
database searching
(n = 4513)
Records screened
(n = 3645)
Records excluded
(n = 3504)
Full-text articles assessed
for eligibility
(n = 148)
Articles included in
qualitative synthesis
(n = 62)
Studies included in
quantitative synthesis
(n = 58)
Full-text articles excluded,
with reasons
(n = 86)
• < 80% of population/subgroup with
   ID, n = 21
• > 25% of population with a specific 
   syndrome, n = 5
• Population aged < 18 years, n = 3
• No reported outcomes, n = 12
• No extractable data, n = 21
• Not a population-based 
   study/population selected based on
   outcome, n = 14
• Study was a case study, n = 1
• Not published in English, n = 3
• Study involved exact duplication of 
   data from another paper, n = 6
Additional full-text articles/
already known to authors
(n = 7)
Duplicates removed
(n = 868)
4 articles reported on same study
2 articles reported on same study
FIGURE 3 Study selection.
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Ten of the studies81–89,102,103 included in the systematic review also presented as general population
comparison data for inclusion in the secondary meta-analysis.
The studies represented 23 countries on five continents. One study109 covered 14 European countries.
Most studies were conducted in the USA/Canada (n= 1783,84,86–88,93–95,110,112,114,117–119,133,136,137). The remaining
studies were conducted in Europe [the Netherlands (n= 781,85,102,123,139,140,145), the UK (n= 950,82,89,105–107,124,128,135),
France (n= 298,130), Norway (n= 1111) and Ireland (n= 2126,127)], Israel (n= 1129), Asia (n= 1089,100,101,113,120–122,142–144),
Australia/New Zealand (n= 6108,115,116,132,138,141) and South Africa (n= 2131,134). Primarily, the included studies were
cross-sectional observational (n= 3181,82,98,100–102,104,106,109–111,114,116,119,121,124,126–135,137,139,142,143,145). The remaining
studies involved retrospective database or medical records data (n= 2283–89,94,95,99,107,113,115,117,118,120,122,123,136,138,140,141)
or secondary data analysis (n= 550,93,105,112,144).
All studies were published in the years 2000–15. The average mean age of participants was 42.8 years,
with an average mean age range of 23.3–65.5 years. The average mean percentage of male participants
was 52.4%. The number of people included in the studies ranged from 25 to 8911, with a mean of 824.
Risk of bias within studies
The funnel plots did not show any obvious asymmetry, and Egger’s test was not statistically significant for
any of the outcome measures (specifically T2DM, t = –0.22; p = 0.84; ischaemic heart disease, t = –0.13;
p = 0.91; cerebrovascular disease, t = 0.35; p = 0.58) (see Appendices 4–6, Figures 27–29, for funnel plots).
Results of individual studies and synthesis of results
Prevalence of type 2 diabetes
Figure 4 shows the individual studies reporting on the prevalence of T2DM and overall pooled prevalence.
The prevalence estimates ranged from 2%84 to 13%.90 The pooled prevalence of T2DM was 7.6%.
The prevalence of any diabetes was 8.7%; this ranged from 2%84 to 11%95,102,117 (data not presented).
Prevalence of cardiovascular disease
Figure 5 shows the individual studies reporting on the prevalence of ischaemic heart disease. The prevalence
estimates for ischaemic heart disease ranged from 0%140 to 12%.126 The pooled prevalence of ischaemic
heart disease was 3.7%.
Author (year) ES (95% CI) % weight
Merrick et al. (2004)129 0.07 (0.03 to 0.11) 54.03
Henderson et al. (2008)84 0.02 (–0.17 to 0.21) 2.25
Frighi et al. (2011)106 0.05 (–0.08 to 0.18) 4.69
Haider et al. (2013)108 0.07 (0.01 to 0.13) 21.30
de Winter et al. (2015)90 0.13 (0.06 to 0.19) 17.72
Overall (I2 = 0.0%; p = 0.621)
Note: weights are from random-effects analysis
0 0.03 0.06 0.09
Pooled prevalence
0.12 0.15
0.08 (0.05 to 0.11) 100.00
FIGURE 4 Individual studies and pooled prevalence of T2DM. ES, effect size.
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Similarly, Figure 6 shows the individual studies reporting on the prevalence of cerebrovascular disease.
The estimates were fairly consistently in the < 1–4% range. The pooled prevalence of cerebrovascular
disease was 2.2%. The pooled prevalence for undefined CVD was 10.6%, but ranged by individual study
from 4%143 to 22%,114 reflecting the diverse case definitions.
Author (year) ES (95% CI) % weight
McDermott et al. (2006)86 0.02 (–0.06 to 0.10) 10.90
Van den Akker et al. (2006)140 0.00 (–0.09 to 0.10) 7.55
de Winter et al. (2009)81 0.01 (–0.08 to 0.10) 8.21
Tyler et al. (2010)88 0.03 (–0.02 to 0.09) 22.63
Chen et al. (2011)101 0.08 (–0.10 to 0.25) 2.18
Haveman et al. (2011)109 0.02 (–0.04 to 0.07) 22.00
Lee et al. (2011)115 0.02 (–0.13 to 0.18) 2.86
Jansen et al. (2013)85 0.02 (–0.07 to 0.10) 8.95
McCarron et al. (2013)126 0.12 (0.05 to 0.19) 14.72
Overall (I2 = 0.0%; p = 0.497)
Note: weights are from random-effects analysis
0 0.030.06 0.09
Pooled prevalence
0.12 0.15
0.04 (0.01 to 0.06) 100.00
FIGURE 5 Individual studies and pooled prevalence of ischaemic heart disease. ES, effect size.
Author (year) ES (95% CI) % weight
McDermott et al. (2006)86 0.00 (–0.08 to 0.08) 10.57
Van den Akker et al. (2006)140 0.01 (–0.09 to 0.10) 7.49
de Winter et al. (2009)81 0.02 (–0.07 to 0.11) 8.21
Haveman et al. (2011)109 0.02 (–0.04 to 0.07) 21.69
Wong (2011)143 0.02 (–0.05 to 0.09) 14.14
Haider et al. (2011)108 0.02 (–0.04 to 0.08) 15.61
McCarron et al. (2013)126 0.03 (–0.04 to 0.10) 13.23
Overall (I2 = 0.0%; p = 0.999)
Note: weights are from random-effects analysis
0 0.02
Pooled prevalence
0.02 (–0.01 to 0.05) 100.00
Jansen et al. (2013)85 0.04 (–0.04 to 0.13) 9.07
0.04 0.06 0.08
FIGURE 6 Individual studies and pooled prevalence of cerebrovascular disease. ES, effect size.
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Prevalence of other risk factors
Table 4 summarises the findings from the individual meta-analyses. The overall estimated prevalence of
hypertension was 18.5%. The estimated prevalence of overweight was 29.2%, the prevalence of obesity
was 27.3% and the prevalence of BMI of ≥ 25 kg/m2 was 53.4%.
On making comparisons with the general population, we found that the population with ID had decreased
odds of having ischaemic heart disease [odds ratio (OR) 0.44, 95% CI 0.34 to 0.58; p < 0.01]. No other
statistically significant results were found, but we observed high heterogeneity for the other outcomes
(Table 5).
Risk of bias across studies
We found high heterogeneity in a number of outcomes when prevalence was pooled (see Table 4), as well
as in a number of outcomes for the general population comparison (see Table 5). We further explored
heterogeneity using metaregression (see below).
TABLE 4 Point prevalence for outcome measures in the ID population
Outcome Study, n Total, N Total n with outcome Pooled estimate (95% CI) I2 (%)
Ischaemic heart disease 9 5586 200 0.04 (0.01 to 0.06) 0
Cerebrovascular disease 8 5748 114 0.02 (0.00 to 0.05) 0
Undefined CVD 8 7773 881 0.10 (0.05 to 0.15) 77.5
T2DM 5 4183 317 0.08 (0.05 to 0.11) 0
Any diabetes 23 19,133 1636 0.09 (0.07 to 0.10) 0
Hypertension 28 17,161 3008 0.19 (0.13 to 0.24) 93.2
Overweight 32 24,923 7434 0.29 (0.26 to 0.33) 89.5
Obese 35 27,274 7741 0.27 (0.23 to 0.32) 93.6
Overweight and above 41 31,172 16,525 0.53 (0.49 to 0.58) 96.4
Hypercholesterolaemia 9 3892 491 0.17 (0.08 to 0.26) 86.9
Metabolic syndrome 3 821 287 0.23 (0.00 to 0.50) 91.7
Negative CIs have been rounded up to 0.00.
TABLE 5 Findings from the general population comparison meta-analysis
Outcomes Study, n ID total, N
ID total, n
with outcome GP total, N
GP total,
n with
outcome OR (95% CI) I2 (%)
Ischaemic
heart disease
3 2395 67 5441 335 0.44 (0.34 to 0.58)* 0
Any diabetes 6 4014 411 13,404 1371 0.96 (0.61 to 1.5) 92.2
Hypertension 6 3588 1097 14,262 4598 0.76 (0.58 to 0.99) 86.9
Overweight 4 1487 477 17,819 5986 1.31 (0.47 to 3.66) 96.5
Obese 7 3838 1004 23,230 6824 1.09 (0.65 to 1.82) 95.3
*p < 0.01.
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Discussion
Summary of evidence
In this systematic review, we found that the prevalence of T2DM was 8% and of any diabetes was 9%.
For CVD, the prevalences of ischaemic heart disease, cerebrovascular disease and undefined CVD were
4%, 2% and 10%, respectively.
The current prevalences of T2DM and CVD and associated risk factors in the population with ID were
found to be similar to those in the general population. However, we found that ischaemic heart disease
was significantly lower in the ID population. The metaregression showed that the method of data
collection had minor effects on pooled diabetes and obesity. Mean age had minor effects on hypertension.
Strengths and limitations
A particular strength of this review is that we used robust methods. We wrote to authors to clarify and
obtain additional data rather than excluding the articles. To our knowledge, this is the first systematic
review and meta-analysis of prevalence of T2DM, CVD and associated risk factors in adults with ID.
In addition, it is the first review of its kind to make comparisons with the general population.
However, we had limited data to separate T2DM from other diabetes, and we were sometimes restricted
to unclear or poorly defined outcome measure definitions.
There were also limited data available to make comparisons with the general population. We would have
benefited from additional general population data alongside the population with ID data to make more
valid, generalisable comparisons.
Findings in relation to other studies
Two recent reviews75,76 have been conducted that have focused on diabetes prevalence among people
with ID. The reviews found mean prevalences of 8.7%75 and 8.3%76 for combined gestational, type 1
diabetes mellitus and T2DM, respectively, but the reviews were unable to report on specific types of
diabetes. The overall prevalence of CVD among people with ID is unclear.52 However, our finding that
ischaemic heart disease was significantly lower in the population with ID differs somewhat from the
literature, which suggests that the prevalence of CVD among people with ID is greater than the
general population.52
Conclusions
Findings from the systematic review and meta-analysis presented in this chapter suggest that T2DM
is at least as common in people with ID as in the general population. The findings also identify a gap
in knowledge in relation to the prevalence of T2DM as many studies did not report this separately.
In addition, none of the studies in our review reported on screen-detected T2DM in the population
with ID.
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Chapter 3 Systematic review of the effectiveness
of multicomponent behaviour change interventions
aimed at reducing modifiable risk factors
Overview
In this chapter, we describe the second of two systematic reviews conducted as part of the research
programme. We present the existing evidence in relation to multicomponent behaviour change
interventions that modify risk factors for T2DM and CVD in people with ID. The PRISMA checklist74 has
been used to guide the reporting of this systematic review.
Rationale
Non-communicable diseases are on the rise globally and there is increasing demand for lifestyle behaviour
change interventions to reduce morbidity, mortality and rising health costs.146 The suggested mechanisms
for this rise are increased availability of energy-rich foods and more sedentary lifestyles.147 T2DM and CVD,
and shared associated risk factors, are major contributors to morbidity and mortality.148
Conditions such as CVD and T2DM share similar risk factors, including dyslipidaemia, hypertension, obesity
and IGR. In the general population, these risk factors can be effectively lowered through interventions
focusing on changes in nutrition and physical activity.149–151 With a suggested increased risk of non-
communicable diseases within populations with ID, special attention needs to be paid to the efficacy and
effectiveness of multicomponent behaviour change interventions to reduce this disparity. However, there is
a lack of quality evidence on the health and health care of people with ID, including the effectiveness of
health interventions.152 Previous systematic reviews of lifestyle behaviour change interventions in ID153–155
have generally been unable to make specific recommendations because of inadequacies in study design
and conduct, a lack of theory basis for intervention and/or unclear reporting.
For the current review, we aimed to consolidate the evidence for the reduction of risk of T2DM and/or
CVD through the delivery of multicomponent behaviour change interventions in the population with ID.
Objectives
The objectives were to establish the effectiveness of multicomponent behaviour change interventions:
l in promoting weight loss in the population with ID
l in reducing other modifiable risk factors for T2DM and/or CVD in the population with ID
l aimed at primary prevention of T2DM or CVD, or reducing associated risk factors in the population
with ID.
Methods
Protocol and registration
The systematic review was registered with the International Prospective Register of Systematic Reviews
(PROSPERO 2015: CRD42015020758).156
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Eligibility criteria
The review was guided by the PICOS model.78 We defined the population as adults (aged ≥ 18 years) with
ID (whole study population or a defined subsample). We defined the intervention as any multicomponent
lifestyle behaviour change intervention aimed at primary prevention of T2DM or CVD, or a reduction in
associated risk factors for people with ID and/or their carers. We included studies with and without
comparison groups. We defined outcome measures as changes in anthropometric measures (weight, BMI,
waist circumference), BP, lipid levels, glucose levels, physical activity levels, sedentary behaviour and dietary
habits. The study design was defined as an experimental study [before-and-after study, randomised
controlled trial (RCT) or non-RCT] with a follow-up period of at least 24 weeks or 6 months from baseline
(to allow for the initiation and maintenance of medium- and longer-term behaviour change)157 (Table 6).
All studies that had been published on or after 1 January 2000 (until 21 April 2015) and in the English
language were eligible. Studies were limited to those published in or after the year 2000, when most large
diabetes prevention trials were first published in the general population.70
We contacted lead authors for further information when inclusion/exclusion could not be determined.
Information sources
We searched the electronic databases EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health
Literature, Cochrane Central Register of Controlled Trials and PsycINFO for this systematic review. The last
date of the search was 21 April 2015. We searched the references lists of relevant systematic reviews and
included papers within those for additional studies.
Search
We combined medical subject heading terms and key words for multicomponent lifestyle interventions and
outcome measures and ID. The search was limited to English-language studies with cohorts of adults aged
≥ 18 years, depending on the database. Box 2 shows the MEDLINE search strategy.
Study selection
Full texts were identified after titles and abstracts were read separately by two investigators (TC and AD),
who discussed discrepancies in selection at a later meeting.
TABLE 6 Inclusion and exclusion criteria of studies included in the systematic review of multicomponent lifestyle
behaviour change interventions
PICOS elements Inclusion criteria Exclusion criteria
Population Whole study population or defined subsample
of adults (aged ≥ 18 years)a
Intervention Multicomponent lifestyle behaviour change
intervention aimed at primary prevention of
T2DM or CVD, or a reduction in associated
risk factors (weight management, increasing
physical activity/reducing sedentary behaviour,
dietary improvement)
Interventions involving meal replacements or those
aimed at increasing physical fitness (in isolation) as
opposed to changes in levels of physical activity
Comparison Studies without comparison groups were
included
Outcomes Changes in anthropometric measures
(e.g. weight, BMI, body fat, waist
circumference), BP, lipid levels, physical
activity, sedentary behaviour, dietary habits
Study designs Before-and-after study, RCT, non-RCT Follow-up period of < 24 weeks/< 6 months from
baseline
a For generalisability to the adult population with ID as a whole, studies with > 20% aged < 18 years, > 20% with a
disability other than ID and > 25% with a specific ID were excluded.
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After retrieval of the full-text articles, the papers were again examined separately by two investigators
(TC and AD) to check their suitability for inclusion.
Data collection process
We created a data extraction form for this review. The data were extracted by one investigator (TC) and
verified for accuracy by another investigator (AD).
Data items
For each study, we collected the first author’s name, title of paper, year of publication, country of the
cohort, study design, sampling method, intervention details, dates of data collection and the intended
recipient of the intervention. For the whole study population (and for each group, if applicable), we
extracted data on total sample size or subpopulation size, mean ages, proportion of males/females, severity
of ID, ethnicity and withdrawals.
For each reported outcome, we extracted information on how outcomes were defined and measured, the
total number measured for each outcome, length of follow-up, mean baseline and post-intervention value,
BOX 2 Search strategy for MEDLINE electronic database
1. (Behav* adj1 (Modif* or therap*)).ti,ab.
2. Cognitive* therap*.ti,ab.
3. (Health* adj2 (Educat* or promot* or behav*)).ti,ab.
4. Educat* adj2 program*.ti,ab.
5. (Diet* adj2 (Intervention* or modif* or therap*)).ti,ab.
6. (Health* adj2 Eating).ti,ab.
7. (Nutrition* adj2 (intervention* or modif* or counsel* or therap*)).ti,ab.
8. (Exercis* adj2 (intervention* or therap*)).ti,ab.
9. (Physical adj (education or fitness or activit* or training or exercise)).ti,ab.
10. (Lifestyle adj2 (advice or guidance or modif* program* or interven*)).ti,ab.
11. (Weight adj2 (control* or los* or reduc* or maintenance or management)).ti,ab.
12. Weight adj loss adj program*.ti,ab.
13. Exercise*.ti,ab.
14. Sport*.ti,ab.
15. exp Health Promotion/
16. exp Nutrition Therapy/
17. exp Exercise Therapy/
18. (Sedentary adj (behav* or lifestyle* or individual* or population*)).ti,ab.
19. or/1-18
20. exp Intellectual disability/
21. ((learning or development* or intellectua* or mental*) adj1 disabilit*).ti,ab.
22. (impair* adj2 intellectual adj2 function*).ti,ab.
23. (mental* adj1 (impair* or handicap*)).ti,ab.
24. Exp mentally disabled persons/
25. (mental* adj2 retard*).ti,ab.
26. Or/20–25
27. 19 and 26
28. animal/not (animal/and human/)
29. 27 not 28
30. limit 29 to english language
31. limit 30 to yr=2000-current
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mean between-group change and/or change baseline to follow-up along with a measure of variability
[standard deviation (SD), standard error (SE), etc.]. We extracted data separately for males and females,
when reported.
Quality assessment
The NICE quality appraisal checklist for quantitative intervention studies158 was used to assess the quality
of the selected studies. The checklist included criteria for assessing the internal and external validity of
experimental and observational quantitative studies (RCTs, non-RCTs, before-and-after studies) and
allowed assignment of an overall quality grade (categories ++, + or –). Studies were assessed by one
reviewer (TC) and verified for accuracy by a second reviewer (RS).
Risk of bias in individual studies
Prior to carrying out this systematic review, we anticipated using funnel plots79 and the Egger’s test80 to
examine potential publication bias in the literature for the collected outcomes. However, owing to the
small number of studies included in this review resulting in low power to detect bias, these methods were
not used.
Data synthesis
Data synthesis for this review involved describing the study characteristics (country, population size, age,
percentage male, ethnicity, severity of ID, eligibility criteria, outcomes report and follow-up period) of the
included articles. We then described the details and behavioural strategies of each of the multicomponent
lifestyle behaviour change interventions, including their structure and delivery, and the underlying theory
behind each of the interventions. Finally, we described the outcome measures and study findings. Given
the low number of studies included, a formal evidence synthesis was not undertaken.
Results
Study selection
The literature searches yielded 3508 articles. After duplicates were removed, 3167 articles remained to be
screened. We retrieved and reviewed the full text of 39 articles for 32 studies (Figure 7). Most potentially
Records identified through
database searching
(n = 3508)
Records screened
(n = 3167)
Records excluded
(n = 3128)
Full-text articles assessed
for eligibility
(n = 39; 32 individual studies)
Studies included in review
(n = 4)
Full-text articles excluded, with reasons
• Not a multicomponent lifestyle intervention, 
   n = 9
• Follow-up of < 24 weeks or 6 months, n = 7
• No reported outcomes, n = 5
• Paper was a protocol, n = 4
• < 80% of population/subgroup had ID, n = 2
• No extractable data, n = 1
• Secondary reporting, n = 7
Duplicates removed
(n = 341)
FIGURE 7 Study selection.
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relevant studies were noted to have small sample size, short follow-up, high attrition rates and/or
incomplete data for key outcomes. We contacted the authors of four study protocols159–162 for further
information. One of the authors did not reply, and we were informed by the remaining three that their
study results were still awaiting publication and could not be included in the review. In total, we identified
only four studies163–166 for inclusion in this review.
Study characteristics
The four studies163–166 included in the systematic review presented data on 700 individuals. The characteristics
of each of the studies163–166 are presented in Table 7.
The studies163–166 covered three countries (USA, UK and Sweden). Two studies163,164 were single arm, and
two studies165,166 had a control group. All of the four studies163–166 reported data for physical activity and/or
sedentary behaviour.
The mean age was 42.2 years and the mean percentage of male participants was 42.9%. The mean
group size was 174 before dropout and 104 after dropout. Group sizes ranged from 54 to 443 before
dropout, and from 44 to 196 after dropout. The majority of participants were white (68% where known);
approximately one-quarter (26%) were black and the remaining 7% were from other ethnic groups. Only
one study164 provided information on severity of ID, but, based on eligibility criteria, the remaining studies
were likely to comprise adults in the mild to moderate ID range. Other descriptive information for each
study is presented in Table 7.
Study quality
A breakdown of study quality is presented in Table 8. The studies163–166 were generally of high quality;
in particular, all of the studies achieved at least a good quality rating for internal and external validity.
However, two163,165 of the four studies failed to account for all of the participants when concluding the
study, and three163–165 of the four studies did not report on whether or not the studies were sufficiently
powered to detect differences.
Results of individual studies and descriptive data synthesis
Table 9 summarises the multicomponent lifestyle behaviour change interventions evaluated in the
individual studies.
Bazzano et al.163 conducted a single-arm before-and-after intervention in already overweight or obese
individuals (BMI of ≥ 25 kg/m2). The intervention involved peer mentoring, one-to-one health education,
supervised physical activity and clinical support aimed at reducing weight, improving diet and increasing
physical activity.
Melville et al.164 also conducted a single-arm study in already-obese individuals (BMI of ≥ 30 kg/m2) who
had been referred to a dietitian by their GP. Nine lessons, every 2–3 weeks, were provided for participants
and their carers. The lessons were aimed at increasing physical activity and better diet, as well as weight
loss. Interventions also consisted of personalised diet plans with calorie restrictions [600 kilocalories (kcal)
per day].
Bergström et al.166 conducted a two-armed trial in community residential homes, targeting both people
with ID and their carers. The intervention offered a ‘study circle’ for carers and also an appointed health
ambassador at each residential home. An educational health course for the residents was also provided.
The community residences in the control arm received the option to take part in the intervention after
study completion (wait list control). The primary outcome for this trial was increasing physical activity;
the secondary outcomes were decreasing weight and BMI.
Finally, McDermott et al.165 conducted a two-arm RCT. Intervention participants were assigned to eight
weekly lessons in nutrition, exercise and changing ways of thinking. The lessons focused on stress
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TABLE 8 Quality assessment of articles included in the systematic review
Section
Bazzano
(2009)163
Melville
(2011)164
McDermott
(2012)165
Bergström
(2013)166
1. Population
Source population/area well described? + ++ ++ ++
Eligible population/area representative of source population/area? ++ + ++ ++
Selected participants/areas represent eligible population? + ++ ++ +
2. Method of allocation to intervention (or comparison)
Allocation to intervention (or comparison). Was selection bias
minimised?
NA NA ++ ++
Interventions (and comparisons) well described and appropriate? ++ ++ ++ ++
Was allocation concealed? NA NA NR ++
Participants or investigators blind to exposure and comparison? NA NA NA NA
Exposure to intervention appropriate? ++ ++ ++ ++
Contamination acceptably low? NA NA ++ ++
Other interventions similar in both groups? NA NA ++ ++
Participants accounted for at study conclusion? – ++ – ++
Did setting reflect usual UK practice? ++ ++ ++ ++
Did intervention or control comparison reflect usual UK practice? ++ + + ++
3. Outcomes
Outcome measures reliable? + + ++ +
All outcome measurements complete? ++ ++ + –
All important outcomes assessed? ++ ++ ++ ++
Outcomes relevant? ++ ++ ++ +
Similar follow-up times in exposure and comparison groups? NA NA ++ +
Follow-up time meaningful? + ++ ++ ++
4. Analyses
Exposure and comparison groups similar at baseline? If not,
were these adjusted?
NA NA NR ++
ITT analysis conducted? – – ++ ++
Sufficiently powered to detect an intervention effect (if one exists)? NR NR NR ++
Estimates of effect size given or can be calculated? NR ++ ++ +
Analytical methods appropriate? + – ++ +
Precision of intervention effects given or able to be calculated?
Were they meaningful?
+ ++ ++ ++
5. Summary
Study results internally valid? (i.e. unbiased) + + ++ +
Findings generalisable to the source population? (i.e. externally valid) ++ + ++ +
ITT, intention to treat; NA, not applicable; NR, not reported.
++, all of the quality assessment checklist criteria were fulfilled.
+, some of the quality assessment checklist criteria have been fulfilled.
–, few or none of the quality assessment criteria were fulfilled.
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management, complications of obesity and behaviour management. The classes emphasised MVPA,
healthy eating and BMI reduction. The control group was assigned to eight weekly lessons on safety
and hygiene.
Table 10 summarises the components of the individual behaviour change interventions. All of the
interventions used both dietary and exercise components.
TABLE 10 Individual components of the interventions evaluated
Component Bazzano (2009)163 Melville (2011)164
McDermott
(2012)165
Bergström
(2013)166
Dietary
Energy restriction 600 kcal/day
Weight loss target 5% of initial body
weight
Nutrition advice ✓ ✓
Try healthy foods in session ✓ ✓ ✓
National recommendations ✓
Healthy dietary habits ✓
Portion sizes ✓
Individualised diet plan 50% carbohydrates
< 35% fats
< 20% protein
Individualised diet goals Set one goal per week
Exercise
Individualised exercise goals Walking targets (using
pedometer)
Set one goal per week
Minimum 30 minutes
of moderate intensity
physical activity at least
5 days per week
Advice regarding time and
intensity
Advice on replacing
sedentary behaviour for
activities in the home
(e.g. housework)
Supervised activity in session 1 hour during each
session
Use of local parks
and fitness facilities
Exercise video
created by peer
mentors
Sessions followed
by optional brisk
walk
Physical activities
in sessions
Information provided
regarding local leisure
facilities
✓
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Of the four included studies,163–166 the two single-arm studies,163,164 with follow-ups of 7 months163 and
24 weeks,164 indicated significantly improved outcomes; reductions in weight, BMI and waist circumference
were demonstrated after the implementation of a behaviour change intervention programme aimed at
increasing physical activity and improving diet. Additionally, both studies163,164 demonstrated a significant
improvement in physical activity outcomes, specifically for ‘minutes per week’ and ‘frequency of sessions’163
and ‘reduction in sedentary behaviour’.164 Both cohorts163,164 were overweight to obese when they were
enrolled into the study. For the further two studies,165,166 for which the cohort was not recruited based on
health status, one of the studies166 showed significant positive improvements in waist circumference, BMI
and steps per day in those who received the intervention compared with the control subjects; the second
study165 did not show any significant differences between control and intervention arms (Table 11).165
TABLE 11 Reported data for included studies
Author and year BMI (kg/m2) Weight (kg)
Waist
circumference
(cm)
Vegetable intake
(servings per day)
Physical activity/
sedentary behaviour
Bazzano (2009)163
(a) Minutes per week;a
(b) sessions per weeka
Baseline 33.3, n = 44b 88, n= 44b 104.9, n= 39 2, n= 44 (a) 133; (b) 3.2; n = 44
Follow-up, 7 months
from baseline)
32.8, n = 44 86.8, n= 44 102.6, n= 39 2.2, n= 44 (a) 206.4; (b) 3.9; n= 44
Intervention group change –1.5%* –1.34%* –2.18%** 10% (a) 54.89%;**
(b) 21.88%**
Melville (2011)164
(a) Sedentary minutes
per day; (b) low physical
activity minutes per day;
(c) MVPA minutes per
day (accelerometer)
Baseline (SD) 40 (8.03),
n= 47
100.6 (26.8),
n = 47
122.1 (15.7),
n= 47
NR (a) 623.3 (121.5);
(b) 73.4 (46.8);
(c) 14.2 (17.5);
n= 45
Follow-up (24 weeks
from baseline) (SD)
39.2 (8.2),
n= 47
96.1 (26.9),
n = 47
115.8 (16.7),
n= 47
NR (a) 581.9 (116.4);
(b) 81.3 (45.6);
(c) 17.8 (17.3);
n= 33
Intervention group change –4.45%** –4.55%** –5.15%** NR (a) –6.64%;* (b) 10.76%;
(c) 25.42%
McDermott (2012)165
MVPA ratio: minutes
performed/minutes
worn (accelerometer)
Baseline (SD) 32.38 (6.85),
n= 437
NR NR NR 3.24 (3.93), n= 401
Follow-up, 12 months
from baseline) (SD)
32.13 (6.59),
n= 195
NR NR NR 4.62 (3.27), n= 118
Intervention group change –0.78% NR NR NR –4.18%
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Discussion
Summary of evidence
This review contributes to the existing knowledge on the effectiveness of multicomponent lifestyle
behaviour change interventions in adults with ID. Three of the interventions included in this review led to
some reductions in BMI, weight and waist circumference,163,164,166 but inferences are limited owing to small
sample sizes, missing data, selected populations and/or lack of control groups.
Strengths and limitations
To our knowledge, this is the first systematic review and meta-analysis focusing on long-term
multicomponent behaviour change interventions for people with ID in order to reduce CVD and/or T2DM
risk. We used robust methods and sought additional information from authors where relevant. However,
only four papers163–166 met our inclusion criteria. Significant findings were observed only for the single-arm
studies, which are known to overestimate effect sizes.168 We were unable to test for publication bias or to
carry out meta-analytical work to explore combined effects, particularly as the interventions that were
evaluated were so diverse. Similarly, research has shown that improvements in health can be difficult to
sustain in the longer term;169 only two of the included studies165,166 had a follow-up period of at least
12 months, and even this may not be enough to indicate long-term sustained benefits.
Findings in relation to other studies
In line with previous systematic reviews in this area,153–155 findings from this systematic review demonstrate a
lack of quality evidence on the effectiveness of multicomponent behaviour change interventions in people
with ID. In 2010, Jinks et al.153 focused a systematic review on qualitative studies of behavioural change
approaches in people with ID to aid weight loss and health. The review found 12 papers, of which only one
was qualitative. The authors noted an overall lack of research on behavioural approaches and using
qualitative methods. Similarly, in 2013, Spanos et al.154 reviewed 22 papers that assessed interventions for
weight loss in people with ID. They noted that many of the interventions did not meet the recommended
duration in clinical guidelines and were too specific. Brooker et al.155 also reviewed interventions with a
primary focus on physical activity in people with ID. Again, the review noted small sample sizes and invalid
measurement tools, and recommended further longer-term intervention studies.
TABLE 11 Reported data for included studies (continued )
Author and year BMI (kg/m2) Weight (kg)
Waist
circumference
(cm)
Vegetable intake
(servings per day)
Physical activity/
sedentary behaviour
Bergstrom (2013)166
Steps per day
(pedometer)a
Baseline (SD) 30 (7.6),
n= 126
NR 94.5 (16.5),
n= 124
1.4 (0.6), n = 101 8042 (5524), n = 99
Follow-up (12–16
months from baseline)
29.7,
n= 108
NR 92.8, n = 103 1.6, n= 66 9650, n= 69
Intervention group
change
–1%a NR –1.8%a 14.29% 19.99%*
*Significant, p< 0.05; **significant, p< 0.01.
NR, not reported.
a Self-/carer-reported data.
b Baseline characteristics of 24 people who did not complete the programme were not reported.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
Implications of findings
This systematic review informed the evidence base for the development of the STOP Diabetes educational
programme, which is described in Chapters 8 and 9. The studies also revealed a high rate of missing follow-up
data for participants who completed the multicomponent lifestyle behaviour change interventions, which
helped to inform further development work on feasibility testing (see Chapter 10). The wider implications for
research and practice are discussed in Chapter 13.
Conclusions
The findings from this systematic review have provided some evidence that multicomponent behaviour
change interventions may be beneficial in modifying risk factors for T2DM and CVD in people with ID.
However, there is a paucity of literature on their long-term effects in this population. In keeping with
existing recommendations,154 we highlight the need for robust RCTs to evaluate the long-term effects of
multicomponent behaviour change interventions, informed by current guideline recommendations, for
people with ID.
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Chapter 4 Service user involvement
Overview
This chapter details the service user involvement throughout the STOP Diabetes research programme.
Involvement was integrated into the research from the early stages.
Introduction
The involvement of service users in research is central to UK policies170,171 and is becoming increasingly
common, both nationally and internationally.172–175 The benefits of such involvement in health and social
care research are manifold. Service users can provide valuable knowledge and insights to research,176–181
encourage recruitment through publicity,177,179,180 improve quality, relevance and impact of research,182–186
and potentially help to meet recruitment targets.172 Service users in England contribute financially to
publicly funded research, so, arguably, have a right to be involved186,187 and can personally benefit from
their involvement.183,185,188 However, challenges to the successful involvement of service users in research
include contrasting priorities,183,189,190 understanding of research methods,189 use of language and jargon,189
and lack of time and resources.183,189
The involvement of people with ID in research can pose additional challenges to those outlined above and
include the need to plan ahead, allow time for effective communication and regular breaks, and ensure
that meeting locations are accessible to all.191–194 Such challenges can be at odds with researchers’ own
demands and priorities,195 and they often resort to seeking the proxy views of ‘sympathetic others’, such as
parents or carers,196 which is disappointing given that people with ID have a lot to say and can improve the
quality and relevance of research.195
Involvement prior to submitting the research proposal
Before submitting the research proposal, members of the team visited three local ID partnership boards to
discuss the study, invite feedback, discuss how adults with ID could be involved in the research process,
and advise on reasonable adjustments and practical considerations. The boards comprised a mix of
professionals and public members, including councillors, commissioners, clinicians, charity representatives,
police officers, family carers, paid carers and people with ID. The boards provided useful advice on tailoring
information sheets to service users (e.g. using pictures as well as text, using a larger font, and modifying
the size and colour of the paper for those with visual impairment) and on communication issues (e.g. using
a staged, step-by-step approach to delivering information). The team also began forming links with two
local self-advocacy groups for people with ID: both groups met at least monthly in a central location and
were led by an experienced facilitator whose role was to ensure that members understood what was being
discussed; they had every opportunity to give their views and contribute to the discussion, and only one
person spoke at a time.
Involvement during the research programme
Selection of service users for involvement
Service users were approached from different sources to encourage a diverse range of views and to
minimise burden. Members from the two self-advocacy groups approached the Speaking up for Health
Group and the Charnwood Action Group, who agreed to help the team with the study. In addition,
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the manager and residents of a communal care establishment were approached through the lead nurse’s
contacts, and they agreed to help us with the study. Service users who entered the poster competition
(see next section) were indirectly involved by providing publicity materials for the team (Figure 8).
Service user involvement in the programme management
A common way of involving service users in research is through representation in steering group
meetings,197 and we discussed the potential for this with the service users. We considered tailoring these
meetings to make them more accessible, but past experience suggested that they could be lengthy,
involving complex discussions about procedures, accelerometer data, health economics and statistical
methodologies, and often used conference call facilities. We were concerned that the meetings would be
isolating for the service users and their supporters so, instead, we agreed to feed back key points from the
meetings and that service users could attend on an ‘ad hoc’ basis.
Service user involvement in promoting the research programme
The study involved a Leicestershire-wide screening programme and it was important to promote the research
as widely as possible. Among other considerations, the study logo and publicity materials needed to be
suitable and appropriate for the target population. Both of the service user groups that we approached used
‘word police’ cards, which were shown whenever another member of the group or visitor used an acronym
or abbreviation that they did not understand. Therefore, the proposed use of an acronym for the programme
was not received favourably and, instead, the team opted to call the programme the ‘STOP Diabetes study’.
The creative director subsequently devised four corresponding logos (Figure 9) and asked the Charnwood
Action Group for their preference, using a feedback form with a scale and pictures. The preferred logo
(see Figure 9, option 4) was shown to the Speaking up for Health Group, and there was discussion about
ways in which the logo and other publicity materials, such as posters and fliers, could be used to publicise
the programme. Service users recommended printing the STOP Diabetes logo on notepads, pens and
fridge magnets. When directly asked, they also thought that the logo should be printed on the study
documentation, such as information leaflets and consent forms. Members of the group also suggested
holding a poster competition as a means of publicising the programme.
FIGURE 8 Service users involved in the research programme. Charnwood logo from Charnwood Action Group
Partnership Board.
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All of the ideas were collated and reported back to the research team for further discussion and to
determine if sufficient resources were available to action them. All of the suggestions were taken up by
the research team.
Service users were invited to enter the poster competition using brief easy-read information distributed by
staff at local day centres, health clinics and other organisations. People who entered the competition were
given a certificate and a small award of art and craft materials. Four of the pictures were chosen for the
promotional materials (Figure 10); this decision was made by both service users and members of the
research team.
The research programme was publicised via the Leicestershire Diabetes Centre website and was also published
in the National Institute for Health Research INVOLVE Summer 2013 newsletter,198 both as means of raising
awareness about the programme and sharing our experiences of service user involvement (Figure 11).
Similarly, having attended one of the programme steering group meetings, one of the co-chairpersons of the
Charnwood Action Group contacted the media and was consequently interviewed about the programme
(radio and newspaper199), which helped with recruitment.
Service user involvement in study documentation and process development
It was important that information about the programme should be available in simple language, free from
jargon and acronyms, and using pictures and symbols, so that potential participants had every opportunity
to understand what the research team were doing and reach an informed decision about whether or not
to take part. Prior to submission to the research ethics committee, the research team, with support from
local ID services, drafted an easy-read (symbols and words) information sheet and consent form to
partnership boards, local ID services and service user groups for feedback on the symbols, text and
whether or not additional communication aids might be necessary.
The service users who we asked to read the easy-read documents did not report any difficulties in
understanding them, but recommended additional modes of communication, such as flash cards and
story cards. A member of the Speaking up for Health Group assisted the team by taking photographs
to illustrate the information leaflet, flash cards and story cards; three service users modelled for the
photographs (Figure 12).
FIGURE 9 Proposed logos for the STOP Diabetes programme. Option 4 was the service users’ preferred logo.
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FIGURE 10 Some of the artwork submitted for the poster competition. The four pictures on the left were used for
the publicity materials.
FIGURE 11 Service users’ involvement in promoting the research programme. Image of article ‘Volunteers needed for
study’ reproduced with permission of Leicester Mercury. Copyright © 2016 Local World. All rights reserved. Image of
article ‘STOP Diabetes study’ reproduced with permission of INVOLVE. Copyright © INVOLVE. All rights reserved 2015.
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Service user involvement in staff recruitment
Research nurses were integral to successful recruitment to the study, needing to be patient, sensitive and
responsive to participants’ needs (e.g. seeing participants outside typical working hours), as well as able
to communicate effectively with people with ID. Two members from the Speaking up for Health Group
offered to help with the interview process for recruiting nurses into the research programme. Supported by
their group facilitator, they created two questions to assess how good the nurses were at communicating
with people with ID, and how they might adapt their style of communication if that person did not
understand them. On the day that the nurses were interviewed, the service users asked these questions in
a separate room, with the facilitator present. They then rated the nurses’ responses on a 4-point scale
(Figure 13). Their input helped to reinforce the panel’s decision on who to recruit and was particularly
valuable in helping the panel to decide between two similar applicants.
Service user involvement in training staff and assessing acceptability of measures
Service users at the participating communal care establishment helped to train staff by allowing them to
practise communication-based interactions, consent-taking and measurement collection. Service users
from one of the self-advocacy groups were invited to attend a follow-on staff training session so that
nurses could put their new skills into practice. They gave feedback on nurses’ skills and discussed what
they liked and what they did not like, enabling staff to gain confidence and develop competency in various
procedures. The mock clinics also helped the research team to determine how long the appointments
might take and how many visits may be needed. The service users reported that some of the questionnaires
were too lengthy and complex. The team met to discuss the issues raised and made changes to reduce
participant burden: these included swapping one of the questionnaires [Psychiatric Assessment Schedules
for Adults with Developmental Disabilities (PAS-ADD) mini200 for the PAS-ADD checklist200] and removing
two questionnaires (Dietary Instrument for Nutrition Education201 and International Physical Activity
Questionnaire202) entirely.
For the research programme, and to help with the design of the anticipated future trial, two members of
the Speaking up for Health Group and one member of the Charnwood Action Group wore the activity
monitors (both wrist- and waist-worn monitors) and provided feedback on their ease of use.
FIGURE 12 Service users’ involvement in assisting with study documentation.
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Service user involvement during final stages of programme
The service user groups were involved in the discussions around disseminating the findings and identifying
relevant conferences. During the consent process, participants were asked if they wished to be informed
of the findings. As a means of supporting this, and to acknowledge the group homes that had allowed
residents to take part in the study, two of the research nurses visited 27 homes to present the findings in
an easy-read format. Other participants received an easy-read report posted to them.
Discussion
This chapter discusses the involvement of service users with ID into our research programme and draws on our
own published work arising from this study.203 In line with previous service user initiatives, the impact of
involving service users in the research study is difficult to quantify.204,205 We feel that involvement of service
users improved the quality of, and recruitment for, our study, but we do not know what would have happened
had we not involved them, and there are no similar studies in the UK on which to draw comparisons.
We can say with certainty that the team benefited from the involvement, developing a greater
understanding of the health and personal issues faced by people with ID. The team also received positive
comments from the service users, particularly in relation to being involved in the interview panel process
and visiting our study offices. In line with previous research,206 we found that people with ID valued the
FIGURE 13 Service users’ rating form for recruitment of nurses.
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opportunity to discuss health issues. Unusually for service user involvement initiatives, our service users
were also allowed to take part in the research (because it was a screening programme); the fact that many
also chose to be participants in the programme is testament to their commitment.
The service users’ involvement in the research programme was collaborative and not participatory (or
‘emancipatory’), which is favoured by many disability academics.207 The agenda was set by the researchers
and final decisions were always made by the lead investigator. Established self-advocacy groups
contributed hugely to the success of the involvement because there was an established group dynamic and
all of the service users were keen to discuss health issues and voice their own opinions. As involvement
initiatives expand, there is a danger that self-advocacy groups will become inundated with requests for
support,208 so we need to ensure that we widen our approach to involvement for future studies. We also
encountered problems when we discussed paying the service users for their contribution, because they
were concerned about loss to their benefits, and we came across organisational restrictions. For future
work, we aim to consider more innovative group payments, such as water coolers or coffee machines,
with prior organisational approval.
We reiterate the recommendations from INVOLVE: that involvement should commence at the early stage
of the research process when identifying and prioritising topics for research.209 We had limited involvement
at this stage of the programme and further involvement is likely to have improved the quality of our
application and reduced the need to make changes once the study had started. When involving people
with ID, it is important to allow extra time for communication and consider their physical and/or
psychosocial needs, which may include working outside normal hours, travelling to different locations,
making suitable venue arrangements and considering the need for carers, advocates or supporters to be
present. We also recommend approaching service users through a number of sources to minimise the
burden of their involvement.
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Chapter 5 Screening programme: methods
Overview
This chapter describes the methods used for the screening component of the STOP Diabetes research
programme included in WP1. The background and rationale are presented in Chapter 1. The methodology
for the cost-effectiveness, which also formed part of this WP, is described in Chapter 12. An additional
physical activity substudy, which was conducted alongside the screening, is described in Chapter 7.
Aims and objectives
The primary aim of the screening component of the research programme was to evaluate the feasibility and
effectiveness of a diabetes screening programme for identifying undiagnosed T2DM and IGR in people with ID.
The specific objectives were to:
l develop and assess the feasibility of a diabetes screening programme in a community setting for adults
with ID
l determine the prevalence and demographic risk factors for T2DM, IGR and CVD in people with mild to
profound ID
l validate the Leicester Self-Assessment diabetes risk score in people with ID
l establish data linkage to Hospital Episode Statistics and the ONS.
Study design
Cross-sectional, population-based screening study.
Study setting
The screening study was conducted between February 2013 and September 2015, in a variety of community
locations within the unitary authorities of Leicester city, Leicestershire and Rutland (see Chapter 1, Approvals).
Based on assumed familiarity and acceptability to service users, the locations initially chosen included day
centres, community hospitals, primary care venues and group residential/nursing homes, which were
identified through existing service listings. This was subsequently widened to include family homes and
independent housing, to maximise recruitment.
Participants
Inclusion and exclusion criteria
Inclusion criteria
The inclusion criteria were adults who:
1. had ID
2. were aged 18–74 years inclusive
3. were registered with a general practice in Leicester city, Leicestershire or Rutland
4. had (or had a carer with) sufficient English-language skills to enable fully informed consent to be obtained.
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Exclusion criteria
The exclusion criteria were adults who:
1. had previous diagnosis of T2DM or type 1 diabetes mellitus
2. had a disability not confirmed to be ID
3. had malignancy or life-limiting terminal illness
4. had severe systemic disease that could interfere with the measurement and interpretation of
HbA1c level.
Participant recruitment process
Eligible participants were invited to take part in the screening programme using a four-pronged approach
(summarised in Figure 14):
1. approach via general practice registers
2. approach via the LLDR
3. approach via specialist ID psychiatric service clinics
4. direct contact with the research team.
Approach via general practice registers
All of the general practices in Leicester City, Leicestershire and Rutland that had patients with ID on their
practice register were sent a letter of invitation about the study. This was followed up, if necessary, by a
postal reminder and/or telephone call. Practices were asked to return a reply slip to the research team to
indicate their willingness to participate. The research team visited interested practices to explain the study
in more detail, answer any questions and confirm their willingness to participate. General practice staff
were then asked to identify people who were eligible to take part in the study from their practice ID
register and to send out a postal invitation.
To adhere to the requirements and underlying principles of the Mental Capacity Act,210 information about
the research was provided in stages. First, practices sent potential participants an easy-read invitation letter
and a brief easy-read information leaflet, outlining the study. Potential participants were then asked to
notify the research team of their willingness to participate (assisted by carers) using an easy-read reply slip
and a Freepost addressed envelope, or via the telephone. To be equitable to people with ID who could not
read, lived alone or lived with carers who also had reading difficulties, those who did not respond were
followed up with a telephone call. The aim of the call was to check if the invitation had been received,
to briefly explain what the information was about and to establish if the person or their carer wished to
find out more about the research programme. The telephone calls were initially made by practice staff;
however, owing to difficulties with practices prioritising the time to undertake them, approval was later
sought for an ID research nurse to be employed on the study to make these telephone calls from the
relevant general practice site. See Appendices 7–9 for examples of easy-read documentation used in the
research programme.
Following this initial approach, a member of the research team telephoned interested people to discuss the
study further. We anticipated that carers would play an important role in supporting the person with ID
with their choice about participation; individuals were encouraged to talk to someone whom they trusted
about whether or not to participate. Potential participants received verbal explanations about the study,
had the opportunity to ask questions and received a preliminary assessment of their decision-making
capacity to consent to participate in the research. Any indication of reluctance or anxiety about taking part
was taken as a refusal. Full study information, in an appropriate format, was then sent to volunteers
and/or an identified consultee. If a personal consultee (i.e. a person who had an interest in the potential
participant’s welfare but not doing so for remuneration, such as a parent) could not be identified then a
nominated consultee (e.g. a key worker) was identified and consulted. Alternatively, for some people,
a face-to-face visit was arranged to facilitate the provision of further/full information, supplemented by
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additional communication aids/methods. See Appendices 10 and 11 for examples of consultee information
leaflets used.
Approach via the Leicestershire Learning Disability Register
When general practices declined to take part in the study, potential participants were approached via the
LLDR.14 Adults who were known to the LLDR were invited to participate following the pathways described
in Figure 14.
l The register operates a rolling programme of home interviews,211 and those who agreed to be
contacted for research purposes at their most recent interview were contacted by the custodian of the
register to confirm that these people were happy to be contacted by the research team. Their contact
details were passed on directly to the research team for invitation.
l People who did not agree to direct contact for research purposes (because of either a lack of
agreement at previous home interview or a refusal when approached by the custodian of the register,
as above) were invited by the principal investigator in LPT.
For both methods outlined above, potential participants were approached in the same way as for those
approached through general practices (easy-read invitation letter, brief information leaflet and reply slip to
be returned to the research team). To avoid duplicates, invitations were cross-checked with those that had
already been sent via general practices.
Non-responders were also followed up in a similar manner as previously described for general practices;
follow-up telephone calls were made by either the custodian of the learning disability register or ID
research nurses working on the research programme. A restricted-access database held on a Microsoft SQL
server (Microsoft Corporation, Redmond, WA, USA) was used to record and track whether or not the
individual had received the letter of invitation, and whether or not they would like any more information
about the project.
Capacity assessment and provision of full study information, including involvement of carers and/or
consultees, also followed the same process as previously described.
The sending of study invitations, via general practices and the LLDR, commenced in December 2012
and January 2013, respectively. Approval to utilise two further ways was obtained in February 2014
(see Approach via specialist intellectual disability psychiatric service clinics and Direct contact with the
research team).
Approach via specialist intellectual disability psychiatric service clinics
An additional approach to potential participants was made via specialist ID psychiatric service clinics.
For patients attending a planned appointment, the consulting psychiatrist briefly described the research
programme and issued an easy-read invitation letter, a brief information leaflet and a reply slip. Service
users were given the opportunity to take the information leaflet and reply slip away with them (to return in
the post) or to have their details passed on to the research team. Those who agreed to pass on their
details were contacted by a member of the research team to provide further information and make an
initial assessment of capacity.
Recruitment and capacity assessment then followed the same procedure as for general practices and the
LLDR. As before, all of the potential participants were cross-checked against those who were already
invited to ensure that they were not invited to take part in the study more than once.
Direct contact with the research team
In some cases, direct contact was made by eligible individuals with ID (and/or their carers) who had heard
about the study via publicity materials or through other people who had taken part in the study. The STOP
SCREENING PROGRAMME: METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
Diabetes team provided them with the same initial brief written information as described for the other
recruitment sources. Recruitment, capacity and cross-checking procedures were similarly undertaken.
Screening process
Following the invitation stage, volunteers were asked to attend an initial screening appointment for
consent (see Informed consent) and data collection (see Data collection). Appointments were arranged by
the research team at a time and location that was convenient to the participants (and carers), often early
morning or late afternoon/evening in their own homes, but also in day centres, residential homes and
primary care settings. The number and length of appointments was flexible to allow for participants’
individual needs.
Informed consent
At the participant’s first appointment, a final face-to-face capacity assessment was undertaken by a trained ID
research nurse and informed consent was obtained; appropriate mental capacity legislation (see Chapter 1,
Adherence to mental capacity legislation) was followed. Consent was taken only when it had been
established that the person understood the consent form and information sheet, and that they had been
given the opportunity to ask questions.
People with capacity to consent were asked to sign a consent form. For those who could decide, but were
unable to read, the consent form was read to them in the presence of an independent witness. For people
who did not have capacity to consent, an appropriate consultee was identified and consulted about the
person’s potential participation. The consultee was asked to sign a consultee declaration form confirming
that they had been consulted, had their questions answered and had considered the study from the
participant’s perspective.
The participant and/or personal/nominated consultee (if appropriate) were asked to confirm that:
l they understood the study and were happy with what taking part would mean for them
l they understood that they could withdraw from the study at any time, without giving a reason
(and that this would not affect their care)
l they had been given a chance to discuss their questions with the research team
l they agreed for their GP to be notified about their participation and of their screening results
l the research team could access their medical records or records held at their residential home or day
centre for additional information, if unable to obtain from the participant or carer
l relevant sections of their medical notes and/or study data could be looked at by responsible people/
regulatory authorities for purposes of auditing the research.
Participants provided their consent for screening to be undertaken (see Informed consent and Box 3),
including a blood test (if the participant was willing). Additional optional consent items that participants
could chose to agree to, or not, included:
l being contacted to take part in further phases of the study if they screened positive for IGR or high risk
of developing T2DM (based on elevated BMI)
l having an additional blood sample taken for storage and future anonymised genetic analyses
l allowing access to medical records for long-term follow-up
l contact details being stored by the research team so that participants could be informed of the study
findings and be contacted about future research studies.
At the end of the appointment, the nurse highlighted the office’s telephone number on the participant
information sheet, which could be used if the participant decided to withdraw from the study or had
any queries.
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At the start of any subsequent appointments, participants’ retention and understanding of the study
was reconfirmed.
Following the final study appointment, a photocopy of the signed consent form/consultee advice form (as
appropriate) was sent to both the participant and the general practice; the copy of the form accompanied
the screening results, which were subsequently sent (see Informing of screening results). The original
consent and advice forms were retained at the research offices. See Appendices 12–14 for examples of the
consent/advice forms.
Data collection
Data collection was usually undertaken over two appointments but could be longer (the maximum was
five). The data collection process is summarised in Box 3. All of the data were collected in a standardised
way by specially trained research nurses, following study-specific standard operating procedures. Full
details of the assessment of outcomes are described below (see Assessment of outcomes).
BOX 3 Summary of data collected during screening
Biomedical measures
Bloods:
l Plasma glucose (2.7-ml fluoride bottle).a
l HbA1c (2.7-ml EDTA bottle).
l Lipids (total cholesterol, LDL, HDL, triglyceridesb).c
l Urea and electrolytes (sodium, potassium, creatinine).c
l Liver function tests (Bili, ALT ALP, GGT).c
l Thyroid function (TSH, free T4).c
l Genetic sample – whole blood (9-ml EDTA bottle).d
l ACR (urine).
Anthropometric:
l Height (cm).
l Weight (kg).
l BMI (kg/m2).
l Waist and hip circumference (cm).
BP (mmHg).
Questionnaires
Depression:
l Glasgow Depression Scale (GDS) and Carer Supplement.
Problem behaviour:
l Aberrant Behaviour Checklist (ABC).
l Health-related quality of life – EQ-5D.
l Psychiatric disorders – PAS-ADD checklist.
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Demographic details
Age.
Sex.
Residential circumstances; level of support.
Ethnic background.
Deprivation score.
Medical and family history
Cause of ID; severity of ID.
Medical history (physical, mental health, ID related).
Family history of diabetes (first degree).
Current medication.
Smoking status.
Lifestyle
Physical activity:
l Brief questions on mobility, walking, sitting and exercise.
Diet and nutrition:
l Brief questions on eating, food preparation, food groups, portions of fruit and vegetables.
Activity levels
Activity and sedentary behaviour:
l Accelerometer – worn for 7 days.e
ACR, albumin-to-creatinine ratio; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Bili, bilirubin;
EDTA, ethylenediaminetetraacetic acid; EQ-5D, EuroQol-5 Dimensions; GGT, gamma glutamyl transferase;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; T4, free thyroxine (FT4); TSH, thyroid-stimulating hormone.
a, Glucose, fasting (8 hours) or non-fasting; b, triglycerides, only requested if fasting; c, one bottle (4.9ml serum gel)
used for all 4; d, only if provided optional consent; e, only for a subgroup.
BOX 3 Summary of data collected during screening (continued)
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Anthropometric measurements, BP and demographic and lifestyle data were frequently obtained at the
first appointment, after consent was obtained, and usually took between 1 hour and 90 minutes.
Questionnaires were completed via interview during the initial screening visit (or at a subsequent
appointment) or were given to carers to be completed outside the appointment, as applicable (see Box 3).
These typically took between 30 and 60 minutes to complete. Venous blood samples were usually taken
during a separate appointment after deciding with participants (and their carers, where relevant) whether a
fasting or non-fasting sample would be more appropriate; this decision was based on potential behavioural
difficulties and/or cognitive understanding of participants. This appointment lasted about 30 minutes.
Medical history and prescribed medication were collected during screening or at a later date from medical
records. Other additional information was extracted by a researcher from the LLDR or from records held at
residential homes or day centres.
Informing of screening results
All participants were informed of their key biomedical screening results in an easy-read format,
supplemented by verbal explanations as appropriate. Anthropometric measures and BP readings were
presented to participants on the day that they were taken. Results of blood tests taken to determine
diabetes status were provided within 7–10 days.
Participants with normal results were informed by post and given the option to contact the research team
and discuss further if they wished. For participants who were screen positive for IGR or T2DM, a research
nurse telephoned them to explain their results and answer any questions, prior to a letter being sent in the
post. In some cases, this also involved a face-to-face visit by the nurse to support the participant and/or
their carer. In accordance with consent taken, these participants were then referred to their general
practice for usual care.
As agreed at the time of consent, participants’ GPs were provided with full details of the screening results,
including diabetes status. Additionally, for all of the participants who were identified as meeting the
criteria for IGR or T2DM, a member of the research team contacted their general practice and informed
their GP, prior to any results letters being sent.
See Appendices 15 and 16 for example letters that were used to inform participants and GPs of
the results.
Outcomes
Primary and secondary outcomes
The primary outcomes for the screening study were the prevalence of T2DM, IGR and abnormal
(T2DM or IGR) blood glucose level.
Diagnosis of T2DM was made following the most recent WHO criteria,28 more specifically a HbA1c level of
≥ 48 mmol/l or 6.5%. IGR was defined as impaired fasting glucose, following the WHO criteria of a HbA1c
level of 42–47 mmol/l or 6.0–6.4% (Figure 15).
The secondary outcomes included:
l physical activity levels, including sedentary behaviour, measured by brief questions and accelerometer
(for a small subgroup)
l lipid levels [triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol]
l BP (systolic, diastolic)
l cardiovascular risk, as measured by the Framingham Risk Score212,213
l health-related quality of life, as measured by the EuroQol-5 Dimensions (EQ-5D) questionnaire214
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l dietary/nutritional intake (food groups and fruit and vegetable intake)
l behavioural disorders, as measured by the Aberrant Behaviour Checklist (ABC)215,216
l psychiatric disorders, as measured by the PAS-ADD checklist217
l depression, as measured using the Glasgow Depression Scale (GDS) and Carer Supplement.218
Assessment of outcomes
All blood and urine samples were analysed at by the University Hospitals of Leicester NHS Trust laboratory
services, using stable methodology standardised to external quality assurance reference values. HbA1c level
was measured using an ARKRAY ADAMS HA-8180T analyser (ARKRAY, Kyoto, Japan). Plasma glucose
level (fasting and non-fasting); serum total cholesterol, HDL cholesterol and triglycerides, and urine albumin
and creatinine were measured using a Siemens Advia 2400 analyser (Siemens Healthcare Diagnostics,
Camberley, UK). The Friedewald equation was used to estimate LDL cholesterol.219
Resting BP was assessed in a seated position on the brachial artery, using an Omron M5-I automatic BP
monitor (Omron Healthcare UK, Milton Keynes, UK); a series of three measurements was recorded, with a
mean value calculated from the final two. Waist circumference was measured to the nearest millimetre
over minimal clothing, midway between the costal margin and the iliac crest, and in the mid-axillary line;
hip circumference was measured to the nearest millimetre at the widest point over the buttocks; a soft
tape was used for both anthropometric measures (WM02 Body Tape; Chasmors Ltd, London, UK). Weight
was assessed in light clothing and no shoes to the nearest 0.1 kg, using a seca 875 digital floor scale
(seca, Birmingham, UK); and height to the nearest centimetre using a Leicester portable height measure
(Chasmors Ltd, London, UK) and with head placed in the Frankfurt plane.
Additional data on health-related quality of life (EQ-5D)214 and depression (GDS and Carer Supplement),218
were collected face to face via interview-administered questionnaires at an appointment. To assess
problem behaviour (ABC)215,216 and psychiatric disorders (PAS-ADD checklist),217 questionnaires were taken
away by carers and self-completed following the appointment. The validated questionnaires used are
described in detail in Appendix 17. Deprivation was assessed according to the 2015 Index of Multiple
Deprivation.220
HbA1c > 6.5%
(48 mmol/l)
Symptoms present T2DM
T2DM
Symptoms absent
(or unable to assess)
Repeat HbA1c 
in 2–4 weeks
HbA1c
> 48 mmol/l
HbA1c
42–47 mmol/l
IGR
HbA1c
6.0–6.4%
(42–47 mmol/l)
FPG > 7.0 mmol/l
T2DM or IGR
based on 
blood results
FPG < 7.0 mmol/l
Repeat HbA1c 
and/or FPG as
appropriate
IGR
HbA1c < 6.0
(42 mmol/l)
FPG 6.1–6.9 mmol/l IGR
FPG < 6.0 mmol/l Normal
FIGURE 15 Diagnosis of T2DM and IGR for participants in the screening programme. FPG, fasting plasma glucose.
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Ambulatory activity and sedentary behaviour were measured for a small subsample of participants;
full details of the physical activity substudy undertaken are presented in Chapter 7.
Uptake of screening was measured by recording the number of (1) invitations sent, (2) people responding
and refusing at each stage and (3) people attending for screening.
If BP, anthropometric measures and/or bloods were unable to be assessed, then details of the reason
were recorded (refused, physical/behavioural difficulty, equipment error, other). For demographic, lifestyle,
medical history and prescribed medication, additional details were recorded on how the data were obtained,
for example from the volunteer, carer/relative or a combination of both, or if personalised records such as a
health action plan4 were used.
Sample size
We aimed to screen 1000 adults with ID, which would measure the overall prevalences of T2DM and IGR
with 1.49% and 2.01% precision (95% CI), respectively, assuming similar prevalence rates of T2DM and
IGR in people with ID as in the general population (6.2% and 12%, respectively).18,21,22
Data analysis
Feasibility of diabetes screening in adults with intellectual disability
The feasibility of conducting a diabetes screening programme in a community setting for adults with ID
was assessed using a flow diagram of the screening process and summarising the number of dropouts and
those for whom data were unobtainable at each step of the screening process. Particular outcomes of
interest in terms of the feasibility are the proportions of people who (1) were invited and who complete
the screening programme (including the blood tests) and (2) attended the screening session but did not
have a blood test. We also assessed the completeness of key data items from the case report form and
questionnaire to assess the feasibility of data collection for future research projects in this group.
Characteristics
The characteristics of those who were screened were summarised using means (SDs for continuous
variables) and ‘n (%)’ for categorical variables.
Additional analyses were conducted to compare the representativeness of the STOP Diabetes study cohort
with the LLDR.14
Prevalence of type 2 diabetes and impaired glucose regulation
The overall prevalence of IGR, T2DM and any abnormal glucose regulation was calculated with 95% CI.
Cardiovascular risk
Cardiovascular risk was calculated for participants aged 35–75 years with no previous history of CVD.
The Framingham CVD risk score212,213 was used to assess risk in white European participants and ETHRISK
(a modified version for British black and minority ethnic groups) was used for South Asians.221 Participants
with incomplete data for key variables (total and HDL cholesterol, systolic BP, smoking status) were unable
to be included in analyses. The overall mean risk at 10 years and the level of risk (high, intermediate, low),
based on thresholds determined by National Cholesterol Education Program,222 were calculated.
Factors associated with abnormal glucose regulation
Logistic regression was used to assess the association between key biomedical and anthropometric
characteristics and the outcome – abnormal glucose regulation. ORs and 95% CIs were calculated.
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Validation of Leicestershire self-assessment risk score
Our initial analysis plan was to update the Leicester Self-Assessment risk score,58 described in Chapter 1
(see Risk scores for the early identification of impaired glucose regulation and type 2 diabetes), for use
in a population with ID. This may have included adding or removing risk factors and updating the relative
weighting given to risk factors. However, given the low prevalence of IGR/T2DM that we found in our
screening study (see Prevalence of type 2 diabetes and impaired glucose regulation), this was not
considered feasible. There are no formal sample size requirements for developing risk scores, although it
has been suggested that data sets that are used to develop risk scores should contain between 10 and
20 events for each risk factor being assessed.223,224 Therefore, our data set would be very underpowered
to develop a risk score.
Hence, it was decided that instead of updating the original Leicester Self-Assessment risk score,
alternatively, we would assess the risk score’s performance to detect undiagnosed IGR/T2DM. Although
this validation would also be underpowered (studies suggest that external validation data sets should have
at least 100 events and 100 non-events),225 this analysis should provide some preliminary results to suggest
if the score is sensitive and specific in our cohort with ID.
The Leicester Self-Assessment risk score contains seven risk factors (age, sex, ethnicity, family history of
diabetes, waist circumference, BMI and high BP).58 To maximise the number of people included in the
analysis, the data were analysed in two ways: (1) complete case basis (including only those with all seven
risk factors recorded and the outcome) and (2) imputing missing data for family history of diabetes and
high BP. For both a family history of diabetes and high BP, the imputed data set assumed a negative
response if these items were missing. In both data sets the sensitivity, specificity, positive predictive value
and negative predictive value were calculated for a cut-off point of ≥ 16 points. This is the cut-off point
that was used in the general population for invitation to screening.58
All of the analysis was conducted using Stata; statistical significance related to p < 0.05 and 95% CIs are
presented throughout.
Establish data linkage to Hospital Episode Statistics and the Office for
National Statistics
An additional optional consent item about which participants were approached at their initial screening
appointment (see Chapter 5, Informed consent) included consent for follow-up for health issues in the
longer term.
Genetic markers
A supplementary component of WP1 involved collecting blood samples for future genetic studies in
individuals who had provided consent (optional). For this, an extra whole blood sample was taken and
stored at –80 °C. These samples will be analysed in a batch at the end of the study. Future work will
involve extracting deoxyribonucleic acid and testing biologically plausible interactions between genetic
markers and T2DM to determine T2DM susceptibility. The analysis of genetic markers does not form part
of the work described in this report.
Concluding remarks
This chapter has described the methods for the screening component of the STOP Diabetes research
programme. The next chapter presents the results of the screening study.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57

Chapter 6 Screening programme: results
Overview
This chapter reports the results of the diabetes screening programme that was undertaken for WP1.
The methods for the screening study were reported in Chapter 5. An additional physical activity substudy,
which was conducted alongside the screening, is described in Chapter 7.
Feasibility of conducting a diabetes screening programme in adults with
intellectual disability
Participant recruitment
Initial approach
Participants were recruited to the STOP Diabetes screening study between February 2013 and September
2015. In total, 3201 adults with ID were invited to take part via the four different routes (Figure 16).
Fifty-one per cent (n = 73) of all general practices in Leicester City, Leicestershire and Rutland (with adults
with ID on their practice list) agreed to be involved with the study. Subsequently, 1736 potentially eligible
people were identified and sent an invitation letter by their practice (median 19, range 3–116). People who
were invited via this route accounted for the majority of study invitations (54%).
For practices refusing, 1595 people were identified for possible approach via the LLDR. Of these, contact
details for 418 people (who had previously agreed to be contacted for research purposes) were passed
directly to the research team so that they could be invited (13% of the overall study total). A further 864
(27%) people were invited directly by the principal investigator in LPT.
A much smaller proportion of people were invited via specialist ID psychiatric service clinics or after making
direct contact with the research team: 2% (n = 52) and 4% (n = 131), respectively.
Full-stage invitation
From the initial invitation, approximately 30% of people refused, 29% were classed as non-responders and
40% expressed an interest in participating in the study (Figure 17). Following a preliminary assessment of
volunteers’ decision-making capacity, 1209 individuals (38% of those initially invited) were then provided
with full study information (postal invitation or a face-to-face visit). Subsequently, 984 (31%) proceeded to
the screening stage.
For people who refused (or agreed) at the initial or full invitation stages, details relating to the method of
recruitment and reasons for refusal are presented in Table 12.
Screening: consent and data collection
At the consent stage, 930 people (29% of those originally approached) agreed to participate and were
recruited to the screening study; 54 people either refused (n = 19) or were ineligible (n = 35) (see Figure 17).
Thirty-eight per cent of participants (n = 350) were able to consent for themselves; the others required a
nominated (39%) or personal (23%) consultee.
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Attended first
appointment
(n = 984)
Consented
(n = 930)
Yes
(n = 1004)
Capacity 3
Capacity 2
Arranged blood
appointment
(n = 825)
Attended blood
appointment
(n = 825)
IGR
(n = 35)
T2DM
(n = 9)
Normal
(n = 631)
Blood results 
possibly unreliable
(n = 5)
(If available)
Blood results
(HbA1c) 
obtained from 
medical records 
(n = 27)
Bloods
Consent
Full stage
Initial stage
Not assessed
(n = 172)
• Refused bloods, 
   n = 125
• Unable to obtain 
   bloods, n = 47
Excluded at consent
• Not eligible, n = 19
• Refused, n = 35
Refusals
(n = 105)
• Withdrew 
   (ill health), n = 2
• Refused, n = 103
Refusals
(n = 12)
Capacity 1
Not eligible
(n = 8)
Refusals
(n = 196)
Not eligible
(n = 9)
Yes
(n = 1259)
Refusals
(n = 918)
Other
(n = 72)
• Not eligible, 
   n = 63
• Deceased, n = 5
• Duplicate, n = 4
Initial invitations
(n = 3201)
Full invitation sent
(n = 1209)
Non-responders
(n = 952)
Contact details not 
valid/unsuccessful 
attempts to contact
Refusals
(n = 25)
Not eligible
(n = 25)
FIGURE 17 Recruitment.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
The availability of data for the key screening outcomes is presented in Table 13. The full details regarding
the availability of data for all study variables are reported in Appendix 18, Table 61. Anthropometric
measures and BP were obtained for most participants: approximately 86% and 89%, respectively. In the
majority of cases, the documented reason for not obtaining anthropometric measures was physical or
behavioural difficulties; for BP, the main reason was participant refusal.
A high proportion of participants agreed to attend for a blood appointment (n = 825); 700 (75% of
those recruited) proceeded to have a blood test, and bloods to allow screening were successfully obtained
for 648 (70%). For a few additional participants, when a blood test was refused or a sample was not
obtained, recent results were available from their medical records (HbA1c test, n = 27; for other tests the
TABLE 12 Responses (%) according to recruitment method at initial and full invitation stages
Characteristics and method
Stage
Initial invitation
(or chasing non-responders)
Full invitation
(or capacity 1 or 2)
Refuse Agree Refuse Agree
Total number N = 918 N = 1259 N = 233 N = 984
Male, n 53a 58 62a 58
Age in years, mean – 43 40a 44
Resided in Leicester City 40a 41 48a 40
Recruitment method, n
GP 50 47 67 41
Learning disability register 33 18 12 19
Previous consent to research 15 19 17 20
Direct invite 1 12 2 14
Psychiatrist clinic 1 5 3 6
Refusal/acceptance method, n
Reply slip 28 28 24 28
Telephone call 14 20 21 20
Chasing person via telephone 55 33 55 28
GP notified team 2 0 0 0
In person 1 18 1 24
Via e-mail 0 1 0 1
Reason for refusing, n
Not known 77 – 72 –
Behavioural issues 7 – 6 –
Carer would not agree consent 7 – 5 –
Health issues 3 – 4 –
Recent health check 3 – 6 –
Too busy 2 – 2 –
Other 1 – 6 –
a Estimates provided were appropriate for refusals; percentages are rounded, so may not add up to 100%.
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number varies) (see Figure 17 and Table 13). For a further five participants, HbA1c results were not included
because of potential unreliability in assessing diabetes status (n= 4) and poor kidney function (n= 1, possible
haemoglobin variant). Therefore, we were able to assess diabetes status for a total of 675 participants.
Validated questionnaires administered via interview were successfully completed for a high number of
participants (EQ-5D ≈94%; GDS or Carer Supplement ≈85%). Carer completion of questionnaires
outside the appointment (for the ≈80% of participants who had an identified carer) was less successful;
approximately 45% of carers completed the ABC and/or the PAS-ADD.
TABLE 13 Data availability for key screening outcomes
Screening outcomes Outcome measured, n (%)
Anthropometric
Height 800 (86.0)
Weight 799 (86.0)
BMI 782 (84.1)
Waist circumference 796 (85.6)
Hip circumference 789 (84.8)
BP
Diastolic/systolic 826 (88.8)
Blood tests
Agreed to blood test 700 (75)
Fasted for test – yes 491 (70)
Bloods obtained 648 (70)
Blood results available Taken for study; obtained from medical records
HbA1c 648 (69.7); 27 (2.9)
Plasma glucose: fasting 417 (44.8); 8
Plasma glucose: non-fasting 223 (24.0); 16
Total cholesterol 614 (66.0); 39
HDL cholesterol 615 (66.1); 29
LDL cholesterol 605 (65.1); 26
Triglyceridesa 404 (43.4); 3
Diabetes status assessed
Normal, high risk, abnormal 675 (72.6)
Validated questionnaires
EQ-5D score 872 (93.8)
EQ-5D visual analogue scale 877 (94.3)
GDS: volunteers with capacity 317 (34.4)
GDS: Carer Supplement 464 (50.2)
ABC 341 (36.7)
PAS-ADD Checklist Section 2 325 (34.9)
a Only if fasted.
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Characteristics of the screened cohort
The key characteristics for the study population are presented in Tables 14–17. The full details for all of the
screening variables are reported in Appendix 18, Table 61.
Demographic characteristics
The mean age of those screened was 43.3 (SD 14.2) years, 58% were male and the majority were of
white ethnicity (80%) (see Table 14).
Most participants lived either with family (36%) or in a residential/nursing home (38%), with 6% living
alone. A high proportion required 24-hour support (71%) and only 7% reported to be independent.
TABLE 14 Key demographic characteristics of cohort screened
Demographic N Mean (± SD), unless stated otherwise
Age (years) 930 43.3 (± 14.2)
Gender, male, n (%) 930 537 (57.7)
Ethnicity, n (%) 930
White 748 (80.4)
Asian 147 (15.8)
Black 14 (1.5)
Mixed 13 (1.4)
Other 8 (0.9)
Residential circumstances, n (%) 929
Alone 51 (5.5)
Lives with family 338 (36.4)
Shared house or supported living 157 (16.9)
Shared care 16 (1.7)
Residential home or nursing home 350 (37.7)
Other 17 (1.8)
Level of support, n (%) 929
Independent 69 (7.4)
Some support 205 (22.1)
24-hour support 655 (70.5)
Current status,a n (%)
Paid employment 928 71 (7.7)
Voluntary work 927 152 (16.4)
College 925 170 (18.4)
Day opportunities or private day centre 928 431 (46.4)
Shared lives (day placement) 928 19 (2.1)
Attending meetings 926 122 (13.2)
Other 924 385 (41.7)
a The percentage will not add up to 100, as participants can positively answer > 1 category.
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The majority of individuals was able to access the community to undertake regular daytime activities.
Common activities included attending college (18%), voluntary work (16%) or involvement in service user/
advocacy meetings (13%). Around half of the participants attended day opportunities/day placements.
Only a small number of people were in regular paid employment (8%).
Anthropometric and biomedical measures
Among those screened, the mean waist size was 100.4 (SD 16.5) cm, weight 76.4 (SD 20.8) kg and
BMI 28.7 (SD 7.1) kg/m2 (see Table 15). Based on their BMI, 31% of participants were classed as
overweight and 37% obese. Mean values for systolic and diastolic BP were 121.4 (SD 16.9) mmHg and
78.2 (SD 11.1) mmHg, respectively.
TABLE 15 Key biomedical measures of cohort screened
Biomedical measurements N total (from medical record) Mean (± SD), Unless stated otherwise
Bloods
Plasma glucose (mmol/l)
Fasting 425 (8) 4.7 (± 0.7)
Non-fasting 239 (16) 5.3 (± 1.5)
HbA1c 675 (27)
HbA1c (mmol/mol) 35.0 (± 5.1)
Derived HbA1c (%) 5.4 (± 0.5)
Lipids (mmol/l)
Total cholesterol 653 4.9 (± 1.0)
HDL cholesterol 644 1.3 (± 0.4)
LDL cholesterol 631 2.9 (± 0.9)
Triglyceridesa 407 1.4 (± 0.9)
Anthropometric
Height (m) 800 1.6 (± 0.1)
Weight (kg) 799 76.4 (± 20.7)
BMI (kg/m2) 782 28.7 (± 7.1)
BMI categories, n (%)
Underweight 30 (3.8)
Normal 223 (28.5)
Overweight 241 (30.8)
Obese 288 (36.8)
Waist circumference (cm) 796 100.4 (± 16.5)
BP measurements (mmHg)
BP 826
Systolic 121.4 (± 16.9)
Diastolic 78.2 (± 11.1)
a Only if fasted.
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TABLE 16 Key medical history and current medication of cohort screened
Medical history and current medication n (%)
Severity of ID (N = 865)
Not known 49 (5.7)
Known 816 (84.3)
Mild 260 (30.1)
Moderate 244 (28.2)
Severe 279 (32.3)
Profound 33 (3.8)
Cause of ID (N = 866)
Not known 581 (67.1)
Known 285 (32.9)
Down syndrome 133 (15.4)
Fragile X 8 (0.9)
Cerebral palsy 58 (6.7)
Hydrocephalus 6 (0.7)
Phenylketonuria 5 (0.6)
Prader–Willi syndrome 4 (0.5)
Medical or health problems (N = 929)
None 117 (12.6)
Yes 812 (87.4)
Physical health
Stroke 13 (1.4)
Peripheral arterial disease 0
CHD 7 (0.8)
Congenital heart disease 19 (2.1)
Other heart problems 15 (1.6)
High BP 63 (6.8)
High cholesterol 62 (6.7)
Hypothyroidism 93 (10.0)
Polycystic ovary syndrome 1 (0.1)
Gestational diabetes 0
Pre-diabetes 1 (0.1)
Chronic breathing problems 88 (9.5)
Sleep apnoea 3 (0.3)
Epilepsy 262 (28.2)
Mental health
Dementia 18 (1.9)
Schizophrenia, schizotypal and delusional 35 (3.8)
Mood (affective) disorders 152 (16.4)
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TABLE 16 Key medical history and current medication of cohort screened (continued )
Medical history and current medication n (%)
Neurotic, stress related and somatoform 143 (15.4)
Personality disorders 13 (1.4)
Drug/alcohol problems 0
ADHD 8 (0.9)
ID related
Autistic spectrum disorders 165 (17.8)
Behavioural problems 128 (13.8)
Current medication (N = 928)
None 172 (18.5)
Yes 756 (81.5)
Anti-psychotic 240 (25.9)
Depression/anxiety/OCD or related 258 (27.8)
For ADHD 4 (0.4)
Antiepileptic 311 (33.5)
Antithrombotic 36 (3.9)
Lipid lowering 74 (8.0)
Statin 72 (7.8)
Fibrate 1 (0.1)
Statin and fibrate 1 (0.1)
Antihypertensive 85 (9.2)
Thyroid medication 93 (10.0)
Steroids 80 (8.6)
Oral 5 (0.5)
Inhaled 62 (6.7)
Topical 9 (1.0)
More than one type of steroid 3 (0.3)
Not known 1 (0.1)
Anti-obesity 1 (0.1)
Other 571 (61.5)
Smoking status (N = 929)
Current smoker 76 (8.2)
Ex-smoker 38 (4.1)
Never smoked 815 (87.7)
Family history of diabetes (N= 592) 180 (30.4)
ADHD, attention deficit hyperactivity disorder; CHD, coronary heart disease; OCD, obsessive–compulsive disorder.
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TABLE 17 Key lifestyle and well-being characteristics of cohort screened
Lifestyle and well-being n (%)
Physical activity/exercise
Able to walk (N = 927)
No 57 (6.2)
Yes (with or without walking stick, aid) 787 (84.9)
Yes, with assistance from person(s) 83 (9.0)
Amount of walking per day (N = 927)
None 74 (8.0)
A short distance 259 (27.9)
Some 359 (38.7)
Lots 235 (25.4)
Frequency of physical activity, per week, (N = 928)
None 184 (19.8)
1–2 times 360 (38.8)
3–4 times 259 (27.9)
≥ 5 times 125 (13.5)
Time spent sitting per day (N = 928)
All/most 180 (19.4)
A lot 252 (27.2)
Sometimes 475 (51.2)
Never 21 (2.3)
Nutrition and diet
Problems relating to eating and drinking
Difficulties with chewing or swallowing (N = 929) 227 (24.4)
Needs help or assistance to feed self (N = 926) 118 (12.7)
Use specialist equipment 95 (10.3)
Fed via an nasogastric tube or gastrostomy 7 (0.8)
Food shopping (N = 922)
Independently 89 (9.7)
With support 230 (25.0)
Relative or carer 297 (32.2)
Purchased by residential home 306 (33.2)
Preparing meals (N = 921)
Relative or carer 561 (60.9)
With supervision 117 (12.7)
Without supervision 145 (15.7)
Without supervision can prepare variety of meals 98 (10.6)
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Among participants for whom blood results were available, the mean HbA1c level was 35.0 mmol/mol
(SD 5.1 mmol/mol) (5.3%; SD 1.5%), FPG was 4.7 mmol/mol (SD 0.7 mmol/mol) and non-FPG was
5.3 mmol/mol (SD 1.5 mmol/mol). For lipids, mean total cholesterol was 4.9 mmol/mol (SD 1.0 mmol/mol),
HDL cholesterol was 1.3 mmol/mol (SD 0.4 mmol/mol), LDL cholesterol was 2.9 mmol/mol (SD 0.9 mmol/mol)
and triglycerides were 1.4 mmol/mol (SD 0.9 mmol/mol).
Current medication and medical history
When details on severity of ID were available (n = 816, 88%), similar proportions of participants were
classified as mild, moderate or severe (≈30% each), and 4% were classified as profound ID (see Table 16).
Most participants had no confirmed diagnosis or identified cause of their ID (≈70%); when the causes
were known, the most common were Down syndrome (n = 133, 14%) and cerebral palsy (n = 58, 6%).
The overall prevalence of existing CVD was 2% (n = 19). A history of stroke was reported for 12 (1.3%)
people and coronary heart disease (CHD) for six (0.6%) people, and one person had a history of both
conditions.
Congenital heart disease (2%) and other heart problems (2%) were less frequently reported.
Seventy-four participants (8%) had a history of high cholesterol and/or were prescribed a lipid-lowering
medication, 85 (9%) had a history of previously diagnosed hypertension and/or were prescribed an
antihypertensive drug, and 36 (4%) were prescribed an anti-thrombotic drug. A minority of participants
were either current smokers (8%) or ex-smokers (4%).
When known, approximately one-third of participants had a first-degree family history of diabetes. Only
one participant reported a previous diagnosis of pre-diabetes and one reported polycystic ovary syndrome.
Nine per cent were currently being prescribed a steroid medication (the majority of these medications
were inhaled).
Overall, the most commonly reported diagnosed physical health problems were epilepsy (n = 262, 28%),
hypothyroidism (n = 93, 10%) and chronic breathing problems (n = 88, 9%). Thirteen per cent of
participants had no significant medical history and 19% were not currently prescribed any medication.
For mental health-related problems, 152 participants (16%) had a history of a mood spectrum disorder
(ICD-10 codes F30–F39), 35 (4%) a psychotic spectrum disorder (ICD-10 codes F20–F29) and 52 (6%) had
a history of both; 143 people (15%) had neurotic, stress-related or somatoform disorders (ICD-10 codes
TABLE 17 Key lifestyle and well-being characteristics of cohort screened (continued )
Lifestyle and well-being n (%)
Daily portions of fruit and vegetables (N = 920)
None 33 (3.6)
1 57 (6.2)
2 130 (14.1)
3 230 (25.0)
4 199 (21.6)
5 213 (23.2)
6 36 (3.9)
≥ 7 22 (2.4)
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F40–F48). Additionally, 28% of participants were prescribed antipsychotic medication and 32% were
prescribed depression- or anxiety-related medication. Other frequently reported problems included autistic
spectrum disorders (18%) and a recognised behavioural problem (14%).
When comorbidities (two or more diagnosed health problems) were considered, 121 (13%) participants
had co-occurring physical health problems, 182 (20%) had co-occurring mental health problems and
286 (31%) had multiple physical and/or mental health problems.
Lifestyle and well-being
Eighty-five per cent of those screened were able to walk independently (without the help/support of
another person), but including 6% who required a walking aid (see Table 17). The data reported directly
by participants and/or carers indicated that most people did at least ‘some’ walking on a typical day, but
only 25% achieved ‘a lot’ of walking. Additionally, around half of the participants reported spending
‘a lot’ or ‘most/all’ of the day sitting.
Sport/exercise or other physical activities that individuals reported undertaking in a typical week included
dance (25%), swimming (20%) or walking (21%). Around half of the participants reported doing
housework (such as dusting/hovering) and ≈20% gardening. A small number of people (7%) did regular
chair-based exercise.
Problems with eating and drinking were reported for some people: 24% had difficulties in chewing or
swallowing and 13% needed help to feed themselves (< 1% were tube fed). For food shopping and
preparation, overall ≈35% of participants did their own food shopping (either independently or with some
support) and a similar number were able to prepare at least simple hot and cold food (with or without
supervision). Reported daily intake of fruit, vegetables or salad indicated that only around 30% of
participants were eating the recommended five or more portions a day.
When questionnaire data were available, the proportion of participants identified with possible depression
(using a cut-off point of 13) by the GDS or GDS Carer Supplement was 22% and 16%, respectively.218
For health-related quality of life, the mean EQ-5D descriptive score was 0.8 (SD 0.3) and for the visual
analogue scale was 78.1 (SD 19.4). The mean scores for the five problem behaviour subscales measured
by the ABC (for participants with carers) were ≈4 for irritability, lethargy and hyperactivity, and ≈1 for
stereotyped behaviour and inappropriate speech. The prevalences of mental health problems for organic,
affective/neurotic and psychotic disorders (as measured by PAS-ADD checklist) were 6%, 9% and
5%, respectively.
Comparison with the Leicestershire Learning Disability Register
Participant demographic characteristics from this study were compared with adults with ID on the Leicester
Learning Disability Register. Comparison of age, sex and ethnicity suggests that the STOP Diabetes cohort
is a representative sample of the population with ID, known to services within the Leicester, Leicestershire
and Rutland area (Table 18).
Prevalence of type 2 diabetes and impaired glucose regulation
Outcome data to establish the prevalence of IGR/T2DM were available for 675 participants. Screening
results indicated that, overall, 44 (6.5%) participants had abnormal glucose regulation, a prevalence of 0.07
(95% CI 0.05 to 0.08); nine participants (1.3%) were found to have undiagnosed T2DM, a prevalence
of 0.01 (95% CI 0.005 to 0.02); and 35 (5.2%) had IGR, a prevalence of 0.05 (95% CI 0.04 to 0.07)
(Table 19).
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Factors associated with abnormal glucose regulation
Table 20 shows the association of anthropometric and biomedical characteristics with having screen-detected
abnormal glucose regulation. Participants of non-white ethnicity were almost four times more likely to
have abnormal glucose levels than white European participants (OR 3.93, 95% CI 2.10 to 7.33); those with
a first-degree family history of diabetes were over three times more likely (OR 3.35, 95% CI 1.64 to 6.86).
In addition, abnormal glucose tolerance was associated with increasing weight, waist circumference, hip
circumference, BMI, diastolic BP and triglycerides, and decreasing HDL cholesterol.
Validation of the Leicester Self-Assessment risk score
Overall, 365 (54%) of the 675 participants with the outcome obtained had complete data for the seven
risk factors assessed by the Leicester Self-Assessment risk score. This was increased to 595 (88.1%) when
imputing family history and high BP (Table 21). Similar percentages of participants fall into the four risk
categories based on the complete case and imputed data. In the complete case data, 43.1% would be
referred for screening based on their risk score (≥ 16 points) and 41.4% based on the imputed data.
TABLE 18 Characteristics of cohort screened compared with LLDR
Characteristic STOP Diabetes (N= 930), n (%) LLDR < 80 years (N= 3867), n (%)
Age (years)
< 30 207 (22.3) 1012 (26.2)
30–39 195 (21.0) 856 (22.1)
40–49 211 (22.7) 776 (20.1)
50–59 185 (19.9) 659 (17.0)
60–69 107 (11.5) 416 (10.8)
70–79 25 (2.7)a 148 (3.8)
Male 537 (57.7) 2222 (57.5)
Ethnicity Of n = 3571 known
White 748 (80.4) 2893 (81.0)
South Asian 147 (15.8) 553 (15.5)
Black/mixed 27 (2.9)b 80 (2.2)
Other 8 (0.9) 45 (1.3)
a Age screened 18–74 years.
b Ethnicity data collected separately (black n= 14, 1.5%; mixed n = 13, 1.4%).
TABLE 19 Prevalence of T2DM, IGR and abnormal glucose regulation
Outcome n (%) Prevalence (95% CI)
Normal glucose 631 (93.5) 0.93 (0.92 to 0.95)
IGR 35 (5.2) 0.05 (0.04 to 0.07)
T2DM 9 (1.3) 0.01 (0.01 to 0.02)
Abnormal glucose 44 (6.5) 0.07 (0.05 to 0.08)
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TABLE 20 Comparison of anthropometric and biomedical characteristics of those with normal and abnormal
glucose regulation
Characteristic
Normal
glucose
(n= 631)
Abnormal
glucose
(n= 44) OR (95% CI) p-value
Age (years), mean (SD) 43.0 (± 14.3) 45.4 (± 13.5) 1.01 (0.99 to 1.03) 0.27
Male, n (%) 377 (59.8) 28 (63.6) 1.18 (0.63 to 2.22) 0.61
Non-white ethnicity, n (%) 119 (18.9) 21 (47.7) 3.93 (2.10 to 7.33) < 0.0001
Weight (kg), mean (SD) 76.6 (± 20.2) 91.7 (± 27.3) 1.03 (1.01 to 1.04) < 0.0001
Waist circumference (cm), mean (SD) 100.1 (± 16.2) 114.0 (± 19.0) 1.04 (1.03 to 1.07) < 0.0001
Hip circumference (cm), mean (SD) 107.4 (± 13.5) 115.6 (± 19.1) 1.03 (1.01 to 1.06) 0.001
BMI (kg/m2), mean (SD) 28.6 (± 6.9) 34.1 (± 10.2) 1.08 (1.04 to 1.13) < 0.0001
Current smoker, n (%) 56 (8.9) 6 (13.6) 1.62 (0.66 to 4.00) 0.30
Family history of diabetes, n (%) 132 (29.9) 20 (58.8) 3.35 (1.64 to 6.86) 0.001
Systolic BP (mmHg), mean (SD) 121.8 (± 17.3) 126.5 (± 14.4) 1.01 (1.00 to 1.03) 0.09
Diastolic BP (mmHg), mean (SD) 78.0 (± 11.2) 83.7 (± 10.0) 1.04 (1.02 to 1.07) 0.002
Total cholesterol (mmol/l), mean (SD) 4.9 (± 1.0) 4.7 (± 0.9) 0.78 (0.56 to 1.10) 0.15
HDL cholesterol (mmol/l), mean (SD) 1.4 (± 0.4) 1.2 (± 0.3) 0.14 (0.05 to 0.43) 0.001
LDL cholesterol (mmol/l), mean (SD) 2.9 (± 0.9) 2.7 (± 0.8) 0.71 (0.48 to 1.07) 0.10
Triglycerides (mmol/l), mean (SD) 1.4 (± 0.9) 1.9 (± 1.0) 1.53 (1.11 to 2.11) 0.01
TABLE 21 Completeness of the Leicester Self-Assessment risk score variables
Variables All (N= 675), n (%) Complete case (N= 365), n (%) Imputed (N= 675), n (%)
Age (years)
≤ 49 445 (65.9) 263 (72.1) 445 (65.9)
50–59 136 (20.2) 69 (18.9) 136 (20.2)
60–69 75 (11.1) 30 (8.2) 75 (11.1)
≥ 70 19 (2.8) 3 (0.8) 19 (2.8)
Sex
Male 405 (60.0) 207 (56.7) 405 (60.0)
Female 270 (40.0) 158 (43.3) 270 (40.0)
Ethnicity
White European 535 (79.3) 278 (76.2) 535 (79.3)
Other ethnic group 140 (20.7) 87 (23.8) 140 (20.7)
Family history of T2DM
No 324 (48.0) 248 (68.0) 523 (77.5)
Yes 152 (22.5) 117 (32.1) 152 (22.5)
Unable to assess 199 (29.5) 0 0
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Table 22 presents the validation of the Leicester Self-Assessment risk score in this population with ID. The
complete case and imputed data have similar results; therefore, only the complete case data are interpreted
here. Of the 22 participants with abnormal glucose regulation and full risk score data, 18 are correctly
classified as high or very high risk by the risk score. This gives a sensitivity of 81.8%. Given the low number
of events, the 95% CI around this estimate is wide: 59.7% to 94.8%. Of the 344 participants with normal
glucose regulation, 204 are correctly identified as being of low or medium risk and therefore would not be
referred on for further screening. One hundred and forty participants would be referred for unnecessary
screening, that is to say that, of those with a high or very high risk score, only 11.4% have undiagnosed
IGR/T2DM. The findings suggest that the score may be useful for ruling out disease; 98.1% of those with a
low or medium risk score are correctly identified and do not have undiagnosed IGR or T2DM.
Cardiovascular risk
Cardiovascular risk, based on Framingham risk score,212,213 or on ETHRISK221 for participants of South Asian
ethnicity, was able to be calculated for 376 (40.4%) participants. The mean risk of CHD in 10 years was
5.9% (SD 4.9%) and of CVD was 7.3% (SD 6.2%). Most participants were at a low future risk of both
TABLE 21 Completeness of the Leicester Self-Assessment risk score variables (continued )
Variables All (N= 675), n (%) Complete case (N= 365), n (%) Imputed (N= 675), n (%)
Waist circumference (cm)
< 90 153 (22.7) 90 (24.7) 153 (22.7)
90–99.9 153 (22.7) 92 (25.2) 153 (22.7)
100–109.9 153 (22.7) 83 (22.7) 153 (22.7)
≥ 110 157 (23.3) 101 (27.4) 157 (23.3)
Unable to assess 59 (8.7) 0 59 (8.7)
BMI (kg/m2)
< 25 188 (27.9) 111 (30.4) 188 (27.9)
25–29 182 (27.0) 116 (31.8) 182 (27.0)
30–34 123 (18.2) 71 (19.5) 123 (18.2)
≥ 35 109 (16.2) 67 (18.4) 109 (16.2)
Unable to assess 73 (10.8) 0 73 (10.8)
Antihypertensive medication or high BP
No 525 (77.8) 325 (89.0) 609 (90.2)
Yes 66 (9.8) 40 (11.0) 66 (9.8)
Unable to assess 84 (12.4) 0 0
Complete data for Leicester Self-Assessment risk score
Total 365 365 595
Final score
Low (0–6) – 63 (17.3) 112 (18.8)
Medium (7–15) – 145 (39.7) 237 (39.8)
High (16–24) – 121 (33.2) 193 (32.4)
Very high (25–47) – 36 (9.9) 53 (8.9)
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CHD (83.5%) and CVD (75.3%) (Table 23). However, 16% of participants were at an intermediate or high
risk of developing CHD in the next 10 years, and 25% of participants were at an intermediate or high risk
of developing CVD in the next 10 years.
Establish data linkage to Hospital Episode Statistics and the
Office for National Statistics
Of the 930 people who were recruited to the main study, 883 (95%) gave additional consent for the
research team to follow up their health in the longer term. Preliminary work to establish data linkage is
currently being conducted.
Discussion
Summary of main findings
Utilising a variety of approaches to identify/invite potential volunteers, 930 adults with ID (29% of those
approached) participated in the screening programme; 38% were able to consent for themselves, whereas
other participants required a consultee. Anthropometric measures (≈86%) and BP (89%) were obtained for
most participants. A high proportion of participants agreed to attend for a blood test and, subsequently,
prevalence of T2DM/IGR was assessed for 675 participants (73%).
The mean age of participants was 43.3 years, 58% were male and the majority were of white ethnicity
(80%). Most lived either with family (36%) or in a residential/nursing home (38%); a high proportion
required 24-hour support (71%). Most participants were either overweight or obese; 2% had a history of
existing CVD.
Screening results indicated the overall prevalence of undiagnosed T2DM was 1.3% (95% CI 0.5% to 2%)
and IGR was 5.2% (95% CI 4% to 7%). Participants of non-white ethnicity were almost four times more
likely to have abnormal glucose levels than white European participants; those with a first-degree family
history of diabetes were over three times more likely.
TABLE 22 Sensitivity, specificity, PPV and NPV with 95% CIs for the cut-off point of ≥ 16 points on the Leicester
Self-Assessment risk score for predicting IGR/T2DM
Analysis Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Complete case (n= 365) 81.8
(59.7 to 94.8)
59.5
(54.1 to 64.7)
11.5
(6.9 to 17.5)
98.1
(95.1 to 99.5)
Imputed (n = 595) 83.3
(67.2 to 93.6)
61.4
(57.2 to 65.4)
12.2
(8.4 to 16.9)
98.3
(96.3 to 99.4)
NPV, negative predictive value; PPV, positive predictive value.
TABLE 23 Ten-year risk of CVD event: Framingham risk score212,213
Risk CHD, n (%) CVD, n (%)
Low (< 10%) 314 (83.5) 283 (75.3)
Intermediate (10–20%) 54 (14.4) 78 (20.7)
High (> 20%) 8 (2.1) 15 (4.0)
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Comparison with previous evidence
The prevalence of previously undiagnosed T2DM detected in the screening programme is much lower than
previously reported.90 Combined evidence from other studies, as presented in the meta-analysis in Chapter 2,
suggests a prevalence rate of 8% for T2DM in adults with ID. Data to enable comparison of rates for T2DM in
the UK population with ID are scarce (it is suggested that 85–90% of diabetes is T2DM20). Current estimated
prevalence of diabetes (type not specified) in England, based on combined data reported by partnership
boards, is 6.8% (range 6.2–8.4%) for people with ID of any age.51 Based on current data supplied by 40
(55%) of the general practices that took part in the STOP Diabetes study, the suggested prevalence of
diagnosed diabetes (type not specified) locally is 9.5% (n = 148 of 1553 adults aged 18–74 years with ID).
The estimates above are based on previously diagnosed diabetes. Our study aimed to screen adults with ID
to identify undiagnosed T2DM. The rates suggested by data supplied by local general practices, alongside
the higher recorded uptake of health checks locally (57–66% across the three CCGs)226 than the national
average (44%),55 suggests that at a local level the lower rate may simply reflect a successful annual health
checks programme. In the general population, estimated prevalence of diabetes rises from 6.2% to 8.0%
when including undiagnosed cases.18 However, it is acknowledged that the proportion of adults with ID
who currently have bloods checked, including for diabetes, as part of their annual health check is unclear.
Strengths and limitations
To our knowledge, this is the first diabetes screening study that has been conducted in adults aged
18–74 years with mild to severe/profound ID. The successful integration of a multidisciplinary team,
consisting of experienced researchers and ID HCPs, enabled the successful development and conduct of
the STOP Diabetes screening programme. This multidisciplinary approach allowed for sharing of knowledge
and best practice, and was complemented by service user involvement, particularly in the early stages of
developing and trialling study procedures/processes.
The screening programme developed utilised robust methods. All of the data were collected by staff who
had undertaken study-specific training and were following standard operating procedures. Minimal
exclusion criteria were applied to the study, and reasonable adjustments to facilitate inclusion – such as
staged invitation, easy-read documents, flexible appointments and carer involvement – maximised
participation. This ensured that as many people as possible participated rather than being arbitrarily
excluded. Additionally, we applied a staged approach to invitation and made efforts to contact/chase all
people when possible.
It is acknowledged that we were unable to establish any contact with approximately 30% of people who
were non-responders. We therefore do not know if they are different in any way from those who were
included in the screening programme; evidence suggests that people with mild ID may be at increased risk
as a result of unhealthier lifestyles and are less likely to access services.11 However, similarities in the
demographic characteristics (age, sex, ethnicity) between participants in this study and adults with ID on
the Leicester Learning Disability Register suggest that the STOP Diabetes cohort is a representative sample
of the population with ID that is known to services within the Leicester, Leicestershire and Rutland area.
The validation of the Leicester Self-Assessment risk score in the population with ID was successful despite the
limited number of events and wide 95% CI. Estimates suggest that the Leicester Self-Assessment risk score
works as well in populations with ID as in the general population: sensitivity 81.8%. Based on this, 140
participants would be referred for unnecessary screening. However, the tool is designed for use in a
multistage screening programme and we would rather send more people through the first stage than
falsely reassure.
Implications for clinical practice and future research
The screening uptake of those approached, at 29%, was relatively low, but it was favourable compared
with two previous screening/prevention studies conducted locally in the general population, for which
22% and 19% of those invited took part.227 These relatively low rates of uptake might reflect the fact that
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participants were invited to screening as part of a research project. If the intervention was rolled out in
clinical practice, higher rates would be expected; for example, uptake rates to the NHS Health Check
Programme,228 which is not a research project, are double those reported in this and other research
screening studies. Future research should focus on increasing uptake to screening in all groups.
Bloods to enable diabetes screening were successfully obtained for a high proportion of participants.
However, future research may want to consider allowing for separate consent for blood tests so as to
not deter people at the initial recruitment stage. Very few people directly expressed ‘the blood test’ as a
reason for refusal to participate in the screening study, but anecdotal evidence suggests that this may have
deterred some. Alternatively, a staged approach to screening, involving risk stratification as recommended
by NICE, might be considered.27
Our findings suggest that the Leicester Self-Assessment risk score is statistically effective at identifying
people with ID who are at a high risk of undetected IGR/T2DM. However, the feasibility of using it in
practice with people with ID – given the levels of heterogeneity within the population with ID – needs to
be considered. It may not be practical or acceptable for people with ID to calculate their own score, with
or without added support from carers. Future research could involve developing an easy-read version (plus
a carer supplement) and additional supportive material/communication aids, such as digital audio/visual
materials; qualitative research would be needed to supplement this work. Alternatively, a better way may
be to integrate the risk score at practice level and incorporate it into the Learning Disability Health Check
(the learning disability Annual Health Check scheme).
Concluding remarks
This chapter presented the main results of the screening programme for WP1. The methods and results of
the physical activity substudy are presented in Chapter 7.
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Chapter 7 Physical activity substudy
Overview
This chapter describes the physical activity substudy, which was conducted alongside the screening
component in WP1. The main methods and results of the screening stage are described in Chapters 5 and 6,
respectively.
Aims and objectives
The aim of this substudy was to assess the feasibility of collecting physical activity data with the use of a
waist-worn accelerometer (ActiGraph, Pensacola, FL, USA) (Figure 18). However, given the poor uptake to
this initial measurement tool, we extended our aim to also include the feasibility of collecting physical
activity via a wrist-worn device (GENEActiv, Activinsights Ltd, Cambridge, UK).
Methods
Participants
Participants who met the eligibility criteria, as outlined below, were asked to wear an accelerometer as
part of the main screening component of WP1.
Inclusion criteria
1. Consented to take part in the main screening component.
2. Able to walk without assistance (stick or similar walking aid permissible).
Participant recruitment process
Initial assessment of eligibility to participate in the physical activity substudy commenced during the
capacity assessment process (outlined in Chapter 5) and was subsequently confirmed once consent to the
main screening study had been obtained. Eligible participants were then approached about wearing an
accelerometer. For most people, this was usually at the end of their first screening appointment.
Data collection
Participants were asked to wear an accelerometer for 7 consecutive days, not including the appointment
day. The procedure for wearing the accelerometer was explained to the participant and/or carer by an ID
research nurse. Participants were also provided with a brief accelerometer information leaflet/diary in an
easy-read format, which explained how to use the accelerometer; this diary was also used to log when
participants had worn the accelerometer, with a page for each of the 7 days.
After wearing the accelerometer, participants were asked to return it at their next appointment. If a
participant was not having another planned appointment, a member of the research team would contact
them to arrange a convenient time for the accelerometer to be collected. If an accelerometer was not
returned or unsuccessfully collected, the research team made repeated attempts (at least three) to try and
retrieve it.
Two different accelerometers were used to collect data. Initially, physical activity data were recorded using a
waist-worn accelerometer. Later, it was decided to also trial a wrist-worn accelerometer, given the poor
compliance that was emerging with the waist-worn device (see Results) and following discussion with service
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users (who were assisting with patient and public involvement activities). The wrist-worn accelerometer was
anticipated to encourage greater compliance, as it is waterproof and can also be worn when sleeping;
therefore, participants could wear it continuously over the 7-day period.
Full details of the assessment of outcomes are described in Assessment of physical activity outcomes.
Outcomes
Physical activity levels were included as one of the secondary outcomes for the main screening study (see
Chapter 5). Other anthropometric (BMI, waist circumference), demographic (ethnicity and social deprivation)
and biochemical (fasting blood glucose and HbA1c levels) outcomes assessed are described in Chapter 5.
Sample size
Initially, we aimed to include at least 50 participants who were wearing the waist-worn accelerometer.
This was updated to include a comparable number with the wrist-worn device.
FIGURE 18 Waist-worn accelerometer (ActiGraph) and wrist-worn (GENEActiv) accelerometer.
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Assessment of physical activity outcomes
The participants who were attending screening were offered the option of having their physical activity
levels assessed by a waist-worn accelerometer. Once we had achieved our initial aim of at least 50
individuals with data, the remaining cohort were offered an alternative wrist-worn accelerometer. Details
of the two accelerometers and analytical methods used are presented below.
Waist-worn accelerometer
ActiGraph waist-worn triaxial accelerometers were attached to the trunk (placed on the right anterior axillary
line) using an elasticated belt. The participants were asked to wear the accelerometer during waking hours for
7 days, taking it off only at night when going to bed or when participating in water-based activities, such as
showering or swimming. Participants (and carers) were shown how to reattach the accelerometer after sleep,
and carers were asked to provide reminders. Data were set to record at 100 Hz and analysed using a
commercially available software package, KineSoft version 3.3.76 (KineSoft, SK, Canada; www.kinesoft.org).
Data were converted into 60-second epochs and count-based format. Time spent sedentary, in light-intensity
physical activity and in MVPA was estimated by applying commonly used thresholds for adults.229 Non-wear
time was classified as 60 minutes of continuous zero counts.
Wrist-worn accelerometer
The GENEActiv original wrist-worn triaxial waterproof accelerometer was worn continuously on the
participant’s non-dominant wrist for a minimum of 7 days. Data were captured in 100 Hz and processed
using two methods.
Data analysis method 1
Raw acceleration data were converted to 60-second epochs using the GENEActiv Post-Processing PC
Software version 2.2 (Activinsights). Next, the 60-second epoch data files were entered into an open-source
Excel macro v2 (Activinsights) in order to classify activity. Subsequently, time spent in sedentary, light-intensity
and MVPA activities was calculated for each participant-day using validated cut-off points.230 Sleep time was
estimated using a defined algorithm (Activinsights) and subtracted from total sedentary time in order to
calculate time spent sedentary while awake.
Data analysis method 2
Given that standard definitions for physical activity categories are lacking for wrist-worn devices, we also
included an alternative approach that was reported in the literature using the Euclidian Norm Method.231
Data were processed in a freely available R package (GGIR version 1.2–0, http://cran.r-project.org, The R
Foundation for Statistical Computing, Vienna, Austria) using the previously described methodology to
include time spent in sedentary, light-intensity physical activity and MVPA.231,232 In additional, total physical
activity levels were reported in mg, where g = gravity.
Inclusion of physical activity data
Physical activity data were included from a device if there was a minimum of 8 hours’ wear per day for at
least 3 days.
Data analysis
Data are presented as means (SDs). Analysis of covariance models were used to compare differences in
levels of assessed physical activity between monitors, adjusted for age, sex, social deprivation and
wear time.
Results
Feasibility of using accelerometers to assess physical activity in adults with
intellectual disabilities
Participants were recruited to take part in the physical activity substudy between October 2013 and August
2015 (Figure 19).
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Overall, 203 participants were approached to wear the ActiGraph waist-worn accelerometer. Subsequently,
97 participants (48%) agreed to wear the ActiGraph, and valid data (≥ 8 hours per day for 3 days) were
obtained for 55 participants (57%). Reasons for attrition included 14 participants (14%) not returning their
accelerometer and 28 participants (29%) not having enough valid days of wear for analysis.
A total of 76 participants were asked to wear the GENEActiv wrist-worn accelerometer and 47 participants
(62%) agreed. Valid data were obtained for 39 participants (83%). Two individuals (4%) did not return
their accelerometer and six participants did not have enough valid days of wear (13%).
Characteristics of participants in physical activity substudy
The characteristics of those who agreed to wear an accelerometer, on either the wrist or the waist, and
those with valid physical activity data stratified by accelerometer type are shown in Table 24. Characteristics
were similar between those who had valid physical activity data and those who did not. Characteristics were
also similar between those who had valid waist-worn and and those who had wrist-worn accelerometer
data. Overall, 54% of participants were male, their mean age was 39.9 (SD 13.0) years and 85% were of
white ethnicity. Thirteen per cent lived alone, 42% lived in supported living and 46% lived with family; the
majority (88%) had support from a carer for at least some of the time.
Main findings
The estimates of time spent in MVPA, light-intensity physical activity time and sedentary time are presented
across the different monitors and physical methods used (Table 25). Estimates for MVPA and sedentary
time were significantly higher with the wrist-worn device, whereas estimates of light-intensity physical
activity were lower. The total physical activity volume measured by the wrist-worn device was 26.7 mg
(SD 8.7 mg).
Refused
(n = 29)
Refused
(n = 106)
Participants
asked
(n = 203)
Participants
asked
(n = 76)
Waist-worn
accelerometer
ActiGraph
Wrist-worn
accelerometer
GENEActiv
Participants
agreed
(n = 97)
Participants
agreed
(n = 47)
No valid data
(n = 6)
No valid data
(n = 28)
Valid data
(n = 55)
Valid data
(n = 39)
Not returned
(n = 2)
• Not contactable, n = 1
• Accelerometer lost, n = 1
• Not contactable, n = 9
• Accelerometer lost, n = 5
Not returned
(n = 14)
Accelerometer
returned
(n = 83)
Accelerometer
returned
(n = 45)
FIGURE 19 Collection of accelerometer data. (Data validity was based on a minimum of 8 hours’ wear per day for
at least 3 days.)
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Discussion
The key finding from this substudy was that the objective measurement of physical activity is likely to be
challenging in adults with ID with high levels of non-compliance; however, compliance can be substantially
improved and loss of accelerometers reduced with wrist-worn monitors. Overall, < 50% of participants
agreed to wear the waist-worn device, with valid data collected for only 57% of the sample. In contrast,
62% agreed to wear the wrist-worn device, with 83% providing valid data.
To our knowledge, this is the first study to access the feasibility of collecting objectively assessed physical
activity data in those with ID. However, other studies have reported high levels of missing data when using
objectively measured physical activity within their study protocol.164,233 These results suggest that studies
including accelerometers may have poor uptake unless the participants are allowed to consent separately
for this element. These factors will need to be taken into account and considered carefully in future
physical activity intervention studies within this population.
To assist with compliance in our study, participants (and carers) were provided with a physical activity diary
(instructions) in an easy-read format. Service users were involved with the development and initial testing
of the diary; however, no formal assessment was conducted to see if the diary increased compliance for
participants (and carers). Given the heterogeneity in capacity levels and support needs of individuals, further
work is needed to explore possible ways to improve compliance with accelerometer wear in people with ID.
Based on estimates from the waist-worn device, our population engaged in more MVPA than several other
studies conducted in those with ID. For example, studies from Scotland and the USA have reported between
7 and 14 minutes per day of MVPA.164,233 Estimates for MVPA from the waist-worn device were also slightly
higher than levels reported in a primary care cohort from Leicestershire, UK.234 Similarly, estimates for total
physical activity from the wrist-worn device were consistent with those reported for healthy non-obese adults
and higher than those reported for obese or unhealthy populations within the UK.235 However, in the UK a
previous research study on those with ID reported similar levels to those found in our study.236 This suggests
that, in the UK, those with ID are not less active than the general population. This is despite institutional
barriers that have been hypothesised to inhibit physical activity engagement in those with ID.237
An important finding from this substudy was the difference in activity levels gained from wrist- and
waist-worn devices. Although waist-worn devices have been widely used in research over the last decade,
with established methods of categorising collected data, which allows for comparisons between studies,
TABLE 25 Levels of physical activity and sedentary behaviour as assessed by the waist- (ActiGraph) and wrist-worn
monitors (GENEActiv)
Physical activity measures Waist worn
Wrist worn
Method 1 Method 2
Method 1 vs.
waist differencea
Method 2 vs.
waist differencea
Time in MVPA (minutes/day) 33.6 (30.8) 136.9 (79.9) 95.8 (51.8) p< 0.001 p< 0.001
Time in light-intensity physical
activity (minutes/day)
269.1 (72.7) 105.7 (47.1) 195.1 (73.7) p< 0.001 p< 0.001
Time spent sedentary
(minutes/day)
499.2 (96.7) 632.5 (136.4) 790.8 (116.1) p< 0.001 p< 0.001
Ambulatory activity (steps/day) 6761 (3483) N/A N/A
N/A, not applicable.
a Adjusted for age, sex, social deprivation and wear time or estimated waking hours.
Data validity: wrist method 1, based on ≥ 8 hours’ wear per day for ≥ 3 days; wrist method 2, based on ≥ 16 hours’ wear
per day for ≥ 3 days.
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wrist-worn devices are newer and lack standardised approaches to data analysis. Although the underlying
raw acceleration data between waist- and wrist-worn monitors are likely to be highly correlated, commonly
used methods of converting these data into meaningful outputs, such as time spent in MVPA, are likely to
be monitor and placement specific. This has important implications for future trials and suggests that
intervention effects, SDs and population means should be estimated using data gained from the same tool
that will be used in the study.
Concluding remarks
This chapter has described a physical activity substudy, which formed part of WP1. Chapter 8 describes the
first phase of the education development process that was carried out as part of WP2, to develop an initial
curriculum for a lifestyle education programme for adults with ID.
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Chapter 8 Development of initial curriculum for
structured education programme
Chapter overview
This chapter describes the work undertaken for WP2 to develop an educational programme for a
population with ID and IGR or a high risk of developing diabetes and/or CVD (based on increased BMI
level). A brief overview of the complete development process is presented below (see Overview of the
development process). The remainder of this chapter details the work conducted to develop an initial
curriculum. Further development work, including two pilot cycles of testing, evaluation and modification,
is described in Chapter 9. An additional feasibility phase, which formed part of WP2, is presented in
Chapter 10.
Aims and objectives
The aim of WP2 was to develop a structured lifestyle education programme for the prevention of T2DM
would be suitable for use in a population with ID.
The specific objectives were to:
1. develop a lifestyle education programme for a population with ID who have IGR or are at a high risk of
developing T2DM and/or CVD based on increased BMI level (see Chapters 8 and 9)
2. assess the feasibility of collecting outcome measures for participants with ID before and 3 months after
they attend the education programme (see Chapter 10).
Overview of the development process
A multidisciplinary team with expertise in ID and in the development of nationally recognised diabetes and
CVD prevention programmes developed the intervention. A systematic approach was used (Figure 20),
based on the current Medical Research Council framework for developing and evaluating complex
interventions238 and intervention mapping.239 This included reviewing the relevant published evidence from
existing programmes and the behaviour change literature. The curriculum was informed by previous
prevention programmes that our research group has developed.240–242 Additional qualitative work was
undertaken to further inform the content, process and style of delivery.
Following the development of an initial curriculum, two cycles of testing, evaluation, modification and
retesting were conducted during the pilot phase (presented in Chapter 9) prior to the programme being
used in a third iteration, in which the feasibility of collecting before-and-after data was explored (presented
in Chapter 10). This iterative and reflective process, supplemented by qualitative research methodology, is
an approach that our group has previously used, successfully, to adapt patient education modules for
different groups.240,243,244
The core multidisciplinary team – including ID nurses, education team members, a qualitative researcher
and the lead study researchers – met monthly throughout all stages of the development, supplemented by
more frequent meetings at key points in the process. The purpose of these meetings was to decide on the
key elements relating to the content, process and style of the initial curriculum, and, subsequently, reach
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agreement on any modifications required. This collaborative multidisciplinary approach allowed the
expertise of all of the members to be used and facilitated the iterative and reflective process.
This development work occurred over a period of approximately 27 months, commencing in October 2012
and ending in January 2015, when the final refinements were made to the curriculum (ready for use in the
feasibility phase described in Chapter 10).
Participants
People invited to engage in WP2 (qualitative interview, see Chapter 8; pilot education sessions, see Chapter 9;
or feasibility testing, see Chapter 10) were service users with mild to moderate ID who had taken part in the
screening stage (see Chapter 5) and screened positive for IGR or had a BMI of ≥ 25 kg/m2, and, at that time,
consented to being approached to assist with later phases of the research programme. Carers were also
approached. An invitation pack, including easy-read documents, was sent directly by the research team.
For people volunteering, the capacity assessment and consent followed a similar process to previous stages
(see Chapter 5).
Development of
curriculum
Qualitative interviews
Service users
HCPs
Commenced May 2013
Review of the evidence
ID-specific research
Behaviour change literature
Existing prevention programmes
Commenced January 2013
Piloting and obtaining
feedback
Two cycles (iterations)
April–July 2014
October–December 2014
Curriculum ready for 
feasibility phase
January 2015
FIGURE 20 How phases of the development work fit together.
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For people with ID who were invited to assist with the qualitative exploratory interviews (see Qualitative
work to inform development: methods), no further eligibility criteria applied. Additional inclusion criteria
for invitation to attend the pilot education sessions and give feedback (see Chapter 9) or the feasibility
phase (see Chapter 10) included:
l having the ability to stand and walk at least short distances
l having the ability to attend group education sessions
l not taking part in any other intervention study.
Intellectual disability HCPs were also invited to contribute/assist with development of the initial curriculum
by agreeing to a qualitative interview. Further details are provided below (see Recruitment for interviews).
Qualitative work to inform development: methods
To help inform development of the initial curriculum, semistructured qualitative exploratory interviews were
conducted with service users (and carers) and with HCPs providing services to adults with ID. This qualitative
work was carried out between May 2013 and June 2014.
Recruitment for interviews
To enable a range of views to be captured, a provisional quota was set of conducting up to 25 interviews
with the various stakeholders (HCPs and service users with ID).
The recruitment of HCPs commenced in May 2013. A variety of HCPs were identified through ID services
at LPT. The invited HCPs all had previous experience of working with adults with ID. Purposive sampling
was used to ensure the inclusion of HCPs who could offer a range of perspectives based on their
occupation/professional background. Potential interviewees were sent an invitation pack.
For service users (and carers) the recruitment began in January 2014. The eligibility criteria and method of
approach are described previously (see Participants).
Data collection and recording
Topic guides were developed to ensure that relevant issues were captured (see Appendix 19 for service
user example). The interviews were semistructured and based on open questioning to elicit issues
surrounding knowledge, understanding and experience of T2DM and modifiable risk factors, relevance of
IGR, perceived barriers to behaviour change and support needs for people with ID. The practical aspects
of the delivery of an education programme were also explored, for example whether or not to develop
separate interventions for carers (family members and/or key workers) and people with ID, the inclusion of
follow-up sessions and the length of the programme.
Questions were asked appropriately depending on who was being interviewed. Additional communication
tools were used when interviewing service users, such as prompt cards depicting images of various
activities (e.g. swimming, bowling, walking) to help with eliciting contributions.
The interviews with HCPs were conducted between June and August 2013. All of the interviews were
conducted by an experienced qualitative researcher at the HCP’s normal place of work.
The interviews with service users were conducted from January to June 2014. There was an initial delay in
finding service users who were either eligible to be invited or willing to be approached/interviewed. All of
the interviews were conducted by the same qualitative researcher, with assistance from an ID research
nurse. The researcher had expertise in developing and modifying diabetes prevention programmes for
different populations; prior to commencing the interviews, the researcher had undertaken additional
training within the research team to increase his or her knowledge and skills in the area of ID. To suit the
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needs and preferences of individual participants, the interviews were conducted in a variety of community
settings, including at a participant’s family home, a residential/care home, an assisted independent-living
flat and a community clinic.
Data analysis
Audio-recordings of interviews were transcribed verbatim and a thematic analysis was conducted using
NVivo version 7 (QSR International, Warrington, UK), a qualitative software programme. Subsequently,
themes that were relevant to the development of the intervention were identified.
Qualitative interviews: findings
Characteristics of participants
Service users
Eighteen service users were invited to participate. A total of seven service users were subsequently
interviewed (Table 26). In two of the interviews, carers were present (one was a family carer and the other
was a care worker). Three of the service users who participated were male; the median age of participants
was 47 (range 28–68) years and all participants were of white European ethnicity. Six participants lived in a
supported environment with family or carers and one lived independently. One of the participants was in
paid employment (and did voluntary work), two attended college, two others carried out voluntary work
and the remaining participants undertook other activities in the community on a regular basis.
Health-care professionals
Twenty HCPs were invited to participate. Subsequently, 14 HCPs were interviewed. All of the HCPs
currently worked with adults with ID as all, or part, of their job. Professionals included ID psychiatrists,
people in nurse-related roles (acommunity/primary care ID nurse, a practice nurse, an acute liaison nurse,
TABLE 26 Characteristics of service users who were interviewed
Characteristics of service users (N= 7) n
Age (years)
18–39 3
40–59 3
60–74 1
Sex
Male 3
Female 4
Accommodation
Alone 1
With family/carers 3
Residential home 3
Level of support
Independent 2
Some support 2
24-hour support 3
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a nursing assistant), allied HCPs (a clinical psychologist, an occupational therapist, a speech and language
therapist) and a day centre manager (Table 27).
Key points from interviews with service users and carers
The interviews conducted with service users ranged between 9 and 15 minutes in duration.
In a few of the interviews it was possible to explore awareness of diabetes. Service users related this to
‘sugar’; they also spoke about family members who had diabetes and recalled them being on tablets
and having injections. Attempts to gauge service users’ knowledge about healthy lifestyles elicited that
some were able to describe basic health messages, such as eating vegetables, eating a high-fibre diet
and exercising.
The interviews did yield some useful insights into the lives of service users, for example the types of
food that they enjoyed and the degree of choice and control they had in relation to foods consumed;
discussions about commonly consumed foods ultimately influenced the food images and food models
in the dietary sections of the curriculum. For a few participants, the additional use of prompt cards
enabled useful discussion around the types of physical activities undertaken; for those who were more
independent, walking appeared to be the most preferred and accessible form of physical activity.
It was difficult to explore service users’ preferences towards learning as part of a group or learning on an
individual basis. However, the majority of participants spoke about going to some form of group activity
sessions, such as sessions held at a local day care centre or a college; activities included arts and crafts,
and learning ‘life skills’ to facilitate independence. Further discussion about participants’ preferences for
photographs or pictorial images (on educational resources) suggested that most preferred photographs.
TABLE 27 Characteristics of HCPs interviewed
Characteristics of HCPs (N= 14) n
Age (years)
20–39 5
40–59 7
Unknown 2
Sex
Male 2
Female 12
Profession
ID psychiatrist 2
Allied HCP 5
Nurse related 6
Other 1
Length of time working with adults with ID (years)
< 5 1
6–10 2
≥ 10 9
Unknown 2
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More general points arising from the interviews included practical considerations to be taken into account.
First, education sessions needed to be held locally (minimal travelling distance/time for participants) in a
setting that was familiar and in a venue that was easily accessible via public transport or similar. Second, it
was important to include carers in the education sessions to help (1) support participants and make them
feel at ease during sessions and (2) facilitate service users in making changes to their diet and physical
activity outside the sessions. It was clear from the interviews that both professional and family carers
currently fulfilled this role in the daily lives of participants.
Key points from interviews with health-care professionals
All of the HCPs were enthusiastic to share their knowledge and experience of working with people with
ID. Most HCPs had previous or current experience of promoting positive behaviour change with people
with ID for behaviour management and/or health promotion.
Pre assessment
The majority of HCPs stressed the importance of undertaking a pre-assessment prior to embarking on
delivery of an education session. Frequently stated reasons relating to carrying out a pre-assessment
included:
l enabling cognition matching, which would involve the assessment of preferred communication styles,
reading and writing abilities, and preferences for working with pictures and/or written sheets/flip charts
l ensuring that any differences in severity of ID (mild to moderate) between individuals in the group are
not too wide
l identifying and supporting people who may face challenges or difficulties with verbal communication
(e.g. some people may be able to say only ‘yes’ or ‘no’)
l preparing people for taking part in a programme and working in a group setting
l gaining a measure of the level of insight that a person may have about their own health and the
perceived relevance of the programme to themselves
l assessing a participant’s ability to identify and engage with their own priorities, and reflect on their
own skills for undertaking change or wanting to change
l assessing how best to support individuals with decision-making.
Suggested activities relating to what pre-assessment could involve were:
l speaking to the person with ID [and their carer(s), as appropriate] and carrying out an assessment via
discussion/interview using established tools (questionnaires and checklists) or observations
l extracting relevant information from health action plans and core information
l eliciting relevant information and knowledge from staff teams involved with the person with ID.
Process and delivery of the programme
Preparing the group for learning
Ensuring that participants are in the right frame of mind or in the ‘best place to learn’ (HCP 07) requires
some thought and preparation; one HCP described some of the strategies that they used to promote this
during a ‘healthy living’ course. These included participants having two or three short breaks over every
1-hour period, or undertaking physical activity, or being encouraged to be physically mobile during the
education sessions:
Because if you get them in the wrong place or they’re not in at the right level of arousal or even in the
right mood, this can impact on their willingness and their ability to take in information.
HCP 07
Other ways in which participants’ receptiveness to learn was developed were through watching videos or
taking part in practical fun activities.
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Choosing methods to promote healthy choices
To deliver knowledge and promote healthy food choices, HCPs described using visual aids, including
photographs and pictures of foods from magazines. They also discussed the importance of undertaking
practical activities, such as preparing healthy foods. The rationale for these kinds of sessions was to show
alternatives in a very literal way. In addition, to try to convey that too much of a particular food was bad for
health, it would be necessary to show actual or pictorial images from real life, rather than cartoon images:
. . . rather than saying ‘too many biscuits’, which are words. You want to show pictures of biscuits and
you want to show one pack, plus two pack, plus three pack is this much. Stuff like that. So real
pictures, or even better real objects.
HCP 04
In relation to the number and type of messages during a session, the advice from HCPs was to keep the
messages simple and not to give too many during one session.
Ways of promoting physical activity
Some HCPs suggested that giving an opportunity for participants to experience some of the activities
during the education sessions (e.g. swimming or going for a walk) would be an effective way to convey
messages about increasing levels of physical activity. If this was not possible, another suggestion was using
pictorial images to stimulate discussion about how physical activity could be integrated into someone’s life.
This would need to take into account individual needs, such as restrictive budgets, physical ability and level
of independence. If going for a walk was not possible for some people, alternatives could be skipping or
dancing to music.
The use of open-ended questions
When asked specifically whether or not the use of open-ended questions was appropriate for adults with
ID, most HCPs went on to describe using this style of questioning with service users. However, they
emphasised the need to follow up this approach with specific and direct questions. This helped to
ensure that questions were not ‘too open’ or in danger of being misinterpreted. For example, as one
HCP explained:
So sometimes open-ended questions can be too open. You have to be more specific, like . . . for
ground rules – ‘What is going to keep us all safe amongst ourselves?’ – Not talking about slips, trips.
Do you see what I mean? That you probably do have to tailor it a little bit . . .
HCP 03
Some HCPs also suggested that educators should not assume that commonly used words will always be
understood by participants. They emphasised the importance of eliciting understanding on a frequent
basis throughout the session and checking for consistency of responses. Other recommended strategies
(particularly for those with autism) included giving two options or choices and changing the order of these
to check that the participant’s selection is based on informed understanding.
One suggested disadvantage of asking open-ended questions was that it could place undue pressure on
some individuals and invoke feelings of distress if they do not know the answer; instead, educators may
need to use pictures to encourage a response.
Retention and recall
To aid the retention and recall of messages, the general advice was to use a combination of visual and
verbal communication, with opportunities to experientially learn. The need to cater for differences in
attention span, types and levels of abilities, and styles of learning, was emphasised. The key message of
the interviews was that a flexible approach is needed, including educators (1) gauging understanding at
regular intervals and addressing appropriately, and (2) using different methods to facilitate delivery to cater
for diversity within a group.
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Health beliefs and behaviours
When specifically asked, the majority of HCPs felt that the exploration of health behaviours may be
challenging. For some adults with ID, the ability to process thoughts and associate them with behaviours,
or to make causal links at a more complex level, may be lacking. The latter, they believed, may partly
be influenced by the environment in which people live; service users may have limited or restricted
opportunities to be in contact with (or be aware of) other people with a health condition. There may also
be a lack of control about dietary choices and/or their association with health conditions. One participant
felt that simple associations could be made, such as ‘too much sugar is not good’, and that these have the
potential to inform changes in health behaviour (HCP 04).
A divergent view was that people with ID are not any different from the general population in relation to
holding health beliefs. It may just be that the communication of these beliefs is different, necessitating
educators taking different approaches, or that their beliefs may be more unusual/idiosyncratic.
Understanding the concept of future health risk of developing diabetes and
self-reflection
When HCPs were asked whether or not people with ID are likely to understand the concept of risk, there
was variation in the responses. This appeared to be related to views on the heterogeneous nature of the
population with ID and also possible perspectives that were linked to the professional backgrounds of HCPs.
One view was that people with mild ID may understand the concept of risk but, generally, people with
autism would have difficulties. However, it was also felt that this would depend on an individual’s attitude
or motivation:
You’re going to have some people who do understand that things change in the future, and things may
deteriorate. Then you may have other people who wouldn’t have that concept at all. Particularly you
know if you’ve got somebody with autism and the future doesn’t really mean a great deal, because it’s
not concrete enough for their understanding and perception quite often. So I think it would depend on
the level of learning disability and many other conditions that the individual might have.
HCP 06
A few HCPs discussed the idea that people with ID may have difficulty understanding risk, as they may have
a cognitive impairment that challenges their ability to conceptualise, including projecting into the future:
I think those sorts of things are more difficult. A lot of the time we probably are used to working in
the here and now. So yes, projecting that this might happen to somebody, I think a lot of people find
that difficult, don’t they, to understand.
HCP 03
However, the following participant acknowledged that there was also evidence to show that it is:
. . . possible for people with a learning disability to be able to handle abstract information, reflect on it,
appraise it and therefore bring change, but that is probably best done by people skilled in offering
those interventions.
HCP 04
Some HCPs suggested ways to explain the concept of future risk, but among these suggestions was a view
that this had to be a balancing act between alerting and not scaring:
It’s really tricky ‘cause you don’t want to scare people, and people can get fixated on something and
worry about it, and worry about it. And it could become a bit of an obsession, and they could be
really worried and scared about that.
HCP 02
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The potential dangers of the above approach were discussed with another HCP, who suggested that
anxieties could be allayed by discussing the future with ‘positive bits’ (HCP 06).
One of the suggestions put forward for helping to promote self-reflection included using ‘DVD clips’ to
show alternative scenarios and facilitate non-threatening reflection (i.e. that it was not about them).
Nevertheless, even with this approach, it was acknowledged that it would take many weeks of guided
discussion and support to facilitate this process.
Drafting of initial curriculum
Key points for initial curriculum from the literature
At the start of the curriculum development process described in this chapter, a structured literature review
was conducted with a focus on existing lifestyle interventions for adults with ID, aimed at the primary
prevention of T2DM and/or CVD or modification of risk factors. This was supplemented by reviewing relevant
published guidelines, consensus statements, interventions currently in practice and service evaluations.
Later, this was formalised by conducting a systematic review to consider evidence on the effectiveness of
multicomponent lifestyle behaviour change interventions for reducing risk factors for T2DM and/or CVD.
The methods and findings of the systematic review are presented in Chapter 3.
Key findings from the literature that directly informed the content, theory and process of the programme
are described below. There were only a small number of studies with a focus on people with ID and
behaviour change lifestyle interventions. Few of these studies163–166 provided a description of their
theoretical underpinning, although they did recommend the use of social cognition models, such as the
Theory of Planned Behavior245 and Reasoned Action.246,247
The Healthy Lifestyle Change Program, which was developed by Bazzano et al.,163 was the only published
intervention at this initial stage in the development of the STOP Diabetes programme that outlined a
conceptual model. Thus, the STOP Diabetes theoretical conceptual framework, as shown in Figure 21, was
influenced by this approach.
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FIGURE 21 Theoretical framework for the education programme. PA, physical activity.
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The STOP Diabetes framework that was developed then informed all aspects of the education programme;
the framework highlights the importance of an individual’s beliefs about health, ill health and its
consequences, specifically the impact on them as individuals and their life. In terms of ‘attitude’, outcome
expectancies were explored, that is to say ‘what would happen if I engage in a particular behaviour and
how important is the outcome for me?’. Methods of learning, specifically vicarious, observational and
concrete kinaesthetic were also highlighted in the literature, as was the importance of social support and
peer norms.163,167,245–247
Self-efficacy is a key component of behaviour change,167 that is, the person’s belief that they can perform
the behaviour. However, there are many real barriers to behaviour change in this population, such as
disability and/or a lack of control over the physical environment, for instance not being the person who
buys or cooks the food. Therefore, the concept of actual behavioural control was included in the
theoretical framework to ensure that these issues were addressed in the programme. The influences of
strong intentions and a detailed action plan were also acknowledged. Intrinsic motivation and the power
of reinforcing feedback loops were also highlighted via distal and proximal reinforcers, and the positive
impact on quality of life and psychological well-being. These specific components of the programme can
be viewed below (see Table 28).
Additional key lessons from the literature were the need to (1) maximise carer involvement; (2) recognise
that people with ID have extremely heterogeneous needs and any intervention would require a multimodal
approach; and (3) acknowledge that pre-group preparation is essential.
Key points from the multidisciplinary development group
The overarching framework, content, process and learning methods for the programme were formed at a
large multidisciplinary meeting following a systematic process; this meeting was additional to the regular
monthly meetings that were held throughout the development process. The qualitative findings from
HCP interviews, relevant literature and core theoretical constructs were presented and debated, and a
consensus was formed. This was later supplemented by findings from the qualitative interviews with
service users (and carers), once available.
The core multidisciplinary team – which included ID nurses, education team members, a qualitative
researcher and the lead study researchers – met monthly throughout all stages of the development,
supplemented by more frequent meetings at key points in the process.
Key points agreed included:
l using a concrete kinaesthetic learning style
l ensuring that the resources developed and methods used to convey messages allowed for tailoring to
different levels of intellectual ability
l developing a specific carer session to engage and promote involvement
l ensuring that participants were appropriately prepared prior to attendance and at the start of
each session
l reflecting on their own levels of risk
l self-monitoring diaries and pedometers
l goal-setting and action planning
l exploring of barriers and individualised solutions.
The specific methods used to ensure that the themes highlighted above were operationalised are
detailed below.
Preparation and grounding
The team agreed that all of the service users (and carers/family members) would need to meet the
educator prior to commencing on the education programme. This would allow the educators to confirm
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suitability to attend the education sessions, make an assessment of any specific needs that would need to
be met, and briefly describe the sessions and check willingness to attend.
A specific carer session was to be held prior to the participant education sessions.
To provide familiarity and consistency, the sessions would be delivered in a familiar community facility on
the same day and time, with the room set out in the same way each week. Additionally, the same core
group of educators would carry out the pre-assessment visits and deliver the programme to ensure
continuity and develop rapport.
Style and principles of the education programme
Gaining an understanding of each participant’s emotional and physical well-being prior to each session
was seen as essential to allow facilitators the flexibility to meet the needs of individual participants.
Therefore, educators were to make time to meet and greet both the participants and carers before the
start of each session. Additionally, educators would establish a set of mutually agreed guidelines for the
group at the outset of the education session in order to support group functioning.
To meet learning styles within the group and tailor the content to meet individual needs, educators would
use multiple methods (to check understanding) and multiple modalities; the additional support of an
experienced ID health-care assistant would be utilised during the sessions.
Regular breaks would be taken, as indicated by the group’s expressed need or level of engagement.
Educators would use the session material to create concrete examples and develop activities that create
movement. In addition, the curriculum would be designed to support the use of recall and repetition to
support learning; resources developed by participants – such as posters, postcards, cue/prompt cards –
would support individuals to maintain behavioural and lifestyle changes.
Curriculum content and activities
The main behavioural goals and content (see Key behavioural goals of the education programme and
Table 28) were to be drawn from previous prevention studies.240–242 In addition, abstract concepts such as
risk and future self were to be developed as activities, games or stories using a concrete kinaesthetic
modality. To promote participant engagement in the programme, the educators would use practical and
participatory methods, such as food models and images, visual memory aids and short walks using a
pedometer. The educators would also use reinforcement methods, including certificates of attendance and
attendance cards, as a regular activity within the programme. Self-monitoring activities/opportunities (such
as diaries to record food and physical activity outside the session) would be promoted if the participant
chose to do these; the opportunity to use a pedometer and scales would also be available to monitor
weight when attending sessions. The curriculum would include action planning and goal-setting
opportunities (in most sessions) around activity, food and other behavioural goals, supported by
individualised resources. The educators would create opportunities through activities to explore barriers
and solutions on an individual basis and in group activities.
Key behavioural goals of the education programme
For the STOP Diabetes programme, the key behavioural goals and lifestyle messages incorporated into the
education sessions were based on those of the Let’s Prevent programme (nutritional)240 and PREPARE
programme (physical activity).241,242 Specific goals included losing weight, reducing consumption of total
and saturated fat, increasing dietary fibre consumption, and increasing physical activity and/or reducing
sedentary behaviour (Table 28). However, the emphasis of the STOP Diabetes programme was on enabling
the individual tailoring of goals, based on a participant’s needs and abilities, including potential mobility
restrictions, level of independence with food shopping and preparation, potential dietary restrictions,
opportunities to access the community, cognitive level, and availability and level of carer support required.
Therefore, more generalised behavioural goals were emphasised, rather than setting specified targets
(see Table 28).
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Discussion
This chapter describes the first phase of the development of a lifestyle behaviour change programme for
adults with ID. We took a pragmatic approach to intervention development, using the Medical Research
Council framework for developing complex interventions238 to combine existing prevention programme,240–242
intervention mapping,239 evidence reviews, stakeholder interviews and expert advice. This systematic process
allowed us to make the following underlying assumptions for the programme:
l People with ID have limited knowledge of healthy lifestyle messages.
l People with ID generally have poorer diet and exercise less often than the general population.
l Health beliefs, knowledge, motivation and social support are key in promoting behaviour change
among people with ID.
l People with mild and moderate ID need a specially tailored intervention to promote behaviour change;
mainstream interventions are not suitable for this population.
Our qualitative findings largely support the literature47–50 in finding that people with ID had limited
knowledge about healthy lifestyle messages and experienced barriers in undertaking physical activity.
However, we acknowledge that findings from the qualitative exploratory interviews with service users may
be limited because of the short interview length (average 9–10 minutes), although this length does not
include the additional time taken to explain the study, assess capacity, obtain consent and allow for
breaks. We recognise that people with ID are not a homogeneous group; some people found it difficult to
concentrate and for other people several visits to allow trust to be built up may have been a better
approach. Additionally, in some circumstances, carers (personal and care workers) were not able to be
TABLE 28 Key behaviour change goals
Specific nutritional and physical activity goals STOP Diabetes key behavioural goals
Weight reduction; sustained weight reduction of > 5% body weight Choose smaller portions
Reduce fat intake from all sources
Reduce sugary drinks and foods
Choose healthier cooking methods
Choose healthier snacks and treats
Increase physical activity/reducing sedentary
Reduce total fat consumption; moderate reduction in total fat to
< 30% energy intake
Reduce fat from all sources
Choose lower-fat options
Reduce processed foods and ready meals
Choose healthier snacks and treats
Low saturated fat intake; reduce saturated fat intake to < 10%
energy intake
Reduce fat from all sources
Reduce processed and ready meals
Choosing healthier snacks and treats
Higher fibre intake; increase fibre intake to > 15 g per 1000 calories Increase fruit and vegetable intake to five-a-day
minimum
Choose healthier snacks and treats
Increase physical activity/reduce sedentary behaviour; a minimum
recommendation of 30 minutes of moderate intensity physical activity
per day
Increase moderate intensity activity by increasing
steps or adding extra physical activity
Reduce sitting time
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present throughout the whole interview or, if there, they did not agree to participate. It would have been
beneficial to purposively seek the views of a larger number of carers (both personal and care workers) at
the development stage. However, we were able to obtain valuable feedback from carers during the
piloting phases (reported in Chapter 9) and modify the programme accordingly.
Concluding remarks
This chapter has described the first phase of the education development process that was carried out to
develop an initial curriculum for a lifestyle education programme for adults with ID. Chapter 9 details a
pilot testing and evaluation phase. Chapter 10 outlines a feasibility study that was conducted following
development of the education programme. Chapter 11 describes development of an intervention fidelity
process that was undertaken for WP3.
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Chapter 9 Pilot testing and evaluation of an
educational curriculum for prevention of type 2
diabetes
Overview
This chapter describes a pilot testing and evaluation phase, which follows on from work conducted to
develop an initial education curriculum (presented in Chapter 8). An additional feasibility phase, which
formed part of WP2, is presented in Chapter 10.
Aims and objectives
The aim of this further phase of the development work was to conduct two pilot cycles of testing,
evaluation and modification of the initial education programme.
Methods
Following development of an initial curriculum, a pilot phase, which involved two cycles of testing,
evaluation, modification and retesting, was conducted (see Figure 20) The first pilot cycle was conducted
between April and July 2014, and the second cycle from October to December 2014.
Participants and recruitment
The inclusion/exclusion criteria for WP2 were described in Chapter 8 (see Participants). Those invited to
engage in the pilot phase were service users who had taken part in the screening stage (see Chapter 5),
had screened positive for IGR or had a BMI of ≥ 25 kg/m2, and at that time consented to being approached
to assist with later phases of the research programme. Recruitment followed a similar process to that in the
earlier development phase (see Chapter 8, Participants). An initial telephone call was made to potential
participants, followed by further information sent in the post or provided at a face-to-face visit.
Delivery of the education
Potential volunteers with ID were approached about attending the education programme, approximately
4–6 weeks prior to the planned programme start date. Carers were invited to an initial session held
1 week before the delivery of the main education sessions. The aim of the carer session was to provide
carers with an overview of the education programme, and explore their role in supporting individuals with
ID, both within and between the sessions.
Subsequently, the initial curriculum was delivered to a group of individuals with ID. Carers were also
invited to attend the sessions to support the service users. Following feedback and refinement of the
curriculum (see Refinement), the modified curriculum was then delivered to a second separate group,
which, again, was followed by feedback and refinement.
Three educators were involved with delivering the programme at each session: a registered ID nurse, a
diabetes specialist with an education background, and an additional ID nurse or health-care assistant in
a supporting role. The educator training process for the study is described in Chapter 11.
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Data collection
A range of methods was used to evaluate the education sessions and collect feedback. These included
observations recorded during the sessions by an experienced researcher, reflections from the educators
leading the programme and qualitative interviews with people who received the programme (those with ID
and carers). Additionally, subsequent to the first pilot phase, educators were also interviewed to explore
their views about the content and style of delivery, experiences from delivering the programme and
perceived practical issues. Feedback and reflection on educator training are described in Chapter 11.
Participants were approached to take part in a feedback interview prior to the last session of the education
programme. Interviews were held as soon as possible after the final session. Written consent was obtained
immediately prior to the interview. Participant interviews took place in July 2014 for the first cycle and
December 2014 for the second cycle.
The purpose of these interviews was to explore participant and carer views about the education sessions,
to identify whether or not the education sessions resulted in changes to participants’ diet and physical
activity, and to inform changes to the next iteration of education sessions based on participant feedback.
Interviews were conducted and analysed by the same qualitative researcher that carried out the previous
interviews (see Findings: second pilot phase). Key areas and topics that were explored included experiences
of receiving the education programme, ease of understanding, views about the content and style of
delivery, usefulness, relevance and practical issues (including duration, provision of support and suggestions
for improvement).
Refinement
At the end of each pilot cycle, modifications were made to the curriculum prior to it being used in the next
iteration. Modifications and refinements were informed by findings from participant and carer interviews,
observations made during the education sessions, and the ongoing reflection and feedback of the educators.
Findings: first pilot phase
Uptake and attendance at education sessions
The first iteration of the education programme was held in a community resource centre. A total of 21
participants were invited to take part in the education programme. Five participants (four of whom had
carers) initially agreed to attend the programme. Following the carers’ session, one person (and their carer)
withdrew completely. Subsequently, four participants (and three carers) took part in the main education
programme. The overall attendance at the education sessions (7 weeks, one session per week) was very
good, with one participant (and carer) attending all of the 7 days and three participants attending 6 days
(Figure 22).
Characteristics of participants
Of the four participants taking part in the first iteration of the education programme, two (50%) were
male, the median age was 35 (range 29–60) years, three (75%) lived in a supported environment with
family or carers, and one lived independently. None of the participants was in paid employment, one
attended college and did voluntary work, and all four participated in other activities within the community.
Feedback interviews: first pilot cycle
Following on from the first iteration of the education programme, all of the participants (n = 4) and carers
(n = 3) agreed to be interviewed. One participant was interviewed independently. For the remaining three
interviews, carers and participants were interviewed together; in two of these interviews the carers made
major contributions to the interviews.
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Interviews with participants
Key learning and behaviour changes
One of the participants had previous experience of attending health-related courses/groups and, initially
during the interview, suggested that she had not learnt anything new. However, through further
exploration of the impact of specific activities/games, it was possible to identify that the programme had
reinforced key health messages, including types of healthy/unhealthy foods, portion sizes, and the link
between food eaten and body weight:
Mm, just be careful what . . . if you do eat any unhealthy [food] not to have so much of it . . . yeah,
makes you think, doesn’t it, er, if you don’t control what you eat, you do put . . . [Interviewer: Weight]
. . . Yeah, because they say this country’s, don’t they, obese?
Participant 2, female
Carers from home
n = 7 (+ carersa)
n = 5 (+ carersa)
n = 7 (+ carersa)
n = 6 (+ carersa)
n = 4 (+ carersa)
n = 5 (+ carersa)
n = 7 (+ carersa)
Second iteration
Participant invited
Agreed to attend
n = 9
n = 7
Initial carer
session
First education
session
Second education
session
Third education
session
Fourth education
session
Fifth education
session
Sixth education
session
Seventh education
session
Invited for feedback
interview
Interviewed
n = 7 (+ carersa)
n = 5 (+ 2 carersa)
n = 4 carers
n = 4 (+ 2 carersa)
n = 3 (+ 3 carersa)
n = 4 (+ 2 carersa)
n = 2 (+ 1 carera)
n = 4 (+ 2 carersa)
n = 4 (+ 2 carersa)
n = 4 (+ 3 carersa)
First iteration
n = 21
n = 5
n = 4 (+ 3 carersa)
n = 4 (+ 3 carersa)
FIGURE 22 Uptake and attendance at first and second testing phases of pilot cycle. a, Participants were supported
by various care workers who were present for part (or some) of the session(s).
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The carer of another participant cited the education sessions as helping the participant to become more
aware of the changes that he needed to make, although the participant was also receiving a form of
therapy (hypnotherapy) that he believed was helping him to make lifestyle changes:
Carer for participant 4: But since we’ve been on the course and you’ve attended the course and
they’ve told you this, you’ve become much more aware of it, haven’t you?
Participant 4, male: I have, yes.
Examples of the dietary changes made by this participant included reducing the portion sizes of less
healthy foods, swapping/replacing some foods for healthier alternatives and moderating the amount of
alcohol that he drank:
Um, I’ve also learned that, um, alcohol is, kind of, fattening, but as long as you don’t drink it too much . . .
Participant 4, male
Changes to physical activity included doing more walking and going to the gym. Consequently, this
participant (and carer) reported that he had initially lost 10 lbs in weight, which was maintained at 7 lbs
(immediately following the intervention). However, this participant also reflected that, as he grew older,
he was paying more attention to his lifestyle:
I just didn’t really care so much, to be quite honest, in the past. But now that I’m a lot more older,
I’m starting to take things more . . . more wrong, aren’t I, Mumsy?
Participant 4, male
Sustaining changes
One participant discussed the wearing of a pedometer (optional) to measure activity; this had helped to
quantify her existing level of activity, and to her surprise it was a lot higher than she had thought.
However, there was a sense of despondency that could be observed during her interview about the
perceived lack of support or encouragement she had in carrying out and sustaining lifestyle changes to her
diet and activity levels outside the sessions/in the future. This issue, coupled with her concerns about her
personal safety, featured in her decision not to seek more opportunities to go out walking:
[B]ut it’s just someone to go with, you know, encouragement . . . sometimes I give up easy with them
sort of things. But I’ve started taking a friend’s dog a walk once a week with my other friend and her
dog, so round [park], that’s nice. I go on the walks with the church and that . . . but I’m not walking
to [town] or [town] because it’s not safe.
Participant 2, female
She also questioned her ability to make changes. When probed further, she identified that she could make
changes if she had encouragement:
But sometimes I can’t believe that I can change it . . . I think I could with a bit of encouragement,
you know.
Participant 2, female
For two of the participants who had expressed a desire and commitment to make lifestyle changes, the
support and encouragement from carers and others in their lives assisted them with making changes and
possibly helping them to sustain these changes. In the case of one participant, the people in his workplace
were actively trying to support him to make changes (specifically changes to his diet). He acknowledged
that this support helped to keep him on track:
Carer for participant 4: . . . and so the girls there are trying to help and support you, aren’t they . . . in
every way they possibly can.
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Participant 4, male: It helps a lot, ‘cause then if I do it all by myself, I’ll be ending up having burgers
or something.
Asked if he could sustain the changes he had made to his lifestyle, the participant responded by saying
that he felt he could if he focused:
. . . if I put my mind to it.
Participant 4, male
The family and friends of another participant had helped by taking an interest in the the participant’s
take-home activities and resources (completed outside the education sessions) and by buying her a bicycle.
These were in addition to the dietary and physical activity changes that the family was making. They talked
about sustaining these changes even when on holiday:
And she kept going . . . I says, no we’re walking, and it’s very early, but we did it didn’t we, [name]?
From the beach right up to the hotel? Yes? Yeah, even though you wanted to sit down!
Carer for participant 3
Symbols and images used to support learning
For some activities, green smiley faces and red sad faces were used to indicate concepts such as healthy
and less healthy. However, some participants found these images/symbols unhelpful and confusing, as
they were open to misinterpretation or could have meaning that were different from those originally
attended in the curriculum. Two of the participants took the red sad face to depict foods that they did not
like as opposed to indicating less healthy food:
Now, if you gave him a bowl of salad and said, does that go in the red or the green, he’d put it in the
red because he don’t like it.
Carer for participant 1
Another participant placed an unhealthy food on the green sticker because she liked the food.
Reasons for continuing to attend the education sessions
One participant wanted to continue with the education sessions, saying that these had helped him by
giving him enjoyment and freedom from work:
. . . to actually carry on with it. ‘Cause I’ve got that much out of the . . . out of the sessions than I
would normally do.
Participant 4, male
Other reasons people gave for continuing to attend included meeting other people and learning new
activities, enjoying the games/activities and having a sense of achievement on completion.
Only one participant discussed that he would have liked a shorter session, about an hour and a half, and
felt that there was too much information, with too much emphasis on food. Another participant felt that
the venue may deter some people from attending, as it was one that cared for a range of people with ID
(including people with behavioural difficulties) and participants may see other people behaving in a
challenging way.
Interviews with carers
Carers benefited from the education sessions in various ways and at different levels. For some, the sessions
reinforced prior learning, and for others the sessions motivated and encouraged them to make changes.
These are described in more detail below.
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Support and encouragement
It was evident from the contributions made by participants and carers during the education sessions that
many of them had existing knowledge and understanding of key healthy lifestyle messages. These
messages had been gained from their attendance at previous health education/promotion courses and
from the media.
We were able to explore this issue with one of the carers, who was asked why participation in the
education sessions appeared to have made such a difference to their life when there were so many health
messages in the media that they could have acted on (e.g. in relation to physical activity). The carer
attributed the impact of the sessions to the person-centred approach, which facilitated their understanding
of ‘how’ to make and sustain lifestyle changes:
Well I think how you explained things to us really. I think that were very helpful, it was . . . on a level
with me . . . you know? And it was as though you were speaking to each individual . . . Not just a
great big party or you got a book . . . you were telling us and explaining more to us how to do it.
Yeah, I think that’s what helped me anyway the most.
Carer for participant 3
When specifically asked whether or not she had heard about the benefits of walking before coming to the
programme, her response confirmed that she had. However, the education sessions contributed by providing
encouragement to put into practice her knowledge about walking:
Oh yes, yes, but we didn’t do it. I think you gave us the encouragement to do it.
Carer for participant 3
Motivation and focus to make changes
On a different level, another carer felt that her levels of knowledge were already higher than those of
other people because, as a paid carer, she had previously attended other continuing development sessions.
The STOP education sessions had helped to jog and refresh her memory. However, she felt that the
sessions had had little impact on her or the participant making further changes, largely because the
participant did not really want to make any changes to their lifestyle:
I don’t think you’ve helped [referring to participant], if I’m honest . . . because [referring to participant]
you’re a bit stuck in your ways as to what you have and what you don’t want, aren’t you. For me, yes,
it sort of jogged my memory and made me think, oh yeah we’ll do this and we’ll do that . . . not just
for me with [participant], for me with me other service users as well. But I think, yeah, she can do that
and what have you. So, although I’m a bit stumped with you [referring to participant].
Carer for participant 1
Another carer described how the experience of attending the education sessions had motivated and
focused her efforts to support the participant in making and sustaining lifestyle changes. Underlying this
motivation was a sense of fear for the participant’s future health, namely in case he needed to go on
medication, and her concern about this if she was not around in the future:
. . . it’s made us focus. You’ve showed us the little smiley faces. We’ve had to put the smiley faces on
the right things and the wrong things, and we’ve focused in with them, you know . . . Um, it makes
us focus in to what he’s doing . . . because I don’t want him to take medication, because I know that
eventually it’ll be insulin, and if I’m not around, goodness, you know . . .
Carer for participant 4
Additionally, carers identified a number of dietary changes that they had made for the whole family as a
result of attending the education sessions, which included reducing sugary foods and fats and increasing
fruit intake.
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Carers’ session
We tried to ascertain how far the carers’ session had contributed to their understanding of what the
education sessions would involve prior to them attending. Unfortunately, very little information was
gleaned, as it was difficult for them to remember. One carer explained that they appreciated the carer
session because it helped to prepare her and the participant for what the programme would involve:
So it were a bit, sort of, rather than being just chucked in, I had an idea of what we were going to be
doing . . . So that I could explain to [name] what we were going to be doing . . . You see, I suppose
really, the carers’ session is for my side of things, and other carers coming in who have to do the
meals and have a bit of input.
Carer for participant 1
When asked what they would say to a new group of carers to motivate them to attend the next round of
education sessions, one of the carers stated:
I’d stand up and I’d say go for it because you learn an awful lot that you think you know, and you
don’t until it’s put down on these. I really would.
Carer for participant 3
Interviews with educators
Six educators, who were involved with delivering some or all of the education sessions for the first
iteration, were invited for interview. Subsequently, face-to-face semistructured interviews were conducted
with five educators, who comprised three registered ID nurses, one diabetes specialist with an education
background and one health-care assistant. One educator was male. Four of the educators had ≥ 10 years’
experience in their professional area; the fifth had ≤ 5 years’ experience.
Overall, the educators felt that the education sessions had been positively received by people with ID and
their carers. The key findings regarding the process, curriculum content and delivery of the education
sessions are presented below.
Self- and peer reflection
The educators reported the process of self- and peer reflection after delivering the education sessions as
invaluable for their role. Discussions with educator colleagues at the end of each session helped to identify
what worked well and areas for improvement, in terms of adapting resources and identifying any sections
of the curriculum or facilitation that required adjustment to meet individual needs on an ongoing basis.
This, in turn, helped to iteratively refine and modify aspects of the curriculum, such as resources, and
explore different strategies to respond to participant group dynamics.
Venue
The overall view was that a ‘day centre’ was a good environment in which to hold the education sessions
because it was familiar to the participants.
Size of the group
Educators felt that the key issue was to balance the need for positive interaction with ensuring that
enough support was given to participants to enable them to learn. The minimum number of participants
suggested was four, and there was a preference for avoiding ‘double’ figures.
Views about resources
Educators highlighted that some of the resources needed to be modified to promote greater visibility and
accessibility for all participants, as they were often used with the group sitting around a table. Suggested
solutions included placing posters on a frame (so they could be displayed upright or flat) or using larger
sizes of all images, including photographs. The need to avoid shiny paper/laminating was also advocated.
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Educators also discussed in detail which participant resources worked well and which might need to be
adapted. They highlighted the possibility of reducing the size, content or number of resources so that
participants (and carers) were not overwhelmed. Some key issues identified were:
l Attendance certificates – reduce to one card for the whole programme instead of individual sheets for
each week.
l The participant folder (handbook of resources) needed to be simplified and the overall amount of
paperwork needed to be reduced.
l Sections and inserts needed to be differentiated (e.g. by using colours).
l Aiding the use of stickers in participant resources – clearer labelling was needed, as were boxes in
which to place the stickers.
l Food diary worked well for some people, but consideration of alternative ways of recording food intake
may be needed.
l Pedometer worked extremely well for some people, but not for others.
l When discussing ‘health checks’ in the programme, actual equipment rather than images is needed to
promote discussion/illustrate.
Views about the overall curriculum, style of delivery and group dynamics
Educators contributed a number of things that were perceived to have worked well within the group:
l Participants had some prior knowledge that they wanted to apply for themselves; the education
sessions contributed towards enabling/supporting this.
l A ‘happy’ and ‘keen’ group, with ‘characters that complemented each other’.
l The sessions were perceived to be ‘pitched‘ correctly, although it was acknowledged that for group
education it may not be possible achieve this for everyone; a flexible approach (altering language, using
different resources) and skilled facilitation helped to address this.
l A lot of participant (and carer) interest in food and weight reduction.
l There were visible changes to a participant’s level of confidence over the course of 7 weeks.
l The bingo (game/activity) was a useful ‘recap’ tool.
l Allowing time to complete ‘homework’ during the first session was perceived to be a better approach;
participants could have been overwhelmed if they were required to take something away to complete
on their first day.
There was a general perception that the short walking activity within sessions worked really well on several
different levels:
l It helped to break up sessions.
l It was energising and helped concentration.
l It sent a ‘massive message’, particularly to carers, to show how a short walk can result in a lot of steps.
l It was a huge motivational tool that sparked discussion.
Educators felt that carer involvement had contributed to a positive learning experience, and that ‘carer’
dynamics in the group had worked well. Some of the suggested ways that carers had helped were:
l identifying difficulties or challenges that participants may have at home and that could impact/affect
making lifestyle change
l helping to support challenging behaviours within the group
l playing a crucial role in supporting and motivating participants to undertake behavioural changes.
What did not work so well
The primary issue underpinning the education sessions was perceived to be keeping the balance between
maintaining the motivation of participants to attend each session and not overwhelming them. A few
educators felt that there were too many messages within the curriculum and that these could be reduced,
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with an emphasis in a future iteration on linking and building on messages. Similar views were expressed
about the amount of resources used and a recommendation to review the amount and timing of their
introduction at different points within the education sessions.
Some specific difficulties raised that related to the second week of the main programme were that:
l There was a lot of repetition (but this might have been linked to educators following the curriculum
too rigidly).
l There was too much discussion when pedometers were introduced, and participants found it difficult
to make the connection about their results.
Other points for consideration were:
l The dominance of one participant highlighted a need to explore different ways of addressing this,
should it arise again in the future.
l At times there was too much talking, during which some people were lost within the discussions.
l A conceptual exercise/activity called ‘Big Daddy’ did not work well with some participants.
l The pace of sessions was too fast earlier in the programme; this was adjusted in later sessions and was
subsequently viewed as working better.
Finally, a few educators recognised that it was difficult to convey the concept of future risk of developing
diabetes, and recommended that the next iteration emphasise the importance of providing foundational
learning to help motivate and understand healthy eating. Educators also perceived that future follow-up
sessions would be an essential part of the education programme and of particular importance in this
population. Future sessions were seen as helping with retaining focus, reinforcing positive behaviour
changes, recapping learning and identifying progress through practical measures (e.g. weighing on scales).
Findings: second pilot phase
Uptake and attendance at education sessions
The second iteration of the education programme was held in a residential setting. A total of nine participants
were invited to take part in the education programme. Several staff (care workers) from the residential home
attended the initial carers’ session, and seven participants agreed to take part in the education programme.
In general, attendance at the education sessions was good, with three participants attending on all 7 days,
one attending on 6 days and the remainder attending on at least 4 days. Care workers from the residential
home also attended at various points during the seven sessions (see Figure 22).
Characteristics of participants
Of the seven participants who took part in the second iteration, three (43%) were male; the median age
was 43 (range 29–50) years and all seven lived in a residential home supported by carers. One of the
participants had paid employment, two did voluntary work and all seven participated in other
community activities.
Feedback interviews: second pilot cycle
After the final education session, a total of five participants with ID were interviewed, along with two
members of staff (carers) who had attended the education sessions. A care support worker who had
attended some of the education sessions provided support to one of the participants during the interview,
helping the participant to feel at ease and assisting her to recall and discuss some of the lifestyle changes
that she had made. The remaining four participants chose to be interviewed in pairs with their partners.
This arrangement worked well in terms of facilitating participants’ recall and support of each other,
although it was challenging to ensure that the contribution of both participants to the interview was
maximised and balanced.
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The presentation of quotations to support the summary of findings includes singular quotations as well as
sections of the discussion with the researcher to help contextualise some of the responses to the questions.
Interviews with participants
Enjoyable sessions
It was fairly evident that the education sessions had been an enjoyable experience for all of the
participants. One participant was particularly happy about achieving weight loss and being able to share
that achievement with his family:
The steps I’ve done, I’m amazed about the certificates. I tell my mum about it, she is very happy . . .
They’re pleased about it, and my weight has gone down with it.
Participant 1, male
Other participants talked about the specific things that they had enjoyed, such as being part of a team/
group, the resources (‘stickies’) they had used or, for one participant, being enthusiastic about all aspects
of the programme:
Group activities . . . and working well as a team.
Participant 4, male
And sticking pictures on the posters, as well.
Participant 5, female
Everything!
Participant 3, female
For three participants, when asked further to expand on what they enjoyed the most, they described
sessions and resources relating to physical activity. Their enjoyment appeared to be linked to group
walking within sessions, using a pedometer (given to them as part of the programme) to record how many
steps they were achieving and recording steps/activity in their physical activity diary in between the
education sessions:
That walking around, kept going and going and going . . .
Participant 3, female
Plus the pedometers. Count how many steps . . . Shows how many steps.
Participant 4, male
Um, actually writing about my miles.
Participant 5, female
Key things learnt
In response to a question about what they had learnt from the education sessions, two participants cited
physical activity and weight loss:
Participant 3, female: I’ve learnt a lot.
Researcher: What kinds of things have you learnt?
Participant 3, female: To lose more weight.
PILOT TESTING AND EVALUATION OF AN EDUCATIONAL CURRICULUM FOR PREVENTION OF TYPE 2 DIABETES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
Participant 4, male: And exercise.
Participant 3, female: And exercise more.
Researcher: And you said exercise, what is it about exercise that you learnt?
Particpant 3, female: It keeps you healthy.
Participant 4, male: And your heart . . .
Participant 3, female: And your heart beating.
Establishing if participants associated key dietary and physical activity messages with specific parts of the
education sessions proved difficult to elicit, as recall about more detailed aspects of individual sessions was
low. Therefore, drawing on observational data that were collected during the seven sessions, the researcher
took the opportunity to explore two sessions (storytelling and bingo) that had noticeably demonstrated a
high level of engagement and participation, to identify whether or not participants could link these sessions
to specific messages.
Both the bingo session and the storytelling session were remembered as enjoyable. One participant’s
comments also conveyed the key message he took from the storytelling session:
And the storybooks were absolutely fantastic . . . Yes, I enjoyed it, there’s nobody stopping me reading
that, because [name] was showing it, or [name] was showing it, what the whole people were eating,
lots of cakes. That’s not good, that’s bad you know.
Participant 1, male
Behaviour changes
All of the participants who were interviewed had discussed during the education sessions that they had
lost some weight (ranging from 2 kg to 5 kg). A few of the participants were motivated to lose weight for
personal goals that they had set for themselves. During the interviews, participants (or carers) described
some of the dietary changes made to help them achieve their goals. These included cutting out fizzy
(sugary) drinks, reducing alcohol, eating smaller portions, replacing chips with jacket potatoes, cutting
down on puddings and eating more salad:
We used to drink loads of fizzy drinks and we don’t now.
Participant 3, female
You’re not having such big portions . . . you have been trying hard for quite a while to eat better,
haven’t you? You don’t have chips; you have a jacket potato on Friday.
Care worker, participant 5
Researcher: You went down by 2 (kgs)? Your weight went down didn’t it?
Participant 2, female: Yes.
Researcher: [Name], what did you do to change things?
Participant 2, female: Salad.
Participant 2, female: Every Monday I don’t have puddings.
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The feedback also suggested that some participants were consciously focused on undertaking physical
activity as a consequence of attending the education sessions:
Participant 1, male: Not to too many sweets, go for a walk, try to get some more miles down, steps.
Researcher: So, that’s something that’s changed for you, you’ve increased your steps?
Participant 1, male: Yes, I’m proving them right, you see.
I’ve done . . . so far I’m going on the walking group and making new friends.
Participant 4, male
I was starting riding my bike long time ago . . . So I’m starting it again.
Participant 5, female
Sustaining changes
In response to a question about whether making the changes had been easy or difficult, two participants
acknowledged that making healthier choices was challenging with respect to reducing portion sizes and
overcoming the temptation of sweets, which were available in the flat they shared with other residents:
Just getting used to the amount you want and stuff.
Participant 3, female
It’s hard; it’s tempting to have sweets in the flat all the time, that’s what tempting.
Participant 1, male
Care workers appeared to play a key role in helping to motivate and support participants to make and
sustain changes to their diet and physical activity. This was illustrated by one participant who had lost a
considerable amount of weight; he described how staff (and his partner) had helped him with making
healthy food choices and eating smaller portions:
We do [help each other], because my link worker is helping me with my diet. She’s got all these
healthy eating in my flat, see what I’ve got in the cupboard. That’s like salad sandwich and wraps as
well, and coffee and oranges as well, squash.
Participant 1, male
When asked for examples of how staff had helped him, he responded by describing the following changes:
Participant 1, male: Eating less, eat salad, eat fresh fruit, coffee, or a sandwich, or something.
Researcher: Is there anyone else who can help you to carry on with the changes?
Participant 1, male: Link workers.
Interviews with carers
Sustaining changes
Care staff had already considered ways to sustain the changes made and the motivation of residents after
the education sessions stopped:
I’ve said, it’s important we keep it up. So while it’s still fresh and you can run with it, because the
weight loss thing, for their only to be one person who hasn’t actually lost weight and even though it’s
a little bit . . . We very often get the talk about how from your little acorns grow the big trees.
Care worker 1
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Things currently being discussed by care workers were a healthy living course and a weekly physical activity
session. According to staff, following residents’ participation in the STOP Diabetes study there was a
general increased level of interest in ‘healthy living’, and a few residents had indicated recently that they
would like to do more exercise:
Yes, it’s [putting on a health living course] come about because you’ve come here, because of how the
residents have responded, but also because I know they’ve made that request about having more exercise.
Care worker 1
Suggestions to facilitate the recall of food messages and to sustain changes outside sessions included
having images of breakfast alternatives that could be stuck on to a fridge door. This idea was being tried
with one of the participants because he found it difficult to remember.
Amount of information covered in sessions
When carers were asked about what they thought of the education sessions, and specifically about the
amount of information, two conflicting views were evident.
One carer stated:
Well, just right, yeah. That was fine for what they were . . . And because it was the mix of those that
could write, could write things, but they have their stickers and their pictures.
Care worker 2
Another carer felt, based on her observation of one of the sessions, that there was too much information
and that participants might find it difficult to retain all of it:
I think in one session I was at there was a lot of information being given and maybe just simplify a
little bit. Maybe just doing very small steps, and even if it’s just one piece of information they learn
that session, at least that might have more chance of sticking.
Care worker 1
To help with retention, this carer felt that concentrating on one aspect of diet, such as drinks, might have
helped to focus efforts and facilitate discussion about alternatives.
Carer involvement
Carers were asked what educators needed to consider for any future programmes held in residential
homes, and they highlighted the need to allow for variation in care worker attendance at sessions to
support participants, as a result of organisational pressures (including low staff numbers).
The above discussions also elicited further suggestions for encouraging carer involvement, including the need to:
l educate staff about what they will need to consider for people for whom they are responsible
l enthuse and engage staff to help with practical support, such as completing the diaries and resetting
the pedometer
l provide information about alternative (healthier) food choices/options and portion sizes.
Modifications made to curriculum after the pilot cycles
A number of modifications were made to the programme based on feedback from participants and carers,
observations made during the education sessions, and the ongoing reflection and feedback of the
educators. Modifications consisted of refinement of resources together with adaptations to educator
facilitation within the sessions.
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Revisions made after the first cycle
The main revisions made after the first cycle included the following.
Modifications to the carer session
l Reducing the amount of information provided at this session.
Modifications to education sessions
Participant resources
l Reducing the amount of worksheets given out at any one time. For the first pilot phase, all of the
activity sheets that were developed for the 7-week programme were given to participants in week 1 in
a folder format. This caused distraction for some participants and impacted on the delivery of the
session. Subsequently, this was changed to allow the work sheets to be provided directly at the point
at which they were required in the programme, and for participants to add them to their programme
folder on a weekly basis.
l Simplifying the physical activity diary to a single sheet of A4, with a table to record the date, steps/
activity and new goal, from a multipaged booklet.
l Making the image cards (used to facilitate and support learning, recognition, recall and summaries) a
much larger size.
l Using realistic images and/or photographs in resources. Images were sourced and checked with service
user groups prior to being changed.
Session content
l Reducing/simplifying the content of some sessions. Providing too much information led to participants
becoming disengaged.
l Changing the symbols used to illustrate healthy and less healthy foods, as these were not universally
understood by participants. Possibly use a menu of symbols tailored to individual cognitive needs.
Ensure that educators explain and check understanding when symbols are used.
Maintaining and maximising engagement
l Educators to create opportunities for movement, both within the room to engage in different activities
and a short walk during each session to address participants becoming disengaged when sitting for
longer periods. Additionally, to use the walking activity to highlight the number of steps achieved in
5–10 minutes of walking.
Communication aids
l Using communication cards (with symbols/pictures) as an aid to manage discussions in the group and
facilitate engagement of people who experience difficulty communicating.
Revisions made after the second cycle
Modifications to education sessions
Maintaining and maximising engagement
l Allowing for educator flexibility to adjust the timetable and breaks to suit the needs of individuals, the
group dynamic, energy levels and engagement.
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l Educators and supporting staff to be aware of the diversity and dynamics in the group, and to arrange
the seating and positioning of participants to support engagement and one-to-one support
when required.
l Including more interactive games/activities, such as bingo and board games, to promote engagement.
Participant resources
l Including a menu of options to encourage prompts and motivation towards goals. For example, fridge
magnets may not be useful to those in a residential setting if they do not have their own fridge.
l Incorporating photographs of participants into their ‘health checklist’, as a way of personalising
documents, and helping individuals to relate this information to themselves.
Outline of the STOP education programme
An overview of the final education programme that was developed, prior to using in the feasibility phase
(see Chapter 10), is outlined.
First, the initial carer session, which is held prior to the main education programme, is presented (Table 29).
Second, in Table 30, the outline structure of a typical session in the main programme is outlined. Finally,
for each individual session (weeks 1–7), the topic areas, the main aims and the key activities/resources that
are designed to support learning and behavioural changes, both within and between sessions, are also
presented (Tables 31–33).
Concluding remarks
This chapter and the previous chapter (see Chapter 8) has described the development and pilot phases
(testing, evaluation, modification and retesting) that were carried out in order to develop a lifestyle
education programme for adults with ID.
The STOP programme development benefited from a systematic process.238,239 The theoretical underpinning
was developed and expanded on from the limited evidence in the literature. This informed the content
and style of approach, alongside the qualitative findings from people with ID, their carers and HCPs with
expertise in working with people with ID. The whole programme was then tailored further to the specific
needs of this group by more user feedback, and adaptation by a multidisciplinary team with expertise in ID
and the development of education programmes.
From the initial phases the programme has been well received and is acceptable to the people it is trying
to support. The initial feedback via qualitative interviews has suggested that some of the elements of
treatment receipt that were initially hypothesised may have been achieved via reported changes in beliefs
and health behaviours.
Chapter 10 details the feasibility phase. Chapter 11 details the intervention fidelity of the education programme.
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TABLE 29 Outline plan of the initial carer session
Session name Overview and main aims of activities Time
Welcome and
introductions
To introduce the educators 15 minutes
To understand the role of any observers
To be aware of the style and aims of the course
To ask questions related to the course
Outline of education
course
To be aware of practical aspects (venue, times, number of sessions) 10 minutes
To be aware that carers can attend with participants
What is different for
people with ID?
To have an opportunity to share their thoughts about learning needs of
the person for whom they care
10 minutes
To share their thoughts about supporting people with ID to make lifestyle
and behavioural changes
Course content To be aware of course content and resources 60 minutes
To be aware of course activities and the support that participants may
need between sessions to complete
What is my role as a
carer?
To explore the benefits of attending the course with the participant 15 minutes
To explore the potential health benefits for the person they are
supporting, and themselves, of attending
To be aware of their potential role in supporting the participant who
chooses to make lifestyle and behavioural change
Questions and concerns To have an answer to any questions 10 minutes
To have concerns explored and addressed
Total 2 hours
TABLE 30 Outline of the structure of a typical session in the main education programme
Session Aims and activities Time
Welcome: ‘Welcome and
getting to know you –
week 1’ or ‘Welcome
back – weeks 2–7’
To ground and settle participants 15 minutes
To outline the aims and style of the course
To outline the topic areas for the day
To reflect on actions from previous sessions – celebrate achievements and
identify/explore barriers
To develop a good working relationship between educator and
participants
Topic area 1 Explore a different topic area each week 30–45 minutes
Break 15-minute break allocated within the session 15 minutes
Breaks to be taken flexibly according to the expressed needs of the group
or as indicated by educators’ assessment of engagement in the session
Topic area 2 New topic area or may build on/consolidate learning from the earlier
session
30–45 minutes
Questions and
preparation for next
week
To provide an opportunity to express concerns, ask questions relating to
the session
10 minutes
To provide information and prepare participants/carers for activities
between sessions
Total Minimum
100 minutes,
maximum
130 minutes
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TABLE 31 Outline plan for the STOP education programme, weeks 1 and 2
Week Overview of main aims
Activities and
resources Theory
Week 1
Topic area 1: ‘What is health?
Being healthy and unhealthy’
To explore what the concept of being
healthy means to the individual
Healthy and unhealthy
character poster
Images to prompt
recognition and recall
Main message summary
cards
SRT, TPB
To explore the behaviours linked to health
Develop images that represent healthy and
unhealthy characters that are used as a
learning tool throughout the programme
Topic area 2: ‘What can go
wrong with my health?’
To explore the health consequences of
lifestyle and behavioural choices
Images to prompt
recognition and recall
SCT, SRT, TPB
To explore lifestyle and behavioural choices
that promote health
To have an opportunity to express their
emotional response to the different lifestyle
choices the characters make
Week 2
Topic area 1: ‘This is me’ and
‘Health checks my doctor or
nurse will do’
To create an image that represents the
individual, their lifestyle and behavioural
choices
Personal lifestyle and
behaviours activity sheet
Images to prompt
recognition and recall
Health profile with
photograph of
individual
Biomedical data
Coloured stickers
SCT, SRT, TPB
To be aware of the health checks that a
doctor or nurse will do and be provided with
their own biomedical data and risk factors
To be aware of which results may be a
problem to their health by placing a sticker
on profile
Plot results on a health profile
Topic area 2: ‘What can I do
to stay healthy?’
To explore the impact of the biomedical
results and risk factors on their own health
Images to prompt
recognition and recall
Confidence activity
sheet
SCT, SRT, TPB
To express any concerns/emotions relating to
their results
Recall the consequences of lifestyle and
behavioural choices
To explore lifestyle or behavioural choices
relating to their risk factors
Have the opportunity to choose and record
lifestyle or behavioural changes on a
personal poster
Record level of confidence to make this
change
SCT, social cognition mode; SRT, self-regulation theory; TPB, theory of planned behaviour.
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TABLE 32 Outline plan for the STOP education programme, weeks 3 and 4
Week Overview of main aims
Activities and
resources Theory
Week 3
Topic area 1: Being active To explore what being active means Images to prompt
recognition and recall
Physical activity record
Pedometer
Walking activity
SCT, SRT, TPB
To be aware of the consequences to health
of being inactive
To explore the benefits to health of being
active, moving more and sitting less
To have an experience of using a pedometer
to measure steps
Topic area 2: Me and my
activity
To have an experience of a short walk and
recording steps or activity in a diary
Images to prompt
recognition and recall
Confidence activity
sheet
Create prompt cards,
send a postcard or
create a fridge magnet
to promote engagement
with their goal within
the session and
between sessions
II, SCT, SRT,
TPB
To identify ways to increase activity by
adding an activity, increasing step count
and/or reducing sitting time
To record personal confidence to carry out
their chosen goal
To create a prompt or reminder for their
chosen goal
To record activity in a diary
Week 4
Topic area 1: How did I do
with my activity?
To reflect on current level of activity Interactive dice game to
explore barriers
Physical activity record
Walking activity
(optional)
SCT, SRT, TPB
Reflect on feelings related to level of activity
To explore own and listen to other group
members’ barriers to physical activity
To explore strategies for overcoming barriers
To experience a short walk to highlight the
increase in steps from short periods of
activity
To identify a new steps or activity goal for
the coming week
Topic area 2: Changes I can
make to be healthy
Recall the lifestyle and behavioural changes
that influence risk factors
Personal lifestyle and
behaviours activity sheet
Storybook
Food diary
II, SCT, SRT,
TPB
To be aware of the impact of unhealthy
lifestyle and behavioural choices over many
years – this is facilitated by using a storybook
Recall the personal lifestyle and behavioural
choices recorded in session 2
Reflect on progress with these choices
Participants prepared and facilitated to
explore sources of support for recording
food, drinks and snacks over the next week
II, implementation intentions; SCT, social cognition mode; SRT, self-regulation theory; TPB, theory of planned behaviour.
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TABLE 33 Outline plan for the STOP education programme, weeks 5–7
Week Overview of main aims Activities and resources Theory
Week 5
Topic area 1: How did I do with
my activity? Eating well, eating
healthy
To reflect on activity levels over the last
week
Physical activity record
Walking activity (optional)
Food models and images
to support recognition and
recall
Food sort task
Stickers
II, SCT, SRT,
TPB
Generate ideas for overcoming barriers
Plan a new activity/step goal
Walking activity (optional – decision
made collaboratively by the group)
Recall the main messages relating to
health
Identify foods that relate to a healthy
lifestyle
Identify foods that contribute to being
unhealthy
Have an awareness of the
consequences of high fat, sugar and
large portions on health
Be aware of the consequences of
lower fat, sugar and smaller portions
on health
Sorting activity with food models and
images
Topic area 2: Changes I can
make to eat well and eat
healthy
Recall the food messages from the
earlier session
Food models and images
Food diary
Create prompt cards, send
a postcard or create a
fridge magnet to promote
engagement with their
goal within the session and
between sessions
II, SCT, SRT,
TPB
Record personal confidence to make a
change to food choices
Identify one or two small changes to
make to personal food choices based
on their food diary
Create personal prompts to behaviour
change
Week 6
Topic area 1: Where am I with
my activity?
To reflect on activity levels over the last
week
Physical activity record
Food diary
Food bingo activity
Bingo prize for the winner
II, SCT, SRT,
TPB
Generate ideas for overcoming barriers
Plan a new activity/step goal
Walking activity (optional – decision
made collaboratively by the group)
Recall the main food messages related
to health and being unhealthy by
participating in an interactive game
Recall the consequences of food
choices
continued
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TABLE 33 Outline plan for the STOP education programme, weeks 5–7 (continued )
Week Overview of main aims Activities and resources Theory
Topic area 2: How am I doing
with my eating well, eating
healthy?
Reflect on the food diary Food diary
Barriers board game
Create or amend prompt
cards, send a postcard or
create a fridge magnet to
promote engagement with
their goal within the
session and between
sessions
II, SCT, SRT,
TPB
Identify successes and barriers to
making changes to food choices
To explore own and listen to other
group members barriers to making
changes to food choices
To explore strategies for overcoming
barriers with an interactive game
Explore how to reward personal
success
Identify sources of support to reach
goals
Plan a new food goal
Week 7
Topic area 1: What have I
learnt?
Reflect on activity levels and the food
diary over the last week
Food diary
Activity diary
Healthy and unhealthy
character posters
Personal lifestyle and
behaviours activity sheet
Images to prompt
recognition and recall
II, SCT, SRT,
TPB
Review the overall programme and
raise any outstanding concerns or
questions
Recall main points of the programme
and revisit associated activities
Identify successes and barriers to
making changes
Topic area 2: What can help me
to keep going with changes to
my food and activity levels?
Record personal changes on activity
worksheet
Worksheet to record
personal changes that
have been made
Postcards, fridge magnets,
flash cards and stickers
Prompt card to give to
carers to ask for help
Confidence activity sheet
Course attendance
certificates
RP, SCT, SRT,
TPB
Explore possible solutions to barriers
Explore strategies to support the
maintenance of changes
Set new goals and use strategies to
help such as writing a postcard to
themselves to be sent in 3 months’
time or creating fridge magnets
Record personal confidence to carry
out their chosen goal
Explore sources of support to help
achieve these goals
Celebrate success
II, implementation intentions; RP, relapse prevention; SCT, social cognition mode; SRT, self-regulation theory; TPB, theory of
planned behaviour.
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Chapter 10 Feasibility study of STOP Diabetes
programme
Overview
This chapter describes a feasibility phase, which follows on from the education development work
described in Chapters 8 and 9, and forms part of WP2.
Aims and objectives
The aim of this substudy was to assess the feasibility of collecting outcome measures for participants with
ID before and 3 months after they attend the lifestyle education programme.
Methods
Study design
Following initial development, testing and refinement of the curriculum (see Chapters 8 and 9), the
education programme was delivered to another group of participants to assess the feasibility of collecting
pre- and post-intervention outcome measures.
Study setting
The feasibility phase was conducted between January and June 2015.
Participants
Inclusion criteria
Eligibility criteria for the feasibility phase were the same as those for the two pilot phases described in
Chapter 8, that is, service users who:
l had participated in the screening stage (see Chapter 5)
l screened positive for IGR or had a BMI of ≥ 25 kg/m2
l indicated a willingness to assist with later phases of the research programme
l had mild to moderate ID
l were able to stand and walk at least short distances
l were able to attend group education sessions
l were not taking part in any other intervention study.
Participant recruitment and consent
Participants were recruited following a similar process to earlier phases (see Chapter 8, Participants).
Potential participants received an initial telephone call to gauge their interest, and this was followed up by
further information sent in the post or provided at a face-to-face visit.
Volunteers were invited to attend an initial appointment at a convenient time for them, in which
information was provided about the study and informed consent was obtained. Consent was obtained
following a similar process to that described previously (see Chapter 5, Informed consent). People were
asked to consent to the collection of baseline data, attendance at the education programme and collection
of 3-month follow-up data.
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Data collection
Baseline data collection
Baseline data were collected using the same schedule as in the screening study (WP1, see Chapter 5).
If participants had taken part in the screening stage within the last 3 months, and valid measurements had
been successfully obtained, these data were used for baseline values. If a participant took part in the
screening stage > 3 months ago then the measurements were repeated.
Data collected included:
l weight
l height
l BMI
l waist circumference
l BP
l dietary intake (fruit, vegetables and salad).
Physical activity (time spent in light, moderate and vigorous activity) and sedentary behaviour (time spent
sedentary) were measured using the wrist-worn accelerometer (GENEActiv). The process for measuring
activity using this accelerometer has previously been described in Chapter 7.
Three-month data collection
At 3 months following the end of the education programme, participants were recalled for repeat data
collection, as per at baseline.
Outcomes
Particular outcomes of interest in terms of the feasibility included (1) the proportion of people invited who
attend the baseline appointment, education programme, individual sessions within the programme and
3-month follow-up; and (2) the completeness of key data items at baseline and 3 months’ follow-up.
Problems encountered during data collection appointments and implementing the education were
also considered.
Delivery of intervention
Following on from the pilot phase of testing, evaluation and modification described in Chapter 9, the final
modified education programme (see Chapter 9, Outline of the STOP education programme) was delivered
to another group of adults with ID, and their carers, at a local community venue.
Sample size
We aimed to conduct the feasibility study with at least one group of participants (four to eight people with
ID, plus carers).
Data analysis
The feasibility of recruiting adults with ID to attend for baseline data collection, education sessions and
3-month follow-up data collection was assessed using a flow diagram to summarise dropouts at each stage.
Completeness of outcome data collected at each stage was summarised using counts and proportions.
Findings
Study timelines for the feasibility phase enabled us to run one iteration of the education programme,
with collection of before-and-after measurements.
FEASIBILITY STUDY OF STOP DIABETES PROGRAMME
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
Recruitment and consent
In total, 19 participants were invited to take part in the feasibility phase, of whom five (26%) agreed to
attend an initial appointment at the end of February 2015, at which consent and baseline data were
obtained. All of the participants had the capacity to give consent for themselves, without the need to
involve a consultee.
Feasibility of collecting baseline data
At baseline, all of the participants required measurements to be taken, as it was > 3 months since they
had originally taken part in the screening study. Baseline data were obtained for all five participants, with
the exception of physical activity data that were collected for only four (80%) participants, as one person
refused to wear the accelerometer (Table 34).
Uptake of and attendance at education programme
Following the baseline appointment, all five of the participants took part in the education programme,
which was held from March to April 2015. A total of four carers (two paid care workers and two family
members) attended at least some of the sessions (three regularly). Overall attendance at the education
sessions was good: four (80%) participants attended on ≥ 5 days and two participants attended on all
7 days (Figure 23). However, one participant attended on only 3 days. It is important to note that the
most common reason for not attending sessions was other existing commitments such as appointments
and holidays.
Feasibility of collecting data at 3-month follow-up
All of the participants agreed to attend a 3-month follow-up appointment at the end of June 2015 to
obtain repeat measures. Four of the participants (80%) attended the appointment as arranged; one
participant needed to have a second appointment arranged because they did not attend the first (this was
the same participant who attended only 3 days of the education programme).
Anthropometric measures (weight, BMI, waist circumference) were obtained for all of the participants
(see Table 34). BP readings were successfully obtained for four (80%) participants. Accelerometer data
were obtained for three of the four participants who wore one at baseline; four participants initially agreed
to wear the accelerometer, but one participant later telephoned the research team to inform them that he
had changed his mind.
TABLE 34 Availability of data at baseline and 3 months’ follow-up
Measurements Baseline, n (%) 3 months’ follow-up, n (%)
Weight (kg) 5 (100) 5 (100)
Height 5 (100) 5 (100)
BMI (kg/m2) 5 (100) 5 (100)
Waist circumference (cm) 5 (100) 5 (100)
Systolic BP (mmHg) 5 (100) 4 (80)
Diastolic BP (mmHg) 5 (100) 4 (80)
Portions of fruit and vegetables 5 (100) 5 (100)
Physical activity and sedentary behaviour (time spent in light,
moderate, vigorous intensity activity; time sedentary)
4 (80) 3 (60)
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Characteristics of participants
The key demographic characteristics for the five participants are presented in Table 35. Four (80%)
participants were male, the median age was 40 (range 20–51) years and all were of white ethnicity. Two
participants lived alone, one lived in supported living accommodation and two lived in a family setting; the
majority (n = 4, 80%) had support from a carer for at least some of the time. None of the participants was
in paid employment, two did voluntary work on a regular basis, and two attended college and other
community-related activities,
n = 2
n = 4 (+ 3 carers)
n = 4 (+ 1 carer)
n = 4 (+ 1 carer)
n = 4 (+ 2 carers)
n = 3 (+ 2 carers)
n = 5 (+ 2 carers)
n = 3 (+ 1 carer)
Participants invited
(n = 19)
Refused
(n = 14)
Attended education
programme
(n = 5; 4 carers)
Measurements, n = 5
Accelerometer, n = 4
Measurements, n = 5
Accelerometer, n = 3
Initial carer
session
First education
session
Second education
session
Third education
session
Fourth education
session
Fifth education
session
Sixth education
session
Seventh education
session
Attended 3-month
follow-up
appointment 
(n = 5)
January 2015
March 2015
April 2015
June 2015
Attended baseline
appointment
(n = 5; 4 carers)
February 2015
FIGURE 23 Uptake of and attendance at data collection and education sessions.
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Baseline data
Biomedical and lifestyle characteristics, from data collected at baseline, are presented in Table 36.
The median values for weight, BMI and waist circumference were 110.2 kg, 36.1 kg/m2 and 114.3 cm,
respectively. For BP, the median systolic value was 123 mmHg and the mean diastolic value was 85 mmHg.
Reported daily intake of fruit, vegetables or salad indicated that only two (40%) participants were eating
the recommended five or more portions a day (median 5). For physical activity, the median minutes per
day for MVPA and light-intensity activity were 107.5 and 93.0, respectively; the median time spent
sedentary was 555.0 minutes per day.
Three months’ follow-up data
Data collected at 3 months’ follow-up are also presented in Table 36. The main aim of the work
conducted was the feasibility of collecting data at two time points, and not looking for change.
However, on an individual basis, three participants lost weight (range 1.0–4.2 kg), but two participants
gained weight. The participant who had gained a lot of weight (17.6 kg) had poor attendance at the
education programme (three out of seven sessions); anecdotal evidence at 3 months’ follow-up suggested
that significant changes had occurred in this participant’s personal circumstances since baseline, including
moving out of the family home to live independently in his/her own flat.
When data were available, participants showed improvements in physical activity levels and sedentary
behaviour at 3 months’ follow-up compared with baseline.
Discussion
Overall, the findings suggest that it is feasible to collect outcome measures at two time points: before and
3 months after attendance at a lifestyle behaviour modification intervention.
Twenty-six per cent (n = 5) of people who were invited to take part in the feasibility phase agreed to
participate. At baseline, anthropometric measures and BP were obtained for all of the participants and
TABLE 35 Characteristics of participants (N= 5)
Characteristic n (%)
Age (years), median (range) 40 (20–51)
Sex, male (%) 80
Ethnicity
White 5 (100)
South Asian 0
Other 0
Accommodation
Alone 2 (40)
With family/carers 2 (40)
Residential/supported living 1 (20)
Support from carer
Yes, at least some of the time 4 (80)
No 1 (20)
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accelerometer data for 80%. Attendance at the education programme was good overall, with 80% of
participants attending on ≥ 5 days (out of seven sessions for the main programme). At 3 months’ follow-up,
repeat data were successfully collected for a high proportion of participants (anthropometric measures
100%, BP 80%, accelerometer data 60%).
It is acknowledged that the feasibility phase involved only a very small number of participants (n = 5) and
carers. Owing to time restrictions we were able to conduct only one feasibility cycle (delivery of intervention,
plus pre- and post-intervention measures). However, the feasibility phase used robust processes, which were
informed by the preliminary findings from the screening phase and lessons learnt from the earlier phases of
education development and delivery.
It is recognised that the feasibility phase was not aimed at seeing significant findings from baseline to
post-intervention follow-up. However, at 3 months there were some beneficial changes for most participants.
These preliminary findings are positive, but we are unable to assess whether or not it is possible to collect
longer-term data, beyond 3 months post intervention or at repeated time points. The 8-week educational
intervention developed as part of WP2 appears to be both feasible and acceptable to people with ID
(and their carers), who are identified as being at high future risk of T2DM and/or CVD. However, the
intervention is yet to be tested more robustly via a RCT, including possible follow-up maintenance
education sessions. Findings from the development and feasibility phases provide valuable data to help
inform future research.
Concluding remarks
This chapter has described a feasibility phase that was carried out to assess the feasibility of collecting
outcome measures for participants with ID before and 3 months after they attend a lifestyle education
programme. Development of the education programme was described in Chapters 8 and 9. Chapter 11
details the intervention fidelity of the education programme.
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Chapter 11 Intervention fidelity process
Overview
The methods and results of the intervention fidelity process for WP3 are described below.
Rationale
Intervention fidelity relates to how an intervention is delivered in practice and whether or not the delivery
of the intervention varies according to the context. It is now recognised as a key component in the
evaluation of complex interventions,238,248,249 enabling the assessment of reliability and validity of an
intervention and the process factors both advancing the study aims and reducing premature abandonment
of future interventions.250
The assessment of intervention fidelity is seen as particularly important when interventions are evaluated
using multicentre RCTs because there is risk of delivering and/or receiving the intervention differently
between sites.249 It was anticipated that findings from the current research programme would inform a
future multicentre RCT.
The Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND)251 model
of structured education,251 which underpins work conducted in this chapter, draws on theoretical and
philosophical perspectives from both health psychology and education;252–254 patient empowerment is at its
centre. DESMOND programmes meet nationally agreed quality criteria255 for patient education, including
delivery by trained and accredited educators, and quality assurance.
One of the key components of quality assurance is intervention fidelity. In practice, assessment of intervention
fidelity involves appraising education delivery, with particular emphasis on the assessment of educator
behaviours. The DESMOND251 education approach purports that individuals, in the main, are responsible for
making their own choices around self-management. Barriers outside the person’s control are acknowledged,
but the role of the facilitator or educator is to encourage the participant to explore his/her motivations for
self-management or engaging in health promoting behaviours, rather than telling them what to do; the
former set of behaviours can be attributed to being ‘DESMOND’251 and the later are non-DESMOND. Further
details of the methods used to assess educator behaviour and the DESMOND251 and non-DESMOND251
approach, are outlined below (see Preliminary assessment of educator behaviour, and Table 38).
The original programme of work included a pilot RCT to assess the effectiveness of the lifestyle education
programme (intervention) developed. However, amendments to the programme of research requested
by the National Institute for Health Research (NIHR) determined that a feasibility phase was conducted
(described in Chapter 10) rather than a RCT. Thus, data collection from multiple iterations of the
programme and across different educators was not practicable. The amended aims and objectives, as
outlined in the next chapter (see Chapter 12, Methods), take the above into account.
Aims and objectives
The primary aim of this component of the research programme was to conduct preliminary work towards
developing an intervention fidelity process and tool that is specifically tailored to this population.
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The specific objectives were to:
l develop an outline educator training programme
l conduct a preliminary assessment of educator behaviour using an existing quality development tool
l identify key important adaptations to the existing tool for use in a programme developed for the
population with ID in the future.
Methods
Educator training
The educators for delivery of the intervention (outlined in Chapter 10) were a registered ID nurse and a
diabetes specialist with an education background, with support from an ID nurse or health-care assistant.
The process of training the educators involved, first, professional development around the DESMOND251
education programme. This stage took place between January and March 2014, and included observations
of DESMOND251-based programmes and attendance at a core DESMOND251 training day. This provided an
introduction to the theoretical basis, philosophy and core skills of DESMOND.251
Second, the educators attended an initial study-specific training day in April 2014, when they were
introduced to the theoretical component, content, structure and delivery of the STOP Diabetes education
programme (see Table 37). This was followed by a second study-specific day in June 2014. A staged
approach was used for delivering the educator training to take into account any necessary changes to the
programme (curriculum content, delivery and structure) based on the delivery of the early sessions.
The training was delivered by two members of the development team, a consultant clinical health psychologist
and diabetes specialist nurse with an education background. Training included detailed information on the
content, structure and delivery of the programme, and incorporated additional support and considerations
around working with people with ID. Guidance around indirect approaches for educating participants (e.g.
role-playing behaviour change techniques) and direct approaches (e.g. presentations) were included.
Educators used a specific training curriculum to equip them to support the delivery of education sessions
and were encouraged to use personal reflection and peer review tools to reflect on their delivery. They
were also supported with mentorship from trainers attached to the research team.
An outline of the training programme is presented in Table 37. The first training day covered the first five
sessions of the education programme (the carers’ session and weeks 1–4).
Day 2 educator training, which covered the curriculum and resources for the final three sessions (weeks 5–7),
followed a similar format to the first training day, taking into account feedback relating to the initial training.
In addition, educators were able to feed back their experiences on delivery of the first four sessions, and to
reflect on their own self-monitoring and behaviour change experiences.
Evaluation of educator training
Subsequent to completion of their training, educators completed an evaluation form (see Appendix 20) for
the STOP Diabetes training sessions. Following their first delivery of the education programme, educators
involved in delivering the sessions were interviewed by a qualitative researcher to explore their views about
the content and style of delivery, experiences from delivering the programme and perceived practical
issues; feedback from these interviews is presented as part of the first pilot phase (see Chapter 9).
Preliminary assessment of educator behaviour
The quality development tool used to conduct the preliminary assessment of educator behaviour was
based on current assessment tools developed by the DESMOND collaborative;251 which recognises that
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training of health professionals to deliver education programmes does not always result in appropriate or
consistent delivery of the programmes.256
The tool was developed in 2015 and consists of five ‘global’ categories, each containing specific items to
evaluate programme delivery; it is a revision of a previous DESMOND tool.257 The tool is designed to be
used by a separate observer who assesses the educator’s behaviours when they teach/deliver education.
Each item in the tool represents a discrete DESMOND251 behaviour, which is paired with an ‘opposite’ item
(labelled as a non-DESMOND251 behaviour), which are coded when observed. The observer is asked to rate
which behaviour (i.e. DESMOND251 or non-DESMOND251) is most commonly seen during the training
session. For example, the first item requires the observer to assess whether or not the educator uses open
body language to support engagement of participants (Table 38). DESMOND251 behaviours for this item
include nodding and smiling at the participants, and non-DESMOND251 behaviours include avoiding eye
TABLE 37 Outline of the education training programme: day 1
Session name Overview and aims Time (minutes)
Welcome and introductions Explore expectations and concerns about training 15
Outline the style and aims of the training
What is different about
group self-management
education for people with ID
Exploring participants’ experience of delivering education to people
with ID
30
Exploring how working with a group may be different from one to one
Methods to promote learning in this programme
Prevention and health
messages
Exploring the key messages for CVD and diabetes prevention 30
Explore the key messages for the education programme
Key messages for each
session
Provide an opportunity to review the curriculum and identify the key
messages and activities for each session
30
Development and theoretical
underpinning
Recap on the theories that underpin this programme 60
Providing an opportunity to explore their own health behaviours and
making a plan
Lunch
Carer session Review curriculum and aims of session 45
Explore how to engage carers
Sessions: weeks 1–3 Review curriculum and resources for sessions 1–3 60
Identify any challenges to delivering these sessions
Session: week 4 and
resources
Review curriculum and resources for week 4 40
Be aware of other resources available for use with the programme
Identify any challenges to delivering the session and using the
resources
Overcoming challenges to
delivering the sessions
Recall the challenges identified 50
Explore options for overcoming the challenges
Reflection and feedback
tools
Explore the purpose of the reflection and feedback tools 15
Explore strategies to increase confidence to deliver the programme
Next steps Give out food diaries, pedometers and activity diaries to provide
experience of self monitoring and behaviour change
15
Explore the benefits of experiencing using the tools and self-monitoring
that participants will use
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TABLE 38 Assessment items in educator behaviour assessment tool
DESMOND251 behaviour Non-DESMOND251 behaviour
Facilitating non-judgemental engagement of all participants
Uses a range of open body language to support engagement
of participants
Tends to use more closed body language behaviours
Uses non-judgemental statements regarding participant verbal
utterances
Uses judgemental statements in response to participant
verbal utterances
Seeks answers from a number of participants before discussing
further, including right and wrong answers
Accepts the first (right) answer and/or immediately
providers correct or up-to-date information
Seeks clarification of participants’ contribution Rarely seeks clarification of participants’ contribution
Avoids giving general healthy messages Provides general healthy messages
Avoids giving their own opinion Gives their own opinion
Eliciting and responding to emotions/feelings (empathetic responding)
Prompts participants to express and explore their feelings
about diabetes
Avoids actively engaging participants in emotional
discussion
Acknowledges and/or prompts exploration of participant
emotional response
Retreats from/ignores/denied participant emotional
response
Facilitating reflective learning
Uses analogiesa Avoids the use of analogiesa
Uses visual tools and resources Does not use visual tools and resources
Uses and refers to participants’ comments and quotations Uses his/her own words when working through session
content
Encourages group to discuss/answer their own questions Answers most questions asked by the group
Prompts participants to explore misconceptions and gaps in
knowledge
Immediately provides correct information to fill apparent
gaps in knowledge
Notices and prompts discussion of personal health beliefs Avoids discussion of health beliefs within the group
Prompts all participants to ask questions about issues discussed Rarely invites (more than once) participants to ask
questions
Prompts group to summarise key messages Tends to summarise key messages
Prompts group to summarise their own understanding Tends to summarise what she/he thinks is the group’s
understanding
Prompts ‘self-talk’ about how the key messages from the
session applies to them
Does not ask participants to reflect on how the key
messages apply to them
Provides new information only after group discussion Regularly provides new information without group
discussion
Behavioural change, planning and goal setting
Acknowledges when participants decide not to make any
future changes to self-care behaviours or beliefs
Expects participants to make necessary changes
Prompts participants to discuss their thoughts about possible
changes
Avoids generating discussion about possible changes
Prompts participants to review the impact of possible choices
on their future health
Avoids generating discussion about range of options/
impact
Prompts participants to talk about what they are going to do
as a result of the session
Rarely asks participants what they are going to do as a
result of the session
Prompts problem-solving of possible barriers to change Avoids ‘active’ problem-solving support
Prompts participants to reflect on their goals/plans Avoids reflective discussion regarding goals/plans
INTERVENTION FIDELITY PROCESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
contact and the educator turning their back on the participants when asking a question. By noting down
these behaviours when they occur, the observer can determine which behaviour was most common during
the training session.
Prior to using the tool to assess educator behaviour for the STOP Diabetes programme, three members of
the education development team reviewed the existing quality development tool and its application in the
STOP Diabetes programme. As a result, only one of the items in the reflective learning category was changed
(see Table 38) because it is recognised that people with ID are more amenable to concrete concepts and
visual imagery than to more abstract concepts, such as analogies165 (see also Chapters 8 and 9).
Between March and April 2015, a member of the research team attended the final iteration of the education
programme using the tool. The researcher was an experienced member of the research team, had attended
specific STOP Diabetes educator training and was involved in the development of the education programme.
The tool was used to describe how the educators interacted with the group, to identify differences between
educators’ behaviours and to assess appropriateness to this client group. The researcher used the quality
development tool to conduct assessments during six out of seven of the education sessions. During these
sessions the researcher positioned themselves outside the group and completed the tool separately for each
educator.
In addition to noting educator behaviour, an assessment of participant–educator interaction was undertaken
during one observation visit, using a 10-second event coding to estimate the amount of time during which the
educators were speaking. When the beep sounded, the coder indicated on a response sheet who was talking
at that point in time (whether an educator or a participant), with other activity classed as ‘miscellaneous’
(indicating silence, laughter or multiple conversations during learning activities). The 10-second event coding is
an objective measure and an established method of measuring talk time-to-educator ratio.258,259
TABLE 38 Assessment items in educator behaviour assessment tool (continued )
DESMOND251 behaviour Non-DESMOND251 behaviour
Facilitates sharing of stories about positive attempts to manage
their health
Avoids use of participant stories of positive success
Supports participants to plot their results on the health
profile/action plan
Provides little support to assist participants with the
completion of their health profile/action plan
Prompts reflection of changes already made Does not prompt reflection of changes made
Overall group management
Uses strategies to manage time Avoids using strategies to manage time
Notices tone/dynamics within the group and uses these to
manage the group
Tends to ignore issues within the group
Prompts engagement of quieter participants Avoids seeking engagement of quieter members of the
group
Uses co-educator to support delivery Appears to work alone despite opportunities that may be
assisted by co-educator
Manages group to provide time and space to complete tasks Avoids managing group to allow time and space
Provides overviews of the sessions/day Does not provide overviews of the sessions/day
Outlines the style of the sessions Does not outline style of sessions
Facilitates full engagement in interactive tasks Tends to facilitate interactive tasks with only a few
participants
Engages participants using rapport-building skills Avoids using rapport-building skills
a The DESMOND behaviour was modified to ‘Does not use analogies’ and non-DESMOND251 behaviour to ‘Does use
analogies’ for the STOP Diabetes education programme.
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Identifying key important educator behaviours
Once the preliminary assessment had been conducted, members of the research team met to explore the
items within the tool, primarily to distinguish between educator behaviours that were seen to be important
compared with those that appeared less core or essential when facilitating adult learners with ID.
Results
Educator training
The STOP Diabetes specific training was attended by two diabetes education specialists, four ID HCPs and
other members of the research team. It is important to note that not all of these members of the team
went on to deliver the education programme.
Based on evaluation forms completed by six of the educators following the two training days, the training
was universally well evaluated. Using a standard evaluation self-report measure, all of the educators agreed
with the statement that they had learned new skills and believed they could apply these skills in practice.
The most helpful aspects of training cited by educators included going through the curriculum and
resources; learning about the development and theoretical underpinning of the programme; and group
discussions and learning from colleagues.
Preliminary assessment of educator behaviour
This was based on findings from one observation visit that was conducted to assess participant–educator
interaction. In general, the observer noted that the diabetes specialist (who was the trained educator)
generally displayed more of the facilitation of learning behaviours, such as using open body language,
seeking clarification of participants’ contributions and providing overviews of the sessions; the ID nurse
displayed more engagement behaviours, prompting exploration of feelings, involvement of quieter
participants and facilitating full engagement in interactive tasks. The DESMOND251 behaviour of prompting
the group to summarise the key messages was rarely observed.
Discussion
Based on initial feedback, the educator training was universally well evaluated. Educators believed that
they had learnt new skills and could apply them in practice. However, we acknowledge training of only
one group of educators.
The preliminary assessment of educator behaviours has identified that different behaviours may be
delivered depending on the educator. The small number of noted differences between educators in terms
of behaviours may be due to professional background and training. The ID nurse may have had more
specialist expertise in engaging people with greater communication and engagement needs. However, this
difference may have also been due to differing roles in the delivery of the programme, as the diabetes
educator had been the original developer of the programme and may have been focused on exploring the
delivery and the content of the programme further. This work has identified what needs to be focused on
for future training in this area.
This work has been a useful first step in the development of a tool that could be used valuably in this area.
Further work is required, as the tool, thus far, has been used on only one programme by one observer.
The first two iterations of the development of the STOP Diabetes programme could not be assessed using
the tool, as the programme was still in development. However, despite this, the tool provided a structure
for the preliminary assessment of intervention fidelity and the variance found between educators at this
early stage will provide a benchmark for future work.
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Recommendations
The findings from this chapter have provided a positive starting point and highlighted a number of
recommendations for future work in this area. The tool is now ready for further adaptation to optimise its
relevance for the target population. Possible adaptions include (1) shortening the tool for simplicity and
(2) omission of some items that are not relevant or appropriate for this client group, such as items that
relate to abstract concepts and that require participants to remember or summarise the training points.
Items essential to this group have also been identified, such as teaching at the group’s pace and being
flexible. In any future work the tool would also be specifically tailored to follow the structure of the STOP
Diabetes programme. The tool would then need to be tested with a wider group of educators across the
delivery of a larger number of programmes.
The health-care assistant and the nurses who supported the STOP Diabetes programme were not included
in the intervention fidelity observations. It is suggested that they be included in future assessments, as they
are also key to the delivery of the programme and need to be demonstrating the same set of behaviours.
In addition, it is recommended that in the future more than one researcher completes the intervention
fidelity tool to increase the reliability of the findings.
Furthermore, the findings from this work can also feed in to recommendations for future educator
training, particularly the importance of being aware of quieter participants and encouraging engagement
to avoid participants feeling isolated.
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Chapter 12 Economic analysis
Overview
In this chapter, we describe the economic work undertaken as part of WP1, in order to estimate the
cost-effectiveness of the STOP Diabetes lifestyle intervention. Development of the lifestyle intervention is
described in Chapters 8 and 9.
Rationale and aims
The overall aim of the economic work undertaken was to estimate the cost-effectiveness of the STOP
Diabetes lifestyle intervention, compared with current care, in reducing cardiometabolic comorbidities
among individuals with ID.
The objectives of the economic analysis reflect the revised protocol for the STOP Diabetes study. The
economic analysis focused on the purpose of the intervention; that is, to increase physical activity (and to a
lesser extent change in dietary behaviours) among overweight or obese individuals with ID. The context of the
analysis reflects the likely real-world implementation of the intervention, including a screening phase, which
could be appended to the established health checks for people with ID that are carried out annually within
current NHS practice, in order to identify individuals who are suitable for the intervention. This screening can
therefore be viewed as a potential additional component of the Learning Disability Health Check (see below
for more details of the Learning Disability Health Check). If the STOP Diabetes intervention was to be rolled
out, it would target only those with mild or moderate ID, as the intervention is not suitable for those with
severe or profound ID. We therefore restrict the economic evaluation to the subset of individuals in STOP
Diabetes with mild/moderate ID.
The economic analysis does not attempt to estimate the cost-effectiveness of screening individuals for IGR
and T2DM because of a lack of evidence and poor clarity of context within current clinical care and the
proposed STOP Diabetes intervention. This is explained more fully in Appendix 21.
Context of proposed screening with existing intellectual disability care pathways
Learning Disability Health Check
The Royal College of General Practitioners guidelines state that NHS general practices should identify
individuals who are a high priority for health checks, expressing that mild cases of ID are a lesser priority.260
However, the current 2015–16 NHS General Medical Services contract states that all individuals with ID
who are aged > 14 years should be offered a Learning Disability Health Check and we therefore do not
exclude those with mild ID from the analysis.
It was assumed that the model starts at the point following attendance of a Learning Disability Health
Check by all baseline individuals.
Figure 24 shows how the screening and intervention elements of the STOP Diabetes study would fit into
the Learning Disability Health Check and the scope of the economic evaluation.
There is no need to explicitly model the Learning Disability Health Check process, as the baseline
characteristics from the STOP Diabetes study are assumed to reflect characteristics post health check and
the resulting baseline risks of CVD and T2DM.
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FIGURE 24 How screening for suitability for the intervention fits within Learning Disability Health Check.
LD, Learning Disability.
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Attending a Learning Disability Health Check obviates the need to participate in the general population
NHS Health Check programme for those aged > 40 years.
In 2013–14, nationally, 44% of those on an ID register attended a Learning Disability Health Check; this
varies greatly by geographical area, ranging from 10% to 60%. Specifically, 29% missed a check, implying
an offer rate of 73% and an uptake rate (among those offered) of 44%/73% = 60%.261
During the Learning Disability Health Check, BP, weight and height are measured260 [unless it is not
possible because of physical disability (meaning that the patient is unable to stand for height and/or weight
measurement) or behavioural difficulties] so that their BMI can be calculated. Some blood tests may also be
carried out during a Learning Disability Health Check (or in advance of their Health Check, or as a follow-up
test recommended by patients in their Health Action Plan). There is also scope to screen for hyperglycaemia
(and dyslipidaemia) and assess cardiovascular risk as part of routine care, although there is much variation in
practice as to whether or not such blood tests are deemed to be necessary or a priority within a Learning
Disability Health Check, or indeed uptake of blood tests by individuals. For the purpose of the modelling,
we assume that these blood tests would be carried out as part of the Learning Disability Health Check.
The model starting point is an individual having been offered, and attending, a Learning Disability Health
Check, that is, one of the 44% of individuals noted above.
Methods
Overview of approach
This section provides an overview of the economic work before more details are described in
subsequent sections.
The first phase of work involved obtaining all necessary parameter inputs and assumptions for the
economic model, specifically:
1. data from the STOP Diabetes study to provide the baseline patient characteristics
2. data collected, and quotations and input from the study team to provide the details required to
calculate the cost per participant of the STOP Diabetes lifestyle intervention
3. assumptions on uncertain inputs such as rate of uptake of the intervention and the durability of the
benefits of the intervention through discussion with the clinical team.
The modelling itself comprised:
1. Model development An existing economic model of cardiovascular and diabetes risk, driven by
characteristics such as BMI, total cholesterol, HDL cholesterol and HbA1c level, was adapted to incorporate
the relationship between changes in physical activity (steps) and changes in the above risk factors.
2. Modelling the screening process Determining those individuals from the STOP Diabetes study who are
suitable for, and take up, the intervention. The modelling takes account of individuals’ BMI and capacity
to participate in the intervention and rates of uptake of the intervention.
Modelling the screening process involved an adaptation of the prevention ‘Sheffield School for Public
Health Research (SPHR) Type 2 Diabetes Model’. The model is used to simulate the lifetime patient clinical
pathways, incidence of complications and associated cost, and health utility impacts arising from an
intervention compared with routine care. The assumptions for the modelling are described in detail later in
the report, but the key ones are listed here:
1. The STOP Diabetes intervention was estimated to cost £1097 for the initial intervention and eight
maintenance sessions, delivered within a 1-year time frame.
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2. The benefits of increases in physical activity could be mapped to changes in BMI, systolic BP, and total
and HDL cholesterol, using a relationship identified in the literature.
3. The durability of the intervention effects was uncertain so, for the modelling, two scenarios were
adopted with the effects lasting (but decreasing linearly) for 3 and 5 years (from the start of the
intervention), respectively.
The usual approach to economic evaluation is to estimate the incremental lifetime discounted costs and
quality-adjusted life-years (QALYs) of an intervention compared with usual (routine) care. From this, the
incremental cost-effectiveness ratio (ICER) can be calculated and compared with usual acceptability
thresholds (£20,000–30,000 per QALY). However, because the clinical effectiveness of the STOP Diabetes
intervention is not known, the economic modelling was primarily based on threshold analysis. Under this
approach, the requisite clinical effect size needed for the intervention to be just cost-effective (given the
cost of the intervention) was estimated. Because the STOP Diabetes intervention promotes physical activity
and dietary change, the output of the threshold analyses was not a single effect size, but various
permutations of these that would be adequate to make the intervention cost-effective.
Uncertainty around the results was analysed primarily using one-way sensitivity analysis. Owing to the
computational demands of undertaking threshold analyses, probabilistic sensitivity analysis (PSA) was
restricted to one scenario to give an indication of the degree of uncertainty around such an intervention.
Data sources: STOP Diabetes study
Baseline population
The baseline population in the model reflected, as far as possible, the patient-level baseline data from the
STOP Diabetes study, during which data from 930 individuals with ID from the Leicester area were
gathered. Other risk factors (left ventricular hypertrophy, heart rate and valve disease) were based on
general population prevalence as data were not available from the STOP Diabetes study.
Only individuals with mild/moderate ID would be targeted with the STOP Diabetes intervention; thus, those
recorded as having severe/profound ID were removed from the sample, leaving a total of 618 individuals in
the modelled cohort. Summary statistics of these individuals are shown in Table 39.
The initial Learning Disability Health Check itself is not simulated to prevent modification of baseline
characteristics (such as diabetes diagnosis or statin treatment) before initiation of the intervention.
Data imputation
Many individuals were lacking responses to some questions in the baseline questionnaire but had data for
others. The SPHR Diabetes Prevention Model uses imputation models based on Health Survey for England
(HSE) 2011 data262 to impute missing anthropometric and metabolic measures. Full details of imputation
models can be found elsewhere in an online discussion document.263
Clinical effectiveness
The feasibility study was intended to assess the practicality of implementing the intervention in the target
group. Sample sizes were, however, too small to quantitatively assess the effectiveness of the intervention
(n = 4 with before-and-after accelerometer data reporting step count); therefore, there were no estimates
of clinical effectiveness available (see Use of threshold analysis).
Assessing suitability for intervention
Process
All of the individuals at the start of the model were assumed to be attending the Learning Disability Health
Check in the first year and therefore potentially eligible for the intervention. However, not all individuals
were deemed to be at sufficiently high risk or capable of receiving a lifestyle intervention. Therefore, in the
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intervention arm of the model, suitable individuals needed to be identified as part of the Health Check
process using pragmatic selection and capacity criteria. The selection criteria for clinical need for the
intervention was being overweight or obese; that is, having a BMI of > 25 kg/m2 (or BMI of > 23 kg/m2 for
individuals from black or minority ethnic groups). It was assumed that individuals were capable of taking
part in the intervention if they could walk (without aids); did not have behaviour problems; and if their ID
was mild, moderate or unknown. The capabilities assessment itself was assumed to occur in all of the
baseline individuals at the start of the model.
These criteria resulted in 62.1% of individuals with mild or moderate disability being eligible for intervention.
The proportion of individuals receiving the intervention was further reduced by taking account of the
willingness of suitable individuals to participate in the programme of intervention sessions, so the model
also incorporates this rate of uptake.
TABLE 39 Baseline characteristics of individuals with mild or moderate ID in the STOP Diabetes study
Parameter Number (N= 618) Percentage
Male 337 54.5
White 537 86.9
IMD 1 (least deprived) 109 17.6
IMD 2 107 17.3
IMD 3 125 20.2
IMD 4 142 23.0
IMD 5 (most deprived) 135 21.8
Non-smoker 512 82.8
Antihypertensive treatment 62 10.0
Statin treatment 55 8.9
CVD 12 1.9
Depression/anxiety 171 27.7
Congenital heart disease 12 1.9
Capable of taking up intervention 484 78.3
Eligible for intervention by BMI criteriaa 458 74.1
Eligible for and capable of intervention 384 62.1
Mean (SD) Median
Age (years) 43.07 (14.15) 42.32
BMI (kg/m2) 29.25 (7.36) 28.10
Total cholesterol (mmol/l) 4.91 (1.02) 4.80
HDL cholesterol (mmol/l) 1.35 (0.49) 1.30
HbA1c (%) 5.37 (0.49) 5.35
Systolic BP (mmHg) 121.60 (17.67) 120.00
Diastolic BP (mmHg) 78.10 (11.07) 78.00
EQ-5D 0.838 (0.219) 0.850
Baseline physical activity in mean steps per day (N = 46) 6892 (3556) 6453
IMD, Index of Multiple Deprivation.
a BMI of > 25 kg/m2 (or a BMI of > 23 kg/m2 if black or Asian ethnicity).
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Screening cost
In order to assess the real-world impact of the intervention if it was rolled out at scale, we assume that the
above assessments would be carried out at the same time as their routine Learning Disability Health Check,
as opposed to a separate appointment that occurred for the screening component of the programme.
Therefore, the additional screening-related costs attributable to STOP Diabetes were simply those to assess
an individual’s (1) need for the intervention and (2) capacity to undertake the intervention (whenever
increased activity is recommended). Recruitment costs from the STOP Diabetes study were excluded, as
these would be covered by the existing recruitment activity for the Learning Disability Health Check.
It was estimated that the BMI calculation, capabilities assessment and time taken to explain, and
potentially gain, consent for the intervention would take on average an extra 15 minutes of health-care
assistant time during the NHS Health Check compared with current care (£5.10). This cost is incurred by all
individuals in the intervention arm of the model.
The process of risk assessment and any associated screening for diabetes or IGR, and any overall
assessment of CVD risk, is assumed to fall within the existing remit of their annual Health Check and
therefore outside the scope of this economic evaluation.
Intervention form, cost, clinical effectiveness and uptake
Form
The costs of the intervention were divided into three phases:
1. Development phase The costs of setting up the intervention, for example the upfront costs of training
the educators and equipping them to deliver the intervention.
2. Delivering the initial intervention The key components are:
¢ seven sessions for patients plus an additional one for their carers
¢ each session lasting 2.5 hours, plus 30 minutes’ set-up/pack-up time
¢ three educators per group – one band 8a, one band 7 and one band 3.
3. Maintenance sessions Eight monthly sessions starting after the initial intervention, as it is recognised
that for lifestyle interventions to have sustained benefits, some ongoing education is needed to
reinforce behaviour change.
Cost
A microcosting exercise was undertaken by colleagues at Leicester, assisted by the economics team, in
order to obtain a cost-per-patient of receiving the intervention. As STOP Diabetes was a feasibility study,
not all elements of the full cost of its delivery are known with precision. Furthermore, some cost would be
different if incurred in a real-world setting. As the economic analysis is essentially a threshold analysis to
inform any further study of the STOP Diabetes intervention within a trial setting, it was decided that there
was little point in separate costings of the intervention so a single costing was undertaken based on actual
resources incurred during the study where available, but modified where appropriate to reflect the costs
that would be incurred in a real-world setting and using price quotations obtained by the clinical team for
some aspects of the intervention’s development.
Within the STOP Diabetes research study, the average number of patients per group was six, but for the
costing an average number of eight people per group was assumed, as this would be an acceptable
maximum number in the ‘real world’.
‘Research costs’, such as recruiting patients to the study and initial development of the intervention, were
excluded because the intervention had already been developed and it was assumed that recruitment costs
were part of the existing annual health checks process for patients with ID.
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Costs of the components of the intervention were obtained from several sources. Unit costs of some nurse
grades are available from the Unit Costs of Health and Social Care.264 Costs for other nurse bands were
obtained by combining salary costs provided by the study team with overhead adjustment in line with the
Unit Costs of Health and Social Care.264 The costs of non-staff items were provided by the study team.
The individual cost elements of the STOP Diabetes intervention are shown in Table 40.
TABLE 40 Cost of the STOP Diabetes intervention
Details Cost apportioned to Cost (£)
One-off costs of intervention
Trainer costs for educator training (one-off): initial
DESMOND + intervention specific:
l Band 7 × 6 days @ £353
l Band 8a × 4 days @ £438
‘Educator team set-up’a 2118 + 1752
In theory, up to a maximum of 15 educators possible per group training
session
Trainer time for quality development intervention fidelity (i.e. sit in on
educator delivering session): band 7 trainer – 1.5 days needed per
educator × three educators @ £353/day
‘Educator team set-up’a 1588
Educator costs: attendance at training (time and travel) – initial
DESMOND + intervention specific:
l Band 3 × 3 days @ £173
l Band 7 × 3 days @ £353
l Band 8a × 3 days @ £438
‘Educator team set-up’a 519 + 1059 + 1314
(This mix reflects a group of educators that can deliver a course
together)
Educator costs: preparation time to deliver curriculum – each educator
time to prepare before delivery of their few courses:
l Band 3 × 2 days @ £173
l Band 7 × 2 days @ £353
l Band 8a × 2 days @ £438
‘Educator team set-up’a 346 + 706 + 876
(This mix reflects a group of educators who can deliver a course
together)
Educator time for quality development intervention fidelity: quality
development and mentorship visits (1.5 days per educator)
l Band 3 × 1.5 days @ £173
l Band 7 × 1.5 days @ £353
l Band 8a × 1.5 days @ £438
‘Educator team set-up’;a
assume this is required
over a cycle of 3 years
(as in DESMOND)
260 + 530 + 657
Developing training package, resources and intervention fidelity tools ‘Trainer team one-off’
What trainers needed to train up educators 1000
Some elements could be reused but some could be consumed
(e.g. food during training)
Assume 50% of the estimated total £2000 costs could be
attributable to a single team of educators (there may be a few
training providers around the country, so cannot spread the cost over
lots and lots of educator teams)
continued
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TABLE 40 Cost of the STOP Diabetes intervention (continued )
Details Cost apportioned to Cost (£)
Delivery materials: education curriculum: three educators × £100 ‘Educator team set-up’a 300
Delivery materials: education resources and resources/food models per
set: initial set £100, more substantive set up to £2000
Per team of educators – assume non-reusable ‘Educator team set-up’a 1000
Venue costs for educator training (one-off): initial
DESMOND + intervention specific – £100 per day × 3 days
In theory, up to maximum of 15 educators possible per group
training session
‘Educator team set-up’a 300
Initial educational intervention
Administrative time and co-ordinator time (combined)
Telephone calls to confirm suitability and willingness: 15 minutes per
person, but would not be needed in real world as would be part of
nurse assessment
l Arrange appointments, send confirmation and follow-up reminder
telephone call(s): 15 minutes per person @ £21 per hour
(estimated on average £18 per hour/administrator, £24 per hour/
co-ordinator)
Per participant 5.25
Booking/confirming venue (30 minutes per group) Per eight-session course 10.50
Co-ordinating educators and resources (60 minutes per session × 8) Per eight-session course 168
Assuming £21 per hour average salary costs
Delivery
Seven sessions to patients plus one carer session= eight sessions
Each session = 2.5 hours’ delivery + 0.5 hour set-up/pack-up time per
session = 3 hours per sessionb
Per eight-session course
Each session run by two educators plus one health-care assistant
(1 × band 3 plus 1 × band 7 plus 1 × band 8a)
Band 3 × 3 hours @ £23 × 8 sessions 552
Band 7 × 3 hours @ £47 × 8 sessions 1128
Band 8a × 3 hours @ £58 × 8 sessions 1392
Participant handbook Included under cost of
course materials, below
Pedometer: one per person + 50% for carers, at £8 each (assume
need 10 per group + 20% for loss), total per group if seven, allow
13 pedometers
Per eight-session course 104
Refreshments: £1 per person, plus 50% for carers, for 8 weeks, total per
group if seven
Per eight-session course 84
Postage/telephone calls: total per group = £10 Per eight-session course 10
Stationery and reprographics: letters/information/course materials – £10
per person, total per group
Per eight-session course 70
Venue hire cost: could be NHS premises (in which case costs absorbed
into Curtis264 rates) or non-NHS community (local authority) – some
would charge
Per eight-session course 360
Assume 50% of venues not in NHS and incur a charge
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To obtain an overall cost per patient, a sequential process of apportioning ‘Educator team set-up’ to
educators, then educator costs to a cost per course, then to course costs to patients was undertaken,
giving a cost per patient of £1097 (combined cost for the initial and maintenance intervention).
Potentially, there might be some scope for either reducing the cost of the intervention or actual costs
incurred being lower than estimated above. For example, the mode or frequency of delivery of maintenance
sessions could be revisited, a different mix of grades of educators may be possible in the real world, some
individuals who attend the initial course may not continue to the maintenance sessions and the method
of apportioning overhead costs within Curtis264 is somewhat arbitrary (appears to load greater overhead
costs to more senior staff). Through a cost-specific threshold analysis, we explored to what degree the cost
of the intervention would need to be reduced in order to make it cost-effective.
Clinical effectiveness
Owing to the small number of individuals in the feasibility study with data on physical activity (as measured
using an accelerometer) before and after the programme (n = 4), effectiveness estimates were not available
from the STOP Diabetes programme itself. Therefore, a threshold analysis approach (see Use of threshold
analysis) was used to estimate the threshold for the effect size needed to make the intervention marginally
cost-effective in the £20,000–30,000 cost per QALY range as recommended by NICE.265 As the intervention
includes dietary advice as well as the physical activity element, we report the threshold in terms of possible
permutations of the number of steps and the additional diet-attributable BMI and systolic BP changes that
would be needed to be able to demonstrate that the intervention is cost-effective.
Durability of effect
The initial intervention-related changes in BMI, systolic BP and HDL cholesterol within the year of
intervention were subsequently assumed to wear off linearly such that, after 3 years from the start of the
intervention, individuals have returned to the BMI, systolic BP and HDL cholesterol trajectories that they
TABLE 40 Cost of the STOP Diabetes intervention (continued )
Details Cost apportioned to Cost (£)
3 hours × 8 weeks, £10–20 per hour (assume £15)
Travel costs: staff – 45p per mile for three educators × eight sessions,
return mileage estimated at 10–30 miles, depending on distance from
base
Per eight-session course 36.00
Travel costs: in STOP Diabetes, participants [taxi travel or reimbursement
of bus fare, assuming 50% of people (three or four per group) need
travel costs paying, estimated £10–20 taxi and £2.00–3.00 bus fare per
journey]. In real world, however, it can be assumed that such travel costs
would all be accounted for with the patient’s free bus pass and/or
mobility allowance
– 0
Monthly ongoing support sessions
Eight monthly sessions: the cost of delivering these sessions is uncertain.
They could be delivered one-to-one or in a group. Although group-based
delivery would normally be cheaper for lifestyle interventions, for
individuals with ID this might not be the case. Delivering maintenance
might be achievable through a single educator visiting the patient’s home
(thereby avoiding venue costs) and provision of a shorter hour-long
one-to-one session might be sufficient. It was therefore judged to be a
conservative approach to allow for maximum potential costs by costing
on the assumption of group-based delivery and cost of a maintenance
session was assumed to be the same as an initial session
As in Initial
educational
intervention
section, above
a Refers to costs to train up a team of three educators.
b No staff time for travel to courses included, as could be on site or, if straight from home, would not be reimbursed if no
further than to workplace.
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would have followed in the absence of intervention. Alongside the above base-case assumption, an
additional scenario analysis was carried out to test the response of the results to 5-year duration of effect.
Intervention uptake
Of individuals who are both eligible for, and capable of taking up, the intervention, we assumed that
55% do so and thereby incur the full costs of the intervention, based on advice for a previous lifestyle
intervention evaluation.266
Modelling the benefits of changes in physical activity (steps)
The economic model chosen for the modelling (the SPHR Diabetes Prevention model, described later) does
not include physical activity as a risk factor for CVD or diabetes. However, the primary measure of interest,
in terms of informing any future follow-on trial from the STOP Diabetes study, is change in steps per day
[and this is a key output of the threshold-based economic analyses (see Use of Threshold analysis), and
any subsequent full trial would be based around change in physical activity measured in steps using a
pedometer]. It was therefore necessary to identify a mechanism to map changes in physical activity
to changes in the above risk factors that already exist in the model (BMI, systolic BP, total and HDL
cholesterol, and glucose-related risk factors) and vice versa.
Rationale for surrogate-based model
A surrogate-based approach was chosen because:
1. The SPHR Diabetes Prevention model uses metabolic trajectories to model long-term progression of risk
factors and incidence of comorbidities.
2. A meta-analysis was identified, which linked changes in physical activity to changes in systolic BP, total
and HDL cholesterol.
3. We are unaware of any meta-analyses of hazard ratios for the effect of changes in physical activity on
incidence of CVD and diabetes.
4. Although we were made aware of a study linking physical activity to CVD (Yates et al., NAVIGATOR
Trial267), the analysis was undertaken assuming a constant change in steps over a 6-year period,
whereas the effect of the STOP Diabetes intervention would decline over time. So any hazard ratio
adjustments to the risks of CVD and diabetes would need to have been analysed in a time-dependent
way. The behavioural changes in this study were also based on dietary advice, but it is unknown how
intensive this was compared with the STOP Diabetes intervention (which contained some dietary advice,
but no weight loss target). The reported hazard ratio may therefore include significant risk reduction
that is attributable to dietary changes. Additionally, this study recruited a cohort of individuals with IGR
at baseline and reported only CVD (not diabetes).
We did believe, however, that it would be useful to compare the predictions of the model (modified to
reflect a constant changes in risk factors for 6 years) with the 6-year results reported in the Yates et al.
study.267 For an increase in activity of 2000 steps, Yates et al.267 reported a hazard ratio of experiencing a
cardiovascular event over the following 6 years of 0.92 (95% CI 0.86 to 0.99), that is a risk reduction of
8%. The hazard ratio from our adapted model was 0.95 (5% risk reduction). The details of the method
behind this comparison are provided in Appendix 22.
There are various reasons why a slightly lower reduction in risk might be expected from the model
compared with that observed in the NAVIGATOR trial. First, patients in the NAVIGATOR trial had IGR but
were not necessarily overweight, whereas the baseline population in the model were mostly normally
glucose tolerant but with BMI values above defined thresholds. BMI and diabetes both input into
cardiovascular risk, but the relative effect this population difference might have on cardiovascular
outcomes is unclear. Second, the trial participants received both exercise and dietary advice, but potential
differences in diet between individuals with different step counts was not accounted for in the trial
analysis. It is possible that individuals who follow exercise advice are more likely to follow dietary advice
too and so may show a greater effect on metabolic trajectories than accounted for in our analysis based
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on steps alone. This would result in the model underestimating the results of the trial as is indeed
observed. Third, there are some differences in the events picked up in the trial and those accounted
for in the model (e.g. transient ischaemic attack and stable angina are in the model but not the trial),
although it is unclear what effect there would be on the hazard ratio from restricting outcomes to those
used in the trial. Finally, it cannot be ruled out that exercise may impact positively on factors that are not
included in the model, which in turn result in reduced cardiovascular risk.
It should be noted that as the Yates et al. study267 reports hard outcomes in terms of cardiovascular events,
but not changes in biomarkers of risk, the results could not be used to parameterise the SPHR model
(which estimates a range of outcomes, including CVD, based on cardiometabolic risk factors and their
projected trajectory over time).
Review of relationship between physical activity (steps) and risk factors for
cardiovascular disease and diabetes in the model
To identify a suitable mapping between steps and model risk factors, a targeted review of the published
literature was carried out using a search of the online PubMed database, a subsequent citation search and
advice from clinicians. This evolved into a three-step process as described below.
Step 1: search strategy for physical activity studies reporting step as an outcome
The search strategy using the PubMed publications database is detailed in Appendix 23, Box 4. The search
yielded 153 results, from which 54 abstracts were selected based on titles. Of these, 19 were relevant,
of which full text was available for 14. One of these studies, by Stuckey et al.,268 discussed a meta-analysis
undertaken by Bravata et al.,269 which is discussed below.
Step 2: citation search for review papers citing Bravata et al.269
This search identified 22 abstracts for review. Abstract/title sifting led to seven full-text papers being
checked. Of these seven papers, four were excluded as narrative reviews only; one was a review of
reviews, but focused on diet only or diet and physical activity interventions and therefore was not relevant;
one was excluded because it was a primary trial not a review or meta-analysis; and one was excluded
because it reported only weight and no metabolic outcomes. This search identified two relevant studies of
potential use for the modelling: Murphy et al.270 and Qui et al.,271 which were reviewed in full text and are
discussed below.
Step 3: conversation with clinical advisors
In discussion with clinicians it was determined that cholesterol changes were also very likely to be observed
as a result of the intervention. In this respect, we were referred to a study by Camhi et al.,272 which is
described below. This conversation also highlighted the Yates et al. study,267 discussed earlier.
Description of key studies
Bravata et al.269 reviewed and combined the results of studies that used a pedometer to measure physical
activity and reported health outcomes (mean duration of studies = 18 weeks). The overall step change
induced by intervention studies was 2491 additional steps per day. Significant reductions were reported
in BMI (–0.38 kg/m2) when 18 studies (n = 562) were combined and in systolic BP (–3.8 mmHg) when
12 studies (n = 468) were combined. There were also non-significant reductions in lipids with a reduction
in total cholesterol of 0.09 mmol/l and an increase in HDL cholesterol of 0.06 mmol/l.
Murphy et al.270 was a review of walking interventions on metabolic risk factors, based on minutes per
week rather than steps. It reported very similar outcomes to Bravata et al.269 (188 additional minutes per
week were associated with 0.95 kg of weight loss, a 0.28-kg/m2 BMI reduction and a 1.54-mmHg diastolic
BP reduction).
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Qui et al.271 was a recent meta-analysis of step counting and its effects on HbA1c control.271 Although it
found evidence of significant increases in steps it found no strong evidence for changes in HbA1c level. This
backs up the results of the previous Bravata et al. review,269 which only found significant changes in BMI
and BP.
The Camhi et al.272 study was cross-sectional, based on the US NHANES survey (National Health and
Nutrition Examination Survey). This study272 assessed the relationship between activity (steps per day) and
cardiometabolic risk factors, including cholesterol. Data for 1371 adults were analysed and significant
changes were observed in triglycerides, HDL cholesterol and waist circumference for each 1000 additional
steps achieved, but does not report BMI changes or BP. The study272 reported results as an OR of
0.91 (95% CI 0.81 to 0.96) of having HDL cholesterol above the cut-off point of 1.03 mmol/l (men) or
1.2 mmol/l (women).
For the purpose of parameterising the model, this study272 was not preferred over the evidence from the
Bravata et al. study269 because this is only a single study and is cross-sectional, whereas the Bravata et al.
study269 is a meta-analysis of intervention studies.
Implementation of mapping steps to risk factors
Physical activity and the mapping are not contained within the simulation model itself. The estimation of
the number of steps needed is calculated manually after the model has been run several times and a
threshold analysis has identified the degree of BMI change needed for the intervention to be marginally
cost-effective (see Use of threshold analysis for more details).
Table 41 shows the mapping between physical activity and risk factors obtained from the Bravata et al. study.269
Model: overview and structure
The SPHR Diabetes Prevention Model is an individual patient simulation model, written in the
programming language R, which was built to enable evaluation of a wide range of different diabetes
prevention and weight loss interventions in the general population. The model was originally developed
using a new conceptual modelling framework for complex public health models,273 in collaboration with a
project stakeholder group comprising health economists, public health specialists, research collaborators
from other SPHR groups, diabetologists, local commissioners and lay members. A review of existing
diabetes prevention models was undertaken to inform conceptual model development,274 resulting in the
model including multiple diabetes risk factors (in particular both BMI and impaired fasting glucose) and
complications of diabetes and obesity.
The model has been adapted to evaluate the outcomes of an intervention to promote physical activity in
high-risk subgroups of a population with ID. Owing to limited data about care pathways, disease risk and
utility values in populations with ID, much of the model is based on general population data; however,
when possible, data from populations with ID have been used.
TABLE 41 Effectiveness outcomes from the Bravata et al. study269 for the mean increase of 2491 steps per day
Risk factor Mean change (95% CI)
BMI (kg/m2) –0.38 (–0.72 to –0.05)
Systolic BP (mmHg) –3.8 (–5.9 to –1.7)
Total cholesterol (mmol/l) –0.09 (–0.32 to 0.15)
HDL cholesterol (mmol/l) 0.06 (–0.012 to 0.14)
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The model is based on individual longitudinal trajectories of metabolic risk factors (BMI, systolic BP,
cholesterol and HbA1c). For each individual, yearly changes in these risk factors occur, dependent on the
individual’s baseline characteristics.
Illustrated in Figure 25 is the sequence of updating clinical characteristics and clinical events that are
estimated within a cycle of the model. This sequence is repeated for every annual cycle of the model.
The first stage of the sequence updates the age of the individual. The second stage estimates how many
times the individual attends the GP. The third stage estimates the change in BMI of the individual from the
previous period. In the fourth stage, the change in glycaemia is estimated using different statistical models
depending on whether or not they have been diagnosed with diabetes (see below). In stages 5 and 6,
the individual’s BP and cholesterol are updated. In stage 7, the individual may undergo assessment for
diabetes, hypertension and dyslipidaemia during a GP consultation. From stage 8 onwards the individual
may experience cardiovascular outcomes, diabetes-related complications, cancer, osteoarthritis or
depression. Individuals with a history of CVD follow a different pathway in stage 8 to those without a
history of CVD. Individuals with a HbA1c level of > 6.5% are assumed to be at risk of diabetes-related
complications: individuals who do not have a history of cancer are at risk of cancer diagnosis, whereas
those with a diagnosis of cancer are at risk of mortality because of cancer; individuals without a history of
osteoarthritis or depression may develop these conditions; and, finally, all individuals are at risk of dying
from causes other than cardiovascular or cancer mortality. Death from renal disease is included in the
estimate of other-cause mortality. The time horizon of the model is the lifetime of all baseline individuals.
Cardiovascular events are modelled using the QRISK2 algorithm (more details are provided in Appendix 24,
Tables 62 and 63). The model uses risk equations from the UK Prospective Diabetes Study (UKPDS)
outcomes model to estimate the occurrence of major events relating to microvascular complications,
including renal failure, amputation, foot ulcer and blindness.275,276
Routine care: components of cardiovascular risk reduction
Both intervention and comparator arms of the model need to include any screening for hyperglycaemia
and high CVD risk that is carried out routinely in clinical practice. This may be through the Learning
Disability Health Check or opportunistic screening.
Learning Disability Health Checks
Individuals with ID should be invited to an annual health check during which they undergo screening for
hypertension, high cardiovascular risk and diabetes among other conditions. Although uptake of health
checks among people with ID is only 44%, it was assumed that, at baseline, all individuals had been
identified through attending a Learning Disability Health Check and would therefore be very likely to
attend future health checks. It was therefore assumed that all of the eligible individuals would attend
annual health checks. Individuals who have been diagnosed with diabetes or CVD, or who are taking
statins or antihypertensive drugs, do not continue to receive Health Checks, as they receive extra GP care
that is specific to their diagnosis.
Not all individuals consent to blood tests as part of their Learning Disability Health Check. It was assumed
that 33% of individuals would never consent to blood tests during a health check (based on uptake of
blood tests and availability of results for the screening programme, presented in Chapter 5); therefore, they
could not be screened for CVD risk or diabetes by this method. However, it was assumed that if such
individuals met the criteria for opportunistic diagnosis (see below), they would consent to blood tests and
so could be diagnosed through this means. A different cost for a Learning Disability Health Check was
used for individuals who do or do not consent to blood tests (see Screening cost).
General practitioner attendance and opportunistic screening
Frequency of GP visits (separate from NHS health checks) was simulated in the data set for two reasons:
first, to estimate the health-care utilisation for the population with ID without diabetes and CVD, and,
second, to predict the likelihood that individuals participate in opportunistic screening for diabetes and
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FIGURE 25 Risk of comorbidities. Osteo, osteoarthritis.
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elevated risk factors for CVD. This is important, as many individuals in the model cannot be diagnosed
through annual health checks either due to ineligibility or because they do not consent to blood tests as
part of their Learning Disability Health Check.
It was assumed that GP attendance in the population with ID occurs at the same frequency as in the
general population. However, for cost purposes, consultations were assumed to take 40% longer than the
general population average (see Screening cost). A model of GP attendance conditional on age, sex, BMI,
ethnicity and health outcomes was derived from analysis of wave 1 of the Yorkshire Health Study263 and is
described elsewhere.
Long-term longitudinal trajectories of metabolic factors
The SPHR Diabetes Prevention model263 is based on individual longitudinal trajectories of metabolic
risk factors (BMI, latent blood glucose, total and HDL cholesterol, and systolic BP), derived from statistical
modelling of the data set from the Whitehall II cohort study.277 The statistical modelling uses parallel
latent growth modelling to incorporate correlations and associations between risk factors that impact on
long-term risk profiles. An advantage of the parallel growth analysis is that it is possible to estimate the
effect of growth in BMI on the other metabolic risk factors so, for example, a change in an individual’s BMI
will result in an indirect change in their HbA1c trajectory. Growth factors are also conditional on several
individual characteristics including age, sex, ethnicity, smoking, family history of CVD and family history of
T2DM. It is also possible to estimate correlation between changes in underlying glycaemia (measured by
HbA1c level), systolic BP, and total and HDL cholesterol. Full details of this analysis are described elsewhere.278
The characteristics of the Whitehall II cohort277 (civil servants living in London) are likely to differ significantly
from that of the STOP Diabetes population. However, there are, to our knowledge, no available longitudinal
surveys of populations with ID on which to base a similar analysis, and no other analysis of metabolic
trajectories takes into account the correlations between risk factors that make the Whitehall model277 so
powerful. Importantly, the baseline values for the metabolic risk factors do come from the STOP Diabetes
population, with the Whitehall-based trajectories277 being used simply to describe the expected changes in
metabolic values over time.
If an individual in the model is diagnosed with diabetes, or starts treatment with antihypertensive drugs or
statins, trajectories alter to reflect the expected changes due to treatment. The criteria for opportunistic
screening and diagnosis of diabetes, hypertension and high CVD risk can be found in Appendix 25,
Table 64, together with details of changes in metabolic trajectories.
Risks of mortality: raised risk in individuals with intellectual disability
In every model cycle, individuals within the model are evaluated to determine whether or not they
experience a fatal event or mortality. The evidence for risk of mortality in individuals with ID compared
with the general population is described below, analysed by cause, that is, CVD, cancer and other causes.
Cardiovascular mortality
Cardiovascular disease mortality is included as an event within the estimated CVD risks calculated by the
QRISK2 score as described below (see Cardiovascular disease). There is some evidence for an increased
risk of CVD mortality in individuals with ID,279 but other studies report no difference or even reduced risk
compared with the general population (see results of meta-analysis presented in Chapter 2). It is also
unclear whether these differences in mortality risk are due to differences in risk factors included in the
QRISK or due to other factors. It was assumed for the purposes of the model that any differences in
cardiovascular mortality between individuals with ID and individuals in the general population occur simply
due to differences in risk factors.
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Cancer mortality
It was assumed that risk of cancer and subsequently cancer mortality would be the same in a population
with ID as in the general population, taking into account individual differences in risk factors. This is
supported by several studies looking at mortality rates from various causes in populations with ID.279,280
Other-cause mortality
This describes the risk of death from any cause except CVD and cancer. This was derived from all-cause
mortality rates by age and sex, extracted from the ONS.281 The mortality statistics report the number of
deaths by ICD codes for 5-year age groups. To obtain other-cause mortality, the number of CVD, breast
cancer- and colorectal cancer-related deaths were subtracted from the all-cause mortality total.
There is good evidence from various sources that the rate of all-cause mortality is higher in individuals with
ID,63,279,282 particularly due to excess deaths from respiratory disorders, neurological diseases, congenital
abnormalities and accidents. Standardised mortality ratios (SMRs) of 2.28 (95% CI 2.02 to 2.56) for men
with ID and 3.24 (95% CI 2.83 to 3.69) for women with ID, compared with the general population,
reported in a 14-year study of individuals from the Leicester area279 were applied to the other-cause
mortality rates that were derived from the ONS data. The SMRs were not adjusted upwards to take into
account the minimal increase and decrease in cancer and CVD mortality, respectively, in populations with
ID, as it was unclear how large this adjustment should be and it was expected to make little difference to
the outcomes.
The rate of other-cause mortality by age and sex was treated as the baseline hazard. An increased risk of
mortality was assigned to individuals with diabetes, using data from a published meta-analysis.283 This
study283 used data from 820,900 people from 97 prospective studies to calculate hazard ratios for cause-
specific death, according to baseline diabetes status. Cause of death was separated into vascular disease,
cancer and other-cause mortality. From this study283 it was estimated that individuals with a diagnosis of
diabetes have a fixed increased risk of other-cause mortality (hazard ratio 1.8, 95% CI 1.71 to 1.9). The
estimates reported in the meta-analysis include increased risk of death from renal disease; therefore,
mortality from renal disease was not simulated separately to avoid double counting of benefits.
Comorbid outcomes with no excess risk in individuals with intellectual
disability
In every model cycle, individuals within the model are evaluated to determine whether or not they have a
clinical event. In each case within the simulation, risk equations estimate the probability that an individual
has an event, and a random number is drawn to determine whether or not the event occurred.
Cardiovascular disease
The QRISK2 model was chosen to estimate cardiovascular risk and incidence as it is a validated model
based on a UK population.284 Probability of a first cardiovascular event in the next year (including
cardiovascular mortality) is calculated, being conditional on ethnicity, smoking status, age, BMI, ratio of
total cholesterol to HDL cholesterol, deprivation score, atrial fibrillation, rheumatoid arthritis, renal disease,
hypertension, diabetes and family history of CVD. Coefficients for the QRISK2 model can be found in
Appendix 24, Tables 62 and 63. The QRISK2 assumptions regarding the relationship between diabetes and
CVD were modified to reflect observations from the UKPDS and the European Prospective Investigation
into Cancer and Nutrition (EPIC) that HbA1c (rather than diabetes) increases the risk of myocardial
infarction (MI) and stroke in a linear manner.275,285
The STOP Diabetes baseline data did not include any information about atrial fibrillation but did include a
category for unspecified other heart conditions, which was recorded for 10 individuals (1.6% of total
population). A diagnosis of atrial fibrillation was randomly assigned to seven of these individuals in line
with an audit of patients with ID in North Essex, which found that 1.1% of individuals had atrial
fibrillation.286 The STOP Diabetes baseline data also had no specific questions about rheumatoid arthritis or
renal disease. However, one individual was noted to suffer from rheumatoid arthritis using the other health
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problems variables, and no individuals were noted to suffer from renal disease so we assumed ‘no renal
disease’ at baseline.
There is conflicting evidence about whether or not individuals with ID have a greater risk of CVD than is
seen in the general population, and if so, whether or not this can be accounted for through the risk
factors already incorporated into the QRISK2 model. Although some studies have found an increase in
prevalence of CVD83 or CVD mortality279 in individuals with ID, other studies report no difference or
reduced risk compared with the general population (see Chapter 2, Results). Lower CVD mortality than in
the general population could partially be explained through competing risks, given that individuals with ID
have higher mortality from other causes, particularly respiratory illnesses, congenital abnormalities,
neurological disorders and accidental injury.279,280
The model estimates that individuals recruited into the STOP Diabetes study have a much lower incidence
of CVD than unmatched (for age) individuals from the HSE 2011262 due to their baseline characteristics
(Table 42). This cannot be explained solely by the lower (by 5 years) mean age of the ID cohort (e.g.
compare year 10 in the ID cohort with year 5 in the general population cohort). Given the lack of a clear
consensus over CVD risk in individuals with ID, it was assumed that the QRISK2 equations were suitable for
use in the population with ID, and that any differences in CVD risk compared with the general population
would be accounted for through the differences in baseline risk factors.
Relationships between risk factors and different types of CVD (e.g. hypertension being more of a risk for
stroke) are not incorporated into the model.
All of the CVD events modelled using QRISK2 are assigned to a specific diagnosis according to age- and
sex-specific distributions of cardiovascular events reported in a previous Health Technology Assessment
(HTA) for statins.287 Events are also split into ‘fatal’ compared with ‘non-fatal’ ones.
Congestive heart disease
Congestive heart failure was coded as a separate cardiovascular event using the Framingham risk equation288
because it is not included as an outcome of the QRISK2. The Framingham equation is not ideal, as it is
based on a US population from the 1990s and there is no evidence for its accuracy in representing risk in a
population with ID. However, it was thought to be the best option in the absence of data that were specific
to a population with ID. The equation includes age, diabetes diagnosis (either formal diagnosis or a HbA1c level
of > 6.5%), BMI, systolic BP, congenital heart disease, left ventricular hypertrophy, heart rate and valve disease
to adjust risk based on individual characteristics. Full details of the equation coefficients can be found in an
online discussion paper.263
No baseline information was available for three of these risk factors (left ventricular hypertrophy, resting
heart rate and valve disease); therefore, these factors could not be included in the model to predict
congestive heart disease. The baseline odds of congestive heart disease were adjusted to reflect the
expected prevalence of these symptoms; this was done using general population data, as data that
were specific to individuals with ID could not be identified. The heart rate for men was assumed to be
TABLE 42 Modelled within-year CVD incidence: STOP Diabetes cohort vs. HSE 2011262 (general population) cohort
CVD incidence (per 10,000)
Year
1 5 10 15 20 25 30 35
Cohort with ID 37 56 63 83 113 124 146 162
General population cohort 77 91 101 123 144 158 169 195
Relative risk with ID 0.48 0.61 0.62 0.68 0.78 0.78 0.86 0.83
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63.0 beats per minute and for women 65.6 beats per minute based on data from previous Whitehall II
cohort analyses.289 The proportion of the UK population with left ventricular hypertrophy was assumed to
be 5%, in line with previous analyses of the Whitehall II cohort.290 The prevalence of valve disease was
estimated from the Echocardiographic Heart of England Screening study.291 Twelve baseline individuals
from the STOP Diabetes study suffered from congenital heart disease (1.9%). This is higher than the
prevalence of congenital heart disease in the general population (0.80% of live births),292 and is
unsurprising given the high proportion of individuals with Down and Williams syndromes, as people with
these conditions are known to suffer from congenital heart defects.293 This means that the risk of
congestive heart failure is higher in individuals with learning difficulties than in the general population.
Microvascular complications of diabetes
Data from UKPDS, derived from a UK diabetic population,275,276 were used to estimate the incidence of
major microvascular complications including ulcer, amputation, renal failure and blindness in individuals
with a HbA1c level of ≥ 6.5%, whether or not they are diagnosed with diabetes. Earlier stages of
microvascular complication were not included in the model, as they have less of an impact on costs and
utilities. It was assumed that risk of microvascular complications would be the same in a population with ID
as in the general population, taking into account individual differences in risk factors.
The UKPDS outcomes model version 2275 includes four statistical models to predict foot ulcers, amputation
with no prior ulcer, amputation with prior ulcer and a second amputation. In order to simplify the simulation
of neuropathy outcomes, the models for first amputation with and without prior ulcer were consolidated
into a single equation. UKPDS outcomes model v2 was also used to estimate the incidence of blindness,
whereas the UKPDS outcomes model v1 was used to estimate the incidence of renal failure.276 Early
validation analyses identified that the UKPDS v2 model implemented in the SPHR model substantially
overestimated the incidence of renal failure. Details of the models used are reported elsewhere in an online
discussion paper.263
All of the equations incorporate a coefficient for age at diabetes diagnosis. This was multiplied by age in
the current year if the individual had not been diagnosed with diabetes or by the age at diagnosis if the
individual had received a diagnosis. The expected values for the risk factors not included in the SPHR
model (heart rate, white blood cell count, micro-/macroalbuminuria, peripheral vascular disease and atrial
fibrillation) were taken from figure 3 of the UKPDS publication in which these are described,275 with the
exception of peripheral vascular disease, which was assumed to affect 2% of the population. The baseline
risk was modified to take account of these mean values.
Cancer
Breast cancer and colorectal cancer risk are related to BMI and so were included in the SPHR model.
Incidence rates for breast and colorectal cancer in the UK were estimated from the EPIC cohort. This is a
large, multicentre cohort study looking at diet and cancer. In 2004, the UK incidence of breast cancer by
menopausal status was reported in a paper from this study investigating the relationship between body
size and breast cancer.294 A second paper from EPIC reported the UK incidence of colorectal cancer by
sex.295 Incidence rates in the model for breast and colorectal cancer are shown in Table 43.
A large meta-analysis that included 221 prospective observational studies has reported relative risks of
cancers per unit increase in BMI, including breast cancer and colorectal cancer.296 A risk adjustment
was included in the model so that individuals with a higher BMI have a higher probability of pre- and
post-menopausal breast cancer or colon cancer (Table 44). In the simulation, the incidence of breast and
colorectal cancer was adjusted by multiplying the linear relative risk by the difference in the individual’s
BMI and the average BMI reported in the EPIC cohort.
Evidence suggests that mortality from breast and colon cancer occurs at a similar rate in populations with
ID as in the general population.279,280 Cancer mortality rates were obtained from the ONS.297 The ONS
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reports 1- and 5-year net survival rates for various cancer types, by age group and sex. Net survival was an
estimate of the probability of survival from the cancer alone. It can be interpreted as the survival of cancer
patients after taking into account the background mortality that the patients would have experienced if
they had not had cancer.
The age-adjusted 5-year survival rates for breast cancer and colorectal cancer were used to estimate an
annual risk of mortality assuming a constant rate of mortality. It was assumed that the mortality rate does
not increase due to cancer beyond 5 years after cancer diagnosis. The 5-year survival rate for breast cancer
is 84.3%, which translated into a 3.37% annual probability of death from breast cancer. The 5-year survival
rate for persons with colorectal cancer is 55.3%, which translated into an 11.16% annual probability of death
from colorectal cancer.
Osteoarthritis
Osteoarthritis is related to BMI and diabetes, and so was included in the SPHR model. It was assumed that
risk of osteoarthritis would be the same in a population with ID as in the general population, taking into
account individual differences in risk factors. The Bruneck cohort,298 a longitudinal study of inhabitants of a
town in Italy, reported diabetes and BMI as independent risk factors for osteoarthritis. The data used to
estimate the incidence of osteoarthritis are reported in Table 45.
Depression
The SPHR Diabetes model includes depression as a health state due to its relationship with diabetes, but
does not model its severity. Further details are available online.263
TABLE 43 UK colorectal/breast cancer incidence
Cancer type and subgroup
Number
of cases Person-years
Mean age
(years)
Mean BMI
(kg/m2)
Incidence
rate per
person-year
Breast
UK pre menopause 102 103,115 n/a 24 0.00099
UK post menopause 238 84,215 n/a 24 0.00283
Colon
Male 125 118,468 53.1 25.4 0.00106
Female 145 277,133 47.7 24.5 0.00052
n/a, not available.
TABLE 44 Relative risk of colon/breast cancer per unit increase in BMI
Cancer type and subgroup Mean relative risk 2.5th CI 97.5th CI
Breast
UK pre menopause 0.89 0.84 0.94
UK post menopause 1.09 1.04 1.14
Colon
UK pre menopause 1.21 1.18 1.24
UK post menopause 1.04 1 1.07
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Economic impact: utilities
Baseline utility
Baseline utilities for all of the individuals in the model were extracted from the STOP Diabetes study. The
tariffs for the responses to the three-level EQ-5D were derived from a UK population study.299 Baseline
utility was assumed to decline because of ageing, as has been found in general population studies. An
absolute decrement of 0.004 per year is applied in the model; this is based on previous HTA modelling
in CVD.287
Body mass index and utility
It was assumed that changes in BMI will impact on the utility of an individual with ID in the same way as
for an individual in the general population. In a previous modelling of diabetes prevention, weight loss
from education interventions was associated with an increase in utility of 0.0025 per kilogram change in
weight.300 This estimate was derived from weight loss trial data for which all of the participants were
overweight or obese. In the population with ID a large proportion of individuals are normal weight or
underweight, so it would not be appropriate to extrapolate the effects of weight loss on utility to these
individuals. A change in utility due to a change in BMI was added to an individual’s EQ-5D if they had
a BMI of > 25 kg/m2. As a consequence, obese individuals who reduce their BMI as a result of the
intervention will experience an increase in EQ-5D.
Utility decrements
Utility decrements for long-term chronic conditions were applied to the age- and BMI-adjusted EQ-5D score.
It was assumed that a diagnosis of diabetes was not associated with a reduction in EQ-5D independent
of the utility decrements associated with complications, comorbidities or depression. CVD, renal failure,
amputation, foot ulcers, blindness, cancer, osteoarthritis and depression were all assumed to result in utility
decrements. The utility decrements are measured as a factor that is applied to the individual’s age- and
BMI-adjusted baseline. If individuals have multiple chronic conditions then the utility decrements are
multiplied together to give the individual’s overall utility decrement from comorbidities and complications,
in line with current NICE guidelines for combining comorbidities.301
Owing to the number of health states it was not practical to conduct a systematic review to identify utility
decrements for all health states. Furthermore, there are very few or no data to inform utility decrements
for comorbid conditions specifically in individuals with ID. A pragmatic approach was taken to search for
health states within existing HTA for the relevant disease area in the general population or by considering
studies that were used in previous economic models for diabetes prevention. Discussions with experts in
health-economic modelling were also used to identify prominent sources of data for health-state utilities.
Two sources of data were identified for diabetes-related complications. A 2014 study from the UKPDS302
estimated the impact of changes in health states from a longitudinal cohort. These data were used to
estimate the utility decrement for amputation and congestive heart failure. The absolute decrement for
amputation was converted into utility decrement factors that could be multiplied by the individual’s current
EQ-5D to estimate the relative effect of the complication. Utility decrements for renal failure and foot
ulcers were not available from the UKPDS study described above, so were obtained from a different
study303 of 2048 subjects with type 1 diabetes mellitus and T2DM.
TABLE 45 Incidence of osteoarthritis and estimated risk factors
Risk factor Hazard ratio 2.5th CI 97.5th CI
Diabetes 2.06 1.11 3.84
BMI 1.076 1.023 1.133
Seventy-three cases of diabetes: mean BMI 24.8 kg/m2; 13,835 person-years; incidence rate 0.00053.
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Utility decrements for the variety of cardiovascular events were taken from a HTA assessing statins to
reflect the utility decrements in the general population.287 A burden-of-illness study with a broad utility
decrement for cancer was identified and used to define utility decrements for breast and colon cancer.304
A utility decrement for osteoarthritis was taken from a HTA,305 and a utility decrement for depression was
calculated from a trial that had used the EQ-5D.306
The multiplicative utility factors that are used in the model to describe health utility decrements from
comorbid complications are shown in Table 46. The mean absolute decrement estimated in each study is
reported alongside the baseline utility for each study. The utility factor was estimated by dividing the
implied health utility with the comorbidity by the baseline utility.
Economic impact: costs
At any given time period of the model individuals can have multiple health complications that incur direct
health-care costs. Some of the health states are mutually exclusive; however, an individual can accrue
multiple complications within the model. Each health state is associated with an average cost, which is
accrued by all of the individuals for every time period for which the state is indicated. Resource use for
each comorbidity is added together and no savings are assumed to be made from the use of the same
resources for two or more comorbidities for an individual. An exception to this is an assumed adjustment
to the utilisation of GP services for individuals with chronic diseases. In the majority of cases it is assumed
that the unit costs of health care for someone with ID would be the same as the unit costs for an
individual in the general population.
TABLE 46 Utility decrement factors
Event/comorbidity
Mean
absolute
decrement
SE for
absolute
decrement
Baseline
utility
Multiplicative
utility factor Source
Foot ulcer –0.099 0.013 0.689 0.856 Coffey et al. (2002)303
Amputation –0.172 0.045 0.807 0.787 UKPDS (2014)302
Blind 0.033 0.027 0.807 1.041 UKPDS (2014)302
Renal failure –0.078 0.026 0.689 0.887 Coffey et al. (2002)303
Stable angina 0.801 Ward et al. HTA (2007)287
Unstable angina, year 1 0.770 Ward et al. HTA (2007)287
Unstable angina, year 2 0.770 Ward et al. HTA (2007)287
MI, year 1 0.760 Ward et al. HTA (2007)287
MI, year 2 0.760 Ward et al. HTA (2007)287
TIA 1.000 Ward et al. HTA (2007)287
Stroke, year 1 0.629 Ward et al. HTA (2007)287
Stroke, year 2 0.629 Ward et al. HTA (2007)287
Breast cancer –0.060 0.800 0.913 Yabroff et al. (2004)304
Colorectal cancer –0.060 0.800 0.913 Yabroff et al. (2004)304
Osteoarthritis –0.101 Black et al. HTA (2009)305
Depression –0.116 0.7905 0.875 Benedict et al. (2010)306
Congestive heart failure –0.101 0.032 0.875 UKPDS (2014)302
TIA, transient ischaemic attack; UKPDS baseline utility 0.807; HSE baseline 0.7905.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
The exception was cost for a GP appointment, which was expected to be 40% higher than in the general
population as a result of increased length of consultation. All costs were inflated to 2014–15 values
using the retail price index where necessary, from the Personal Social Services Research Unit sources
of information.264
At the present time, the following costs incorporated are:
l costs of GP appointments
l costs of hypertension/dyslipidaemia/diabetes diagnosis and treatment with statins and antihypertensive
drugs; statins have a 65% uptake rate
l diabetes costs [three-stage treatment regimen incorporating metformin (Glucophage®, Merck Serono
Ltd, Feltham, UK) monotherapy (HbA1c level of > 6.5%), metformin plus a dipeptidyl peptidase-4
inhibitor (DPP-IV) (when HbA1c level is > 7.4%) and insulin plus antidiabetic drugs (when HbA1c level is
> 8.5%)], together with associated costs such as blood tests and extra GP visits
l CVD and heart failure costs (including hospital and primary care costs, medications and ongoing care
costs for people with stroke)
l microvascular costs (including renal dialysis and transplant, treatment costs for amputation, ulcer
and blindness)
l cancer costs (including screening and treatment by cancer stage)
l osteoarthritis costs (including extra primary care, medications and joint replacement)
l depression costs (including nurse costs, medication and emergency care).
A summary of all of the unit costs used in the model and their sources are shown in Table 47.264,307–326
Diabetes costs
A three-stage diabetes treatment regimen is applied in the model as a trade-off between model simplicity
and capturing key cost differences between the interventions. At diagnosis, all patients are prescribed
low-cost treatments, represented by metformin (weighted average of standard and modified release) to
describe the average cost of these medications. If the HbA1c level increases above a threshold, the
individual is prescribed one of the more expensive DPP-IV inhibitors in addition to metformin. The
individual continues to receive metformin plus the DPP-IV inhibitor for a period of time until he/she
requires insulin. The cost of diabetes in the year of diagnosis is assumed to be greater than subsequent
years because the individual will receive more contact time while their diabetes is being controlled.
Simulated individuals experience an annual increase in HbA1c level. It is assumed that individuals switch to
dual treatment in the first annual cycle in which HbA1c level increases above 7.4%, based on a 2014
HTA.327 For costing purposes, the second drug to be added to metformin was assumed to be sitagliptin.
The second major treatment change is assumed to be initiation of insulin. Within the model the individual
is switched to insulin in the first annual cycle at which HbA1c levels exceed 8.5%.327 The insulin glargine
was chosen to represent insulin treatment in the UK.
Health checks
The cost of a health check in the population with ID was derived from the Department of Health Economic
Modelling for vascular checks.314 This study estimated the cost of a health check in the general population
to be £23.70 in 2009, including blood tests, HCP time, follow-up and administration costs. For individuals
with ID, it was assumed that all staff costs would double, as the health check would take twice as long to
perform (Professor K Khunti, Diabetes Research Centre, University of Leicester, October 2015, personal
communication). All of the other costs were assumed to stay the same. Costs were inflated to 2014–15
prices, giving a final value of £43.48 for a full Learning Disability Health Check.
Some individuals refuse to have blood taken as part of the health check. For these individuals a modified
health check cost was derived, removing the cost of blood tests (consumables and laboratory costs) and
the cost of nurse follow-up from the total. After inflation this came to £18.67.
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TABLE 47 Summary of all drug, treatment, care and resource costs that were included in the model
Drug, treatment, care and resource costs
Cost per year/incident
in 2014–15 prices (£) Source
STOP Diabetes intervention per person 1097 Microcosting
Screening and intervention costs
Standard Learning Disability Health Check 43.48 Department of Health314
Learning Disability Health Check without blood tests 18.67
Health Check capabilities assessment and explanation of
intervention (10 minutes of health-care assistant time)
3.40 PSSRU264
First-line diabetes treatment: low-cost diabetes monotherapy
Ongoing costs of diabetes monotherapy 79.06
Metformin 500 mg b.i.d. standard (85% of patients)
or modified-release (15%) tablets
18.83 BNF313
Nurse at GP (consultation) 25.52 PSSRU264
Health-care assistant (10 minutes) 3.40 PSSRU264
Urine sample 1.00 Department of Health324
Eye screening 24.31 Burr et al.318
Laboratory tests 6.00
HbA1c test 3.00 Department of Health
324
Lipids test 1.00 Department of Health324
Liver function test 1.00 Department of Health324
B12 test 1.00 Department of Health324
Additional first year costs of diabetes monotherapy: 103
Nurse at GP (2 × consultations) 51.03 PSSRU264
Health-care assistant (2 × 10 minutes) 6.80 PSSRU264
Urine sample (×2) 2.00 Department of Health324
Laboratory tests as above (×2) 12.00 Department of Health324
Smoking cessation (central estimate of cost of nicotine
replacement therapy) taken up by 50% of the assumed
20% of population who smoke
30.90 PSSRU264
Second-line diabetes treatment
Metformin and a DPP-IV inhibitor 529
Sitagliptina 100mg daily 434 BNF313
Metformin 500 mg b.i.d. standard (85% of patients)
or modified-release (15%) tablets
85 BNF313
Self-monitoring strips (82 per annum)320 16.36 BNF313
Nurse at GP (consultation) 25.52 PSSRU264
Health-care assistant (10 minutes) 3.40 PSSRU264
Urine sample 1.00 Department of Health324
Eye screening 24.31 Burr et al.318
Laboratory tests as for first-line treatment 6.00 Department of Health324
continued
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
TABLE 47 Summary of all drug, treatment, care and resource costs that were included in the model (continued )
Drug, treatment, care and resource costs
Cost per year/incident
in 2014–15 prices (£) Source
Third-line diabetes treatment
Insulin and oral antidiabetic drugs, weighted composite 1503
Nurse at GP (3 × consultations) 76.55 PSSRU264
Health-care assistant (3 × 10 minutes) 10.21 PSSRU264
Urine sample (×3) 3.00 Department of Health324
Eye screening 24.31 Burr et al.318
Laboratory tests as for first-line treatment (×3) 18.00 Department of Health324
Insulin treatment costs: 1376
Glargine 830.83 Poole et al.310
Oral antidiabetic drugs 57.75 Poole et al.310
Reagent test strips 292.74 Poole et al.310
Hypoglycaemic rescue 30.98 Poole et al.310
Pen delivery devices 72.44 Poole et al.310
Sharps 90.98 Poole et al.310
Other primary care costs
GP visit (17 minutes) 68.38 PSSRU264
Diagnosis of hypertension (including ambulatory BP
monitoring)
56.51 NICE325
Annual treatment with statins (simvastatinb 20 mg b.i.d.) 26.59 BNF313
Annual treatment with antihypertensive drugs 195.94 Blak et al.319
CVD costs
Unstable angina, year 1: secondary care costs – 100%
hospitalisation, 50% revascularisation procedure, three
outpatient appointments); primary care costs (three GP
visits) and medications
4674 Ara et al.322
MI, year 1: secondary care costs – 100% hospitalisation,
50% revascularisation procedure, three outpatient
appointments); primary care costs (three GP visits) and
medications
4813 Ara et al.322
Subsequent ACS care costs: secondary care costs
(one outpatient appointment); primary care costs
(three GP visits) and medications
410 Ara et al.322
Stroke, year 1 (NHS costs): costs of acute events reported
in Youman et al.307 weighted by the distribution of
severity of stroke21
9716 Youman et al.307
Social care costs of stroke in subsequent years: the costs
of ongoing care at home or in an institution weighted by
the distribution of severity of stroke and discharge
locations
2730 Ara et al.322
Fatal CHD: assumed that 50% of fatalities incurred cost 713 Palmer et al.311
Fatal non-cardiovascular event: assumed that 50% of
fatalities incurred cost
4443 Youman et al.307
Congestive heart failure 3091 UKPDS316
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TABLE 47 Summary of all drug, treatment, care and resource costs that were included in the model (continued )
Drug, treatment, care and resource costs
Cost per year/incident
in 2014–15 prices (£) Source
Other complications of diabetes costs
Renal failure: weighted composite 25,046
Haemodialysis with overheads 42,049 Baboolal et al.321
Automated peritoneal dialysis 27,217 Baboolal et al.321
Continuous ambulatory peritoneal dialysis 19,742 Baboolal et al.321
Transplant (year 1) 23,660 NHS Blood and Transplant308
Immunosuppressant (10 years) 6959 NHS Blood and Transplant308
Foot ulcers 216 Gordois et al.315
Amputation first year 10,101 UKPDS323
Amputation subsequent years 1896 UKPDS323
Blindness first year 1434 UKPDS323
Blindness subsequent years 479 UKPDS323
Breast cancer 13,818 Madan et al.312
Colorectal cancer 18,729 Tappenden et al.309
Osteoarthritis 962 NICE326
Depression: made up of – 137 Chalder et al.317
Practice nurse at surgery 13.70
Practice nurse at home visit 0.54
Practice nurse telephone 0.99
Health visitor 1.94
District nurse 0.38
Other nurse 1.17
Health-care assistant/phlebotomist 1.05
Other primary care 4.85
Out of hours 6.18
NHS Direct 2.28
Walk-in centre 8.15
Prescribed medications 74
Secondary care 21
ACS, acute coronary syndrome; b.i.d., twice a day; BNF, British National Formulary; PSSRU, Personal Social Services Research
Unit; SANG, stable angina; UANG, unstable angina; UKPDS, United Kingdom Prospective Diabetes Study.
a Januvia®, Merck Sharp & Dohme Ltd, Hoddesdon, UK.
b Zocor®, Merck Sharp & Dohme Ltd.
Assumed 20% smoking prevalence and 50% uptake of smoking cessation services.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
159
Other primary care costs
Individuals with ID are assumed to visit their GP with the same frequency as individuals in the general
population; however, each consultation is estimated to take 40% longer than the average consultation
(based on personal communication, Professor K Khunti). Personal Social Services Research Unit unit costs
were used to estimate the cost of a 17.2-minute consultation at £67,264 which was then inflated to
2014–15 prices. Individuals who are prescribed statins receive a daily dose of 40 mg of generic simvastatin.
The individual remains on statins for the rest of their life. A unit cost of antihypertensive treatments
was obtained from a 2004 study319 and inflated to 2014–15 prices. Owing to the number of different
antihypertensive treatments available and possibilities for combination therapies, using the cost from this
study of prescriptions was preferred to using costs directly from the British National Formulary.
Cardiovascular costs
Costs for CVD were obtained from a 2009 HTA for high-dose, lipid-lowering therapy.322 The costs included
are shown in Table 47. The costs of fatal stroke and MI were obtained from two separate studies,307,311 and
it was assumed that 50% of individuals would incur these costs. The costs of congestive heart failure were
estimated from the UKPDS costing study316 for complications related to diabetes.
Costs of other comorbidities
More details of the costs of microvascular complications of diabetes, cancers, osteoarthritis and depression
are available online.263
Other model inputs
l Perspective The model adopts a NHS and social care perspective. Societal costs are not included.
l Horizon The time horizon of the model is the lifetime of all baseline individuals.
l Discount rates Costs and QALYs are discounted at 1.5% per annum, in line with NICE guidance for
economic evaluations of public health interventions.158
Reporting outcomes of the economic modelling
The model compares the outcomes of an identical baseline population undergoing the screening (and
possible intervention) with the outcomes if current care was followed. The model allows a variety of
different clinical outcomes to be gathered, as well as costs and QALYs. The model also allows a range
of other incremental outcomes to be collected including life-years saved and diabetes/cardiovascular
cases prevented.
Use of threshold analysis
The usual output of an economic evaluation, for a prespecified intervention with known clinical effectiveness
and cost per patient, is the ICER (see below for formulae), which can then be compared with the
£20,000–30,000 cost per QALY acceptability threshold set out by NICE.
However, as the clinical effectiveness of the STOP Diabetes intervention was not tested as part of the
current programme of research (only its feasibility), a different approach for this analysis was needed. The
output was the change in effectiveness needed for the intervention to be marginally cost-effective, that is,
the ICER equals the cost per QALY acceptability threshold. As the primary clinical outcome of interest to
the STOP Diabetes study investigators is change in steps per day, the economic analysis deals with the
change in physical activity (steps) and associated risk factors (BMI, SBP, and total and HDL cholesterol)
needed for the intervention to be marginally cost-effective. The STOP Diabetes intervention also contains
dietary advice (but no specific weight goal), so the threshold analysis needs to take account of benefits
attributable to physical activity and diet. The results tables for the threshold analyses therefore show
alternative permutations of step changes together with the additional benefit from dietary change that
would be necessary for the intervention to be cost-effective overall.
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Analyses, scenarios and sensitivity analyses undertaken
All statements herein about an increase in the number of steps refer to the increase in steps per day.
Exploratory analysis
An initial analysis was undertaken to assess how cost-effective the STOP Diabetes intervention would be if
it achieved the average 2491 change in daily steps reported in the Bravata meta-analysis.269 Initially, it was
assumed that the intervention would increase mean daily step count by 2491 steps as detailed in Bravata
et al.,269 leading to:
l a mean reduction in BMI of 0.38 kg/m2
l a mean reduction in systolic BP of 3.8 mmHg
l a mean reduction in total cholesterol of 0.09 mmol/l
l a mean increase in HDL cholesterol of 0.06 mmol/l.
The intervention effect was assumed to decline linearly such that by 3 years (from the start of the
intervention), the risk factors have reverted back to their trajectory had there been no intervention.
The ICER is obtained using the incremental costs and QALYs gained from implementing the intervention
rather than current care, calculated using the following formulae:
Incremental costs (£) = total costs intervention (£) − total costs comparator (£) (1)
Incremental QALYs = total QALYs intervention (£)− total QALYs comparator (£) (2)
ICER (£/QALY) = incremental costs (£)/incremental QALYs. (3)
Although total costs and QALYs can be assessed at any year in the model, allowing estimation of both
short- and long-term cost-effectiveness, we report the long-term cost-effectiveness, as this is what
regulatory bodies are primarily interested in.
In addition, a simple budget impact was calculated, as follows:
1. The number of adults in England with moderate to critical needs using social care was taken from 2015
estimates by Public Health England’s learning disabilities observatory for adults (546,489).328
2. The percentage of the above who have IGR was based on the percentage in the STOP Diabetes
screening study who were found to have IGR after screening, recruitment and blood testing (5%).
3. The percentage that was likely to take up an intervention was based on the percentage of those in the
feasibility study who were invited to take part on the STOP Diabetes programme, who actually attended
sessions (26%).
4. The resulting number of likely STOP Diabetes users for the whole of England (7104) was multiplied
by the intervention cost per user to give the total budget impact of implementing the STOP Diabetes
programme.
Scenarios for duration of effect
For all of the analyses undertaken, we model two fundamental alternative scenarios to test the sensitivity
of the cost-effectiveness to two alternative durations of effect of the intervention, that is, after starting to
reduce after year 1, by which time point the benefits of intervention have worn off. The first scenario,
assuming a 3-year duration, is considered most likely given that the proposed maintenance sessions finish
at the end of the first year and the alternative 5-year scenario is presented as a ‘what if’ scenario.
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Deterministic one-way sensitivity analysis
Previous analyses using the model and of economic evaluations of lifestyle interventions suggested which
parameters are likely to have the largest effect on model results, so the following were considered for
one-way sensitivity analysis.
Increased clinical effects
There is significant uncertainty around the relationship reported by Bravata et al.,269 so we explored the
impact of a more beneficial impact by taking the 65th percentile for the possible magnitude of beneficial
change in BMI, systolic BP, total cholesterol and HDL cholesterol from the CIs reported by Bravata et al.269
(assuming that the distributions are normally distributed). In this case, an increase in mean daily step count
of 2491 steps, as detailed by Bravata et al.,269 is estimated to lead to:
l a mean reduction in BMI of 0.45 kg/m2
l a mean reduction in systolic BP of 4.21 mmHg
l a mean reduction in total cholesterol of 0.14 mmol/l
l a mean increase in HDL cholesterol of 0.07 mmol/l.
This alternative mapping was explored in the context of both the 3- and 5-year duration of effect
scenarios above.
Uptake rates
These were considered not to be a key driver because individuals who do not uptake the intervention incur
no costs other than the very small cost of screening relative to the cost of the intervention.
Discount rates
Alternative rates were considered, but testing out rates that were < 1.5% seems implausible and higher
rates would not have altered the conclusions.
Subgroup analyses
As initial analyses suggested that the intervention would be unlikely to be cost-effective in the overall
population with ID, further work was set out in order to identify the most beneficial subgroups. Three
subgroups were identified to explore if the cost-effectiveness of the intervention might be improved if
screening were more targeted, by:
1. Age band Based on the distribution of age in the STOP Diabetes study, the following age bands were
chosen: < 35 years; ≥ 35 and < 40 years; ≥ 40 and < 45 years; ≥ 45 and < 50 years; and ≥ 50 years.
Selecting individuals aged ‘≥ 35 years’ would include 65% of the STOP Diabetes cohort, and those
aged ‘≥ 40 years’ and ‘≥ 45 years’ and ‘≥ 50 years’ would include 55%, 45% and 35%, respectively.
Age cut-off points of ≥ 55 and ≥ 60 years would have covered only 24% and 14% of the cohort
only, respectively.
2. BMI We carried out a subgroup analysis in which everyone was screened, but only obese individuals
were eligible for intervention.
3. Baseline cardiovascular risk We calculated the baseline 10-year CVD risk using the QRISK score and
excluded any individuals with a risk of < 5%. This is a low cut-off point but using a higher cut-off point
would have meant fewer than 25% of the cohort being screened, and a very low proportion actually
receiving and benefiting from intervention.
Probabilistic sensitivity analysis
Owing to the exploratory nature of the analysis (described in Exploratory analysis), full PSA was carried
out on only one of the threshold scenarios, with the aim of illustrating the extent of non-linearity in the
model (i.e. by comparing the results of the PSA with the corresponding deterministic results). PSA, which
describes the uncertainty in model parameter inputs, is not suitable for describing the decision uncertainty
in this analysis, that is, the current research was leading to the stage at which the intervention could be
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considered for implementation into clinical practice. Instead, analyses were more exploratory to inform
potential future research and intervention refinement.
In addition, the true uncertainty around the effectiveness estimates is much wider than that around the
parameters available from the Bravata et al.269-based relationship. There is also uncertainty around the
effectiveness of the planned intervention in increasing physical activity and uncertainty around whether or
not increasing the number of steps increases metabolic benefits in a linear way. This uncertainty cannot
be accurately quantified (although it could potentially be estimated through a time-consuming expert
elicitation, which is outside the scope of this investigation), but PSA analysis without it would vastly
underestimate the uncertainty in the cost-effectiveness estimates.
For the single PSA completed, a suitable distribution was selected for each parameter, based on its mean
and SE, and, within the simulations, random sampling across all input parameter distributions was
undertaken. A total of 2000 different random samples of parameter values were selected, and each was
applied to a different random cohort of 5000 individuals who were randomly sampled with replacement
from the baseline STOP Diabetes population. For each PSA sample, the model was run and results
ompiled.
More details of the distributions around key model parameters are shown in Appendix 26, Tables 67
and 68.
Results
This section presents a series of results for the scenarios and sensitivity analyses described earlier. First, is
an analysis of how cost-effective the STOP Diabetes intervention would be if it achieved the average
change for a physical activity intervention, 2491 steps, as reported in the Bravata et al.269 meta-analysis.
Next, results of the threshold analyses for the necessary risk factor changes needed to achieve
cost-effectiveness are presented under a variety of scenarios and subgroups. Finally, an alternative
threshold analysis explores what the maximum budget for the intervention would be given certain
changes in risk factors.
Whenever results are stated as the ‘base case’, these reflect the base-case assumption for the effects a
change in steps has on risk factors for CVD (BMI, systolic BP, and total and HDL cholesterol). Most analyses
present results for both 3- and 5-year durations of intervention effect, but, if not specified, the base case
of 3 years applies.
It should be noted that effects lasting to year 3 means that they have worn off 2 years from the end of
year 1 (which is close to when the last monthly maintenance session occurs). Similarly, effects that have
worn off by year 5 effectively last for 4 years from the end of the maintenance sessions.
Cost per quality-adjusted life-year results based on Bravata step count
Before the threshold analyses were undertaken, an exploratory analysis was undertaken to see how
cost-effective the STOP Diabetes intervention would be, assuming an increase in steps in line with that
calculated in the meta-analysis by Bravata et al.269 This analysis assumes no dietary intervention.
The estimated ICER (cost per QALY gained) under the base case is £275,000 compared with a usual
acceptability threshold (what funders are willing to pay) in the range £20,000–30,000 per QALY. Savings
in lifetime costs of CVD and primary care, and savings in treating diabetes and its complications are far
outweighed by the £1097 intervention cost per person. A much greater intervention effect in terms of
either physical activity, diet or both, or a reduction in intervention cost would be required to make the
intervention cost-effective.
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The estimated budget impact for delivering the STOP Diabetes programme to 7104 adults with ID and IGR
across England was estimated at £7.8M. If the programme were taken up by all adults with ID and IGR in
England (> 27,000) then the total cost could be as high as £30M. There is uncertainty around the true
prevalence of IGR among adults with ID. If this is actually 10% (rather than 5%), the above budget
impacts would rise to £15.6M and £60M, respectively.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis was carried out for the above Bravata et al.269-based analysis (an increase
of 2491 steps), giving a probabilistic central estimate of the ICER of £253,000, which is lower than the
deterministic estimate by about 6%, demonstrating a small degree of non-linearity in the model. Given
how high the deterministic ICER was compared with the acceptability threshold of £30,000 per QALY, this
is clearly a negligible difference for the overall conclusion about the intervention.
The probability that such an intervention is cost-effective compared with current care at a threshold of
£30,000 per QALY is almost zero, at 0.15%. However, as described above (see Methods), the uncertainty
around intervention effectiveness is much higher than the uncertainty described in the Bravata et al.
study269 and used in the PSA, meaning that the PSA will underestimate the total uncertainty.
The cost-effectiveness plane for the intervention compared with current care at £30,000 per QALY is
shown in Appendix 27 (see Figure 30).
Threshold analyses for effect sizes needed
A series of model simulations was performed in order to determine the thresholds required for the
intervention to be cost-effective at acceptability thresholds of £20,000 and £30,000 per QALY.
The presented thresholds are rounded to the nearest 500 steps.
At the calculated thresholds, the ICER for the intervention is £20,000 (or £30,000) per QALY and the
greater savings from CVD and diabetes treatment and primary care costs, together with the value of the
health gain (QALYs), are just enough to outweigh the additional cost of the intervention.
Ascertainment of the thresholds relies on the assumption of a linear relationship between change in steps
and risk factors (that observed in the Bravata et al. study269) being maintained over the wide range of
steps inherent within the calculation of the thresholds.
It is recognised that under many, if not most, scenarios, the magnitude of the additional diet-related
changes in BMI and systolic BP (that are necessary to attain cost-effectiveness) are implausible in terms
of their achievability. They are nevertheless genuine estimates from the threshold approach that is
fundamental to this economic analysis.
Summary of key results from threshold analyses
In the subsequent section (see Full threshold analysis results tables), detailed results are presented for a
number of alternative levels of increase in steps per day, up to 15,000. However, there are many tables,
each containing many permutations of the magnitude of physical activity- and dietary-related BMI change
that could achieve cost-effectiveness (see Table 52). To aid digestion of the results, in this section the
results are summarised for some mid-range levels of change in steps: 3000, 5000 and 7000 per day.
In Table 48, the necessary diet-related effects that would need to be achieved, in addition to the effects
arising from an increase of 5000 steps, are shown across various scenarios and subgroups (see Use of
threshold analysis for the rationale of the threshold analyses as presented).
As an example, consider the base-case row of Table 48, assuming an acceptability threshold of £30,000 per
QALY and 3-year duration of effects. BMI and systolic BP reductions of 2.9 kg/m2 and 29 mmHg, respectively,
would be needed, in addition to the BMI and systolic BP benefits of 5000 additional steps, in order for the
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intervention to be cost-effective. An increase of 5000 steps corresponds to a BMI reduction of 0.76 kg/m2, a
systolic BP reduction of 7.6 mmHg and a reduction in the lipid ratio of 0.22 (all purely through physical activity
without diet). So the overall (steps plus dietary) BMI and systolic BP reductions needed for a cost-effective
intervention would be 3.66 kg/m2 and 36.6 mmHg, which are clearly unachievable in practice.
Tables 49 and 50 present similar analyses for changes in steps of 3000 and 7000, respectively.
Intervention cost threshold analysis
As an alternative type of threshold analysis, we explored the maximum intervention cost that could be
afforded for a given increase in steps per day. At a value of £30,000 per QALY, for the subgroup of
individuals aged > 50 years, with an assumed duration of effect of 3 years, the maximum intervention
budget (combined initial plus maintenance cost) to achieve cost-effectiveness is around £280 for an increase
of 4000 steps per day (0.61-kg/m2 BMI reduction and 6-mmHg systolic BP reduction), and around £420 for
an increase of 6000 steps per day (0.91-kg/m2 BMI reduction and 9-mmHg systolic BP reduction). For the
subgroup of individuals with increased CVD risk, the maximum budget for a cost-effective intervention is
around £500 for an increase of 4000 steps per day and around £700 for an increase of 6000 steps per day.
TABLE 48 Summary of dietary effects needed in addition to 5000 steps
Population group
£20,000 per QALY £30,000 per QALY
3 years 5 years 3 years 5 years
Base case –4.2 (–42) –2.6 (–26) –2.9 (–29) –1.5 (–15)
Increased effectiveness intervention –4.0 (–40) –2.0 (–20) –2.4 (–24) –1.2 (–12)
Obese subgroup –4.0 (–40) –2.0 (–20) –2.6 (–26) –1.3 (–13)
45–49 years subgroup –1.8 (–18) –1.1 (–11) –1.4 (–14) –0.9 (–9)
≥ 50 years age group –3.4 (–34) –2.0 (–20) –1.8 (–18) –0.9 (–9)
High CVD risk group (≥ 5% 10-year risk) –2.7 (–27) –1.4 (–14) –1.5 (–15) –0.8 (–8)
Dietary contributions only.
Data shown as BMI in kg/m2 (systolic BP in mmHg2).
TABLE 49 Summary for 3000 steps
Population group
£20,000 per QALY £30,000 per QALY
3 years 5 years 3 years 5 years
Base case –4.5 (–45) –2.9 (–29) –3.2 (–32) –1.8 (–18)
Increased effectiveness intervention –4.3 (–43) –2.3 (–23) –2.7 (–27) –1.5 (–15)
Obese subgroup –4.3 (–43) –2.3 (–23) –2.9 (–29) –1.6 (–16)
45–49 years subgroup –2.1 (–21) –1.4 (–14) –1.7 (–17) –1.2 (–12)
≥ 50 years age group –3.7 (–37) –2.3 (–23) –2.1 (–21) –1.2 (–12)
High CVD risk group (≥ 5% 10-year risk) –3.1 (–31) –1.7 (–17) –1.8 (–18) –1.1 (–11)
Dietary contributions only.
Data shown as BMI in kg/m2 (systolic BP in mmHg).
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Interpretation of threshold analysis results
First, we summarise the implications of aiming to achieve cost-effectiveness through step changes alone.
For the overall STOP Diabetes cohort, to achieve cost-effectiveness at a value of £20,000 per QALY, the
results suggest that in excess of 30,000 additional steps per day would be required (around 5-kg/m2
reduction in BMI and 50-mmHg reduction in systolic BP), which is biologically implausible. At £30,000 per
QALY the threshold was around 24,000 additional steps per day (3.7-kg/m2 reduction in BMI and 37-mmHg
reduction in systolic BP). If the intervention effect is assumed to last (decreasing linearly) until year 5, the
threshold reduces to around 22,000 steps (2.4-kg/m2 reduction in BMI and 34-mmHg reduction in systolic
BP) at £20,000 per QALY and 15,000 steps (2.3-kg/m2 reduction in BMI and 23-mmHg reduction in systolic
BP) at £30,000 per QALY. Note that as all of these values represent effect sizes that are more than five times
those achieved in the source study,269 they are inherently reliant on extrapolations of the Bravata relationship269
well outside the range in which extrapolation can be done with a desirable level of reliability.
Cost-effective effect sizes could, alternatively, be achieved through a combination of risk factor changes
through physical activity and risk factor changes through dietary intervention. Clearly, there are many
permutations of the magnitude of physical activity- and dietary-related changes that could achieve
cost-effectiveness. A necessary increase of 13,000 steps under an assumption of increased effectiveness
and 5 years’ duration (at £30,000 per QALY) equates to a BMI change of –2.75 kg/m2 based on Bravata
et al.269 This overall BMI change could be achieved, for example, through the effect of an additional 7000
steps per day together with further BMI reduction achieved through dietary intervention of –1.68 kg/m2.
Alternative body mass index and systolic blood pressure equivalents
A limitation of the threshold results presented above is that the necessary BMI and systolic BP changes
attributed to diet exclusively use the Bravata et al. study269 in their calculation. This results in the small
combined (steps plus diet) BMI changes relative to the systolic BP changes reflecting the ratio of benefits
that could be expected from a physical activity rather than a dietary intervention.
To aim to address this, as an exploratory analysis, Table 51 shows an alternative set of permutations, the
difference being that the diet-related BMI and systolic BP changes are now ‘realigned’ to reflect more
realistically the relative ratio of BMI and systolic BP changes likely through dietary change. The calculations
are underpinned by the BMI and systolic BP hazard ratios in the QRISK score for CVD, and thereby the
analysis relies on the assumption that most of the economic benefits of intervention accrue through CVD
risk reduction. We estimated that a reduction in systolic BP of 1 mmHg gives approximately the same
benefit as 0.6 kg/m2 of BMI reduction.
TABLE 50 Summary for 7000 steps
Population group
£20,000 per QALY £30,000 per QALY
3 years 5 years 3 years 5 years
Base case –3.9 (–39) –2.3 (–23) –2.6 (–26) –1.2 (–12)
Increased effectiveness intervention –3.7 (–37) –1.7 (–17) –2.1 (–21) –0.9 (–9)
Obese subgroup –3.7 (–37) –1.7 (–17) –2.3 (–23) –1.0 (–10)
45–49 years subgroup –1.5 (–15) –0.8 (–8) –1.1 (–11) –0.6 (–6)
≥ 50 years age group –3.1 (–31) –1.7 (–17) –1.5 (–15) –0.6 (–6)
High CVD risk group (≥ 5% 10-year risk) –2.4 (–24) –1.1 (–11) –1.2 (–12) –0.5 (–5)
Dietary contributions only.
Data shown as BMI in kg/m2 (systolic BP in mmHg).
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The analysis was undertaken just in the context of a change of 5000 steps, that is, a reworking of results
presented earlier in Table 48.
For the high-CVD-risk groups, if the effects could be maintained such that the effect is not completely lost
until year 5 then the effect sizes needed are becoming closer to those achievable in practice.
Full threshold analysis results tables
Here we present the full set of model results for a wide range of changes in step count. For disadvantaged
groups, there is a higher likelihood than normal of NICE recommending a treatment at the upper end of
the usual £20,000–30,000 per QALY bracket, so the results presented in Table 52 are for a willingness to
pay of £30,000 per QALY. The diet-related improvements in BMI, systolic BP and cholesterol that would be
needed at £20,000 per QALY would be even more challenging (or implausible) than those presented here,
so the results for £20,000 per QALY are presented in Appendix 28, Tables 67–72.
TABLE 51 Body mass index/systolic BP equivalents for the diet-attributable benefits that are needed to be
cost-effective
Population group
£20,000 per QALY £30,000 per QALY
3 years 5 years 3 years 5 years
Base case –11.8 (–29) –7.3 (–18) –8.1 (–20) –4.2 (–11)
Increased effectiveness intervention –11.2 (–28) –5.6 (–14) –6.7 (–17) –3.4 (–8)
Obese subgroup –11.2 (–28) –5.6 (–14) –7.3 (–18) –3.6 (–9)
45–49 years subgroup –5 (–13) –3.1 (–8) –3.9 (–10) –2.5 (–6)
≥ 50 years age group –9.5 (–24) –5.6 (–14) –5 (–13) –2.5 (–6)
High CVD risk group (≥ 5% 10-year risk) –7.6 (–19) –3.9 (–10) –4.2 (–11) –2.2 (–6)
Data presented as BMI in kg/m2 (systolic BP in mmHg).
TABLE 52 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for base-case intervention effects, at £30,000 per QALY, assuming that all of the risk factors
change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –3.7 –37 –1.54 –2.3 –23 –1.08
1000 –0.2 –2 –0.09 –3.5 –35 –1.49 –2.1 –21 –1.03
3000 –0.5 –5 –0.26 –3.2 –32 –1.40 –1.8 –18 –0.90
5000 –0.8 –8 –0.42 –2.9 –29 –1.30 –1.5 –15 –0.78
7000 –1.1 –11 –0.57 –2.6 –26 –1.19 –1.2 –12 –0.64
9000 –1.4 –14 –0.71 –2.3 –23 –1.08 –0.9 –9 –0.50
11,000 –1.7 –17 –0.84 –2.0 –20 –0.97 –0.6 –6 –0.34
13,000 –2.0 –20 –0.97 –1.7 –17 –0.84 –0.3 –3 –0.18
15,000 –2.3 –23 –1.08 –1.4 –14 –0.71 0.0 0 0.00
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Base-case results
The systolic BP and cholesterol ratio effects shown in the sixth and seventh columns of Table 52 are the
total (step-related) effects for these parameters, that is, effects mediated indirectly through BMI reduction
and direct effects of physical activity.
A more detailed breakdown of the base-case events, costs and QALYs is shown in Table 53. The mean
QALY gain per person screened equates to an average of < 1 day of additional life (in full health).
Sensitivity analyses: increased clinical effects
In this analysis, it was assumed that effects on BMI, systolic BP and the lipid ratio of a given increase in
steps would be greater than the base case, as described above (see Methods).
Under this modified assumption, and assuming 3-year duration of effects, the estimated incremental cost
per QALY gained for an increase of 2491 steps (with no dietary intervention) was £228,000.
To achieve cost-effectiveness at a value of £20,000 per QALY, threshold analysis suggests that in excess
of 30,000 additional steps per day would be required (some 4.7-kg/m2 reduction in BMI and 47-mmHg
reduction in systolic BP), which is still biologically implausible. At £30,000 per QALY the threshold is around
21,000 additional steps per day (3.2-kg/m2 reduction in BMI and 32-mmHg reduction in systolic BP). If the
intervention effect is assumed to last (decreasing linearly) until year 5, the threshold reduces to around
18,000 steps (2.8-kg/m2 reduction in BMI and 27-mmHg reduction in systolic BP) at £20,000 per QALY, and
13,000 steps (2.0-kg/m2 reduction in BMI and 20-mmHg reduction in systolic BP) at £30,000 per QALY.
The combination of step change and additional dietary change needed to reach cost-effectiveness
(assuming that all risk factors change together) is shown in Table 54 (see Appendix 28, Table 68, for
£20,000 per QALY acceptability).
Subgroup analysis: obese
Separate results are reported for a subgroup of the population only (using the base-case clinical effects)
who were defined as obese (Table 55).
The estimated incremental cost per QALY gained for a 2491 increase in steps under this scenario
was £276,000.
TABLE 53 Detailed breakdown of results for 2491 steps
Incremental outcomes per person
Base-case effectiveness Increased effectiveness
3-year duration 5-year duration 3-year duration 5-year duration
Total costs (£) 329 326 328 322
Total QALYs 0.0012 0.0018 0.0014 0.0021
ICER (£) 273,000 183,000 231,000 154,000
Cardiovascular cases (per 1 million) –130 –187 –153 –239
STOP Diabetes intervention cost (£) 336 336 336 336
Diabetes treatment costs (£) 0 1 0 0
Cardiovascular costs (£) –5 –6 –5 –7
Costs: other diabetes complications (£) –6 –8 –7 –10
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To achieve cost-effectiveness at a value of £20,000 per QALY, threshold analyses suggest that in excess of
30,000 additional steps per day would be required, and at £30,000 per QALY the threshold is around
22,000 additional steps per day. If the intervention effect is assumed to last (decreasing linearly) until
year 5, the threshold reduces to around 18,000 steps at £20,000 per QALY, and 13,500 steps at £30,000
per QALY. These values are very similar to the whole population results.
TABLE 54 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for an increased effectiveness intervention at £30,000 per QALY, assuming that all of the
risk factors change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –3.2 –32 –1.40 –2.0 –20 –0.97
1000 –0.2 –2 –0.09 –3.1 –31 –1.35 –1.8 –18 –0.90
3000 –0.5 –5 –0.26 –2.7 –27 –1.25 –1.5 –15 –0.78
5000 –0.8 –8 –0.42 –2.4 –24 –1.14 –1.2 –12 –0.64
7000 –1.1 –11 –0.57 –2.1 –21 –1.03 –0.9 –9 –0.50
9000 –1.4 –14 –0.71 –1.8 –18 –0.90 –0.6 –6 –0.34
11,000 –1.7 –17 –0.84 –1.5 –15 –0.78 –0.3 –3 –0.18
13,000 –2.0 –20 –0.97 –1.2 –12 –0.64 0.0 0 0.00
15,000 –2.3 –23 –1.08 –0.9 –9 –0.50 0.0 0 0.00
TABLE 55 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for an obese subgroup in a base-case intervention at £30,000 per QALY, assuming that all
of the risk factors change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –3.4 –34 –1.45 –2.1 –21 –1.00
1000 –0.2 –2 –0.09 –3.2 –32 –1.40 –1.9 –19 –0.94
3000 –0.5 –5 –0.26 –2.9 –29 –1.30 –1.6 –16 –0.81
5000 –0.8 –8 –0.42 –2.6 –26 –1.19 –1.3 –13 –0.68
7000 –1.1 –11 –0.57 –2.3 –23 –1.08 –1.0 –10 –0.53
9000 –1.4 –14 –0.71 –2.0 –20 –0.97 –0.7 –7 –0.38
11,000 –1.7 –17 –0.84 –1.7 –17 –0.84 –0.4 –4 –0.22
13,000 –2.0 –20 –0.97 –1.4 –14 –0.71 –0.1 –1 –0.05
15,000 –2.3 –23 –1.08 –1.1 –11 –0.57 0.0 0 0.00
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Subgroup analysis: age subgroups
The results in Table 56 show the effect sizes needed for subgroups by age (for both the base-case clinical
effects and increased effects sensitivity assumption).
The estimated ICER (cost per QALY gained) in the base case across the whole baseline population was
£276,000. For age-based subgroups, this ICER varied from £172,000 (ages ≥ 50 years) to £482,000 (ages
35–39 years). In the base case with 5-year durability, the ICER varied from £107,000 (ages ≥ 50 years) to
£301,000 (ages < 35 years). In the increased effectiveness scenario with 5-year durability, the ICER ranged
from £92,000 (ages ≥ 50 years) to £262,000 (ages < 35 years).
To achieve cost-effectiveness at a value of £30,000 per QALY in the overall cohort with ID, threshold
analyses suggest that 25,000 additional steps per day would be required. For age subgroups, this threshold
varied from 14,000 additional steps per day (ages 45–49 years) to 52,000 (ages < 35 years). If the durability
was extended to 5 years, the threshold ranges from 11,000 additional steps (ages ≥ 45 years) to 22,000
additional steps (ages < 35 years) and if effectiveness is increased the threshold ranges from 8500 additional
steps (ages ≥ 50 years) to 18,500 steps (ages < 35 years). The combinations of steps and additional dietary
changes needed to reach cost-effectiveness for people aged 45–49 years and aged ≥ 50 years at £30,000
(£20,000) per QALY are shown in Tables 57 and 58 (and Appendix 28, Tables 70 and 71).
Subgroup analysis: high cardiovascular risk subgroup
We ran an additional analysis looking at effectiveness of intervening in a subgroup of the population with
a 10-year CVD risk of at least 5% using the base-case assumptions about clinical effects. A 5% cut-off
point was chosen because if the cut-off point had been ≥ 10% then this would have resulted in around
only 10% of the population being screened (before factoring in eligibility, suitability and willingness,
so probably < 5% would have actually received the intervention).
The estimated ICER (cost per QALY gained in the base case across the whole baseline population) was
£177,000. With 5-year durability of effects, the ICER falls to £133,000.
TABLE 56 Change in BMI (kg/m2)/systolic BP (mmHg) that are required to achieve a cost-effective outcome for
individual age bands
Population group
Base-case clinical effects Increased clinical effects
£20,000 per QALY £30,000 per QALY £20,000 per QALY £30,000 per QALY
Base case
(3 years) 5 years
Base case
(3 years) 5 years
Base case
(3 years) 5 years
Base case
(3 years) 5 years
All ages –5.8/–58 –3.4/–34 –3.8/–38 –2.3/–23 –5.6/–56 –2.9/–29 –3.5/–35 –1.9/–19
Age < 35 years –18.3/–183 –4.7/–47 –7.9/–79 –3.4/–34 –13/–130 –4/–40 –6.7/–67 –2.8/–28
Age 35–39 years –4.3/–43 –2.7/–27 –3.6/–36 –2.2/–22 –2.8/–28 –2.4/–24 –2.4/–24 –2/–20
Age 40–44 years –5.3/–53 –3.1/–31 –3.7/–37 –2.2/–22 –5.2/–52 –2.7/–27 –3.4/–34 –1.9/–19
Age 45–49 years –2.6/–26 –1.9/–19 –2.1/–21 –1.7/–17 –2.8/–28 –2.1/–21 –2.2/–22 –1.6/–16
Age ≥ 50 years –4.1/–41 –2.7/–27 –2.6/–26 –1.7/–17 –4.6/–46 –2.1/–21 –2.5/–25 –1.3/–13
Only BMI and systolic BP effects are shown, but corresponding changes in the lipid ratio in line with the Bravata et al.
study269 would also be needed.
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To achieve cost-effectiveness in the base case at a value of £30,000 per QALY, threshold analyses suggest
that 15,000 additional steps per day would be required with 3-year durability, and 10,000 if the durability
was extended to 5 years. The combinations of steps and additional dietary changes needed to reach
cost-effectiveness for people with a high CVD risk at £30,000 per QALY are shown in Table 59 (see
Appendix 28, Table 72, for £20,000 per QALY).
TABLE 58 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a subgroup aged ≥ 50 years in a base-case intervention at £30,000 per QALY, assuming
that all of the risk factors change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –2.6 –26 –1.19 –1.7 –16.8 –0.8
1000 –0.2 –2 –0.09 –2.4 –24 –1.14 –1.5 –15.3 –0.8
3000 –0.5 –5 –0.26 –2.1 –21 –1.03 –1.2 –12.2 –0.6
5000 –0.8 –8 –0.42 –1.8 –18 –0.90 –0.9 –9.2 –0.5
7000 –1.1 –11 –0.57 –1.5 –15 –0.78 –0.6 –6.1 –0.3
9000 –1.4 –14 –0.71 –1.2 –12 –0.64 –0.3 –3.1 –0.2
11,000 –1.7 –17 –0.84 –0.9 –9 –0.50 0.0 0.0 0.0
13,000 –2.0 –20 –0.97 –0.6 –6 –0.34 0.0 0.0 0.0
15,000 –2.3 –23 –1.08 –0.3 –3 –0.18 0.0 0.0 0.0
TABLE 57 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a subgroup aged 45–49 years in a base-case intervention at £30,000 per QALY, assuming
that all of the risk factors change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –2.1 –21 –1.03 –1.7 –16.8 –0.8
1000 –0.2 –2 –0.09 –2.0 –20 –0.97 –1.5 –15.3 –0.8
3000 –0.5 –5 –0.26 –1.7 –17 –0.84 –1.2 –12.2 –0.6
5000 –0.8 –8 –0.42 –1.4 –14 –0.71 –0.9 –9.2 –0.5
7000 –1.1 –11 –0.57 –1.1 –11 –0.57 –0.6 –6.1 –0.3
9000 –1.4 –14 –0.71 –0.8 –8 –0.42 –0.3 –3.1 –0.2
11,000 –1.7 –17 –0.84 –0.5 –5 –0.26 0.0 0.0 0.0
13,000 –2.0 –20 –0.97 –0.2 –2 –0.09 0.0 0 0.00
15,000 –2.3 –23 –1.08 0.0 0 0.00 0.0 0 0.00
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Discussion
Statement of principal findings
Using a threshold analysis approach, the base-case results indicate that the STOP Diabetes intervention
that we have evaluated, costing £1097 per patient, would need to result in a very large overall increase in
steps, systolic BP, BMI and cholesterol for it to be cost-effective at a threshold in the £20,000–30,000 cost
per QALY range that is usually adopted by NICE. These increases are much more than could be expected
to be achievable in practice, even for the general population. Specifically for steps, an increase of
3000–5000 per day appears to be much more commonly reported for an intervention.
If we adopt two very favourable assumptions, that (1) the benefits of the intervention would not be fully
lost until 4 years after the intervention (5 years from the start) and (2) commissioners/payers would be
willing to fund the intervention up to a threshold of £30,000 per QALY, then some of the scenarios begin
to show more favourable results to some extent.
Targeting screening at individuals who are either aged > 45 years or obese, or at those at relatively high
baseline risk of CVD, improves the cost-effectiveness of the intervention, but it is still not cost-effective at
readily achievable combinations of steps and diet-attributable changes in risk factors (unless the cost of the
intervention could be reduced).
Strengths and limitations
A strength of the analysis is that it was based on a relatively large set of baseline data for a cohort with ID,
so the baseline risks of the cohort were well evidenced. However, there are large uncertainties around the
intervention cost, and the precise relationship between changes in physical activity and cardiovascular risk
factors. ‘Number of steps’ per day was the primary outcome of interest from the modelling, based on
the fact that it is the primary measure of interest to the STOP Diabetes study investigators. The available
evidence linking steps to biomarkers is somewhat limited, and comes from very diverse studies. Each
intervention is unique and therefore estimates of effectiveness are unlikely to predict exactly the outcomes
of the intervention in question. In addition, identified studies were undertaken in the general population,
TABLE 59 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a high cardiovascular risk subgroup in a base-case intervention at £30,000 per QALY,
assuming that all of the risk factors change together
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
Systolic BP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –2.3 –23 –1.08 –1.5 –15 –0.78
1000 –0.2 –2 –0.09 –2.1 –21 –1.03 –1.4 –14 –0.71
3000 –0.5 –5 –0.26 –1.8 –18 –0.90 –1.1 –11 –0.57
5000 –0.8 –8 –0.42 –1.5 –15 –0.78 –0.8 –8 –0.42
7000 –1.1 –11 –0.57 –1.2 –12 –0.64 –0.5 –5 –0.26
9000 –1.4 –14 –0.71 –0.9 –9 –0.50 –0.2 –2 –0.09
11,000 –1.7 –17 –0.84 –0.6 –6 –0.34 0.0 0 0.00
13,000 –2.0 –20 –0.97 –0.3 –3 –0.18 0.0 0 0.00
15,000 –2.3 –23 –1.08 0.0 0 0.00 0.0 0 0.00
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not a population with ID, and it is unknown whether differences in either behavioural or physiological
response to intervention vary in the community with ID.
Despite the fact that most diabetes prevention interventions combine dietary and physical activity elements,
in order to model the threshold level of the primary measure of interest (steps) we had to use steps as the
key variable in our estimates, with its effects mediated through changes in BMI, systolic BP and cholesterol.
This complicates interpretation because it then becomes necessary to show what permutations of combined
diet and activity intervention may achieve the necessary magnitude of changes to BMI, systolic BP and
cholesterol. The fact that the intervention is not cost-effective with 2491 additional steps (in line with the
effect size observed by Bravata et al.269) means that, in order to determine the cost-effective threshold,
extrapolation is required. The extrapolation makes an assumption of a linear relationship between step
increase and change in biomarkers; however, the true relationship may be non-linear.
The Bravata et al. study269 was considered to provide the most suitable data for the mapping between
steps and risk factors. This study269 reported a seemingly large change in systolic BP (–3.8 mmHg) relative
to the change in BMI (–0.38) for an increase of 2491 steps. Further evidence confirming this relationship is
desirable. If this ratio of systolic BP change relative to BMI is overstated then the true results may be less
favourable than presented. A further limitation is the inevitable disparity between the STOP Diabetes
intervention and the heterogeneous mix of interventions (in terms of number of sessions, delivery period,
end-point timing) that were pooled in the Bravata et al. meta-analysis.269 The effects of uncertainty around
the effectiveness and other parameter estimates were assessed using an illustrative PSA; however, it is
not possible to incorporate the full uncertainty around the applicability of pooled estimates from Bravata
et al.269 to this specific intervention in the target population. Further uncertainty analysis would be required
once the clinical effectiveness of the STOP Diabetes programme has been quantitatively assessed.
There is a lack of good evidence on the durability of effects of an intervention such as STOP Diabetes,
especially when the maintenance sessions all take place within the same year as the initial intervention.
Additionally, the STOP Diabetes cohort does not overall appear to be a particularly unhealthy one at
baseline, perhaps due to recruitment criteria or self-selection, or just purely due to the average age of
individuals recruited. There may be some obscure mechanisms that are not captured within the model
structure and that drive the reported reduced life expectancy for individuals with ID. If such mechanisms
exist, and can be modified by lifestyle intervention, then the results will not capture the economic impact
of such benefits.
Comparison with related studies
There are several factors concerning the form of the intervention that lead to a high intervention cost per
patient compared with other preventative lifestyle interventions:
1. Relative small group size of eight that the clinical team considered most appropriate for educating those
with ID.
2. Longer sessions for those with ID than the general population: 2 hours, compared with 1 hour and
15 minutes for the NICE prevention modelling.300
3. The need for three educators rather than two, and more advanced, at a higher grade.
4. The need for maintenance sessions to be spaced fairly close together, such as monthly, for information
to be retained by individuals with ID. This compares with less frequent sessions, every 4 months in years
2–4 in the case of the modelling undertaken for the NICE diabetes prevention guidance.300
Implications
The purpose of the economic analysis was to provide a reasonable estimate of the cost-effectiveness of the
STOP Diabetes intervention with a view to a subsequent full trial to assess effectiveness. The results of the
current analysis suggest that, in the likely range of effectiveness achievable, the STOP Diabetes intervention
in its current form would not be cost-effective at a £20,000–30,000 cost/QALY threshold.
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Risk profile of STOP Diabetes and the population with intellectual disability in general
The large effect sizes needed for the intervention to be cost-effective are partly a result of the low risk
profile of the STOP Diabetes cohort, in particular the average age being 43 years.
The intervention primarily reduces risks of CVD and cancer. The evidence suggests that excess risks in cohorts
with ID compared with the general population are attributable primarily to respiratory disorders, neurological
diseases, congenital abnormalities and accidents. These risks are unlikely to be reduced through an
intervention such as STOP Diabetes. The mortality aspects of these risks may be captured through the
increased other-cause mortality for individuals with ID (see Other-cause mortality), but other-cause mortality is
not linked to the risk factors modified by the STOP Diabetes intervention (BMI, systolic BP, and total and HDL
cholesterol). It is therefore rational that an intervention targeting CVD risks, costing £1097 (three to four times
the cost of diabetes prevention lifestyle interventions), will necessitate our reported very large reductions in
risk factors in order to fall within usual NICE thresholds for cost-effectiveness.
The low risk profile is reflected in the mean QALY gain per person screened (with a subsequent increase in
steps of 2491 for suitable individuals) equating to an average of < 1 day of additional life (in full health).
Equity is a factor that decision-makers take into account when deciding whether or not to recommend
an intervention. Given that the population with ID is a disadvantaged group, decision-makers might be
prepared to pay more per QALY than for the general population.265 In practice, this means that there is a
greater likelihood of recommending an intervention at the upper end of the usual £20,000–30,000 per
QALY range than for the general population; £30,000 per QALY tends to be the upper limit except in the
context of end of life.
Although the average person with ID is overweight (and nearly obese), the 10-year CVD risk using cohort
averages (mild/moderate severity only) is around only 2%. This is because risk factors seem to be well
controlled in STOP Diabetes: the average systolic BP was 121 mmHg, the lipid ratio was a healthy 3.63 and
it was a relatively young cohort.
A limitation of the STOP Diabetes intervention is that the reduction in CVD risk is likely to be confined to
a few years after intervention. Combined with the average baseline age of 43 years and associated low
average CVD risk, this explains why the intervention has such as high cost per QALY for the overall group.
An alternative more cost-effective structuring of the intervention sessions may be possible, such that a
smaller initial benefit is achieved but sustained for more years, possibly through additional maintenance
sessions beyond the first year.
A minority – although a significant one – of individuals who are identified as suitable for intervention
may not make the desired progress towards reducing their risk factors for CVD. This could be due to an
individual’s physiological response to the intervention or the numbers of intervention sessions that he/she
actually attends, or a combination of both factors. For such patients, continuing with the maintenance
session may be reducing the overall effectiveness of the intervention that might be more cost-effective,
potentially at favourable cost-per-QALY levels, in those who achieve a good initial response.
Unanswered questions and further research
Further subgroup analyses could be undertaken in groups at a 10%, 15% or 20% 10-year risk of CVD
(diabetes risk could also be factored in), although such subgroups would result in a very small proportion
of the STOP Diabetes cohort actually receiving the intervention.
Further research is needed to identify the optimal mix of initial and maintenance sessions for physical
activity programmes, together with a better understanding of how long benefits are likely to last.
Modelling may also help to inform primary research into the optimal trade-off between investment in
initial intervention and maintenance sessions.
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
Weight loss can be difficult to maintain even with ongoing maintenance, as seen in the Finnish Diabetes
Prevention Study.329 However, physical activity can help to maintain weight loss so it is unknown if benefits
of physical activity can be sustained for longer than dietary-induced weight loss (hence why we explored
3 and 5 years as scenarios for durability of effect).
Further analysis may help to identify optimal permutations of the magnitude/intensity of the physical
activity and dietary advice components to maximise the cost-effectiveness.
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Chapter 13 Discussion and conclusions
Overview
In this chapter, we summarise and discuss the research programme’s findings against each of its objectives. We
also summarise the findings in terms of outputs and implications for practice, make research recommendations,
and discuss dissemination activities and plans for the research programme.
Development and assessment of the feasibility of a diabetes
screening programme in adults with intellectual disability
Main findings
Adults with ID were identified for the screening programme through general practices, specialist ID services
(through the LLDR), specialist ID clinics and through direct contact with the research team. In total, 930 (29%
of those originally approached) took part in the screening programme, of whom 38% were able to consent
for themselves; other participants required a consultee. There were slightly more men than women among
those screened (58%) and participants were relatively young (mean age 43.3 years), mainly of white ethnicity
(80%) and most were overweight (31%) or obese (37%). We were able to collect data on anthropometric
measures for most participants (≈ 86%), and BP (89%) and outcome data for 675 participants (73%) to
assess the prevalence of IGR/T2DM.
Physical activity substudy
We found that the objective measurement of physical activity is likely to be challenging in adults with ID,
given that there are high levels of non-compliance. However, compliance could be substantially improved
using wrist-worn monitors. Of 203 people approached, fewer than half (n = 97; 48%) consented to wear the
waist-worn device, compared with 62% (47 of 76 approached) of those consenting to wear the wrist-worn
device. Similarly, valid data were obtained from 57% (n = 55) of the sample who wore the waist-worn
devices compared with 83% (n = 39) of those wearing the wrist-worn devices.
Other studies among adults with ID have found a high proportion of missing data when using objectively
measured physical activity data.164,233 However, to our knowledge, this is the first time the feasibility of
collecting objectively measured physical activity data in those with ID has been formally assessed. The
results suggest that poor compliance needs to be considered when conducting studies of physical activity
interventions in this population. Researchers may also need to explore the potential for allowing separate
consent in their study design for proposed accelerometer components.
Another somewhat unexpected finding was the high level of physical activity that was observed in our
study population. We found that adults with ID engaged in similar amounts of physical activity as the
general population, whereas most,164,233 but not all,236 studies have found that people with ID generally
engage less. This might reflect the current policy drives to improve health and fitness in this population,
but may also indicate selection bias (i.e. active people preferentially choosing to wear the monitors) or
behaviour change as a result of accelerometer wear.
Prevalence and demographic risk factors for type 2 diabetes and
impaired glucose regulation in people with intellectual disability
The overall prevalence of screen-detected (previously undiagnosed) T2DM was 1.3% (95% CI 0.5% to
2%) and IGR was 5% (95% CI 4% to 7%) among people with ID, which is lower than previously
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reported. Our systematic review (see Chapter 2) found that the prevalence of diagnosed T2DM was
approximately 8% (95% CI 5% to 11%), similar to that found in the general population. None of the
studies in the review reported on screen-detected T2DM (they included prevalent known cases, we
excluded, so it is not possible to make direct comparisons. Our lower-than-expected rates of T2DM may
simply reflect a successful annual health check programme, at least in the study’s geographical location,
and the younger age of participants.
Abnormal glucose levels were associated with non-white ethnicity (OR 3.93, 95% CI 2.10 to 7.33),
a first-degree family history of diabetes (OR 3.35, 95% CI 1.64 to 6.86), increasing weight, waist
circumference, BMI, diastolic BP, triglycerides and decreasing HDL cholesterol.
Validation of the Leicester Self-Assessment diabetes risk score
in people with intellectual disability
When the seven risk factors in the Leicester Self-Assessment risk score were used to explore risk of having
undiagnosed IGR/T2DM among people with ID (with data available), the risk score achieved a sensitivity of
82% in identifying those with abnormal glucose regulation. High sensitivity is generally considered most
important for screening tools because the priority is to ‘rule out’ the disease without missing true cases.
Ninety-eight per cent of participants with a low-/medium-risk score were correctly identified as being at low
risk. Our findings suggest that the Leicester Self-Assessment risk score is statistically effective at identifying
people with ID who are at risk of undiagnosed IGR/T2DM and does not require modification if it should be
integrated at practice level. However, it may not be practical or acceptable for people with ID to calculate
their own score; development of an easy-read version (plus a carer supplement) and additional supportive
material would need to be explored.
Cost-effectiveness
Findings from the health-economic analysis showed that, in its current form, the STOP Diabetes
multicomponent intervention would need to result in a very large overall increase in steps, systolic BP, BMI
and lipid levels for it to be cost-effective at a threshold in the £20,000–30,000 cost-per-QALY range usually
adopted by NICE.
The results would be favourable under the assumptions that:
1. the benefits of the intervention would not be fully lost until 4 years after the intervention (5 years from
the start)
2. commissioners/payers would be willing to fund the intervention up to a threshold of £30,000 per QALY.
The cost-effectiveness of the intervention would be improved by targeting screening at the following
groups, that is, individuals:
l aged > 45 years
l with BMI in the obese range
l with a relatively high baseline risk of CVD.
However, it is still not cost-effective at readily achievable levels of change in steps and diet-attributable risk
factors, unless the cost of the intervention could be reduced.
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The relatively high cost of the STOP Diabetes intervention compared with other similar multicomponent
behaviour change interventions is due to a number of factors:
l small samples needed for each group session
l longer sessions
l the need for three educators rather than two
l the need for more experienced educators
l the need for regular, monthly refresher sessions.
Many of these factors were identified in advance as being important for the interventions to be appropriate
and relevant for people with ID. It is known that the high support needs of this population – including
co-existing challenging behaviour,64 psychiatric disorders,330 physical health problems32 and communication
difficulties – make this a challenging group for behavioural interventions. We aim to explore other ways
in which the intervention may be adapted to minimise resources, such as the potential to target carers
under certain circumstances.
Finally, the findings also revealed a lack of good-quality evidence for the durability of effects of
multicomponent behaviour change interventions, such as that developed for the STOP Diabetes programme.
Data linkage to Hospital Episode Statistics and the Office for
National Statistics
In total, 883 (95%) participants gave consent for the research team to follow up their health in the longer
term via data linkage.
Development of a lifestyle education programme for people
with intellectual disability and impaired glucose regulation
The research involved the development of a structured lifestyle education programme for a population
with ID with IGR or at high risk of developing T2DM and/or CVD based on a high BMI. This was a complex
process encompassing initial curriculum development, two cycles of testing, evaluation, modification and
retesting, prior to final refinement of the programme.
The STOP Diabetes programme development benefited from a systematic process.238,239 The theoretical
underpinning was developed and expanded on from the limited evidence in the literature. This informed
the content and style of approach, alongside the qualitative findings from people with ID, their carers and
HCPs with expertise in working with people with ID. The whole programme was then tailored further to
the specific needs of this group by more user feedback and adaptation by a multidisciplinary team with
expertise in ID and the development of education programmes (with psychological underpinning).
From the initial phases, the programme has been well received and is acceptable to the people it is trying to
support. The initial feedback via qualitative interviews has suggested that some of the elements of treatment
receipt initially hypothesised may have been achieved via reported changes in beliefs and health behaviours.
The research also involved an assessment of feasibility of collecting outcome measures from participants
with ID before and 3 months after delivering the intervention programme. For this component, our findings
suggest that it is both acceptable and feasible to collect outcome measures for weight, height, BMI, waist
circumference, BP and dietary intake (portions of fruit and vegetables), and objective measures for physical
activity and sedentary behaviour, using wrist-worn accelerometers, both before and after (3 months)
attending the programme. At baseline, anthropometric measures and BP were obtained for all of the
participants and accelerometer data for 80%. Attendance at the education programme was overall good,
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with 80% of participants attending for ≥ 5 days (out of seven sessions for the main programme). At 3 months’
follow-up, repeat data were successfully collected for a high proportion of participants (anthropometric
measures 100%; BP 80%; accelerometer data 60%). Owing to time restrictions, we were able to conduct only
one feasibility cycle and were also unable to assess whether or not it is possible to collect longer-term data,
but these preliminary findings are overall positive.
Only four of the five participants who took part in the intervention agreed to wear the wrist-worn
accelerometers at baseline, and this suggests that an assessment of willingness to wear the accelerometer
is an important component of any future evaluation work. Furthermore, the feasibility component of our
work suggested that lifestyle circumstances could play an important role in adhering to the education
programme and this needs to be considered for future work.
Development of an intervention fidelity process for the assessment of
educators delivering the intervention
As part of this research, we successfully completed the first step in developing a tool for assessing intervention
fidelity of the STOP Diabetes educational programme. Preliminary findings using the tool already suggest
some variance between educators, which will provide a benchmark for future work. One of the key
considerations for this component of the research involved reconsidering existing learning methods that are
known to be effective in the general population to meet the needs of people with ID. This included removing
abstract concepts, avoiding abbreviations and jargon, teaching at the group’s pace and, above all, avoiding
isolating the learners by ‘putting them on the spot’ to summarise key messages.
Main findings and outputs
The main findings and outputs arising from this extensive research programme are summarised as follows.
l We developed and assessed the feasibility of a diabetes screening programme for adults with ID.
l In total, 930 (29% of those originally approached) people with ID took part in the screening
programme; 58% were men and the average (mean) age of participants was 43 years.
l Most people who took part in the screening programme (68%) were overweight or obese.
l We were able to collect blood samples from 73% of participants and anthropometric measures on
> 85% of participants.
l To measure physical activity, we found that wrist-worn accelerometers were more acceptable to
participants with ID than waist-worn accelerometers.
l We found that 1.3% of people with ID had undiagnosed T2DM and 5% of people with ID had IGR
(screen detected).
l We found that abnormal glucose tolerance was associated with non-white ethnicity, first-degree family
history of diabetes, increasing weight, waist circumference, hip circumference, BMI, diastolic BP,
triglycerides and lower HDL cholesterol.
l We developed a lifestyle intervention programme for a population with ID with IGR or at a high risk of
developing T2DM and/or CVD based on a high BMI.
l Using concrete messages and visual aids facilitated learning in this group; abstract and conceptual
examples tended to be less well received.
l We found that the collection of outcome measures prior to, and after (3 months), delivering the
intervention was both acceptable and feasible.
l We identified that for the intervention to be cost-effective (£20,000–30,000 cost-per-QALY range), the
required change in steps and diet-attributable risk factors may be more than is achievable in practice.
l We found that if commissioners were willing to fund the intervention up to a higher threshold,
cost-effectiveness may improve by targeting specific individuals (aged > 45 years, obese, high CVD risk).
l We developed a preliminary quality development tool to assess intervention fidelity of the educational
programme for people with ID.
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Limitations
We have found that conducting a programme of research to enhance the knowledge and understanding
of IGR and T2DM in people with ID, including development of a lifestyle education programme, is feasible,
but not without challenges. We acknowledge the following limitations:
l With regard to the systematic review of the evidence in relation to prevalence of T2DM and IGR, we
acknowledge that limited data were available on T2DM in people with ID and that reported outcomes
were sometimes poorly defined or unclear. We would also have benefited from more general
population data for comparison.
l Similarly, for the systematic review of long-term multicomponent behaviour change interventions for
the prevention of CVD and T2DM in people with ID, we acknowledge that only four papers met our
inclusion criteria, which limited our ability to draw meaningful conclusions. However, our findings do
highlight the lack of work in this area and the need for robust interventions, such as that developed for
this programme of work.
l Despite highlighting a number of achievements in involving service users in our research programme,
we acknowledge that we could have done more to involve them in the design and dissemination
phases of our programme.
l We acknowledge that the recruitment approach utilised for the screening study may not be transferable to
other geographical areas in England. Recruitment was facilitated by the LLDR14 (either via direct invitation
from the register or for people previously agreeing to be approached about future research), which
accounted for 40% of people invited (≈39% of participants). The register is only one of three adult ID
case registers in England and has a strong research tradition. However, we approached people via this
route only for general practices that declined to take part in the study and we feel that approaches such as
direct invitation and invitation via ID psychiatric service clinics could be replicated in other areas.
l We acknowledge some difficulties in recruiting services users to the development phase (WP2) despite
using a direct approach to people who had already participated in the screening phase. For the
qualitative development interviews, low recruitment was largely due to an initial lack of people who
were either ineligible (based on severity of ID and/or a BMI of ≥ 25 kg/m2 or IGR) or unwilling. Additionally,
for the later phases, for which participation involved attending a course of education sessions held over
several weeks (with little flexibility in scheduling), reported barriers were largely linked to the regular
daytime commitments (social activities/work/education) of service users that they were either unwilling
or unable to change. The ‘busy schedules’ of potential participants has previously been identified as a
barrier to recruitment for people with ID.331 Unfortunately, within the constraints of this research study
there was no flexibility to offer alternative dates to attend the programme. However, for the second
pilot education cycle, which was held in a residential setting, the day and timing of sessions were
arranged as much as possible to suit the needs of both service users and care workers, and recruitment
levels were much higher.
l For the economic evaluation, we acknowledge the exploratory nature of the work, given that data on
clinical effectiveness for the STOP Diabetes programme were not available. In particular, the analysis
involved extrapolating data outcomes, which assumed a linear relationship between step increase and
changes in biomarkers (BMI, systolic BP and cholesterol), which may not reflect their true relationship.
l We further acknowledge limitations with using the EQ-5D for the economic evaluation, as this has not
been validated in people with ID. We look forward to the outputs from current work to validate the
EQ-5D in this population.159
Implications for practice
We have found that, at least in Leicester/Leicestershire, there is a low prevalence of previously undiagnosed
(screen detected) IGR/T2DM. However, we also found that a significant proportion of people with ID are
overweight or obese and are likely to be at risk of developing T2DM and/or CVD in the future. Our non-invasive
risk score might also help to identify people at risk of undiagnosed IGR/T2DM. The development of the STOP
Diabetes educational programme is the first stage in identifying preventative strategies for future research.
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Research recommendations
We make the following recommendations for further research:
l The recruitment rate for the screening study was relatively low (29%). In some cases the use of
gatekeepers, including GPs, residential home managers and family carers presented a barrier to
recruitment. We recommend utilising a multipronged/multilayered approach, actively engaging with
both intermediaries and service users, and following up all of the potential participants to ensure that
people are given an equitable chance to participate.
l In order to be truly inclusive, we highlight the importance of making reasonable adjustments, including
offering appointments whenever and wherever is most appropriate for the person, minimising disruption
to their routine and ensuring that appropriate support is in place. Given limited resources, it is likely that
researchers and funders need to lower the threshold for an ‘acceptable’ response in this population,
so that adults with ID are not excluded altogether from taking part in research.
l We recommend a staggered consent process when recruiting people with ID into research to enable
them to opt out of some components, such as having blood tests or wearing accelerometers.
l We have demonstrated that adults with ID can be meaningfully involved in the research process;
we recommend exploring further ways in which people with ID can be involved in research and be
recompensed for their time.
l We recommend further work to explore ways in which compliance with accelerometer wear can be
improved in people with ID.
l We recommend ongoing monitoring of the participants in our study to identify longer-term health and
mortality outcomes.
l Finally, we have found preliminary evidence that the STOP Diabetes education programme is acceptable
and feasible. We recommend further work to evaluate its clinical effectiveness and cost-effectiveness in
a RCT informed by the Medical Research Council framework for evaluating complex interventions,238
with a view to integrating the programme into national preventative strategies and reducing health
inequalities among people with ID.
Dissemination activities and plans
During the consent process, participants were asked if they wished to be informed of the findings. Between
September and December 2015 we disseminated the results to participants (and carers). Two of the ID
research nurses visited 57 homes (group homes, supported living, and residential and nursing homes)
to present the findings to participants in an easy-read format, supplemented by verbal explanations/
presentations. Other participants received a brief easy-read report that was sent in the post. We have begun
to disseminate the findings to HCPs locally, both in primary care and within ID services.
The work from the service user involvement component of this research has been published in one of the
NIHR INVOLVE newsletters198 and in the academic literature.203 The initial education development work has
previously been presented at the Diabetes UK Professional Conference in March 2015.332 Similarly, the
screening study was presented at the 2016 Diabetes UK Professional Conference.333
The next steps will involve writing up and submitting academic articles in relation to the individual components
of the research programme. This will include the screening study, risk score validation, cost-effectiveness
component, intervention development and updated versions of the two systematic reviews. We will continue
to present the findings both locally, through existing collaborations with NIHR Collaboration for Leadership in
Applied Health Research and Care East Midlands and the East Midlands Academic Health Services Network,
and nationally. We have been invited to present our work at a meeting of the Royal Society for Medicine
Intellectual Disability Forum (Managing Diabetes in People with Intellectual Disabilities: Recent Advances) in
November 2016.
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Summary
Results from this programme of work have significantly enhanced existing knowledge and understanding
of T2DM and IGR in people with ID, and enabled us to test strategies for the early identification of IGR and
T2DM in people with ID. This is the first large diabetes screening study in people with ID in the UK and,
to our knowledge, the largest screening study globally. We have also developed a lifestyle education
programme and educator training protocol to promote behaviour change in a population with ID who are
at risk of developing T2DM. Further work is now needed to evaluate the intervention we have developed
and identify cost-effective strategies for its implementation.
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Appendix 1 Assessment of capacity and consent
Declines participation
Preliminary assessment
of capacity
Approach for capacity
assessment and consent
Has capacity
Does not need
more information
Needs more
information
Does not have capacity
Seek personal
consultee
Personal 
consultee 
available
Consultee not 
available
Seek nominated
consultee
Ask advice
 from personal 
consultee
Ask advice from
nominated 
consultee
Unclear if has capacity
FIGURE 26 How capacity and consent were assessed in the study. Adapted from Dixon-Woods and Angell.334
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Appendix 2 Example from Leicester
Self-Assessment risk score
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Appendix 3 Outcome definitions for type 2
diabetes and cardiovascular disease prevalence and
risk factors
(See main report for reference list.)
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
215
TA
B
LE
60
O
u
tc
o
m
e
d
ef
in
it
io
n
s
fo
r
ar
ti
cl
es
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
o
f
T2
D
M
an
d
C
V
D
p
re
va
le
n
ce
an
d
ri
sk
fa
ct
o
rs
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
M
ol
te
no
(2
00
0)
13
1
O
b
es
e:
BM
Io
f
>
30
kg
/m
2
M
IL
D
0.
3%
,
M
O
D
18
.7
%
,
SE
V
37
.7
%
,
PR
O
F
33
.5
%
,
M
IS
SI
N
G
D
A
TA
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
Ro
be
rt
so
n
(2
00
0)
50
O
b
es
e:
BM
Io
f
>
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
25
.1
–
30
kg
/m
2
Ja
ni
ck
i(
20
02
)1
14
C
V
D
:a
N
R
D
ia
b
et
es
:a
ad
ul
t
on
se
t
O
b
es
e:
a
BM
Io
f
>
27
kg
/m
2
H
yp
er
te
n
si
o
n
:a
N
R
H
yp
er
lip
id
ae
m
ia
:a
N
R
M
IL
D
1.
3%
,
M
O
D
50
.3
%
,
SE
V
/P
RO
F,
47
%
O
ve
rw
ei
g
h
t:
a
BM
Io
f
22
–
27
kg
/m
2
Le
w
is
(2
00
2)
11
9
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
El
ev
at
ed
B
P:
SB
P
>
14
0
m
m
H
g
or
D
BP
>
90
m
m
H
g
H
yp
er
ch
o
le
st
er
o
la
em
ia
:
to
ta
lc
ho
le
st
er
ol
≥
13
.3
m
m
ol
/l
M
IL
D
37
.1
%
,
M
O
D
16
.4
%
,
SE
V
14
.7
%
,
PR
O
F
15
.3
%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
29
.9
kg
/m
2
M
ar
sh
al
l(
20
03
)1
24
O
b
es
e:
BM
Io
f
≥
31
kg
/m
2
H
yp
er
te
n
si
o
n
:
SB
P
>
14
0
m
m
H
g
El
ev
at
ed
ch
o
le
st
er
o
l
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t:
BM
Io
f
26
–
30
kg
/m
2
H
av
er
ca
m
p
(2
00
4)
83
C
V
D
:a
de
fin
iti
on
N
R
D
ia
b
et
es
:a
de
fin
iti
on
N
R
O
b
es
e:
de
fin
iti
on
N
R
–
BM
I
da
ta
w
er
e
co
lle
ct
ed
El
ev
at
ed
B
P:
a
de
fin
iti
on
N
R
M
IL
D
39
.4
%
,
M
O
D
26
.6
%
,
SE
V
14
.7
%
,
PR
O
F
10
.6
%
O
ve
rw
ei
g
h
t:
de
fin
iti
on
N
R
–
BM
Id
at
a
w
er
e
co
lle
ct
ed
H
ov
e
(2
00
4)
11
1
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
M
IL
D
39
.2
%
,
M
O
D
42
.1
%
,
SE
V
15
.5
%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
29
.9
kg
/m
2
M
er
ric
k
(2
00
4)
12
9
H
ea
rt
d
is
ea
se
:a
de
fin
iti
on
N
R
T2
D
M
:a
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
:a
BM
Io
f
>
27
kg
/m
2
H
yp
er
te
n
si
o
n
:a
de
fin
iti
on
N
R
H
yp
er
lip
id
ae
m
ia
:a
de
fin
iti
on
N
R
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
M
oo
re
(2
00
4)
13
2
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
Em
er
so
n
(2
00
5)
10
5
O
b
es
e:
b
BM
Io
f
>
30
kg
/m
2
O
ve
rw
ei
g
h
t:
b
BM
Io
f
25
.1
–
30
kg
/m
2
Y
en
(2
00
5)
14
4
O
b
es
e:
a
BM
Io
f
≥
27
kg
/m
2
M
IL
D
22
.2
%
,
M
O
D
34
.9
%
,
SE
V
28
.1
%
,
PR
O
F
14
.8
%
O
ve
rw
ei
g
h
t:
b
BM
Io
f
24
to
<
27
kg
/m
2
Ito
(2
00
6)
89
O
b
es
e:
a
BM
Io
f
>
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
30
kg
/m
2
Le
nn
ox
(2
00
6)
11
6
O
b
es
e:
BM
Io
f
>
30
kg
/m
2
El
ev
at
ed
B
P:
SB
P
>
14
0
m
m
H
g
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
30
kg
/m
2
Le
vy
(2
00
6)
11
7
D
ia
b
et
es
:b
de
fin
iti
on
N
R
O
b
es
e:
b
BM
Io
f
≥
30
kg
/m
2
El
ev
at
ed
B
P:
b
de
fin
iti
on
N
R
H
yp
er
ch
o
le
st
er
o
la
em
ia
:b
de
fin
iti
on
N
R
M
IL
D
47
.6
%
,
M
O
D
31
.1
%
,
SE
V
14
.6
%
,
PR
O
F
6.
8%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
29
.9
kg
/m
2
O
b
es
e/
o
ve
rw
ei
g
h
t:
BM
Io
f
≥
25
kg
/m
2
M
cD
er
m
ot
t
(2
00
6)
86
C
o
ro
n
ar
y
ar
te
ry
d
is
ea
se
:b
IC
D
-9
co
de
s
T1
D
M
an
d
T2
D
M
:b
IC
D
-9
co
de
s
O
b
es
e:
b
N
R
H
yp
er
te
n
si
o
n
an
d
el
ev
at
ed
B
P:
b
IC
D
-9
co
de
s
TI
A
:b
IC
D
-9
co
de
s
Ru
ra
ng
irw
a
(2
00
6)
93
O
ve
rw
ei
g
h
t/
o
b
es
e:
a
BM
Io
f
≥
25
kg
/m
2
Sh
ah
(2
00
6)
13
5
D
ia
b
et
es
:a
de
fin
iti
on
N
R
co
nt
in
ue
d
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
217
TA
B
LE
60
O
u
tc
o
m
e
d
ef
in
it
io
n
s
fo
r
ar
ti
cl
es
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
o
f
T2
D
M
an
d
C
V
D
p
re
va
le
n
ce
an
d
ri
sk
fa
ct
o
rs
(c
o
n
ti
n
u
ed
)
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
V
an
D
en
A
kk
er
(2
00
6)
14
0
C
H
D
:b
IC
D
-1
0
co
de
s
H
yp
er
te
n
si
o
n
:b
IC
D
-1
0
co
de
s
M
IL
D
11
%
,
M
O
D
53
%
,
SE
V
28
%
,
PR
O
F
8%
C
er
eb
ro
va
sc
u
la
r
d
is
ea
se
:b
IC
D
-1
0
co
de
s
Le
vy
(2
00
7)
11
8
D
ia
b
et
es
:b
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
:
BM
Io
f
≥
25
kg
/m
2
El
ev
at
ed
B
P:
b
de
fin
iti
on
N
R
H
yp
er
ch
o
le
st
er
o
la
em
ia
:b
de
fin
iti
on
N
R
SE
V
65
.4
%
,
PR
O
F
34
.6
%
M
cD
er
m
ot
t
(2
00
7)
87
D
ia
b
et
es
:b
al
th
ou
gh
a
de
ta
ile
d
de
sc
rip
tio
n
is
gi
ve
n,
it
is
no
t
po
ss
ib
le
to
de
fin
e
th
e
ty
pe
of
di
ab
et
es
is
us
ed
as
an
ou
tc
om
e
M
cG
ui
re
(2
00
7)
12
7
O
b
es
e:
a
BM
Io
f
>
30
kg
/m
2
M
IL
D
14
.1
%
,
M
O
D
63
.5
%
,
SE
V
12
.8
%
,
PR
O
F
9%
O
ve
rw
ei
g
h
t:
a
BM
Io
f
>
25
kg
/m
2
W
an
g
(2
00
7)
14
2
H
ea
rt
d
is
ea
se
:a
IC
D
-9
co
de
s;
sp
ec
ifi
c
co
de
s
in
m
an
ua
lf
or
th
e
Ro
ch
es
te
r
he
al
th
st
at
us
su
rv
ey
(in
cl
ud
es
so
m
e
no
n-
C
V
D
co
de
s)
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
a
Bh
au
m
ik
(2
00
8)
33
0
O
b
es
e:
b
BM
Io
f
≥
30
kg
/m
2
H
yp
er
te
n
si
o
n
:b
SB
P
≥
14
0
m
m
H
g
an
d/
or
D
BP
≥
90
m
m
H
g
O
ve
rw
ei
g
h
t:
BM
Io
f
25
.1
to
<
30
kg
/m
2
H
en
de
rs
on
(2
00
8)
84
T2
D
M
:b
de
riv
ed
fr
om
m
ed
ic
al
pr
ob
le
m
lis
ts
O
b
es
e:
b
BM
Io
f
>
30
kg
/m
2
H
yp
er
te
n
si
o
n
:b
de
riv
ed
fr
om
m
ed
ic
al
pr
ob
le
m
lis
ts
D
ys
lip
id
ae
m
ia
:b
de
riv
ed
fr
om
m
ed
ic
al
pr
ob
le
m
lis
ts
O
ve
rw
ei
g
h
t:
b
BM
Io
f
≥
25
≤
30
kg
/m
2
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
218
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
M
el
vi
lle
(2
00
8)
12
8
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
M
IL
D
40
.9
%
,
M
O
D
25
.1
%
,
SE
V
18
.2
%
,
PR
O
F
15
.8
%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
W
al
la
ce
(2
00
8)
14
1
C
V
D
:b
hi
st
or
y
of
pe
rip
he
ra
lv
as
cu
la
r
di
se
as
e,
st
ro
ke
or
C
H
D
El
ev
at
ed
g
lu
co
se
:b
>
6.
1
m
m
ol
/l
(f
as
tin
g
an
d
no
n-
fa
st
in
g
te
st
s
gr
ou
pe
d
to
ge
th
er
in
re
su
lts
)
O
b
es
e:
b
BM
Io
f
≥
30
kg
/m
2
H
yp
er
te
n
si
o
n
:b
SB
P
>
14
0
m
m
H
g
El
ev
at
ed
ch
o
le
st
er
o
l:b
>
5.
5
m
m
ol
/l
(f
as
tin
g
an
d
no
n-
fa
st
in
g
te
st
s
gr
ou
pe
d
to
ge
th
er
in
re
su
lts
)
T1
D
M
an
d
T2
D
M
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
29
.9
kg
/m
2
de
W
in
te
r
(2
00
9)
81
C
er
eb
ro
va
sc
u
la
r
d
is
ea
se
:b
di
ag
no
se
d
by
C
T
sc
an
D
ia
b
et
es
:g
lu
co
se
≥
7.
0
m
m
ol
/l
or
us
e
of
an
tid
ia
be
tic
dr
ug
s
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
H
yp
er
te
n
si
o
n
:
SB
P
≥
14
0
m
m
H
g
or
us
e
of
dr
ug
s
H
yp
er
ch
o
le
st
er
o
la
em
ia
:
to
ta
lc
ho
le
st
er
ol
>
5.
1
m
m
ol
/l
to
≥
6.
5
m
m
ol
/l
(d
ep
en
di
ng
on
la
bo
ra
to
ry
re
fe
re
nc
e
va
lu
es
)o
r
us
e
of
ch
ol
es
te
ro
l-
lo
w
er
in
g
dr
ug
s
M
IL
D
12
.1
%
,
M
O
D
33
.2
%
,
SE
V
34
.3
%
,
PR
O
F
20
.4
%
M
I:b
di
ag
no
se
d
by
EC
G
ch
an
ge
s
El
ev
at
ed
LD
L:
≥
3.
5
m
m
ol
/l
G
al
e
(2
00
9)
10
7
O
b
es
e:
BM
Io
f
30
to
<
40
kg
/m
2
Se
ve
re
ly
o
b
es
e:
BM
Io
f
≥
40
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
H
en
de
rs
on
(2
00
9)
11
0
O
ve
rw
ei
g
h
t
o
r
ab
o
ve
:a
BM
Io
f
≥
25
kg
/m
2
M
IL
D
/M
O
D
53
%
,
SE
V
/
PR
O
F,
47
%
M
aa
sk
an
t
(2
00
9)
12
3
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
co
nt
in
ue
d
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
219
TA
B
LE
60
O
u
tc
o
m
e
d
ef
in
it
io
n
s
fo
r
ar
ti
cl
es
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
o
f
T2
D
M
an
d
C
V
D
p
re
va
le
n
ce
an
d
ri
sk
fa
ct
o
rs
(c
o
n
ti
n
u
ed
)
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
M
os
s
(2
00
9)
13
4
El
ev
at
ed
g
lu
co
se
:
no
n-
fa
st
in
g
te
st
–
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
:
BM
Io
f
>
25
kg
/m
2
H
yp
er
te
n
si
o
n
:
de
fin
iti
on
N
R
El
ev
at
ed
to
ta
lc
h
o
le
st
er
o
l:
no
n-
fa
st
in
g
te
st
–
de
fin
iti
on
N
R
So
hl
er
(2
00
9)
13
6
D
ia
b
et
es
:b
de
fin
iti
on
N
R
O
b
es
e:
b
BM
Io
f
≥
30
kg
/m
2
H
yp
er
te
n
si
o
n
:b
de
fin
iti
on
N
R
H
yp
er
ch
o
le
st
er
o
la
em
ia
:b
to
ta
lc
ho
le
st
er
ol
>
13
.3
m
m
ol
/l
O
ve
rw
ei
g
h
t:
BM
Io
f
25
–
29
.9
kg
/m
2
V
an
de
Lo
uw
(2
00
9)
13
9
H
yp
er
te
n
si
o
n
:
SB
P
>
14
0
m
m
H
g
M
IL
D
10
%
,
M
O
D
38
%
,
SE
V
/P
RO
F
52
%
Sh
ire
m
an
(2
01
0)
95
D
ia
b
et
es
:b
IC
D
-9
co
de
s
St
ed
m
an
(2
01
0)
13
8
O
b
es
e:
b
BM
Io
f
≥
30
kg
/m
2
O
ve
rw
ei
g
h
t:
b
BM
Io
f
25
–
29
.9
kg
/m
2
Ty
le
r
(2
01
0)
88
C
H
D
:b
IC
D
-9
co
de
s
D
ia
b
et
es
:b
IC
D
-9
co
de
s
O
b
es
e:
b
IC
D
-9
co
de
s
H
yp
er
te
n
si
o
n
:b
IC
D
-9
co
de
s
H
yp
er
lip
id
ae
m
ia
:b
IC
D
-9
co
de
s
C
he
n
(2
01
1)
10
1
H
ea
rt
d
is
ea
se
:s
uc
h
as
ca
rd
ia
c
ar
rh
yt
hm
ia
s
an
d
co
ro
na
ry
at
he
ro
sc
le
ro
si
s.
D
ia
gn
os
es
ba
se
d
on
cl
in
ic
al
m
an
ife
st
at
io
ns
or
EC
G
fin
di
ng
s
El
ev
at
ed
b
lo
o
d
g
lu
co
se
:
ex
ce
ed
in
g
no
rm
al
ra
ng
e
3.
9–
6.
1
m
m
ol
/l
H
yp
er
te
n
si
o
n
:
SB
P
≥
14
0
m
m
H
g
or
D
BP
≥
90
m
m
H
g
El
ev
at
ed
to
ta
lc
h
o
le
st
er
o
l:
≥
6.
2
m
m
ol
/l
D
ia
b
et
es
:F
PG
≥
7
m
m
ol
/l
or
2-
ho
ur
pl
as
m
a
gl
uc
os
e
≥
11
.1
m
m
ol
/l
or
2-
ho
ur
O
G
TT
>
11
.1
m
m
ol
/l
El
ev
at
ed
tr
ig
ly
ce
ri
d
es
:
≥
2.
26
m
m
ol
/l
Fr
ig
hi
(2
01
1)
10
6
T2
D
M
:
N
R
O
ve
rw
ei
g
h
t
o
r
ab
o
ve
:
de
fin
iti
on
N
R
–
BM
Id
at
a
an
d
W
C
w
er
e
co
lle
ct
ed
M
IL
D
48
%
,
M
O
D
30
.2
%
,
SE
V
/P
RO
F
21
.8
%
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
220
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
PO
M
O
N
A
II
st
ud
y:
H
av
em
an
(2
01
1)
10
9
pl
us
M
ar
tin
ez
-L
ea
l
(2
01
1)
12
5
(o
be
si
ty
da
ta
)
H
ea
rt
at
ta
ck
:a
de
fin
iti
on
N
R
D
ia
b
et
es
:a
de
fin
iti
on
N
R
O
b
es
e:
de
fin
iti
on
N
R
–
BM
I
da
ta
w
er
e
co
lle
ct
ed
H
yp
er
te
n
si
o
n
:a
de
fin
iti
on
N
R
H
av
em
an
:1
09
M
IL
D
22
.7
%
,
M
O
D
28
.2
%
,
SE
V
20
.7
%
,
PR
O
F
11
.8
%
;
M
ar
tin
ez
-
Le
al
:1
25
M
IL
D
21
.8
%
,
M
O
D
27
.7
%
,
SE
V
19
.7
%
,
PR
O
F
11
.4
%
C
er
eb
ro
va
sc
u
la
r
d
is
ea
se
:a
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t:
de
fin
iti
on
N
R
–
BM
Id
at
a
w
er
e
co
lle
ct
ed
H
su
(2
01
2)
11
3
O
ve
rw
ei
g
h
t
o
r
ab
o
ve
:b
BM
Io
f
≥
24
kg
/m
2
3/
5
cr
ite
ria
,
N
C
EP
-A
TP
II
M
IL
D
/M
O
D
,
47
%
,
SE
V
/
PR
O
F
53
%
Le
e
(2
01
1)
11
5
C
ar
d
ia
c
ill
n
es
s:
b
hi
st
or
y
of
C
H
D
or
co
ng
es
tiv
e
ca
rd
ia
c
fa
ilu
re
D
ia
b
et
es
:b
im
pl
ie
d
by
pr
es
cr
ip
tio
n
of
hy
po
gl
yc
ae
m
ic
dr
ug
s
O
b
es
e:
b
BM
Io
f
≥
31
kg
/m
2
H
yp
er
te
n
si
o
n
:b
de
fin
iti
on
N
R
M
IL
D
33
%
,
M
O
D
22
%
,
SE
V
23
%
,
PR
O
F
21
%
O
ve
rw
ei
g
h
t:
b
BM
Io
f
26
–
30
kg
/m
2
St
an
cl
iff
e
(2
01
1)
13
7
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
≥
25
to
<
30
kg
/m
2
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
:
BM
Io
f
≥
25
kg
/m
2
W
on
g
(2
01
1)
14
3
H
ea
rt
d
is
ea
se
:a
de
fin
iti
on
N
R
D
ia
b
et
es
:a
de
fin
iti
on
N
R
O
ve
rw
ei
g
h
t
an
d
ab
o
ve
:a
BM
Io
f
>
23
kg
/m
2
H
yp
er
te
n
si
o
n
:a
de
fin
iti
on
N
R
H
yp
er
ch
o
le
st
er
o
la
em
ia
:a
de
fin
iti
on
N
R
M
IL
D
4.
9%
,
M
O
D
41
.8
%
,
SE
V
/P
RO
F
51
.9
%
C
er
eb
ro
va
sc
u
la
r
d
is
ea
se
:a
de
fin
iti
on
N
R
co
nt
in
ue
d
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
TA
B
LE
60
O
u
tc
o
m
e
d
ef
in
it
io
n
s
fo
r
ar
ti
cl
es
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
o
f
T2
D
M
an
d
C
V
D
p
re
va
le
n
ce
an
d
ri
sk
fa
ct
o
rs
(c
o
n
ti
n
u
ed
)
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
C
ha
ng
(2
01
2)
10
0
El
ev
at
ed
b
lo
o
d
su
g
ar
:
FP
G
≥
5.
6
m
m
ol
/l
or
us
e
of
dr
ug
s
O
b
es
it
y:
BM
I(
de
fin
iti
on
N
R)
H
yp
er
te
n
si
ve
SB
P:
≥
13
0
m
m
H
g
or
us
e
of
dr
ug
s
El
ev
at
ed
tr
ig
ly
ce
ri
d
es
:
≥
8.
3
m
m
ol
/l
(o
r
us
e
of
dr
ug
)
3/
5
cr
ite
ria
N
C
EP
-A
TP
III
an
d
M
et
S
cr
ite
ria
fo
r
Ta
iw
an
es
e
pe
op
le
M
IL
D
65
%
,
M
O
D
16
%
,
SE
V
9%
,
PR
O
F
10
%
O
ve
rw
ei
g
h
t:
BM
I
(d
ef
in
iti
on
N
R)
H
yp
er
te
n
si
ve
D
B
P:
≥
85
m
m
H
g
or
us
e
of
dr
ug
s
R
ed
u
ce
d
H
D
L:
H
D
L
–
m
al
e
<
2.
2
m
m
ol
/l,
fe
m
al
e
<
2.
8
m
m
ol
/l
(o
r
us
e
of
dr
ug
s)
C
en
tr
al
o
ve
rw
ei
g
h
t:
FW
C
≥
80
cm
/M
W
C
≥
90
cm
D
e
W
in
te
r
(2
01
2)
-1
,
H
A
-ID
st
ud
y1
03
O
b
es
it
y:
BM
Io
f
≥
30
kg
/m
2
M
IL
D
24
.8
%
,
M
O
D
48
%
,
SE
V
16
%
,
PR
O
F
8.
9%
O
ve
rw
ei
g
h
t:
BM
Io
f
≥
25
kg
/m
2
C
en
tr
al
o
b
es
e:
FW
H
R
≥
88
cm
/M
W
H
R
≥
10
2
cm
C
en
tr
al
o
ve
rw
ei
g
h
t:
FW
H
R
≥
80
cm
/M
W
H
R
≥
94
cm
D
e
W
in
te
r
(2
01
2)
-2
,
H
A
-ID
st
ud
y1
02
D
ia
b
et
es
:F
SG
≥
6.
1
m
m
ol
/l
or
us
e
of
dr
ug
s
H
yp
er
te
n
si
o
n
:
SB
P
≥
14
0
m
m
H
g
or
D
BP
≥
90
m
m
H
g
an
d/
or
m
ed
ic
at
io
n
H
yp
er
ch
o
le
st
er
o
la
em
ia
:
fa
st
in
g
se
ru
m
to
ta
l
ch
ol
es
te
ro
l>
6.
5
m
m
ol
/l
or
us
e
of
dr
ug
s
D
ef
in
ed
se
p
ar
at
el
y
b
y:
3/
5
cr
ite
ria
(jo
in
t
in
te
rim
st
at
em
en
t)
an
d
3/
5
cr
ite
ria
N
C
EP
-A
TP
III
M
IL
D
24
.5
%
,
M
O
D
48
.6
%
,
SE
V
16
%
,
PR
O
F
8.
7%
G
az
iz
ov
a
(2
01
2)
82
O
b
es
e:
BM
Io
f
>
30
kg
/m
2
M
IL
D
61
%
,
M
O
D
24
%
,
SE
V
15
%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
.1
–
30
kg
/m
2
Li
n
(2
01
2)
12
2
H
yp
er
te
n
si
o
n
:
SB
P
≥
14
0
m
m
H
g
or
D
BP
≥
90
m
m
H
g
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
222
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
M
or
in
(2
01
2)
13
3
H
ea
rt
d
is
ea
se
:a
IC
D
-1
0
co
de
s
D
ia
b
et
es
:a
IC
D
-1
0
co
de
s
M
IL
D
32
.9
%
,
M
O
D
46
.4
%
,
SE
V
11
.2
%
,
PR
O
F
5.
2%
Bé
ga
rie
(2
01
3)
98
O
b
es
e:
BM
Io
f
≥
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
≥
25
to
<
30
kg
/m
2
D
e
W
in
te
r
(2
01
3)
,1
04
H
A
-ID
st
ud
y
Pe
ri
p
h
er
al
ar
te
ri
al
d
is
ea
se
:a
nk
le
-
br
ac
hi
al
pr
es
su
re
in
de
x
≤
0.
9
(m
ea
su
re
d
on
ly
in
su
bj
ec
ts
w
ith
>
1
C
V
D
ris
k)
M
IL
D
24
.9
%
,
M
O
D
53
%
,
SE
V
13
.4
%
,
PR
O
F
4.
6%
H
ai
de
r
(2
01
3)
10
8
H
ea
rt
d
is
ea
se
:a
ev
er
di
ag
no
se
d
by
a
do
ct
or
/r
el
ev
an
t
H
C
P
T2
D
M
:a
In
th
e
pa
pe
r
it
gr
ou
ps
T1
D
M
an
d
T2
D
M
to
ge
th
er
,
bu
t
in
a
se
pa
ra
te
re
po
rt
ou
tc
om
es
ar
e
av
ai
la
bl
e
se
pa
ra
te
ly
,
it
al
so
sa
ys
if
be
en
to
ld
by
do
ct
or
O
b
es
e:
a
BM
Io
f
>
30
kg
/m
2
St
ro
ke
:a
ev
er
di
ag
no
se
d
by
a
do
ct
or
/r
el
ev
an
t
H
C
P
O
ve
rw
ei
g
h
t:
a
BM
Io
f
25
to
<
30
kg
/m
2
Ja
ns
en
(2
01
3)
85
C
er
eb
ro
va
sc
u
la
r
ac
ci
d
en
t:
b
ac
ut
e
di
sr
up
tio
n
of
ce
re
br
al
ci
rc
ul
at
io
n
w
ith
fo
ca
l
ne
ur
ol
og
ic
al
sy
m
pt
om
s
≥
24
ho
ur
s
M
IL
D
6.
9%
,
M
O
D
37
.8
%
,
SE
V
29
%
,
PR
O
F
26
.3
%
M
I:b
cl
in
ic
al
si
gn
s
an
d
EC
G
di
ag
no
si
s
an
d/
or
la
bo
ra
to
ry
re
su
lts
co
nt
in
ue
d
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
223
TA
B
LE
60
O
u
tc
o
m
e
d
ef
in
it
io
n
s
fo
r
ar
ti
cl
es
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
vi
ew
o
f
T2
D
M
an
d
C
V
D
p
re
va
le
n
ce
an
d
ri
sk
fa
ct
o
rs
(c
o
n
ti
n
u
ed
)
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
Li
n,
JD
(2
01
3)
12
0
H
yp
er
g
ly
ca
em
ia
:b
FP
G
≥
7
m
m
ol
/l
H
yp
er
te
n
si
o
n
:b
SB
P
≥
14
0
m
m
H
g
or
D
BP
≥
90
m
m
H
g
or
us
e
of
dr
ug
s
H
yp
er
lip
id
ae
m
ia
:b
tr
ig
ly
ce
rid
e
≥
11
.1
m
m
ol
/l
or
to
ta
lc
ho
le
st
er
ol
≥
13
.3
m
m
ol
/l
M
cC
ar
ro
n
(2
01
3)
12
6
H
ea
rt
d
is
ea
se
:a
hi
st
or
y
of
an
gi
na
,
he
ar
t
at
ta
ck
,
co
ro
na
ry
he
ar
t
fa
ilu
re
,
op
en
he
ar
t
su
rg
er
y
(e
ve
r
di
ag
no
se
d
by
a
do
ct
or
/r
el
ev
an
t
H
C
P)
H
yp
er
te
n
si
o
n
:a
ev
er
di
ag
no
se
d
by
a
do
ct
or
/r
el
ev
an
t
H
C
P
St
ro
ke
/T
IA
:a
ev
er
di
ag
no
se
d
by
a
do
ct
or
/r
el
ev
an
t
H
C
P
V
ac
ek
(2
01
3)
94
H
yp
er
te
n
si
o
n
:b
IC
D
-9
co
de
s
H
si
eh
(2
01
4)
11
2
O
b
es
e:
a
BM
Io
f
≥
30
kg
/m
2
M
IL
D
44
.9
%
,
M
O
D
23
.7
%
,
SE
V
/P
RO
F
8.
4%
O
ve
rw
ei
g
h
t:
BM
Io
f
25
to
<
30
kg
/m
2
M
ik
ul
ov
ic
(2
01
4)
13
0
O
b
es
e:
BM
Io
f
>
30
kg
/m
2
O
ve
rw
ei
g
h
t:
BM
Io
f
≥
25
kg
/m
2
de
W
in
te
r
(2
01
5)
90
T1
D
M
,
T2
D
M
C
en
tr
al
o
b
es
e:
FW
H
R
≥
88
cm
/M
W
H
R
≥
10
2
cm
H
yp
er
te
n
si
o
n
:
SB
P
≥
14
0
m
m
H
g,
or
D
BP
≥
90
m
m
H
g
an
d/
or
m
ed
ic
at
io
n
H
yp
er
ch
o
le
st
er
o
la
em
ia
:
fa
st
in
g
se
ru
m
to
ta
l
ch
ol
es
te
ro
l>
6.
5
m
m
ol
/l
or
us
e
of
dr
ug
s
D
ef
in
ed
se
p
ar
at
el
y
b
y:
3/
5
cr
ite
ria
(jo
in
t
in
te
rim
st
at
em
en
t)
,
an
d
3/
5
cr
ite
ria
N
C
EP
-A
TP
III
M
IL
D
24
.5
%
,
M
O
D
48
.6
%
,
SE
V
16
%
,
PR
O
F
8.
7%
D
ia
b
et
es
:F
SG
≥
6.
1
m
m
ol
/l
or
us
e
of
dr
ug
s
C
en
tr
al
o
ve
rw
ei
g
h
t:
FW
H
R
≥
80
cm
/M
W
H
R
≥
94
cm
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
224
Fi
rs
t
au
th
o
r
(y
ea
r)
C
V
D
o
u
tc
o
m
es
D
ia
b
et
es
/b
lo
o
d
su
g
ar
o
u
tc
o
m
es
O
b
es
it
y/
o
ve
rw
ei
g
h
t
o
u
tc
o
m
es
B
P
o
u
tc
o
m
es
Li
p
id
o
u
tc
o
m
es
M
et
ab
o
lic
sy
n
d
ro
m
e
Sp
lit
b
y
ID
se
ve
ri
ty
Li
n,
LP
(2
01
5)
12
1
O
b
es
e:
BM
Io
f
≥
27
kg
/m
2
M
IL
D
6.
5%
,
M
O
D
32
.6
%
,
SE
V
34
.8
%
,
PR
O
F
26
.1
%
O
ve
rw
ei
g
h
t:
BM
Io
f
24
–
26
.9
kg
/m
2
Za
al
-S
ch
ul
le
r
(2
01
4)
14
5
Pe
ri
p
h
er
al
ar
te
ri
al
d
is
ea
se
:a
nk
le
–
br
ac
hi
al
pr
es
su
re
in
de
x
<
0.
9
M
IL
D
/M
O
D
51
.1
%
,
SE
V
/
PR
O
F
48
.9
%
C
T,
co
m
pu
te
ris
ed
to
m
og
ra
ph
y;
D
BP
,
di
as
to
lic
bl
oo
d
pr
es
su
re
;
EC
G
,
el
ec
tr
oc
ar
di
og
ra
m
;
FP
G
,
fa
st
in
g
pl
as
m
a
gl
uc
os
e;
FS
G
,
fa
st
in
g
se
ru
m
gl
uc
os
e;
FW
C
,
fe
m
al
e
w
ai
st
ci
rc
um
fe
re
nc
e;
FW
H
R,
fe
m
al
e
w
ai
st
-t
o-
hi
p
ra
tio
;
IC
D
-9
,
In
te
rn
at
io
na
lC
la
ss
ifi
ca
tio
n
of
D
is
ea
se
s,
N
in
th
Ed
iti
on
;
M
et
S,
m
et
ab
ol
ic
sy
nd
ro
m
e;
M
O
D
,
m
od
er
at
e;
M
W
C
,
m
al
e
w
ai
st
ci
rc
um
fe
re
nc
e;
M
W
H
R,
m
al
e
w
ai
st
-t
o-
hi
p
ra
tio
;
N
C
EP
-A
TP
III
,
N
at
io
na
lC
ho
le
st
er
ol
Ed
uc
at
io
n
Pr
og
ra
m
A
du
lt
Tr
ea
tm
en
t
Pa
ne
lI
II;
N
R,
no
t
re
po
rt
ed
;
O
G
TT
,
or
al
gl
uc
os
e
to
le
ra
nc
e
te
st
;
PR
O
F,
pr
of
ou
nd
;
SB
P,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
;
SE
V
,
se
ve
re
;
T1
D
M
,
ty
pe
1
di
ab
et
es
m
el
lit
us
;
TI
A
,
tr
an
si
en
t
is
ch
ae
m
ic
at
ta
ck
;
W
C
,
w
ai
st
ci
rc
um
fe
re
nc
e.
a
D
at
a
se
lf-
re
po
rt
ed
or
re
po
rt
ed
by
ca
re
r.
b
Re
tr
os
pe
ct
iv
e
da
ta
ex
tr
ac
te
d
fr
om
da
ta
ba
se
/m
ed
ic
al
re
co
rd
s.
D
ef
in
it
io
n
s
Is
ch
ae
m
ic
he
ar
t
di
se
as
e
D
ef
in
ed
as
is
ch
ae
m
ic
he
ar
t
di
se
as
e,
M
I,
he
ar
t
at
ta
ck
,
co
ro
na
ry
at
he
ro
sc
le
ro
si
s
an
d/
or
co
ro
na
ry
ar
te
ry
di
se
as
e.
C
er
eb
ro
va
sc
ul
ar
di
se
as
e
D
ef
in
ed
as
ce
re
br
ov
as
cu
la
r
di
se
as
e,
st
ro
ke
an
d/
or
TI
A
s.
U
nd
ef
in
ed
C
V
D
D
ef
in
ed
as
un
de
fin
ed
he
ar
t
di
se
as
e,
un
de
fin
ed
C
V
D
,
or
a
co
m
bi
ne
d
C
V
D
ou
tc
om
e
w
he
re
th
e
m
aj
or
ity
is
un
de
fin
ed
.
T2
D
M
D
ef
in
ed
as
T2
D
M
on
ly
.
DOI: 10.3310/pgfar05110 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 11
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Dunkley et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225

Appendix 4 Funnel plot for type 2 diabetes
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FIGURE 27 Funnel plot with pseudo 95% confidence limits for T2DM.
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Appendix 5 Funnel plot for ischaemic heart
disease
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FIGURE 28 Funnel plot with pseudo 95% confidence limits for ischaemic heart disease.
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Appendix 6 Funnel plot for cerebrovascular
disease
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FIGURE 29 Funnel plot with pseudo 95% confidence limits for cerebrovascular disease.
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Appendix 7 Example easy-read invitation letter
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Appendix 8 Full easy-read information sheet
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Appendix 9 Full easy-read reply form
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Appendix 10 Personal consultee information
leaflet
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Appendix 11 Nominated consultee information
leaflet
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Appendix 12 Easy-read consent form
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Appendix 13 Personal consultee advice form
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Appendix 14 Nominated consultee advice form
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Appendix 15 Example of letter to inform
participants of results
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Appendix 16 Example letter to inform general
practice of results
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Appendix 17 Questionnaires used in the
research programme
EuroQol-5 Dimensions (EQ-5D)
A generic instrument for the measurement of health-related quality of life.214 It provides a simple
descriptive profile in five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/
depression), each with three levels. This instrument can be used in the clinical and economic evaluation of
health care and to analyse changes in the health status of individuals or groups of individuals over time.
Aberrant Behaviour Checklist (ABC)
An informant-based problem behaviour rating scale, which assesses a wide range of behavioural disorders
and has been shown to be a reliable and valid behaviour rating instrument.216 The questionnaire consists of
58 items, scored on a four-point scale.215 The subcategories are (1) irritability, agitation, crying; (2) lethargy,
social withdrawal; (3) stereotypic behaviour; (4) hyperactivity, noncompliance; and (5) inappropriate speech.
Psychiatric Assessment Schedules for Adults with Developmental
Disabilities (PAS-ADD) Checklist
A 25-item questionnaire and can be used to make an initial assessment for mental illness/psychiatric
disorders in people with ID.217 The instrument generates threshold scores, which are then used as a
measure to indicate the likely absence or presence of possible psychiatric problems. The scores produced
relate to (1) affective or neurotic disorder, (2) possible organic condition (including dementia) and
(3) psychotic disorder.
Glasgow Depression Scale (GDS)
An established measure of depression among people with ID.218 The GDS for people with learning
disability (GDS-LD) differentiates depression and non-depression groups, correlates with the Beck
Depression Inventory II (r = 0.88), has good test–retest reliability (r = 0.97) and internal consistency
[Cronbach’s alpha (α) = 0.90], and a cut-off score of 13 yielded 96% sensitivity and 90% specificity.
The Carer Supplement is also reliable (r = 0.98; α = 0.88), correlating with the GDS-LD (r = 0.93).
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Appendix 18 Summary of baseline characteristics
TABLE 61 Baseline characteristics of participants in the screening study
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Biomedical measurements
Plasma glucose, mmol/l
Fasting 425 (8) 4.7 (± 0.7)
Non-fasting 239 (16) 5.3 (± 1.5)
HbA1c 675 (27)
HbA1c (mmol/mol) 35.0 (± 5.1)
Derived HbA1c (%) 5.4 (± 0.5)
Lipids, mmol/l
Total cholesterol 653 4.9 (± 1.0)
HDL cholesterol 644 1.3 (± 0.4)
LDL cholesterol 631 2.9 (± 0.9)
Triglycerides (only if fasted) 407 1.4 (± 0.9)
Urea and electrolytes
Sodium (mmol/l) 713 (84) 139.6 (± 3.1)
Potassium (mmol/l) 701 (80) 4.3 (± 0.5)
Urea (mmol/l) 712 (83) 5.4 (± 1.9)
Creatinine (mmol/l) 714 (84) 69.0 (± 22.7)
eGFR (ml/minute), n (%) 603 (80)
≥ 90 476 (78.9)
60–89 110 (18.2)
45–59 10 (1.7)
30–44 4 (0.7)
≤ 29 3 (0.5)
Liver function tests
Bilirubin (µmol/l) 683 (52) 9.6 (± 5.9)
Alanine transaminase (IU/l) 691 (61) 24.8 (± 15.8)
Alkaline phosphatase (IU/l) 694 (67) 86.8 (± 27.6)
GGT (IU/l) 621 (3) 32.5 (± 32.2)
Thyroid function
Thyroid-stimulating hormone (mIU/l) 637 (22) 2.6 (± 2.1)
Free thyroxine (T4) (pmol/l) 621 (10) 14.0 (± 2.4)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Urine ACR
Urine ACR (mg/mmol) 569 (1) 2.5 (± 12.5)
Anthropometric measurements
Height (m) 800 1.6 (± 0.1)
Weight (kg) 799 76.4 (± 20.7)
BMI (kg/m2) 782 28.7 (± 7.1)
BMI categories, n (%)
Underweight 30 (3.8)
Normal 223 (28.5)
Overweight 241 (30.8)
Obese 288 (36.8)
Waist circumference (cm) 796 100.4 (± 16.5)
Hip circumference (cm) 789 107.6 (± 14.0)
BP measurements
BP (mmHg) 826
Systolic 121.4 (± 16.9)
Diastolic 78.2 (± 11.1)
Demographic and lifestyle
Age in years 930 43.3 (± 14.2)
Sex (male), n (%) 930 537 (57.7)
Ethnicity, n (%) 930
White 748 (80.4)
Asian 147 (15.8)
Black 14 (1.5)
Mixed 13 (1.4)
Other 8 (0.9)
Residential circumstances, n (%) 929
Alone 51 (5.5)
Lives with family 338 (36.4)
Shared house or supported living 157 (16.9)
Shared care 16 (1.7)
Residential home or nursing home 350 (37.7)
Other 17 (1.8)
Level of support, n (%) 929
Independent 69 (7.4)
Some support 205 (22.1)
24-hour support 655 (70.5)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Current status,a n (%)
Paid employment 928 71 (7.7)
Voluntary work 927 152 (16.4)
College 925 170 (18.4)
Day opportunities or private day centre 928 431 (46.4)
Shared lives (day placement) 928 19 (2.1)
Attending meetings 926 122 (13.2)
Other 924 385 (41.7)
Deprivation (IMD 2015),b median (IQR) 930 16,353 (7351–23,606)
Medical history
Severity of ID, n (%) 865
Not known 49 (5.7)
Known 816 (84.3)
Mild 260 (30.1)
Moderate 244 (28.2)
Severe 279 (32.3)
Profound 33 (3.8)
Cause of ID, n (%) 866
Not known 581 (67.1)
Known 285 (32.9)
Down syndrome 133 (15.4)
Fragile X 8 (0.9)
Cerebral palsy 58 (6.7)
Angelman syndrome 4 (0.5)
Cytomegalovirus 1 (0.1)
Fetal alcohol syndrome 0
Homocystinuria 0
Hydrocephalus 6 (0.7)
Hurler syndrome 0
Klinefelter syndrome 3 (0.4)
Lesch–Nyan syndrome 0
Neurofibromatosis 2 (0.2)
Phenylketonuria 5 (0.6)
Prader–Willi syndrome 4 (0.5)
Rett syndrome 1 (0.1)
Sturge–Weber syndrome 1 (0.1)
Tay–Sachs disease 0
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Triple X syndrome 0
Trisomy 13 0
Trisomy 18 0
Tuberous sclerosis 2 (0.2)
Turner syndrome 0
Other cause 57 (6.6)
Medical or health problems, n (%) 929
None 117 (12.6)
Yes 812 (87.4)
Physical health
Stroke 13 (1.4)
Peripheral arterial disease 0
CHD 7 (0.8)
Congenital heart disease 19 (2.1)
Other heart problems 15 (1.6)
High BP 63 (6.8)
High cholesterol 62 (6.7)
Hypothyroidism 93 (10.0)
Polycystic ovary syndrome 1 (0.1)
Gestational diabetes 0
Pre-diabetes 1 (0.1)
Chronic breathing problems 88 (9.5)
Sleep apnoea 3 (0.3)
Epilepsy 262 (28.2)
Mental health
Dementia 18 (1.9)
Schizophrenia, schizotypal and delusional 35 (3.8)
Mood (affective) disorders 152 (16.4)
Neurotic, stress-related and somatoform 143 (15.4)
Two or more disorders 52 (5.6)
Personality disorders 13 (1.4)
Drug/alcohol problems 0
Attention deficit hyperactivity disorder 8 (0.9)
ID
Autistic spectrum disorders 165 (17.8)
Behavioural problems 128 (13.8)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Current medication, n (%) 928
None 172 (18.5)
Yes 756 (81.5)
Anti-psychotic 240 (25.9)
Two or more medications 24 (2.6)
Depression/anxiety/OCD or related 258 (27.8)
Two or more medications 43 (4.6)
For ADHD 4 (0.4)
Antiepileptic 311 (33.5)
Antithrombotic 36 (3.9)
Lipid lowering 74 (8.0)
Statin 72 (7.8)
Fibrate 1 (0.1)
Statin and fibrate 1 (0.1)
Antihypertensive 85 (9.2)
Thyroid medication 93 (10.0)
Steroids 80 (8.6)
Oral 5 (0.5)
Inhaled 62 (6.7)
Topical 9 (1.0)
More than one type of steroid medication 3 (0.3)
Not known 1 (0.1)
Anti-obesity 1 (0.1)
Other 571 (61.5)
Smoking status, n (%) 929
Current 76 (8.2)
Ex 38 (4.1)
Never 815 (87.7)
Family history of diabetes, n (%) 592 180 (30.4)
Physical activity/exercise
Able to stand, n (%) 929
No 58 (6.2)
Yes 871 (93.8)
Able to walk, n (%) 927
No 57 (6.2)
Yes (with or without walking stick, aid) 787 (84.9)
Yes, with assistance from person(s) 83 (9.0)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Mobility aids, n (%) 928
No 703 (75.8)
Yes 225 (24.3)
Uses a walking aid 52 (5.6)
Uses a wheelchair, all or most 81 (8.7)
Uses a wheelchair, some 78 (8.4)
Other 12 (1.3)
Not known 2 (0.2)
Amount of walking per day, n (%) 927
None 74 (8.0)
A short distance 259 (27.9)
Some 359 (38.7)
Lots 235 (25.4)
Speed of normal walking (if can walk), n (%) 850
Slow 301 (35.4)
Steady 373 (43.9)
Brisk or fast 176 (20.7)
Activities,a n (%)
Keep fit/aerobics 928 83 (8.9)
Walking 197 (21.2)
Running/jogging 929 39 (4.2)
Swimming 190 (20.5)
Dance 233 (25.1)
Bowling 155 (16.7)
Gym 92 (9.9)
Horse riding 32 (3.4)
Cycling 62 (6.7)
Gardening 179 (19.3)
Housework 927 489 (52.8)
Chair-based exercise 863 68 (7.9)
Other 925 131 (14.2)
Amount of physical activity per week, n (%) 928
None 184 (19.8)
1–2 times 360 (38.8)
3–4 times 259 (27.9)
5 or more 125 (13.5)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Time spent sitting per day, n (%) 928
All/most 180 (19.4)
A lot 252 (27.2)
Sometimes 475 (51.2)
Never 21 (2.3)
Nutrition and diet
Problems relating to eating and drinking, n (%)
Difficulties with chewing or swallowing 929 227 (24.4)
Needs help or assistance to feed self 926 118 (12.7)
Use specialist equipment 95 (10.3)
Fed via an nasogastric tube or a gastrostomy 7 (0.8)
Only included if not fed via tube 922
Food shopping, n (%)
Independently 89 (9.7)
With support 230 (25.0)
Relative or carer 297 (32.2)
Purchased by residential home 306 (33.2)
Prepare meals, n (%) 921
Relative or carer 561 (60.9)
With supervision 117 (12.7)
Without supervision 145 (15.7)
Without supervision and prepare variety of meals 98 (10.6)
Types of food daily eaten, n (%)
Starch 919 916 (99.7)
Fruit/vegetables 921 864 (93.8)
Milk/yoghurt 920 896 (97.4)
Meat, fish, eggs/other vegetarian, alternative 919 898 (97.7)
Daily proportion of fruit, vegetable, n (%) 920
None 33 (3.6)
1 a day 57 (6.2)
2 a day 130 (14.1)
3 a day 230 (25.0)
4 a day 199 (21.6)
5 a day 213 (23.2)
6 a day 36 (3.9)
7 or more a day 22 (2.4)
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TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Questionnaires
Administered via interview 930
Health-related quality of life
EQ-5D score 872 0.8 (± 0.3)
EQ-5D scale 877 78.1 (± 19.4)
Depression
GDS-LD 317 7.5 (± 6.7)
Number depressed, n (%) 67 (21.1)
GDS-LD Carer Supplement 464 5.5 (± 5.8)
Number depressed, n (%) 71 (15.3)
Carer completed outside appointment 930
Behaviour problem
ABC 341
1. irritability, agitation, crying 4.3 (± 6.7)
2. lethargy, social withdrawal 3.5 (± 5.5)
3. stereotypic behaviour 1.2 (± 2.6)
4. hyperactivity, noncompliance 3.9 (± 6.0)
5. inappropriate speech 1.3 (± 2.2)
Total score 14.0 (± 19.5)
Psychiatric disorders
PAS-ADD Checklist Section 1 930
No events 207 (22.3)
Death of a first-degree relative 34 (3.7)
Death of a close friend, carer or relative 36 (3.9)
Serious illness or injury 21 (2.3)
Retirement form work 1 (0.1)
Serious illness of relative, carer or friend 28 (3.0)
Move of house or residence 45 (4.8)
Break-up of steady relationship 10 (1.1)
Separation or divorce 1 (0.1)
Alcohol problem 1 (0.1)
Drug problem 1 (0.1)
Serious problem with relative, carer/friend 11 (1.2)
Unemployed/seeking work 4 (0.4)
Breakdown of relationship with parent(s) 4 (0.4)
Laid off or sacked from work 0
Something valuable lost or stolen 4 (0.4)
Problems with police or other authority 7 (0.8)
APPENDIX 18
NIHR Journals Library www.journalslibrary.nihr.ac.uk
290
TABLE 61 Baseline characteristics of participants in the screening study (continued )
Characteristic N (medical record)
Mean (±SD) unless
stated otherwise
Major financial crisis 1 (0.1)
Sexual problem 2 (0.2)
Other event 38 (4.1)
PAS-ADD Checklist Section 2 325
Possible organic condition 1.0 (± 1.7)
Threshold score or above, n (%) 20 (6.2)
Affective or neurotic disorder 1.4 (± 3.2)
Threshold score or above, n (%) 28 (8.6)
Psychotic disorder 0.2 (± 0.6)
Threshold score or above, n (%) 16 (4.9)
ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transpeptidase;
IMD, Index of Multiple Deprivation; IU, international unit; mIU, milli-international unit.
a Percentage will not add to 100, as participants can positively answer more than one category.
b IMD 2015 ranks every small area in England from 1 (most deprived area) to 32,844 (least deprived area).
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Appendix 19 Example topic guide for service
users interviews: education development stage
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Appendix 20 Example form for educator training
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Appendix 21 Scope of the economic evaluation
The reasons for not attempting to estimate the cost-effectiveness of screening people with ID fordiabetes (including T2DM)/IGR and overweight/obese) are listed below.
Lack of evidence
There is a dearth of good-quality evidence in relation to the costs and effects of diabetes prevention
interventions in people with ID.
Number of pathways/screening strategies
The economic model needs to take account of all of the permutations of screening for diabetes only,
screening for diabetes and IGR, and screening for overweight/obese. As screening cannot be considered in
isolation (i.e. it depends on interventions), the economic model would need to take into account of how
standard prevention interventions and the STOP Diabetes education programme would be implemented
for people with ID. It is also unclear how such screening would fit into existing policy in relation to
Learning Disability Health Checks.
Evaluation of screening outside the UK
Evaluating screening outside the UK in people with ID would lead to unreliable conclusions because:
l we do not have estimates for the prevalence of undiagnosed diabetes and IGR, and the rates are likely
to be different in other countries (even those within Europe)
l there are different thresholds for HbA1c for diagnosing IGR
l we do not know how effective prevention interventions would be
l we would need to model different countries’ diagnostic and care pathways, use country-specific costs
and use different thresholds for ‘willingness to pay’.
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Appendix 22 Comparison of surrogate-based
physical activity approach against Yates et al.267
When using biomarkers (e.g. changes in physical activity through BMI and SBP level) to predict clinicalevents, it is important, where possible, to undertake validation against a study that is reporting hard
clinical outcomes. Potentially, surrogate-based modelling could overlook some other mechanism of
reduction in risk of CVD. To the extent that any such other mechanisms are correlated with changes in
BMI and systolic BP, these mechanisms would be captured within our mapping. It was decided to compare
the model’s predicted impact on CVD outcomes with another study.
In consultation with clinical experts we were directed to the NAVIGATOR trial results,267 which could be
used for the validation. In this study, all of the groups participated in a lifestyle modification programme
that was designed to help them achieve and maintain a 5% weight loss, reduce the amount of saturated
and total fats in their diet and increase physical activity to 150 minutes per week. The study reported the
relationship between activity (steps) and CVD outcomes (events) in a cohort of 9306 people. The analysis
controlled for changes in BMI.
For the validation, a model adaptation was created, which mimicked the NAVIGATOR trial267 by assuming
that changes in daily step counts continued without declining for a period of 6 years (the study followed
participants for 6 years, but it was not an intervention trial so we assumed that steps/day was stationary
rather than declining). For an increase in activity of 2000 steps, Yates et al.267 reported a hazard ratio of
experiencing a cardiovascular event over the following 6 years of 0.92 (95% CI 0.86 to 0.99), that is, a risk
reduction of 8%. The hazard ratio from our adapted model was 0.95 (5% risk reduction).
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Appendix 23 Database search terms for
health-economic analysis
BOX 4 PubMed database search terms for physical activity studies
(‘activity’[title] OR ‘sedentary’[title] OR ‘exercise’[title])
AND
(‘weight’[title] OR ‘diabetes’[title] OR ‘BMI’[title] or ‘cardio-metabolic’[title] or ‘glucose’[title])
AND
(‘steps’[All Fields] OR ‘step-counter’[All Fields] OR ‘accelerometer’[All Fields])
AND (‘weight’[All Fields] OR ‘diabetes’[All Fields] OR ‘BMI’[All Fields])
AND (‘blood glucose’[All Fields] OR ‘hba1c’[All Fields] OR ‘cholesterol’[All Fields] OR ‘BMI’[All Fields] OR
‘weight’[All Fields] OR ‘waist’[All Fields] OR ‘hip’[All Fields] OR ‘blood pressure’[All Fields] OR ‘glycated
haemoglobin’[All Fields] OR ‘blood sugar’[All Fields])
NOT (‘school’[title] OR ‘child’[title] OR ‘children’[title] OR ‘childhood’[title])
Date of search: 23 October 2015.
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Appendix 24 Modelling cardiovascular events
The QRISK2 risk equation can be used to calculate the probability of a cardiovascular event, includingCHD (angina or MI), stroke, transient ischaemic attacks (TIAs) and fatality due to CVD.
The QRISK assumptions regarding the relationship between IGR, diabetes and CVD were modified for the
model and are outlined below:
1. It was assumed that individuals with HbA1c levels of > 6.5 mmol/l have an increased risk of CVD, even if
they have not received a formal diagnosis.
2. Risk of CVD was assumed to increase with HbA1c levels for test results of > 6.5% to reflect the
observations from the UKPDS – that HbA1c increases the risk of MI and stroke.275
3. Prior to T2DM (HbA1c level of > 6.5 mmol/l), HbA1c was assumed to be linearly associated with CVD.
A study from the EPIC cohort found that a unit increase in HbA1c increases the risk of CHD by a hazard
ratio of 1.25, after adjustment for other risk factors.285 Individuals with a HbA1c level of greater than the
mean HbA1c level that was observed in the HSE 2011 cohort were at greater risk of CVD than those
with a HbA1c level that was lower than the HSE mean.262
The QRISK algorithm identifies which individuals experience a cardiovascular event, but does not specify the
nature of that event. The nature of the cardiovascular event was determined independently. A targeted
search of recent health technology appraisals of CVD was performed to identify a model for the progression
of CVD following a first event (Table 62).
All QRISK events are assigned to a specific diagnosis according to age- and sex-specific distributions of
cardiovascular events used in a previous HTA.287 The probability of cardiovascular outcomes by age and sex
is shown in Table 63.
After an individual has experienced a cardiovascular event, it is not possible to predict the transition to
subsequent cardiovascular events using QRISK2. Instead, as with assigning first CVD events, the statin HTA
reports the probability of future events, conditional on the nature of the previous event.287 More details on
the probabilities within a year of transitioning from stable angina, unstable angina, MI, TIA or stroke for
individuals in different age groups can be found in an online discussion paper.263
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TABLE 63 Probability distribution of cardiovascular events by age and sex
Sex Age (years)
Angina
MI rate Fatal CHD TIA Stroke Fatal CVDStable Unstable
Men 45–54 0.307 0.107 0.295 0.071 0.060 0.129 0.030
55–64 0.328 0.071 0.172 0.086 0.089 0.206 0.048
65–74 0.214 0.083 0.173 0.097 0.100 0.270 0.063
75–84 0.191 0.081 0.161 0.063 0.080 0.343 0.080
≥ 85 0.214 0.096 0.186 0.055 0.016 0.351 0.082
Women 45–54 0.325 0.117 0.080 0.037 0.160 0.229 0.054
55–64 0.346 0.073 0.092 0.039 0.095 0.288 0.067
65–74 0.202 0.052 0.121 0.081 0.073 0.382 0.090
75–84 0.149 0.034 0.102 0.043 0.098 0.464 0.109
≥ 85 0.136 0.029 0.100 0.030 0.087 0.501 0.117
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Appendix 25 Assumptions made for diagnosis
and treatment of diabetes, hypertension and
cardiovascular disease risk for health-economic
analysis
TABLE 64 Assumptions made for diagnosis and treatment of diabetes hypertension and high CVD risk
Diabetes Hypertension High CVD risk
Diagnosis
At baseline, individuals are assigned a
HbA1c threshold above which diabetes
is detected opportunistically
Assumed that people who are eligible
for antihypertensive treatment will be
identified through opportunistic
screening if they meet certain criteria
and see the GP at least once during
the simulation period
Assumed that people who are eligible
for statins will be identified through
opportunistic screening if they meet
certain criteria and see the GP at least
once during the simulation periodIndividuals with HbA1c levels that are
above their individual threshold will
attend the GP to be diagnosed with
diabetes
Treatment
Assumed that there are three, non-mutually exclusive outcomes from the vascular checks and opportunistic screening
Patient’s blood glucose test indicates
T2DM as measured by HbA1c level of
> 6.5 mmol/l (assumed that FPG and
the 2-hour glucose test are not used
for diabetes diagnosis, but future
adaptations of the model could
include these criteria)
Patient has high BP and should be
treated with antihypertensive
medication. Antihypertensive
treatment initiated if:
l systolic BP is > 160mmHg
l systolic BP is > 140mmHg and
individual also has a history of
CVD, diabetes or CVD risk of
> 20%335
Patient receives statins to reduce
cardiovascular risk:
l statins initiated if > 20% 10-year
CVD risk estimated from the
QRISK284 2012 algorithm336
A three-stage treatment regime is
assumed (as a trade-off between
model simplicity and capturing key
cost differences between
interventions):
(a) at diagnosis patients are
prescribed low-cost treatments,
represented by metformin
500 mg/day
(b) if HbA1c level rises to > 7.4%,
individual is prescribed a more
expensive DPP-IV inhibitor plus
metformin
Individual is assumed to continue with
DPP-IV inhibitor plus metformin until
the HbA1c level rises to > 8.5%,
whereby he/she is assumed to require
insulin
More details are available online.263
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Appendix 26 Distributions for key parameters
within the probabilistic sensitivity analysis
G iven the very large numbers of parameters in the model, many of which belong to complex forms ofstatistical modelling, it would not be helpful to present all of them in this report. In Table 65 we
present distributions for parameters that are related to the intervention, the relationship between physical
activity (steps)269 and BMI, and other risk factors. Details of distributions for the other model parameters
are reported elsewhere.263
No uncertainty is included around uptake rates. As duration of effect is explored through scenario
analyses, no uncertainty is included around this parameter.
Mortality
Mortality rates from other causes by age were assumed to be constant in the PSA.281 The parameter
distributions for the hazard ratio for other-cause mortality with diabetes and for the SMRs for other-cause
mortality in males and females with ID are reported in Table 66. The table shows the probability
distribution for each model parameter and the mean value (central estimate). Parameters 1 and 2 are
arguments for the specific forms of statistical model, such as log-normal.
TABLE 65 Uncertainty around the Bravata269-based intervention effect size (assuming 2491 steps)
Parameter description Distribution
Parameter
Central estimate Source1 2
BMI Normal –0.38 0.171 –0.38 Bravata et al. 2007269
SBP –3.8 1.071 –3.8
Total cholesterol –0.09 0.120 –0.09
HDL cholesterol 0.06 0.039 0.06
SBP, systolic blood pressure.
TABLE 66 Input parameters for mortality hazard ratio for diabetes and SMRs for ID
Parameter description Distribution
Distribution parameter
Central estimate1 2
Mortality hazard ratio for diabetes Log-normal 0.588 0.186 1.80
SMR for ID in males Normal 3.24 0.219 3.24
SMR for ID in females Normal 2.28 0.138 2.28
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Appendix 27 Results: cost-effectiveness plane
In Figure 30, each green dot represents a result from a sample run of the PSA. The green line representsthe cost-effectiveness frontier; points below this line represent sample results, from the PSA, which lie in
the cost-effective region. The spread of the points gives an indication, for this type of intervention, of how
much uncertainty there is around the reported mean incremental costs and QALYs.
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FIGURE 30 Cost-effectiveness plane for an increase of 2491 steps at £30,000 per QALY.
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Appendix 28 Detailed threshold analysis results
tables at £20,000 per quality-adjusted life-year
TABLE 67 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome (base-case intervention £20,000 per QALY, assuming that all of the risk factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –5.0 –50 –1.88 –3.4 –34 –1.45
1000 –0.2 –2 –0.09 –4.8 –48 –1.85 –3.2 –32 –1.40
3000 –0.5 –5 –0.26 –4.5 –45 –1.77 –2.9 –29 –1.30
5000 –0.8 –8 –0.42 –4.2 –42 –1.69 –2.6 –26 –1.19
7000 –1.1 –11 –0.57 –3.9 –39 –1.60 –2.3 –23 –1.08
9000 –1.4 –14 –0.71 –3.6 –36 –1.52 –2.0 –20 –0.97
11,000 –1.7 –17 –0.84 –3.3 –33 –1.42 –1.7 –17 –0.84
13,000 –2.0 –20 –0.97 –3.0 –30 –1.32 –1.4 –14 –0.71
15,000 –2.3 –23 –1.08 –2.7 –27 –1.22 –1.1 –11 –0.57
SBP, systolic blood pressure.
TABLE 68 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome (increased effectiveness intervention at £20,000 per QALY, assuming that all of the risk
factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –4.7 –47 –1.83 –2.7 –27 –1.25
1000 –0.2 –2 –0.09 –4.6 –46 –1.79 –2.6 –26 –1.19
3000 –0.5 –5 –0.26 –4.3 –43 –1.71 –2.3 –23 –1.08
5000 –0.8 –8 –0.42 –4.0 –40 –1.63 –2.0 –20 –0.97
7000 –1.1 –11 –0.57 –3.7 –37 –1.54 –1.7 –17 –0.84
9000 –1.4 –14 –0.71 –3.4 –34 –1.45 –1.4 –14 –0.71
11,000 –1.7 –17 –0.84 –3.1 –31 –1.35 –1.1 –11 –0.57
13,000 –2.0 –20 –0.97 –2.7 –27 –1.25 –0.8 –8 –0.42
15,000 –2.3 –23 –1.08 –2.4 –24 –1.14 –0.5 –5 –0.26
SBP, systolic blood pressure.
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TABLE 69 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for an obese subgroup (base-case intervention at £20,000 per QALY, assuming that all of
the risk factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –4.7 –47 –1.83 –2.7 –27 –1.25
1000 –0.2 –2 –0.09 –4.6 –46 –1.79 –2.6 –26 –1.19
3000 –0.5 –5 –0.26 –4.3 –43 –1.71 –2.3 –23 –1.08
5000 –0.8 –8 –0.42 –4.0 –40 –1.63 –2.0 –20 –0.97
7000 –1.1 –11 –0.57 –3.7 –37 –1.54 –1.7 –17 –0.84
9000 –1.4 –14 –0.71 –3.4 –34 –1.45 –1.4 –14 –0.71
11,000 –1.7 –17 –0.84 –3.1 –31 –1.35 –1.1 –11 –0.57
13,000 –2.0 –20 –0.97 –2.7 –27 –1.25 –0.8 –8 –0.42
15,000 –2.3 –23 –1.08 –2.4 –24 –1.14 –0.5 –5 –0.26
SBP, systolic blood pressure.
TABLE 70 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a subgroup aged 45–49 years (base-case intervention at £20,000 per QALY, assuming
that all of the risk factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –2.6 –26 –1.19 –1.9 –19 –0.94
1000 –0.2 –2 –0.09 –2.4 –24 –1.14 –1.8 –18 –0.87
3000 –0.5 –5 –0.26 –2.1 –21 –1.03 –1.4 –14 –0.74
5000 –0.8 –8 –0.42 –1.8 –18 –0.90 –1.1 –11 –0.61
7000 –1.1 –11 –0.57 –1.5 –15 –0.78 –0.8 –8 –0.46
9000 –1.4 –14 –0.71 –1.2 –12 –0.64 –0.5 –5 –0.30
11,000 –1.7 –17 –0.84 –0.9 –9 –0.50 –0.2 –2 –0.13
13,000 –2.0 –20 –0.97 –0.6 –6 –0.34 0.0 0 0.00
15,000 –2.3 –23 –1.08 –0.3 –3 –0.18 0.0 0 0.00
SBP, systolic blood pressure.
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TABLE 71 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a subgroup aged ≥ 50 years (base-case intervention at £20,000 per QALY, assuming that
all of the risk factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –4.1 –41 –1.67 –2.7 –27.5 –1.2
1000 –0.2 –2 –0.09 –4.0 –40 –1.63 –2.6 –25.9 –1.2
3000 –0.5 –5 –0.26 –3.7 –37 –1.54 –2.3 –22.9 –1.1
5000 –0.8 –8 –0.42 –3.4 –34 –1.45 –2.0 –19.8 –1.0
7000 –1.1 –11 –0.57 –3.1 –31 –1.35 –1.7 –16.8 –0.8
9000 –1.4 –14 –0.71 –2.7 –27 –1.25 –1.4 –13.7 –0.7
11,000 –1.7 –17 –0.84 –2.4 –24 –1.14 –1.1 –10.7 –0.6
13,000 –2.0 –20 –0.97 –2.1 –21 –1.03 –0.8 –7.6 –0.4
15,000 –2.3 –23 –1.08 –1.8 –18 –0.90 –0.5 –4.6 –0.3
SBP, systolic blood pressure.
TABLE 72 Combinations of daily step increases and additional dietary changes that are required to achieve a
cost-effective outcome for a high CVD risk subgroup (base-case intervention at £20,000 per QALY, assuming that
all of the risk factors change together)
Initial
increase
in steps
needed
Change attributable to the
increase in steps
Additional change needed to be generated through diet
Base case (3-year durability) 5-year durability
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
BMI
(kg/m2)
SBP
(mmHg)
Total/HDL
cholesterol
ratio
0 0.0 0 0.00 –3.5 –35 –1.49 –2.1 –21 –1.03
1000 –0.2 –2 –0.09 –3.4 –34 –1.45 –2.0 –20 –0.97
3000 –0.5 –5 –0.26 –3.1 –31 –1.35 –1.7 –17 –0.84
5000 –0.8 –8 –0.42 –2.7 –27 –1.25 –1.4 –14 –0.71
7000 –1.1 –11 –0.57 –2.4 –24 –1.14 –1.1 –11 –0.57
9000 –1.4 –14 –0.71 –2.1 –21 –1.03 –0.8 –8 –0.42
11,000 –1.7 –17 –0.84 –1.8 –18 –0.90 –0.5 –5 –0.26
13,000 –2.0 –20 –0.97 –1.5 –15 –0.78 –0.2 –2 –0.09
15,000 –2.3 –23 –1.08 –1.2 –12 –0.64 0.0 0 0.00
SBP, systolic blood pressure.
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